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                                                                   Abstract 
 
Activation of the transmembrane death receptor Fas (CD95/APO-1) by a membrane 
bound  ligand  (FasL/CD95L)  activates  the  extrinsic  pathway  of  apoptosis. 
Intracellular Fas death domains (DDs) are induced to oligomerise enabling binding 
to the adaptor protein FADD, thereby leading to the recruitment of procaspase 8 and 
other  proteins  to  form  the  death  inducing  signalling  complex  (DISC).This  thesis 
describes an investigation of the structure and function of the cytoplasmic Fas-DD. 
A model for the solution structure of the Fas-DD was published in 1996, it has since 
been reported that the death domain can form at least one other conformation when 
in  complex  with  FADD.  As  a  foundation  to  the  work  in  this  thesis,  modern 
multidimensional NMR techniques have been used to solve the structure of the Fas-
DD, to further probe the potential for alternative conformations. 
It has previously been reported that Fas can be phosphorylated at Tyr291, providing 
a  platform  for  the  recruitment  of  binding  partners  that  can  affect  non-apoptotic 
signalling. The second part of this thesis details the development of an expressed 
protein ligation methodology to prepare a Tyr291 phosphorylated Fas DD to provide 
a  basis  for  in  vitro  studies  of  the  structural,  dynamic  and  functional  effects  of 
phosphorylation. 
It  is  widely  accepted  that  Fas  is  palmitoylated  at  Cys199  and  recognised  by  the 
membrane cytoskeletal protein, ezrin. Fas palmitoylation is important for clathrin-
mediated  internalisation  of  the  DISC,  and  amplification  of  the  caspase  cascade. 
There are multiple reports detailing the binding of ezrin to Fas, but it is not clear 
whether  this  interaction  occurs  in  a  palmitoylation-dependent  manner.  Efforts  to 
characterise an interaction between bacterially expressed intracellular Fas and ezrin 
proteins were carried out using a number of biophysical assays, described in the third 
part of this thesis. Building upon this, the fourth section explores the preparation of a 
palmitoylated  Fas  construct  suitable  for  biophysical  analysis  by  incubating 
recombinant Fas with palmitoyl-CoA.    4 
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1.1  T-cell  stimulation  eliminates  infected  cells  and  activates  the  adaptive 
immune response 
The development of the adaptive immune system is undeniably one of the greatest 
milestones in the evolution of jawed vertebrates. Innate immunity provides a non-
specific  first  line  of  defence  against  potentially  harmful  microorganisms  and 
molecules. In contrast, the adaptive immune system is more specific resulting in a 
highly  specialised,  pathogen-specific  immune  response  and  a  long-lasting 
immunological memory of each infection. The functions of the adaptive immune 
response  are  carried  out  by  the  lymphocytes.  There  are  two  main  classes  of 
lymphocytes, T-cells and B-cells; B-cells are involved in antibody production and 
response while T-cells carry out cell-mediated immune responses. 
Upon  pathogen  detection  and  initiation  of  the  cell  mediated  immune  response, 
antigen presenting cells, such as B-cells, dendritic cells and macrophages internalise 
and degrade the pathogen. Peptide fragments of the pathogen are then incorporated 
into  major  histocompatibility  complexes  (MHC)  which  are  trafficked  to  and 
presented on the cell surface. T-cell activation occurs through the recognition and 
direct interaction with an antigen upon an MHC by the T-cell receptor (TCR). 
Much  like  antibodies,  T-cell  receptors  are  hypervariable,  with  the  T-cell  only 
becoming active when the TCR is able to bind the antigen fragment bound to the 
MHC. An activated T-cell can either go on to initiate cell death in cells infected with 
intracellular  pathogens  or  produce  signalling  molecules  that  amplify  the  immune 
response.  T-cell  signalling  acts  by  stimulating  and  activating  immune  cell 
proliferation, antibody production, phagocytosis, and elimination of the infected cell. 
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1.2 The population of activated T-cells is tightly regulated by apoptosis 
In order to prevent an excessive immune response, T-cell homeostasis is achieved 
through programmed cell death (PCD), also known as apoptosis. PCD results in the 
systematic breakdown of the cell by the cysteine proteases known as caspases. The 
final outcome of PCD is the formation of membrane-enclosed cellular breakdown 
products  called  apoptotic  bodies,  which  are  eliminated  by  phagocytosis.  Unlike 
necrosis,  which  is  the  result  of  cell  injury  or  external  factors,  PCD  is  a  highly 
regulated planned cell death and, because it does not result in the leakage of cell 
contents, it does not cause inflammation of the surrounding tissues. 
Apoptosis  can  be  initiated  intrinsically,  when  started  internally  from  the 
mitochondria, or extrinsically when triggered via the activation of a transmembrane 
receptor. These two mechanisms are not mutually exclusive and they can probably 
influence  one  another
1.  In  both  pathways  the  outcome  is  cellular  breakdown, 
culminating in the formation of the apoptotic bodies (Figure 1.1). 
In the case of T-cell homeostasis, intrinsic apoptosis is triggered by the absence of 
survival  stimuli  such  as  growth  factors  and  cytokines,  whereas  in  other  cell 
populations  the  intrinsic  pathway  can  be  triggered  by  external  stimuli  such  as 
radiation,  toxins  and  hypoxia.  The  removal  of  pro-survival  signalling  molecules 
triggers cytochrome C release from the mitochondria, inducing activation of caspase 
9 through the formation of a complex known as the apoptosome and activation of 
caspase  2  through  the  formation  of  a  complex  known  as  the  PIDDosome.  The 
extrinsic pathway is triggered by ligand biding to one of the members of the tumour 
necrosis factor receptor (TNFR) family. These transmembrane receptors are formed 
by several cysteine-rich extracellular domains, and a cytoplasmic region comprising 
a death domain
2. Upon activation, the death domain of the receptor is able to recruit 
other death-domain containing cytoplasmic adaptor proteins which in turn activate 
the caspases. The most well studied death receptor/ligand interactions are the ones 
between Fas (CD95) and Fas ligand (FasL) and TNFR1 and TNF-α, although many 
others exist (e.g. Death Receptor 3 (DR3) and TNF12, DR4 and TNFSF10). 





Figure 1.1 – Schematic representation of apoptotic pathways 
The  extrinsic  and  intrinsic  pathways  are  the  two  main  apoptotic  pathways.  Extrinsic  apoptosis  is  activated 
through death receptor mediated signalling activating procaspase 8. Intrinsic apoptosis is initiated through cell 
stress  which  affects  the  mitochondria  inducing  apoptosome  formation  and  activation  of  procaspase  9. 
Procaspases 8 and 9 initiate the execution pathway resulting in cell breakdown. DISC – death inducing signalling 
complex. Adapted from Elmore 2007. 
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The extrinsic and the intrinsic PCD pathways converge on the execution pathway 
that results in activation of the highly regulated process of caspase activation known 
as the caspase cascade. Caspases exist in the cell in an inactive ‘procaspase’ form 
until  cellular  signalling  enables  the  release  of  the  active  enzyme  through  an 
autocatalytic mechanism (discussed in more detail below). Caspases 8, 10, 2 and 9 
are known as ‘initiator’ caspases as they are the first members of the caspase cascade 
to be activated. Caspases 8 and 10 are activated in the extrinsic pathway, while 2 and 
9 are activated in the intrinsic pathway. 
The  initiator  caspases  have  limited  target  specificity,  cleaving  and  activating  the 
‘effector’ caspases, 3, 6 and 7. Effector caspases execute cell death by digesting 
cellular components such as the cytoskeleton and nuclear lamins. This specific order 
of caspase activation enables tight regulation of the enzymes that are responsible for 
cellular breakdown, with initiator caspases acting as a check point to ensure that the 
effector caspases are only activated under the correct stimuli. Caspases are not just 
involved in cell death, there are other ‘inflammatory’ caspases (1, 4, 5, 11, 12, 14) 
that are activated in response to pathogenic infection and autoimmune disorders
3.  30 
1.3  Homotypic  interactions  between death  domain  superfamily  members  are 
widespread in apoptosis and inflammation signalling 
TNFRs and initiator caspases are some of the many proteins involved in apoptosis 
signalling that interact  with each other through a domain belonging to the death 
domain  superfamily  (DDsf).  Although  there  is  up  to  90%  sequence  divergence 
between members of this domain superfamily, they all fold to form a 80-100 residue 
long globular antiparallel six helical Greek key motif
4 with a minimal hydrophobic 
core.  
Subtle differences between each domain in the length and orientation of the helices 
and the location of surface charge affect their mechanisms of interaction and are 
used to classify them into four families
5: Death domain (DD), death effector domain 
(DED), caspase recruitment domain (CARD) and pyrin domain (PYDs). Figure 1.2 
and Figure 1.3 illustrate structural and sequence differences between the members of 
the four subfamilies. According to the SMART database, DD and CARD families 
are present in all metazoan phyla, but only deuterostomes possess proteins with PYD 
domains and only chordates, cnidarians and echinoderms have proteins with DEDs. 
The human proteome has 27 proteins with DDs, 7 proteins with DEDs, 29 proteins 
with CARDs, and 22 proteins with PYDs. Some families of double-stranded DNA 
viruses  possess  proteins  with  DEDs  and  PYDs;  this  is  thought  to  have  occurred 
through horizontal gene transfer
4. A distinctive and puzzling feature of the DDsf is 
that  they  only  interact  in  a  homotypic  manner,  i.e.  DD-DD,  DED-DED,  CARD-
CARD or PYD-PYD
5. 












































































































































































































































































































































































































































Figure 1.3 Schematic representations of the structures of representative members of the death 
domain superfamily 
A, the death domain of Fas (PDB:1DDF); B, the death effector domain of FADD (PDB:1A1W); C, the caspase 
recruitment domain of Apaf1 (PDB:3YGS); D, the pryin (PYD) domain of ASC (PDB:1UCP). Helix colour 
corresponds to helix number. A, B and C are positioned in the same orientation. D is rotated 180
o along the Y 
axis to highlight the shorter helix 3. 
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1.3.1 Death domains assemble to form large signalling complexes 
Death  domains  (DDs)  were  the  first  members  of  the  DDsf  to  be  identified  both 
structurally and functionally
5. They are found in the intracellular region of the family 
of transmembrane death receptors and of the UNC5 netrin receptors, as well as in 
intracellular  proteins  involved  in  apoptosis,  necrosis  and  inflammation,  such  as 
Receptor-interacting  protein  1  kinase  (RIP1K),  interleukin-1  receptor-associated 
kinase (IRAK) 3 and 4, THO complex subunit 1 (THOC1), Myeloid differentiation 
primary response protein MyD88, and the p100 subunit of the nuclear factor kappa-
B. Adaptor proteins with DDs that are involved in apoptosis activation or modulation 
include FAS-associated death domain protein (FADD), RIP-associated Ich-1 protein 
with a death domain (RAIDD), Tumour necrosis factor receptor type 1-associated 
death  domain  protein  (TRADD),  and  p53  induced  protein  with  a  death  domain 
(PIDD). 
The solution structures of the isolated DDs of Fas, FADD, TNFR1, and TNFR16 and 
the crystal structures of the IRAK4, RAIDD, PELLE, TUBE, MyD88 death domains 
have highlighted common features within this domain family
5. The overall structure 
of the death domain forms a six amphipathic helical structure that is considered a 
perpendicular  arrangement  of  two  three-helix  bundles.  The  feature  that  is 
characteristic of the DDs is that helix one and two are centrally located and helix 
three  is  more  flexible  and  surface  exposed.  The  surfaces  of  the  DDs  are 
characteristically  charged,  and  it  is  thought  that  DD-DD  interactions  are 
predominantly mediated through electrostatic interactions
4,6.  
Some proteins with death domains form heteromeric complexes that activate effector 
molecules. For example, the DDs of Fas and FADD have been identified as the core 
blocks of the death inducing signalling complex (DISC), a structure that leads to the 
activation of caspases 8 and 10 in the extrinsic apoptotic pathway. Also, the DDs of 
RAIDD and PIDD form the core of the PIDDosome, a structure responsible for the 
activation of caspase 2 in the intrinsic apoptotic pathway. Death domains show a 
tendency  to  self-aggregate  and  this  is  thought  to  be  important  for  function.  For 
example,  for  DISC  progression  the  Fas  death  domains  must  initially  homo-
oligomerise prior to interacting with FADD
5. Based on extrapolation of the crystal 
structure data of the death-domain containing complexes PIDDosome, MyDDosome 34 
and  the  DISC,  it  has  been  proposed  that  each  DD  has  six  potential  interaction 
surfaces. These surfaces arise by a combination of three non-overlapping interaction 
types
4. Chapter three presents more in depth information about the 3D structure of 
the Fas death domain and other known death domain structures. 
1.3.2 Death effector domains interact via hydrophobic interactions 
There are only seven known human proteins with death effector domains (DEDs): 
activator  caspases  8  and  10;  adaptor  proteins  FADD,  DEDD  and  DEDD2,  anti-
apoptotic protein PEA-15 and the apoptotic regulator cellular FLICE-like inhibitory 
protein (c-FLIP). DEDs contain shorter and more irregular loop structures than DDs 
as well as a characteristic beta-turn in the loop between helices four and five
7. DEDs 
have two distinctive motifs: An Arg-X-Asp-Leu motif (R-X-D-L, X denoting any 
amino acid) in helix six, and a hydrophobic patch on the surface of helix two (Figure 
1.3).  
Little is known about DED-DED interactions because no structure of a complex has 
been  solved,  but  it  is  thought  that  DEDs  interact  mainly  through  hydrophobic 
interactions
8. Some extrapolations about general modes of interaction can be made 
from observations in individual members. For example, the RXDL motif enables 
FADD to self-associate, an event that is necessary for apoptosis onset
7. Furthermore, 
mutagenesis studies have shown that this motif is essential for the anti-apoptotic 
properties of the viral FLIP protein MC159
9. Caspases 8 and 10 as well as c-FLIP 
have  tandem  DEDs  and  this  arrangement  is  believed  to  enable  the  assembly  of 
chains of DEDs. In the case of the caspases the chains form higher order structures 
called death effector filaments (DEF), that are  able to recruit more caspases and 
amplify the apoptotic stimulus
10,11.  
1.2.3 Caspase recruitment domains form heterodimers or rings  
Proteins with a CARD domain include the activator caspases of the intrinsic pathway 
(caspases 2 and 9) and the inflammatory caspases 1, 4, 5, 11 and 12. Also, several 
apoptosis  regulators  and  adapter  proteins  have  this  domain,  including  RAIDD, 
Caspase recruitment domain-containing protein 16 (CARD16), Apoptotic protease-
activating  factor  1  (APAF1),  and  Baculoviral  IAP  repeat-containing  protein  3 
(BIRC3). 35 
It was not until the NMR solution structure of the RAIDD death domain was solved 
that the common origin of DDs, DEDs and CARDs became evident
5. CARDs are 
characterised by a highly conserved polar surface, in which one side of the domain is 
basic and the other is acidic
12, as well as by a bent or interrupted helix 1 (named H1a 
and H1b), and increased variability in helix length and orientations, including the 
stacking of three of the helices in a vertical direction
5,12. Only one structure of a 
CARD-CARD domain complex has been solved, that of APAF1 with procaspase 9. 
Their mode of interaction is predominantly mediated by electrostatic charges and 
shape complementation
13 and is thought to be conserved throughout the family.  
CARD domains are frequently found in large oligomeric complexes including, as 
part  of  the  innate  immune  response  complexes  the  NODosome  and  the 
inflammasome, and also as part of the PIDDosome. In the PIDDosome, PIDD and 
RAIDD interact through their DDs and RAIDD interacts via its CARD with the 
CARD of procaspase 2 . However, the CARD-mediated complexes that have been 
studied  so  far  have  a  different  topology  from  those  involving  DDs,  as  CARDs 
typically present one or two interaction sites per domain forming rings
14,15, while 
DDs have up to six interaction surfaces.  
1.2.4 Pyrin domains may interact in the same mode as DEDs 
The pyrin domain is the most recently identified and least well characterised of the 
DDsf
5. PYD-containing proteins are involved mainly in the innate immune response, 
mediating inflammation and apoptosis. The best characterised proteins with PYDs 
are  the  NOD-like  receptors  (NLRPs).  NLRPs  are  cytoplasmic  proteins  that  are 
activated by stress signals and pathogen-associated molecular patterns. Once active, 
NLRPs  are  able  to  recruit  adaptor  proteins  through  their  PYD  and/or  CARD 
domains,  leading  to  the  assembly  of  NODosomes  and  inflammasomes,  and 
activation of NFκB and caspase 1, respectively. Other proteins with PYD domains 
include the  apoptosis and inflammation mediator Apoptosis-associated speck like 
protein containing a CARD (ASC) and pyrin itself, which is one of the components 
of the inflammosome. 
It was hypothesised from sequence analysis that pyrin domain containing proteins 
were related to death domains
16, however this was not confirmed until the structures 
of  the  PYD  domains  of  ASC  and  NLRP  protein  NALP1  were  solved
17,18.  The 36 
solution structure of NALP1 revealed the overall helical fold of the death domain 
superfamily, however, helix three was found to be completely disordered
17. Whereas 
in the solution structure of ASC, helix three was much smaller than expected for a 
DD, with the stability for the domain coming from hydrophobic interactions located 
in the loop region between helices two and three
18. A bipolar distribution of charge 
on the surface of the PYD is another identifying feature; helices 1 and 4 show acidic 
properties, whereas helices two and three show basic properties. There is currently 
no structural information about the mode of interaction between the PYD domains. 




1.4 Activation of Fas by FasL results in the formation of the death inducing 
signalling complex 
Fas is a ubiquitously expressed 335-residue type I transmembrane protein. Fas is 
synthesised containing an N-terminal sixteen residue signal peptide that is cleaved 
from the mature protein prior to plasma membrane association. The extracellular 
region of Fas contains three disulphide-bonded cysteine rich-domains responsible for 
ligand binding, these are referred to as tumour necrosis factor receptor/nerve growth 
factor  receptor  repeats  (TNFr).  Fas  resides  in  the  membrane  as  a  pre-associated 
homotrimer,  trimerisation  initiated  by  the  preligand  assembly  domain  (PLAD) 
location at residues 17 to 82
20. The intracellular region of Fas contains the 90 residue 
death domain (DD), formed by six antiparallel amphipathic alpha helices joined by 
short loops
6 (Figure 1.3A).  
Activation  of  Fas  occurs  by  Fas  Ligand  (FasL).  FasL  is  a  281-residue  type  II 
transmembrane protein, expressed primarily by cytotoxic T cells and natural killer 
cells,  but  also  in  tissues  where  immune  cell  presence  needs  to  be  suppressed  to 
prevent inflammation, such as the eye
21. The extracellular region of FasL forms a 
tumour necrosis factor domain, and it is thought that FasL needs to trimerise to be 
active. FasL can be processed by metalloproteases to form a soluble ligand
22.  In 
soluble  form  only  the  hexamer  is  highly  cytotoxic
23,  suggesting  that  high 
concentrations are needed in vivo for the soluble ligand to be active. Fas can also be 
activated by cross-linking with agonistic antibodies
24. 37 
Upon  Fas  ligation,  the  death  domain  recruits  the  adaptor  protein  FADD  and 
procaspase 8 in an actin dependent manner. This recruitment results in the formation 
of microaggregates that are called death inducing signalling complexes (DISC)
25. 
The  DISC  acts  as  a  molecular  platform  to  recruit  and  activate  initiator  caspases 
triggering extrinsic apoptosis
26 (Figure 1.1 and Figure 1.4). FADD is a 208 amino 
acid  cytoplasmic  protein,  with  the  function  of  coupling  receptors  with  DDs  to 
effector  proteins.  FADD  contains  two  functional  domains,  a  C-terminal  DD  to 
interact with Fas and other TNFRs and an N-terminal DED enabling binding to other 
DED-containing proteins such as procaspase 8 and 10. FADD self-association seems 
to be required prior to interaction with other DED-containing molecules
27,28 followed 
by procaspase 8 being recruited to Fas-bound FADD, via a DED-DED interaction
29. 
Autoproteolytic  cleavage  of  the  procaspases  occurs  after  proximity-induced 
dimerisation resulting in the formation of an active heterotetramer of two p18 and 
two p10 subunits
30 (Figure 1.4). The activated form of the caspase is released from 
the DISC, transducing the primary apoptotic signal by cleaving and activating the 
effector  caspases  (caspases  3,  6  and  7)
31.  Caspases  initially  cleave  cytoskeletal 
components,  which    is  followed  by  the  cleavage  of  nuclear  lamins  and  the 
fragmenting  of  DNA.  The  final  stages  of  cell  death  are  characterised  as  cellular 
fragmentation, observed as membrane blebbing and resulting in the  formation of 
apoptotic bodies
32. 
At the point of DISC formation, the molecule c-FLIP (cellular FLICE inhibitory 
protein) acts as a regulator of extrinsic apoptosis
29. c-FLIP is a structural homologue 
of procaspase 8. It contains two DEDs which enable it to bind to the initial DISC but 
are  lacking  the  critical  protease  active  site  Cys  residue  and,  thus,  prevent 
autoproteolytic activation
32. It has been suggested that c-FLIP-mediated prevention 
of DISC progression and caspase activation can result in alternative signalling via 
non apoptotic pathways
33, which will be discussed further below. cFLIP-mediated 
inhibition of procaspase 8 and 10 activation is illustrated in Figure 1.4. 






Figure 1.4 Initiator caspase processing, activation and inhibition 
A; Schematic representation showing adaptor proteins FADD and procaspase associating with Fas-DD to form 
the DISC. Proximity induced dimerization enables the procaspase molecules to undergo autoproteolytic cleavage 
forming an active heterotetramer of two p18 and two p10 subunits. Arrows indicate autocatalytic cleavage and 
rearrangement to form an active caspase B; cFLIP recruitment inhibits procaspase processing resulting in the 
onset of alternative signalling pathways. 
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Mathematical modelling and quantitative mass spectrometry have been used in an 
attempt to elucidate the stoichiometry of the DISC. Through doing this, Schleich and 
colleagues  discovered  that  upon  DISC  formation,  there  is  a  much  higher 
concentration  of  caspase  8  present  when  compared  to  the  amount  of  FADD.  In 
conjunction with this, procaspase 8 can hetereodimerise with cFLIP which is present 
in lower abundance than procaspase 8
34. This sub stoichiometric concentration of 
FADD:procaspase 8 at the DISC was also observed by Dickens and colleagues who 
observed up to nine times more procaspase 8 compared to FADD
10. The authors 
postulate that this mechanism of recruitment acts as a method of amplification of the 
apoptosis response in which a small amount of initial DISC is able to activate a large 
number of caspases. As explained above, it is thought that DEDs are able to form 
long  death-effector  filaments  that  can  recruit  more  caspases  and  amplify  the 
apoptotic response away from the cell membrane
11. 
1.4.1 The response to Fas stimulation is cell type dependent 
The  speed  and  order  of  events  that  occur  upon  receptor  stimulation  during  Fas-
mediated  apoptosis  are  somewhat  variable  dependent  on  the  cell  type.  Two 
categories of immune cells have been designated: Type I and Type II. Type I cells 
undergo  rapid  procaspase  8  activation  with  high  detectable  volumes  of  DISC 
formation, and caspase 3 activation occurring within thirty minutes. Type II cells 
show  a  reduced  level  of  DISC  formation  with  evidence  of  little  caspase  8 
recruitment, and depend on the intrinsic pathway to amplify the caspase cascade. It is 
important to point out that this classification was a result of experiments carried out 
in stable cell lines, so it may not reflect Fas signalling in an organism. However, the 
authors who proposed this classification have argued that that peripheral T-cells do 
undergo apoptosis when Fas is induced
35, but hepatocytes do not
36, and therefore are 
Type  I  and  II  respectively
37.  It  is  important  to  take  into  account  that  any 
experimental observations of the Fas signalling pathway may be influenced by the 
type of cell line used. 
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1.4.2  Full  DISC  activation  is  dependent  upon  oligomerisation  and  subsequent 
internalisation 
The first step in DISC formation depends on the ability of the Fas homotrimers to 
oligomerise. This step has been characterised experimentally by the formation of 
SDS/β-merceptoethanol stable Fas aggregates, which correspond to a high molecular 
weight  form  of  Fas,  approximately  180  kDa  in  size,  termed  CD95
hi 
30,38.  Once 
aggregated,  Fas  is  thought  to  be  targeted  to  lipid  rafts  enabling  FADD  and 
procaspase  8  recruitment.  This  step  is  characterised  by  the  formation  of 
immunofluorescence-visible SPOTs (signalling protein oligomerisation transduction 
structures)
30. SPOTs are able to recruit more  Fas receptors and adaptor proteins, 
leading to co-localisation into “caps” on one pole of the cell and the formation of 
megadalton DISC complexes (hiDISCs). It is from this point that clathrin-mediated 
internalisation can occur
30,38 (Figure 1.5). It is not until internalisation takes place 
that full caspase 8 activation occurs
38,39.  
The initial recruitment of Fas into lipid rafts is a contentious issue. However, there 
have been a number of studies showing that upon TCR activation Fas is redistributed 
into lipid microdomains containing low density lipoproteins (LDLs), cholesterol and 
glycosphingolipids
40,41, a structure they named detergent resistant microdomains
42. 
Chakrabandhu and coworkers also show that perturbing lipid rafts by cholesterol 
depletion reduces the level of cell death occurring
25. It is hypothesised that clustering 
around  lipid  rafts  favours  the  lateral  interaction  between  Fas  in  the  membrane, 
increasing the efficiency of receptor stimulation
40, with minimal caspase 8 activation 
being observed prior to Fas recruitment into membrane microdomains
38. However, 
the membrane localisation of Fas may not be conserved throughout all cell types. 
Eramo and colleagues have reported that in Type I cells at a resting state Fas is 
preferentially  found  in  lipid  raft  locations,  whereas  in  Type  II  cells  Fas  is  only 
trafficked into lipid rafts upon receptor stimulation
43.  










































































































































































































































































































































































































































































































   42 
The membrane location of Fas may therefore play a role in the differing of the speed 
in the onset of apoptosis that is observed within different cell line types. It is unclear 
how Fas is repositioned into lipid rafts, but it has been suggested that this process is 
mediated by lipidation. This is discussed in more detail below.  
Clathrin mediated internalisation and DISC recruitment into an endosome is thought 
to enable maximum adaptor protein interaction and caspase activation. For efficient 
clathrin mediated internalisation, an interaction between the DISC and the endocytic 
machinery must be required. Lee and colleagues suggest an interaction between AP2 
(crucial  scaffold  protein  for  membrane  distortion)  and  the  Fas-DD  and 
Chakrabandhu and colleagues report that an extracellular glycophospholipid motif 
could  play  a  role  in  the  clustering  of  the  Fas  receptor  and  clathrin  mediated 
internalisation,  commenting  that  compartmentalisation  and  internalisation  is  a 
method  to  regulate  cell  surface  signals
44.  It  has  also  been  reported  that  the 
association of the actin cytoskeleton is critical to DISC activation and progression
45. 
With Kulms suggesting that the distribution of the cytoskeleton is mediated by Fas 
activation, showing clustering between Fas and actin, which may also be linked to 
the onset of internalisation of the receptor
46. The relationship between Fas and the 
actin cytoskeleton will be discussed further below. 
 
1.5 Post translational modifications of Fas tune the strength and nature of the 
response 
It is thought that the degree of oligomerisation and the occurrence or absence of 
certain  post  translational  modifications  play  an  important  role  in  directing  the 
recruitment  of  components,  internalisation,  activation  and  resulting  signalling 
pathways  of  the  DISC
38.  A  number  of  post  translational  modifications  in  the 
cytoplasmic region of Fas have been studied; their location and the organisation of 
the intracellular region of Fas is illustrated in Figure 1.6. 
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Figure 1.6 Cartoon representation of the Fas death domain and the locations of the reported 
post translational modifications 
Cartoon representation based upon the Fas structure published by Haung et al (1996), PDB accession code, 
1DDF. The site of phosphorylation and nitrosylation, Tyr291 is highlighted in blue. The site of palmitoylation 
Cys199  is  highlighted  in  yellow  The  site  of  glutathionylation,  Cys304    is  highlighted  in  red.  Schematic 
representation of the protein is not to scale. 
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1.5.1 Fas palmitoylation is required for the onset of cell death 
Fas is S-palmitoylated on the membrane proximal cysteine 199
25. S-palmitoylation is 
the reversible addition of the saturated sixteen carbon palmitate moiety to a cysteine 
residue through a thioester linkage. Palmitoylation is carried out in vivo by a class of 
enzymes  known  as  protein  acyl  transferases  (PAT)  and  removed  by  protein 
palmitoyl  thioesterases.  The  addition  of  a  hydrophobic  lipid  group  is  most 
commonly  associated  with  the  trafficking  of  soluble  proteins  to  membranous 
locations around the cell. The effect of palmitoylation in already membrane bound 
proteins  such  as  Fas  is  less  intuitive,  but  it  is  thought  to  be  able  to  alter  the 
conformation  of  the  transmembrane  domain  creating  a  tilt
47  that  might  expose 
otherwise inaccessible residues, encourage recruitment to lipid rafts
38 and influence 
protein:protein interactions
48, effects such as these might influence DISC formation. 
Due  to  the  difficulties  associated  with  studying  a  lipidated  protein  in  solution, 
palmitoylation  is  one  of  the  least  well  characterised  protein  post-translational 
modifications. 
Palmitoylation on Cys 199 is thought to redistribute and partition Fas into lipid raft 
regions of the cell membrane prior to receptor internalisation, and to influence the 
events that lead to DISC internalisation. The first detectable event following Fas 
ligation is the formation of CD95
hi. Upon palmitoylation Fas is reported to aggregate 
more efficiently with increased oligomer stability enhancing CD95
hi formation. Feig 
and  colleagues  have  shown  that  mutation  of  Cys199  to  Ser  conserves  lipid  raft 
localisation but significantly reduces DISC internalisation and caspase activation
30, 
suggesting that the role of palmitoylation in DISC progression is not restricted to raft 
recruitment. It has also been proposed that the redistribution of Fas into lipid rafts is 
a prerequisite for Fas internalisation by orientating the receptor to engage with the 
actin cytoskeleton via the membrane cytoskeletal protein ezrin
25.  
Cysteine 199 was identified as the palmitoylation site in the Fas intracellular region 
through mutational studies and investigating the effect of the C199S mutation on the 
onset  of  apoptosis
30.  This  cysteine  is  located  within  the  membrane  proximal 
/juxtamembrane region of Fas, eight amino acids from the transmembrane domain 
(Figure 1.7).  













Figure 1.7 Sequence comparison of the membrane proximal regions of death receptors 
Sequence comparison of the membrane proximal region of Fas (UniProt:P25445), TNFR1 (UniProt:P19438), 
DR4 (UniProt: O00220) and DR5 (UniProt:O14763). The transmembrane and juxtamembrane regions of the 
proteins are represented above the sequences. Cysteine residues highlighted in orange have been shown to be 
palmitoylated, putative palmitoylation sites are highlighted in green and basic residues in purple. The sequence 
comparison is adapted from the sequence comparison carried out by Rossin et al. (2009). 46 
Cys199 is surrounded by a number of basic residues which is a common feature of 
palmitoylation sites, as this environment greatly reduces the pKa of the cysteine
49. 
Rossin and collaborators showed that the five lysines located around C199 (K191, 
193, 197, 201 and 204) are also required for Fas localisation into lipid rafts. By 
creating a mutant Fas in which these lysines were changed into asparagines, they 
showed that the mutant does undergo palmitoylation but does not get recruited to 
lipid rafts and perhaps as a consequence, is unable to signal cell death, but actives 
other non-apoptotic pathways through ERK and AKT pathways instead
25,50.  
Fas  is  not  the  only  member  of  the  DDsf  that  has  been  shown  to  require 
palmitoylation to function, the death receptor DR4 is also palmitoylated on either 
transmembrane  or  membrane  proximal  cysteines
51.  DR4  is  activated  by  TRAIL 
(TNF-related inducing ligand) and like the Fas DISC, the DR4 DISC is thought to 
progress through a series of activation steps involving oligomerisation and lipid raft 
recruitment,  and  results  in  cell  death.  Rossin  and  colleagues  identified  that 
palmitoylation of DR4 was required for the receptors lipid raft location and its ability 
to oligomerise upon activation
51. However, the same authors demonstrated that DR5 
and TNFR are not palmitoylated during activation, suggesting that palmitoylation is 
not a general feature of death receptors
51.  
The palmitoylation of the membrane bound form of the Fas ligand (FasL) also seems 
to  be  essential  for  efficient  ligand  processing  and  the  onset  of  cell  death. 
Palmitoylation on Cys82 targets FasL to lipid rafts where it undergoes processing to 
become active. It is reported that palmitoylation of FasL is required upstream of Fas 
receptor  binding,  as  ligand:receptor  interactions  are  abnormal  when  FasL 
palmitoylation is limited
52. The requirement for tight regulation of FasL due to its 
cytotoxic role is therefore perhaps palmitoylation dependent, illustrating another role 
of palmitoylation within Fas-mediated apoptosis. 
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1.5.2  Fas  tyrosine  phosphorylation  is  involved  in  both  apoptosis  and  cell 
proliferation  
The Fas death domain is reported to be phosphorylated upon tyrosine 291. Although 
this post translational modification of Fas has been reported in a number of cell types 
and a number of different situations, with variable downstream effects
53. Upon pro-
apoptotic  stimuli,  phosphorylation  of  Tyr291  has  been  observed  to  result  in  an 
increase in Fas oligomerisation and a faster onset of apoptotic pathways
54,55. It is 
unclear which tyrosine kinases are involved in Fas phosphorylation, but p56Lck
56 is 
recruited to the membrane upon Fas activation and 59fynT
57 has been found to be 
physically associated with Fas. The epidermal growth factor receptor (EGFR) might 
also be able to phosphorylate Fas. Treatment with FasL in hepatocytes, leads to Fas 
association with the EGFR, phosphorylation
58 and DISC formation. The authors also 
showed that only the double mutation Y232/291F supresses Fas apoptotic signalling, 
suggesting that Y232 might become phosphorylated as well. 
Tyrosine 291 is located in the residue formation EAYDTL, which resembles the 
immunoreceptor tyrosine inhibitory (ITIM) motif S/I/V/LxYxxI/V/L (where x can be 
any amino acid), a known SH2 (src-homology 2) domain target binding site. The 
presence  of  the  YxxL  motif  suggests  that  phosphorylated  Fas  can  recruit  SH2 
domain  containing  proteins,  expanding  the  signalling  capabilities  of  the  death 
domain
54. SH2 domain containing phosphatases, SHP1 and SHP2 can be recruited to 
the Fas death domains, after Tyr291 phosphorylation. Gradl and colleagues describe 
the YxxL motif present in death domains as a ‘functionally active tyrosine-based 
inhibition  motif’  as  their  results  link  the  association  of  SHP1/2  with  Fas  as  a 
mechanism  to  disrupt  anti-apoptotic  pathways  and  cell  survival  in  neutrophils, 
linking  Fas  phosphorylation  to  cell  death  pathways
59.  This  mechanism  is  still  a 
matter  of  debate,  because  other  authors  have  shown  that  in  B  cells  SHP1  is 
associated  with  Fas,  but  that  upon  Fas  activation,  it  down  modulates  Fas-
internalisation and thus cell death by dephosophorylating Vav, a protein involved in 
the regulation of  cytoskeleton rearrangements
45. Other phosphatases without SH2 
domains have also been implicated in apoptosis tuning by Fas dephosphorylation, 
notably Fas associated phosphatase (FAP-1) 
60,61. 48 
In other contexts, tyrosine phosphorylation of Fas can result in the onset of non-
apoptotic  effects  involving  the  SH2  domain  containing  protein  PI3K 
(phosphoinositide 3 kinase). The molecular link between Fas and the activation of 
PI3K was seen in the context of glioblatome multiforme
62, the most common form of 
malignant primary brain tumour. Kleber and collaborators reported that upon Fas 
stimulation by FasL a PI3K-Activation-Complex (PAC) is formed, containing the 
PI3K regulatory subunit p85 and the Src family kinase Yes. The authors showed that 
by knocking down Yes kinase and inhibiting PI3K they could block phosphorylation 
of  AKT/PKB,  inactivating  glycogen  synthase  kinase  3β  (GSK3  β)  resulting  in 
migration and cellular proliferation. The authors also showed that formation of the 
PAC inhibited DISC formation and apoptosis, speculating that the PAC outcompetes 
FADD and procaspase 8 in binding to Fas. Therefore the stoichiometry of the PAC 
may have an impact on cell fate
63,64,65. The activation of PI3K upon Fas stimulation 
and other non-apoptotic signalling pathways are illustrated in Figure 1.8.  
Ser/Thr  phosphatase  inhibitors  have  been  shown  to  block  Fas  receptor 
oligomerisation and caspase 8 activation, suggesting that Fas also undergoes Ser/Thr 
phosphorylation
66. The signalling cascade involved in this event is not known, but 
the  inhibitors  increase  the  level  of  ERK  activity,  a  pathway  that  is  believed  to 
promote cell survival
67. 
These  results  show  that  Fas  phosphorylation  and  dephosphorylation  are  crucial 
mechanisms in the modulation of Fas signalling both in cell death, cell survival and 
proliferation cascades. However it is possible that the precise nature of the response 
depends on cell type and activation status as well as the type and intensity of Fas 
stimulation. 
1.5.3 Other post translational modifications modulate Fas activity  
Glutathionylation refers to the reversible addition of the glutathione tripeptide to a 
cysteine side chain thiol, enabling the formation of a disulphide bond. Anathy and 
coworkers have reported that Fas ligation is able to trigger S-glutathionylation at 
C295  in  mouse  Fas
68,  a  position  equivalent  to  human  C304,  and  that  S-
glutathionylated Fas enhances DISC assembly.  










































































































































































































































































































































































































































































In a subsequent paper, they provided evidence that glutathionylation of Fas occurs in 
the ER upon FasL stimulation, and that it functions as a switch to target reservoir 
pools of Fas located in the ER to the membrane and thus control the extent of the 
apoptotic response
68. 
S-nitrosylation refers to the reversible addition of a nitroso group to a cysteine side 
chain thiol, forming a nitrosothiol (R–S–N=O). Leon-Bollotte and collaborators have 
reported that when colon and mammary cancer cell lines are treated with NO donors, 
Fas  undergoes  S-nitrosylation  on  both  cysteines  199  and  304.  However,  only 
nitrosylation  at  C304,  promotes  recruitment  to  lipid  rafts  and  DISC  assembly
69. 
Whether this effect has a biological implication remains to be studied; however, it is 
known that some protein:protein interactions are NO dependent. For example, Talbot 
and collaborators reported that S-nitrosylation of cFLIP is necessary for recruitment 
of RIP1K and the activation of NFkB 
70.   
 
1.6 Fas activation can also trigger non-apoptotic signalling cascades  
Under  certain  circumstances  the  formation  of  the  DISC  does  not  lead  to  its 
internalisation and instead triggers non-apoptotic signals from the  cell membrane 
that result in cell survival, proliferation, migration and inflammation. Some of the 
alternative  signalling  pathways  have  been  elucidated  through  the  study  of  Fas 
signalling  in  cancer  cell  lines,  which  are  known  to  be  able  to  avert  Fas-induced 
apoptosis.  Therefore,  it  is  not  possible  to  generalise  on  the  prevalence  of  these 
pathways or their relevance in healthy cell functions. Nevertheless, their study is 
providing valuable information on possible alternative targets for cancer therapy
71.  
As described previously, in glioblastoma cells the phosphorylation of the Fas death 
domain on tyrosine 291 results in AKT activation, suppression of apoptosis, and 
increased cell mobility and migration
62. In other systems Fas activation results in the 
recruitment of other adaptor proteins triggering different signalling effects. Starved 
fibroblasts  and  CD3-activated  T  cells  respond  to  FasL  by  activating  NFκB  via 
mitogen-activated protein kinases ERK and/or JNK. NFκB activation was found to 
induce  the  expression  of  cytokines  able  to  promote  proliferation,  migration  and 
inflammation
72,73,74.  Other  cell  lines  and  a  variety  of  primary  tumour  cells  have 51 
recently been shown to activate transcription factor AP-1 via JNK kinase, resulting 
in  cell  growth
75,76.  However,  in  regulatory  dendritic  cells,  pERK  production 
following  Fas  activation  via  T  cells  led  to  the  production  of  immunosuppresive 
agents
77.  Accordingly,  activation  of  MAPK  kinases  cannot  be  directly  associated 
with cell proliferation pathways. 
A  number  of  studies  have  shown  that  the  stoichiometry  of  the  adaptor  proteins 
recruited to the DISC can affect cellular fate, for example, an increased level of c-
FLIP or decreased levels of caspase 8 and FADD at the DISC prevent apoptosis and 
promotes  proliferation
78,79.  The  fact  that  c-FLIP  is  involved  in  proliferative 
signalling  pathways  has  been  considered  following  evidence  that  in  Jurkat  cells 
cFLIP appears to inhibit NF-κB activity
73 with activation occurring in a procaspase 8 
and FADD dependent manner
80. However, both pathways of NF-kB activation rely 
on the recruitment and activation of RIP1K via its DD domain. Therefore, it seems 
plausible  that  RIP1K  can  be  recruited  by  both  cFLIP  and  procaspase  8  and  that 
additional signals and/or the stoichiometry of the DISC influence the outcome. For 
example,  it  has  recently  been  proposed  that  RIP1K  recruitment  by  cFLIP  is 
dependent  on  cFLIP  nitrosylation
70.  In  TNFR  signalling  RIP1K  activity  is  also 
controlled by ubiquitination
81, a factor which has yet to be explored in the case of 
Fas.  
The examples described above illustrate that the Fas death receptor is able to initiate 
cellular  signalling  through  a  number  of  different  apoptotic  and  non-apoptotic 
signalling  pathways.  Evidence  has  been  presented  that  both  pathways  may  be 
occurring at the same time involving cross-talk between formations of the DISC
33. 
For example, in Jurkat cells the NF-kB and the PI3K pathways are both active at the 
same time, and both cFLIP and Akt can inhibit NF-κB activity
82. Also Fas activation 
of NF-kB is a self-perpetuating signalling pathway, with NF-kB directly regulating 
the transcription of Fas in a positive feedback loop
83. A summary of these alternative 
DISC signalling pathways is shown in Figure 1.8. Most probably, the components 
and stoichiometry, local concentration, level of oligomerisation, the degree of the 
activation, the signalling of other death receptors and the spatiotemporal location of 
the  DISC  influence  one  another  to  define  the  final  outcome  of  the  signalling 
events
38,84.  What  is  clear  is  that,  in  light  of  the  pleiotropic  signals  that  Fas  can 52 
initiate, the label of “death receptor” is not as explicit to its function as originally 
thought. 
 
1.7  Germline  and  somatic  mutations  in  Fas  cause  deregulation  of  cell 
homeostasis 
1.7.1  Mutations  in  Fas  are  the  most  common  cause  of  autoimmune 
lymphoproliferative syndrome 
Autoimmune  lymphoproliferative  syndrome  (ALPs)  is  caused  by  detrimental 
mutations in apoptotic genes leading to the dysregulation of Fas-mediated apoptosis, 
which  results  in  an  unbalance  in  immune  cell  homeostasis
85.  Patients  present  a 
proliferation of polyclonal T lymphocytes that respond poorly to antigens and fail to 
produce cytokines upon activation, they also present increased levels of the anti-
inflammatory  cytokine  IL-10  and  g-interferon.  The  accumulation  of  excess 
leukocytes causes enlargement of the liver, the spleen (hepatosplenomegaly) and the 
lymph nodes (lymphadenopathy) as well as autoimmune disorders such as anaemia 
and  decreased  platelets  (thrombocytopenia)
85,86.  Patients  with  ALPs  also  have  a 
greater risk of developing lymphoma and other types of cancer. In order to control 
the symptoms, patients are generally treated with immunosuppresive drugs such as 
glucocorticoids, and blood transfusions with the use of intravenous globulin in cases 
of severe  anaemia. The antimalarial drug ‘Fasidar’ has been tested  as  a possible 
alternative  treatment.  The  authors  reported  reduction  in  the  levels  of  the 
inflammation cytokine IL-10 and induction of apoptosis via the intrinsic pathway
85. 
ALPs is classified according to the genotype of the defective protein involved in 
apoptosis signalling. Type 0 ALPS is defined by homozygous mutations in the Fas 
gene; it causes high levels of lymphoproliferation and spontaneous apoptosis and it 
is only treatable with a complete bone marrow transplant. Type I ALPS is divided 
into  two  subtypes,  Type  Ia  and  Ib,  depending  on  whether  the  heterozygous 
detrimental mutation is located in Fas or FasL. The mutations found in these patients 
are generally point mutations and small deletions. Abnormal Fas or FasL proteins act 
in a dominant negative manner, forming trimeric receptors that are a combination of 
wild  type  and  mutant  proteins,  resulting  in  reduced  binding  and/or  reduced 53 
recruitment or activation of caspase 8
87,88. Type Ia ALPS is the predominant form of 
ALPS.  Type  II  ALPS  is  characterised  by  heterozygous  mutations  in  the  initiator 
caspases 8 or 10, therefore both Fas expression and signalling are normal. Mutations 
in caspase 10 that impair the auto processing and activation are most common. In 
these patients DISC formation is normal but the initiation of apoptosis is prevented. 
Mutations  in  caspase  8  are  more  severe,  because  they  also  cause  defects  in  the 
activation of T cells, B cells and natural killer cells. Type II ALPS results in a more 
severe  autoimmune  outcome  than  the  other  forms  of  the  disease.  ALPS  is 
categorised as type  III,  when the ALPS symptoms are present, but no molecular 
defects can be found in Fas, FasL, caspases 8 or caspase 10
85,86. 
The study and characterisation of ALPS has been greatly aided by the existence of 
the natural MRL lpr mouse mutant strain. The MRL lpr mouse mutant strain was 
initially used as a model for human lupus however as the mice age they develop 
CD4
- CD8
- T cells resulting in a phenotype similar ALPS. The use of this mouse 
model and the underlying disease mutations in ALPS have  greatly increased our 
knowledge of the protein:protein interactions that occur at the Fas DISC, identifying 
the point mutations that can abrogate binding
86. For example ALPS point mutations 
identified in both systems revealed the location of FADD binding on helix 3 of the 
Fas death domain
6.  
1.7.2 Mutations in Fas have been associated with cancer 
As  inferred  from  the  non-apoptotic  and  proliferative  effects  of  Fas  stimulation 
described above, Fas stimulation has been associated with a number of cancers
42,89,75. 
A study suggested that people with germ line mutations in the FAS gene, even if they 
do  not  develop  ALPs,  have  a  higher  risk  of  developing  B-cell  and  T-cell 
lymphomas
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1.8 Ezrin is crucial for Fas internalisation and transmission of the apoptotic 
signal 
The endosome machinery  plays a very important role in Fas-mediated apoptosis. 
Current  understanding  of  the  mechanism  of  Fas  activation  suggests  that 
internalisation only takes place in the apoptotic route and not when the activation of 
Fas leads to the non-apoptotic outcomes. Of special interest is the interaction of Fas 
with  the  cytoskeletal  elements  that  are  responsible  for  attachment  to  the  plasma 
membrane. In many cell types, these elements are the members of the ERM family 
(named after the first three proteins in the family: ezrin, radixin and moesin), which 
act as a bridge between proteins in the membrane and actin. In the case of Fas, a 
number of reports implicate ezrin specifically as the crucial link between Fas and the 
actin cytoskeleton.  
1.8.1 Extracellular and intracellular signals regulate the attachment of actin to the 
proteins in the cell membrane through the ERM proteins 
Proteins belonging to the ERM family (ERMs) have been associated with a number 
of processes at the cell membrane, such as cell adhesion, cell motility, cell shape and 
the progression of endocytosis and exocytosis as well as specific protein localisation, 
membrane  transport  and  signal  transduction
92.  ERMs  are  structurally  and 
functionally  related  showing  a  high  level  of  sequence  and  structural  similarity 
(illustrated in Figure 1.9), which is most probably the result of a gene duplication in 
the last common ancestor of all vertebrates. The great similarities within this protein 
family make the functions of ERMs both similar and redundant
93, making cell based 
studies of this family challenging, as the knockout of one protein is compensated for 
by one of the others. However, in an organism, only moesin seems redundant
93, this 
is probably a result of non-overlapping tissue distributions for radixin and ezrin. The 
absence of radixin results in liver damage
94 and the absence of ezrin is incompatible 
with life
95. ERM proteins have also been shown to be structurally and functionally 
related  to  the  tumour  suppressor  protein  Merlin,  which  shows  essential  but  non 
overlapping functions to the other ERMs
92. 











































































































































































































































































































































































































































Figure 1.10 Structural alignment of the FERM domains of ezrin radixin and moesin 
Ezrin shown in green (PDB:1NI2); radixin shown in blue (PDB:1GC7); moesin shown in orange (PDB:1E5W). 
Structures aligned within Pymol. 
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ERMs have three functional domains: an N terminal globular FERM (four point one, 
ezrin, radixin, moesin) domain, a central coiled-coil region and a C terminal tail
96,97. 
ERMs are negatively regulated by intramolecular interactions between the N and C 
termini of the molecule. In the resting state, ERMs adopt a compact closed structure 
in which 90 residues from the C-terminus bind to the N-terminal FERM domain, 
thereby masking both the F actin-binding site, formed by the most C-terminal 34 
residues, and the different protein interaction sites in the FERM domain
92,98. This 
interaction between the N-ERMAD (ezrin, radixin, moesin association domain) and 
the C-ERMAD also enables homo- and heterodimerisation of ERMs forming large 
intracellular  complexes
99.  Inactive  ERMs  are  predominantly  found  in  the  cell 
cytosol. 
To enable activation and membrane protein association, the ERMs need to undergo 
post translational modifications as well as a large structural reorganisation, adopting 
an extended conformation. Phosphorylation of threonine 567, which is present in the 
C-ERMAD, by either ROCK, PKCα or PKCθ reduces the affinity between the N- 
and  C-ERMADs  and  allows  the  ERMs  to  open
98.  Besides  phosphorylation,  an 
interaction of the FERM domain with phospholipids is necessary for the activation 
of the ERMs
100. In particular, phosphatidylinositol 4,5-bisphosphate (PIP2) binding 
to the ezrin FERM domain has been reported to be necessary for an interaction to 
occur in vitro
101.  
The crystal structures of the FERM domains of ezrin, moesin and radaxin have been 
solved both in isolation
96,102,103 and in association with known binding partners. Of 
particular interest to elucidate their mechanisms of activation, structures have been 
solved of radixin in complex with the PIP2 mimic, IP3
104, moesin FERM domain in 
complex  with  the  C-terminal  tail
98  and  moesin  with  a  portion  of  the  coiled  coil 
region directly C terminal to the FERM domain
103. These structures have provided 
valuable information about the possible modes of interaction and the effects that 
these interactions have on the molecule. The FERM domain is formed of three lobes 
(named F1-F3) orientated in a clover shape, each with distinct structural homology 
to other known protein folds. Lobe F1 contains a structure similar to ubiquitin, lobe 
F2  shows  similarity  to  acyl  CoA-binding  protein  whereas  lobe  F3  contains  a 
pleckstrin homology (PH) domain like that found in protein kinase B
98. The variety 
of folds in the FERM domain enables a number of different modes of binding to 58 
occur. The structures of the free FERM domains of ezrin radixin and moesin are 
shown in Figure 1.10. The structure of the radixin FERM domain in complex with 
IP3  showed  no  difference  in  structure  between  the  free  and  bound  forms.  In  the 
crystal, IP3 was bound inside a basic groove between F1 and F3
104. However, this 
location  was  different  to  the  PIP2  binding  site  that  has  been  mapped  using  site 
directed mutagenesis
101, so the mechanism by which lipids mediate ERM protein 
activation is still unclear. The presence of the C-ERMAD in complex with moesin
98 
showed that there are great changes in the F3 lobe, with the C terminal β-strand 
moving by about 6 angstroms. This F3 region was the location where IP3 was found 
bound  in  the  radixin  FERM
104,  so  perhaps  the  change  in  conformation  of  F3  is 
indeed involved in the transition from the inactive to the active state. 
Two  modes  of  interaction  with  membrane  proteins  have  been  observed  for  the 
ERMs, either through direct ERM:membrane protein interactions, or through indirect 
association of the ERM protein and the membrane protein, mediated via a scaffold 
protein
92.  Direct  ERM:membrane  protein  interactions  have  predominantly  been 
described with adhesion receptors, such as the positively charged juxtamembrane 
region  of  the  hyaluronate  receptor  –  CD44  and  the  Ig  like  domains  of  ICAM2 
(intracellular adhesion molecule 2). These interactions are discussed in more detail 
below
105,106. Scaffold protein mediated interactions involve the NHERF1 (Na
+/H
+ 
exchange  regulatory  factor  1  also  called  EBP50)  and  NHERF2  (also  called 
E3KARP)  proteins  as  the  link  between  the  ERMs  and  the  cytoplasmic  tail  of  a 
membrane protein. NHERF1 and NHERF2 fold into two PDZ domains and a thirty 
amino acid C terminal region which is recognised by the ERMs
107,92. Proteins that 
are known to be bound to ERMs in this fashion are the β2-adrenergic receptor
108 and 
podocalyxin,  a  sialoglycoprotein  important  for  maintaining  the  structural 
organization and blood plasma filtration in kidney cells
109. Figure 1.11 illustrates the 
activation and two binding mechanisms of ERM proteins at the cell membrane. 





Figure 1.11 Activation and interaction of ERM proteins 
ERM proteins exist in an inactive closed conformation in the cytosol. Upon activation by phosphorylation and 
interactions with PIP2 they are recruited to the plasma membrane to enable either A, scaffold protein mediated 
interactions with membrane proteins or B, direct membrane protein interactions. Adapted from Bretscher et al 





Figure 1.12 Structural representations of known radixin FERM domain:ligand interactions 
Crystal  structure of  the  Radixin  FERM domain  (grey)  crystallised  with peptides  from  four  different  protein 
binding  partners.  A,  ICAM-2  peptide  in  yellow  (PDB:1J19);  B,  CD44  peptide  in  orange  (PDB:2ZPY);  C, 
NHERF  peptide  in  blue  (PBD:1SGH);  D,  NHERF1  peptide  in  red  (PDB:2D10).  Abbreviations,  ICAM-2  – 
intracellular adhesion protein 2,  NHERF1 – Na
+/H
+ exchanger regulatory factor.  
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1.8.2 ERMs bind their targets using a variety of binding modes 
Some of the interactions between ERMs and their targets and scaffold proteins have 
been extensively characterised. Structures have been solved showing the mode of 
interaction of moesin FERM with NHERF1, radixin FERM with both NHERF1 and 
NHERF2 as well as with the target proteins adhesion molecule PSGL-1, adhesion 
molecule CD43, neutral endopeptidase 24.11, the ICAM2 cytoplasmic peptide, and a 
CD44 cytoplasmic peptide
110–112. Despite the fact that these structures  have been 
solved  with  radixin,  the  sequence  conservation  among  the  ERMs  is  so  high  that 
similar  modes  of  interaction  are  expected  for  all  of  the  ERMs.  Some  of  these 
structures are shown in Figure 1.12. The binding region recognised by the FERM 
domain is usually a short, basic twenty to thirty amino acid stretch with little regular 
secondary structure. In Chapter Five of this study some of these well-characterised 
ERM interactions have been used as positive controls for ezrin binding and as a 
model for the interaction between Fas and ezrin. 
1.8.3 The interaction of Fas with ezrin is necessary for DISC internalisation and 
apoptosis onset 
The  first  report  linking  the  ERMs  to  Fas-mediated  apoptosis  observed  that  FasL 
stimulation  in  fibroblasts  resulted  in  the  translocation  of  ezrin  from  the  plasma 
membrane to the cytoplasm, and that absence of ezrin from the plasma membrane 
was concomitant with the breakdown of the cell microvilli
113. It was later observed 
that ezrin knockdown protected cells from undergoing apoptosis and that Fas and 
ezrin  co-immunoprecipitated  in  CD4
+  T-cells  lysates
114,  suggesting  that  the 
interaction of ezrin with Fas was key to the onset of apoptosis. Hèbert and coworkers 
further built upon this work, showing that in Jurkat and peripheral blood T cells not 
only ezrin, but also moesin is involved and necessary for Fas-mediated apoptosis. 
The  authors  also  observed  that  upon  Fas  stimulation  both  ezrin  and  moesin  are 
phosphorylated  by  Rho  activated  ROCK1,  and  that  inhibition  of  either  Rho  or 
ROCK1 was sufficient to stop the formation of Fas aggregates
115. In contrast, Parlato 
and colleagues did not find moesin in association with Fas in lymphoblastoid CD4+ 
T  cells  and  day  6  activated  lymphocytes
114.  Both  Hebert  and  collaborators  and 
Parlato  and  colleagues  found  that  the  association  between  Fas  and  ezrin  was 
constitutive,  as  it  was  observed  without  any  stimulation.  However,  Hebert  and 62 
coworkers  found  that  immediately  after  Fas  activation,  there  is  a  transient 
dephosphorylation of ezrin and moesin, presumably to allow membrane remodelling. 
Rho-ROCK1 ezrin phosphorylation at the onset of Fas-mediated apoptosis was also 
observed by Rebillard and collaborators in colon cancer cells treated with cisplatin
41. 
Kuo and colleagues  also observed that in T cells, Fas and ezrin association was 
constitutive
116. However, in their system ezrin deficiency facilitated DISC formation 
and increased the level of apoptosis in Type I cells, having no detrimental effect on 
the endocytosis of the DISC. This illustrates that there is not a consensus on the role 
of the interaction between Fas and ezrin during apoptosis. These discrepancies could 
be due to experiments being done in a variety of cell types and with different types 
of stimulating reagents, for example, FasL vs activating Fas antibodies. 
Lozupone and colleagues mapped the Fas binding site on ezrin to the central lobe of 
the ezrin FERM domain at residues 149-168
117 (Figure 1.13). They arrived to this 
conclusion  through  performing  GST  pull  down  assays,  in  which  short  ezrin 
fragments were immobilised upon GST beads to pull down the whole cytoplasmic 
domain of recombinant E. coli expressed Fas and full length Fas from Jurkat cell 
lysates, respectively. To verify their results, the authors made a chimeric ezrin in 
which  the  region  149-168  was  replaced  with  that  of  moesin  and  transiently  co-
transfected into HeLa and Hut78 cells containing both wild type and chimeric ezrin. 
Upon Fas activation, cells with chimeric ezrin, but not those with wild type ezrin, 
showed protection against apoptosis. Fas could also be co-immunoprecipitated with 
GST-tagged  wild  type  ezrin  but  not  GST-tagged  chimeric  ezrin  from  Hut78 
lysates
117. Given that Hèbert and colleagues did observe Fas binding to moesin, the 
fact that the moesin peptide 149-168 cannot interact with Fas suggests that there is 
more than one mode of interaction taking place.  
Subsequently, Ruan and coworkers performed the reciprocal experiment to locate the 
region  of  Fas  that  was  being  recognised  by  ezrin.  Their  experimental  design 
consisted  of  making  GST-tagged  constructs  comprising  different  regions  of  the 
intracellular portion of Fas and using them as prey in pull-down assays with COS-7 
cell lysates as bait. They could pull down ezrin with all Fas constructs except those 
lacking  residues  191-204  in  the  juxtamembrane  region,  a  region  they  called  the 
membrane proximal domain





Figure 1.13 Schematic diagrams of the reported Fas and ezrin interaction sites 
A, FERM domain of ezrin (PDB:1NI2) shown in green, with the reported Fas binding site, residues 149-168 
highlighted  in  blue.  B,  schematic  representation  of  the  Fas  protein  highlighting  the  different  domains.  The 
reported  ezrin  binding  site,  the  membrane  proximal  domains  (MPD),  is  highlighted  in  green.
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Ruan and colleagues went on to transfect a version of Fas lacking the MPD and 
found that this construct was unable to activate the apoptotic and non-apoptotic Fas 
signalling pathways. Others have pointed out that the region they deleted contains 
the palmitoylation site C199 and the lysine-rich region that have been shown to be 
necessary for lipid raft targeting and activity
50,25. Nevertheless, binding of ezrin to 
the positively charged juxtamembrane region of Fas would be in agreement with the 
mode of binding observed in other ezrin targets
100,119. 
The interaction of Fas  with other molecules has also been  reported to  affect the 
association of Fas with ezrin. The disialoganglioside GD3 is reported to colocalise 
with  ezrin,  and  has  been  suggested  to  play  an  early  role  in  Fas  oligomerisation, 
possibly  mediating  DISC  progression
120.  Moreover,  the  phosphorylation  of  the 
guanine exchange factor (GEF) vav1 has been hypothesised to act as a fine tuning 




1.9 Aims, objectives and scope of this study 
Fas  receptor  stimulation  activates  the  Fas  death  domain  (Fas-DD),  resulting  in 
receptor clustering, and recruitment of adaptor proteins and formation of the DISC. 
The DISC is assembled through homotypic interactions between members of the 
death  domain  superfamily,  DD:DD  interactions  between  Fas  and  FADD  and 
DED:DED interactions between FADD and procaspase 8
38. This oligomerisation is 
crucial for the onset of both apoptotic or non-apoptotic cell signalling pathways
71, as 
it enables autoproteolytic activation of procaspase 8 and initiation of the caspase 
cascade.  The  Fas-DD  is  at  the  heart  of  these  interactions,  being  the  activating 
molecule and the nucleation point for FADD, procaspase 8 and also other proteins 
with death domains. The 3D structure of the Fas-DD was solved in 1996 by nuclear 
magnetic resonance
6. It was the first 3D structure of a member of the death domain 
superfamily. Ever since, much work has been carried out to characterise the modes 
of interaction of the Fas-DD and the molecular mechanisms of DISC formation
121–
124. Throughout these structural studies of the Fas-DD and of other DDs a debate has 
arisen  regarding  the  structural  plasticity  of  this  fold.  The  original  NMR  solution 
structure of the Fas DD depicts the canonical DD fold composed of six antiparallel 65 
alpha helices in a bundle arrangement. Years later, a crystal structure of the Fas and 
FADD death domain complex was published showing the Fas-DD in a different, 
more  open  conformation
121.  In  this  new  arrangement,  helices  5  and  6  merged 
creating a long stem helix formation with an extra a-helix at the C-terminus. A 
number  of  studies  have  since  disproved  that  this  arrangement  is  biologically 
relevant
122–124. However, it does indicate that the Fas-DD has the potential to exist in 
a different conformation to the canonical death domain fold.  
Different  lines  of  evidence  suggest  that  structural  plasticity  is  a  feature  of  death 
domains.  For  example,  it  is  clear  that  Tyr291  in  the  DD  of  Fas  can  become 
phosphorylated, but in the canonical structure this residue is not solvent accessible. 
The question arises as to how a kinase can access Tyr291 and to what extent this 
negatively charged modification can have upon the death domain fold
54. Along the 
same lines, a recent structure of calmodulin with a peptide derived from Fas-DD 
indicates that the opening of the death domain would be necessary for calmodulin 
binding
125. The first results chapter of this thesis reports the use of nuclear magnetic 
resonance techniques to explore the possibility that the Fas-DD exists in different 
conformations. This objective was approached by measuring the dynamic behaviour 
of  the  Fas-DD  at  different  timescales  and  in  destabilising  conditions,  i.e.  in  the 
presence of the buffer used to obtain the crystal structure of the open conformation 
and after the introduction of a phosphomimetic mutation at Tyr291. 
Being  a  transmembrane  receptor,  it  is  not  surprising  that  posttranslational 
modifications in the intracellular region of Fas are important for signalling, but given 
that Fas lacks enzymatic activity, the nature and consequences of these modifications 
are more difficult to explore. The evidence suggesting that the structure of Fas-DD is 
flexible makes it tempting to hypothesise that these modifications are able to alter 
the structure and dynamics of the Fas-DD. To the best of my knowledge, there are no 
previous  studies  exploring  the  molecular  effects  that  any  posttranslational 
modification might have on a death domain structure. Unfortunately, the necessary 
methodology to enable the study of posttranslational modifications using biophysical 
techniques has yet to become standard. Chapters Four and Six of this thesis describe 
my  efforts  to  establish  protocols  to  prepare  tyrosine  phosphorylated  and 
palmitoylated death domains respectively.    66 
Chapter Four documents the development of techniques to prepare phosphorylated 
Fas death domain in vitro using expressed protein ligation technology. Expressed 
protein ligation is a technique that creates a native peptide bond between a fragment 
prepared  using  recombinant  expression  and  a  fragment  obtained  using  peptide 
synthesis. The chemical flexibility of peptide synthesis enables the incorporation of 
modified residues, non-natural amino acids and a variety of molecular probes into 
the synthetic peptide; while the convenience, plasticity  and economy of bacterial 
expression allows for better yields and the generation of much longer proteins than 
by chemical synthesis alone. Established methods of chemical ligation are restricted 
by the need of a cysteine at the C-terminus of the junction
126. However, developing 
molecules with cysteine mimicking properties is a promising development to lift this 
limitation in the near future
127. Part of my objective in Chapter Four was to assess 
the applicability of a novel cysteine mimic for expressed protein ligation. 
Internalisation of the DISC is understood to be the point at which the cell commits to 
apoptosis;  it  is  the  undisputable  event  that  differentiates  apoptotic  from  non-
apoptotic  Fas  signalling  cascades.  It  is  believed  that  this  internalisation  requires 
interactions  between  the  cytoplasmic  region  of  Fas  and  the  cytoskeleton  adaptor 
proteins ezrin and/or moesin, which function as a bridge between transmembrane 
proteins and actin. It is not clear whether the interaction with ezrin is necessary to 
enable or disable DISC internalisation. However, it is clear that ezrin interaction with 
Fas is important in Fas-mediated signalling. Possible sites of interaction in both Fas 
and  ezrin  have  been  mapped  using  deletion  constructs
117,118  but  no  structural  or 
biophysical  confirmation  of  this  interaction  has  been  reported.  Chapter  Five 
describes my efforts to replicate this interaction in vitro and to detect binding using 
nuclear magnetic resonance spectroscopy, analytical ultracentrifugation and biolayer 
interferometry. 
Finally,  Chapter  Six  describes  my  brief  experience  with  in  vitro  protein 
palmitoylation. Palmitoylation of a cysteine thiol is the only acylation modification 
that is reversible, and as such enables dynamic partition of proteins in and out of 
membrane compartments within the cell. Given that Fas is a transmembrane protein, 
the  effects  are  less  straightforward  to  understand,  and  the  behaviour  of  a 
palmitoylated version of Fas would certainly provide valuable and novel information 
regarding  the  effects  on  the  structure  and  dynamics  of  such  a  modification.  In 67 
particular, I was interested in addressing the possibility that upon palmitoylation, Fas 
experiences a change in configuration that allows interaction with ezrin to occur. 
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                                                                      Chapter 2 
 Materials and Methods 
 
 
2.1 General equipment and chemicals 
Chemicals used were purchased from Sigma or Fisher Scientific, unless otherwise 
stated.  Oligonucleotides  were  purchased  from  Integrated  DNA  Technologies  or 
Sigma.  Isotope  labelled  chemicals  were  purchased  from  Cambridge  Isotope 
Laboratories,  Inc.  All  enzymes  for  DNA  manipulation  were  acquired  from  New 
England Biolabs, unless otherwise stated. 
Polymerase chain reactions (PCRs) were carried out in a Mastercycler Gradient S 
thermal  cycler  (Eppendorf).  Plasmid  mini-preparations,  DNA  gel  extractions  and 
PCR purifications were carried out using the Qiagen Qiaprep and Qiaquick kits.  
UV/Visible absorbance was measured using BioMate3 or Nanodrop 2000 UV/Vis 
spectrophotometers (Thermo Scientific).  
Protein concentration was carried out by centrifugal ultrafiltration with a molecular 
weight cut off (MWCO) of either 3 kDa, 5 KDa or 10 KDa (Vivaspin 20, Vivaspin 2 
Sartorious Stedim Biotech GmbH). Unless otherwise stated, centrifugation up to a 
speed of 4500 rpm and a volume of 50 ml was carried out using Universal 320R, for 
larger samples or higher speeds in either a J2-21 or an Avanti J26-XP Beckman 
centrifuge, and JA-10 or JA-20 rotors (Beckman Coulter). All buffers and solutions 
were  prepared  using  deionised  water  from  Arium611VF  Ultrapure  water  system 
(Sartorious Stedim Biotech GmbH). 
 
2.2 Bioinformatics  
Nucleotide  sequences  of  target  proteins  were  obtained  from  the  NCBI  website 
(www.ncbi.nlm.nih.gov), protein and DNA homologues were identified  using the 69 
NCBI BLAST tool. Protein sequences and domain boundary information was found 
at the Uniprot database (www.uniprot.org). DNA and protein sequence alignments 
were  carried  out  using  the  MAFFT  algorithm
128  as  implemented  in  their  server 
(mafft.cbrc.jp/alignment/server/)  and  analysed  with  Jalview
129.  Theoretical 
extinction coefficients were calculated from the primary amino acid sequence of the 
relevant protein using the Protparam tool on the Expasy Bioinformatics Resource 
Portal (web.expasy.org/protparam/), which uses a modified version of the Edelhoch 
method
130, but with the extinction coefficients for Trp and Tyr suggested by Pace 
and collaborators
131. The Expasy translator was used to translate DNA to protein 
sequences.  The  Scripps  Mass  calculator  (protcalc.sourceforge.net/)  was  used  to 
calculate 
15N  averaged  masses  for  mass  spectrometry  analysis.  Peptidemass 
(web.expasy.org/peptide_mass)  on  the  Expasy  server  was  used  to  calculate 
theoretical peptide masses following trypsin digestion. 
 
2.3 General molecular biology techniques 
2.3.1 Expression plasmid construction 
The expression plasmid for Fas death domain and Fas death domain and C terminal 
tail  constructs  were  constructed  by  Dr  Diego  Esposito  prior  to  the  start  of  this 
project. The constructs comprise residues 202-302 and 202-319 of the intracellular 
region  of  Fas  respectively.  The  vector  incorporates  an  N-terminal  hexa-histidine 
sequence  to  allow  for  immobilised  metal  affinity  purification  of  the  expression 
construct. 
pTWIN1 is a commercial vector from New England Biolabs. pET-His_1a was a kind 
gift  from  Dr  Gunter  Stier,  then  at  the  European  Molecular  Biology  Laboratory 
Heidelberg  (babel.ucmp.umu.se/cpep/web_content/Pages/CPEP_09_vectors.html). 
pET-His-Bio was generated in-house from pET-His_1a. pNIC vectors were a kind 
gift  from  Dr  Charles  Allerston  and  Dr  Opher  Gileadi,  at  the  Oxford  site  of  the 
Structural  Genomics  Consortium  (www.addgene.org/Opher_Gileadi/),  pNIC-GB1 
was constructed in-house from pNIC-GST.  
Variations  on  the  Fas  expression  constructs  as  well  as  other  constructs  used 
throughout this project (ezrin, moesin, radixin and others) were generated by PCR 70 
amplification  from  human  neural  cDNA  (DV  Biologics).  This  was  followed  by 
either enzymatic digestion and ligation into the multiple cloning site (MCS) of the 
vector,  or  by  ligation  independent  cloning  (LIC)  as  specified  for  each  construct 
throughout  this  report.  PCR  primers  were  designed  using  the  Oligocalc 
website
132(www.basic.northwestern.edu/biotools/oligocalc.html) to calculate melting 
temperature and likelihood of secondary structure formation, in order to ensure they 
fitted within the following parameters: primer length <50 bp, GC content 40-60% 
and a melting temperature (TM) of ~55 
oC (nearest neighbour score on OligoCalc 
website).  For  cloning  into  pTWIN  the  SapI  and  NdeI  restriction  sites  were 
incorporated into the 5’ and 3’ end of the primers respectively. For cloning into pET-
His_1a  and  pET-His-Bio  vectors  the  NcoI  and  XhoI  restriction  sites  were 
incorporated into the 5’ and 3’ end of the primers. For cloning into pNIC vectors 5’ 
and  3’  LIC  sequences  were  incorporated  into  the  5’  and  3’  end  of  the  primers. 
Vectors used throughout this study are shown in table 2.1 
Table 2.1 Expression vectors used throughout this study 
Vector  Antibiotic 
Resistance 
Marker 





pNIC-GST  Kan  T7  GST (N-terminal)  TEV 
pNIC-GB1  Kan  T7  His6-GB1(N-terminal)  TEV 
pNIC-MBP  Kan  T7  His6-MBP(N-terminal)  TEV 
pNIC-Zb  Kan  T7  His6-Zb(N-terminal)  TEV 
pET-His_1a  Kan  T7  His6(N-terminal)  TEV 
pET-His-Bio  Kan  T7  His6-Avi (N-terminal)  TEV 




2.3.2 Competent cell transformation 
Chemically competent cells were either purchased or prepared using the standard 
Maniatis CaCl2 protocol
133. E. coli competent cells were transformed as follows: 50 
μl of thawed competent cells were incubated on ice for 30 minutes with 1-5 µl of 
purified plasmid. Cells were then subjected to a 30 second heat shock at 42 
oC and 
then kept on ice for 5 minutes. 950 µl of warmed SOC medium was then added and 
cells were incubated in a shaking incubator at 37 
oC for one hour. The culture was 71 
then spread onto an agar plate containing the appropriate antibiotic. For supercoiled 
plasmids, 50-100 µl of culture were plated out, whereas for ligations and plasmids 
which had undergone site directed mutagenesis, the culture was spun down at 5000 
rpm for 1 minute, the supernatant discarded and the whole cell pellet was plated out. 
Plates were incubated at 37 
oC overnight (12-16 hours) to allow colony growth. 
2.3.3 Preparation of E. coli glycerol stocks 
A well isolated colony from a fresh transformation was used to inoculate 10 ml of 
sterile LB medium containing the appropriate antibiotics in a 50 ml centrifuge tube 
(BD Falcon). The culture was grown in a shaking incubator at 37 
oC for 4-6 hours 
until  the  optical  density  at  600  nm  had  reached  0.6,  1  ml  of  culture was  mixed 
vigorously with 400 µl of sterile glycerol (40% w/v) in 1.5 ml cryovials and stored at 
-80 
oC. 
2.3.4 Plasmid DNA preparation 
Plasmid DNA was transformed into E. coli NEB5α strain (New England Biolabs) as 
described in section 2.3.2. A fresh isolated colony was used to inoculate 10 ml of 
sterile LB medium containing the correct antibiotic and incubated at 37 
oC overnight 
in  a  shaking  incubator  at  250  rpm.  Following  overnight  incubation,  cells  were 
harvested by centrifugation at 4500 rpm for ten minutes. Plasmid DNA was prepared 
from  the  cell  pellet  using  the  Qiaprep  miniprep  kit  following  manufacturer’s 
instructions.  The  concentration  was  determined  using  a  Nanodrop  2000  UV-Vis 
spectrophotometer. 
2.3.5 Agarose gel electrophoresis 
Agarose gels were cast at 0.8% or 2% w/v in Tris-acetate-EDTA (TAE) buffer (40 
mM Tris acetate pH ~8.5, 1 mM EDTA) containing 1:10,000 Sybrsafe (molecular 
probes) for DNA visualisation. DNA samples were prepared with the addition of 6X 
gel loading buffer (30% w/v glycerol containing trace amounts of bromophenol blue 
or  xylene  cyanol  FF,  for  DNA  fragments  at  <1  kbp  or  >4  kbp  respectively). 
Appropriate molecular weight markers (100 bp or 1 kbp, NEB) were also prepared in 
this way. Electrophoresis was carried out at 50-100 V in TAE buffer. Gels were 
visualised under UV light. 72 
2.4 Cloning and mutagenesis 
2.4.1 Cloning using restriction enzymes  
2.4.1.1 Insert preparation 
DNA for the proteins of interest was amplified by PCR from cDNA, synthetic genes 
or from an expression plasmid previously cloned in our laboratory. PCR reactions 
were prepared in thin walled PCR tubes on ice using the KOD Hotstart Polymerase 
kit (Novagen). An example of a typical PCR reaction is shown in table 2.2. A typical 
PCR program is shown in table 2.3 
Table 2.2 PCR reaction for insert preparation in 100 µl 
Reagent  Final Concentration  Volume 
Template DNA  20 ng  Up to 1 µl 
KOD Hotstart buffer  1x  10 µl 
dNTP mix  200 µM  10 µl 
MgSO4  1.5 mM  6 µl 
Forward primer  0.5 µM  5 µl of 10 µM stock 
Reverse primer  0.5 µM  5 µl of 10 µM stock 
KOD enzyme  1 U  2 µl 
H2O  N/A  Up to 100 µl 
 
Table 2.3 A typical PCR program for insert preparation 
Step  Time  Temperature (
oC)  Cycles 
Denaturation  2 min  95  1 
Denaturation  30 sec  95   
30  Annealing  30 sec  56 
Extension  30 sec*  72 
Extension  10 min  72  1 
Hold    4  1 
* 1 min per 1kB 
PCR reactions were set up in 100 µl volumes to ensure a large amount of insert was 
amplified. PCR products were analysed in a 2% agarose gel. If the template DNA 
was a vector, it was digested by adding 1 µl of the endonuclease DpnI to the reaction 
and incubated at 37 
oC in a water bath for two hours. PCR products were finally 
purified  using  the  QIAquick  PCR  cleanup  kit  according  to  the  manufacturer’s 
instructions, eluted in 50 µl of deionized H2O. 73 
2.4.1.2 Vector preparation 
Cloning vectors were prepared by the plasmid DNA preparation method described in 
section 2.3.4. To ensure enough plasmid DNA was purified, larger overnight cultures 
(10-20 ml) were separated into 5 ml aliquots and treated as separate preparations up 
to precipitation and pelleting of the proteins and chromosomal DNA. A this point all 
supernatants  were  sequentially  loaded  onto  the  same  spin  column,  in  order  to 
increase the final yield and concentration of the eluted DNA. 
2.4.1.3 DNA digestion and purification by agarose gel electrophoresis 
Both plasmid vector and insert were digested with compatible restriction enzymes at 
37 
oC  for  three  hours.  Digestions  were  set  up  according  to  the  manufacturers 
recommendations including a compatible buffer and (where appropriate) 1 mM BSA 
to  a  total  volume  of  60  µl.  The  digestions  contained  less  than  10%  total  v/v  of 
restriction enzyme to avoid the star activity of the enzyme. Following digestion, the 
vector DNA was treated with Antarctic phosphatase (3 µl) at 37 
oC for three hours, 
in order to remove the 5´ phosphate groups from the vector and prevent vector re-
circularisation. 
 Following digestions and phosphatase treatment of the vector preparative agarose 
gel electrophoresis was carried out to purify the digested products. Vector DNA was 
run  and  excised  from  0.8%  agarose  gels  and  the  insert  DNA  from  2%  gel.  To 
increase the efficiency of the ligation/transformation, gels were stained with 2% v/v 
methylene  blue  to  enable  gel  extraction  without  the  use  of  UV  light.  DNA  was 
purified from excised gel fragments using a QIAquick gel extraction kit following 
the manufacturer’s instructions. 
2.4.1.4 DNA ligation and transformation 
Ligation reactions were done with T4 DNA ligase. The set up was commonly ~50 ng 
of digested plasmid DNA and a molar vector:insert ratio of 1:3 and 1:6. A typical 
ligation reaction is shown in table 2.4. To control for vector re-circularisation and/or 
inefficient digestion, as well as for improper purification of the insert and vector, 
control ligations were also set up containing vector or insert only.  
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Table 2.4 Typical DNA ligation reaction  
Reagent  Concentration  Volume 
Insert  3-6x more than vector 
(molar ratio) 
X µl 
Vector  50 ng  Y µl 
T4 DNA ligase buffer  1x  1 µl 
T4 DNA ligase  1 Unit  1 µl 
H2O    Up to 10 µl 
 
Ligation reactions were set up on ice and incubated overnight at 16 
oC. Following 
overnight incubation the ligase was inactivated by heating at 65 
oC for ten minutes. 5 
µl of each ligation reaction was then transformed into NEB5a competent cells as 
described in 2.3.2 
2.4.2 Ligation Independent Cloning (LIC) 
Ligation independent cloning was used for the majority of cloning for Fas and ezrin 
constructs into a number of pNIC vectors containing TEV cleavable purification tags 
(see table 2.1). 
2.4.2.1 LIC vector preparation 
5 µg of pNIC vector were linearised by digestion with BsaI at 50 
oC for 2-3 hours. 
The digested product was purified by preparative gel electrophoresis as described in 
2.4.1.3 
2.4.2.2 LIC insert preparation 
Inserts for LIC cloning need to contain complementary overhangs to those found in 
the target vector. In the case of the pNIC vectors with N-terminal purification tags, 
as are all the ones used in the study, the following 5’ extensions are added to the 
primers: TAC TTC CAA TCC ATG to the 5’ end of the upstream primer, in which 
ATG is in-frame with the desired coding sequence; and TAT CCA CCT TTA CTG 
to 5’ end of the downstream primer. 
Insert amplification was carried out in a 50 µl reaction volume using the methods 
described in 2.4.1.1, and 2.4.1.3. If the template was a plasmid, the PCR reaction 
was treated with DpnI for 1-2 hours prior to preparative gel electrophoresis. 75 
2.4.2.3 T4 DNA polymerase treatment of LIC insert and vector 
Reactions for controlled digestions exploit the 3' - 5' exonuclease activity of T4 DNA 
polymerase.  T4  DNA  polymerase  treatment  was  carried  out  at  22 
oC  for  thirty 
minutes and then the polymerase was inactivated by incubation at 75 
oC for twenty 
minutes. Typical T4 DNA polymerase treatments of vector and insert are shown in 
tables 2.5 and 2.6. 
Table 2.5 Vector T4 DNA polymerase treatment reaction 
Reagent  Concentration  Volume 
BsaI digested plasmid  600 ng  X µl 
Buffer NEB2  1x  2 µl 
DTT  100 mM  0.5 µl 
dGTP  25 mM  0.5 µl 
BSA  1x  0.2 µl 
T4 DNA polymerase  1x  0.4 µl 
H2O    Up to 20 µl 
 
Table 2.6 Insert T4 DNA polymerase treatment set up 
Reagent  Concentration  Volume 
Insert  0.2 pmole  Y µl 
Buffer NEB2  1x  2 µl 
DTT  100 mM  1 µl 
dCTP  25 mM  0.5 µl 
BSA  1x  0.2 µl 
T4 DNA polymerase  1x  0.4 µl 
H2O    Up to 20 µl 
 
2.4.2.4 Annealing and transformation 
To anneal insert and vector, 0.02 pmol of insert was incubated with 25-50 ng of 
prepared vector for 5 mins at room temperature. 1 µl 25 mM EDTA was then added 
and  the  reaction  incubated  at  room  temperature  for  a  further  5  minutes.  1  µl  of 
annealed product was transformed into BL21 (DE3) Gold competent cells (Agilent 
Technologies) as described in 2.3.2. 
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2.4.3 Site-directed mutagenesis 
Point  mutations  were  inserted  into  the  construct  of  interest  using  the  linear 
amplification  technique,  with  completely  overlapping  complementary  mutagenic 
primers. Primers were designed according to Agilent’s Quikchange Primer Design 
Guidelines, i.e. with a length between 25 and 45 bp, minimum GC content of 40% 
and a melting temperature more than or equal to 78 
oC, using the formula:  
Tm = 81.5+ 0.41(%GC) (675/N) - % mismatch. 
Where  N  is  the  length  of  the  primer.  The  base  mutation  of  interest  was  usually 
placed within the centre of the oligonucleotides. A typical PCR reaction and program 
used for site directed mutagenesis are shown in tables 2.7 and 2.8 respectively. 
Table 2.7 Typical reaction mixture for site-directed mutagenesis (50 µl) 
Reagent  Concentration  Volume 
Template DNA  50 ng   
KOD Hotstart buffer  1x  5 µl 
dNTP mix  200 µM  5 µl 
MgSO4  1.5 µM  3 µl 
Forward primer  0.14 µM  0.7 µl of 10 µM stock 
Reverse primer  0.14 µM  0.7 µl of 10 µM stock 
KOD enzyme  1U  1 µl 
H2O    Up to 50 µl 
 
Table 2.8 Typical PCR program used for site- directed mutagenesis 
Reaction step  Time  Temperature (
oC)  Cycles 
Denaturation  2 min  95  1 
Denaturation  20 sec  95   
20  Annealing  20 sec  55 
Extension  2 min 30 sec  70 
Extension  10 min  72  1 
Hold    4  1 
 
Following  PCR  amplification,  in  order  to  digest  the  parent  DNA,  1  µl  of  the 
endonuclease DpnI was added to the reaction and incubated at 37 
oC in a water bath 
for two hours. A 5 µl aliquot was removed before digestion to control for the DpnI 
digestion. PCR amplification and DpnI digestion was verified by running a 0.8% 77 
agarose gel. Positive reactions were transformed into NEB5α as described in section 
2.3.2. Selected colonies were used to inoculate 10 ml of sterile LB medium and 
cultured  overnight  in  a  shaking  incubator  at  37 
oC.  Plasmid  DNA  was  extracted 
using the Qiaprep spin miniprep kit and mutations verified by DNA sequencing. 
Fas-DD is known to aggregate in vitro. It has been shown that the K247A point 
mutation  reduces  this  aggregation  allowing  increased  concentrations  to  be 
achieved
50. All Fas-DD constructs contain this mutation unless otherwise stated.  
2.4.4 Colony PCR for detection of positive clones  
Following cloning, colonies were screened by colony PCR method using 5 PRIME 
Taq DNA polymerase MasterMix. A suitable number of isolated colonies (typically 
10-12) were picked and independently re-suspended in 20 µl of LB medium which 
was  split  into  two  10  µl  aliquots.  One  of  the  aliquots  was  stored  at  4 
oC  for 
propagation and storage in case the colony was positive. The other aliquot was lysed 
by heating to 95 
oC for five minutes and centrifuged at 13000 rpm for 1 minute. This 
cleared  lysate  was  used  as  template  for  the  colony-PCR.  A  typical  colony-PCR 
reaction is shown in table 2.9. PCR program/protocol used for colony PCR is shown 
in Table 2.10. 
Table 2.9 Typical reaction mixture used for colony PCR 
Reagent  Concentration  Volume 
5 PRIME Master Mix  1x  10 µl 
Forward primer  0.2 mM  0.5 µl of 10 µM stock 
Reverse primer  0.2 µM  0.5 µl of 10 µM stock 
Colony  N/A  1 µl 
H2O  N/A  Up to 25 µl 
 
Table 2.10 PCR program for colony PCR  
Reaction step  Time  Temperature (
oC)  Cycles 
Denaturation  2 min  95  1 
Denaturation  30 sec  95   
35  Annealing  45 sec  55 
Extension  1 min  72 
Extension  2 min  72  1 
Hold    4  1 
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The reaction products were analysed in a 2% w/v agarose gel to verify whether a 
correctly sized PCR product had been generated. Positive colonies were used to seed 
10 ml of sterile LB medium containing appropriate antibiotics and grown overnight 
at 37 
oC in a shaking incubator. Plasmid DNA was purified from overnight cultures 
using the Qiaprep miniprep kit and purified plasmids sent for sequencing to verify 
the sequence of the DNA product. 
2.4.5 Megaprimer insertion of MBP into Fas-DD-Mxe-CBD 
The exponential megapriming (EMP) PCR method of Ulrich et al. 2012
134 was used 
to incorporate the MBP solubility tag into the pTWIN1 N-terminal Fas construct to 
improve solubility. 
2.4.5.1 Megaprimer preparation 
Three  primers  are  needed,  named  F1,  R1  and  R2.  F1  and  R1  are  for  initial 
amplification of the megaprimer from the target, they are complementary to the 5' 
and 3' (respectively) ends to the insert, R1 also contains 20-25 nucleotide overlap to 
the target plasmid, 3' to the insertion site. R2 is used to clone the insert into the target 
vector and is complementary to the 5' end of the insertion site on the target plasmid. 
Amplification of the megaprimer was carried out using the PCR program described 
in  table  2.10  using  the  reaction  set  up  detailed  below  in  table  2.11.  Following 
megaprimer amplification it was gel extracted as described in 2.4.1.3 
Table 2.11 Reaction mixture for megaprimer preparation 
Reagent  Concentration  Volume 
buffer for KOD hot start 
polymerase 
1x  5 µl 
dNTP mix  200 µM  5 µl 
MgSO4  1.5 µM  3 µl 
F1  0.5 µM  2.5 µl 
R1  0.5 µM  2.5 µl 
Template DNA  50 ng   
KOD hot start 
polymerase 
1U  1 µl 
ddH2O    Up to 50 µl 
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2.4.5.2 Insertion of megaprimer into target vector 
The megaprimer was inserted into the target vector by PCR using the reaction and 
PCR program shown below. 
Table 2.12 Reaction mixture for megaprimer insertion into target vector 
Reagent  Concentration  Volume 
Buffer for KOD Hot Start 
master mix 
1x  25 µl 
R2  0.5 µM  2.5 µl 
Template DNA  25 ng  X µl 
Megaprimer  200 ng  Y µl 
DMSO  5%  2.5 µl 
ddH2O    Up to 50 µl 
 
Table 2.13 PCR program used for megaprimer insertion into target vector 
Reaction Step  Time  Temperature (
oC)  Cycles 
Denaturation  2 min  95  1 
Denaturation  20 sec  95   
20  Annealing  20 sec  46-55 
# 
Extension  2 min 30 sec *  70 
Extension  10 min  72  1 
*dependant  on  size  of  vector,  #  annealing  temperature  was  varied  in  respect  to 
primer R2. 
The final product was further amplified using the reaction mixture in table 2.14 and 
the PCR program shown in table 2.10. 
Table 2.14 Reaction mixture to amplify EMP product 
Reagent  Concentration  Volume 
Buffer for KOD Hot Start 
master mix 
1x  25 µl 
F1  0.5 µM  2.5 µl 
R2  25 ng  2.5 µl 
Previous PCR reaction    5 µl 
ddH2O    Up to 50 µl 
 
This PCR reaction was purified using the method described in 2.4.1.1 with the final 
DNA eluted in 30 μl 10 mM Tris-HCl pH 8, 1 mM EDTA. 80 
2.4.5.3 In vitro ligation and transformation 
To improve transformation efficiency, in vitro ligation was carried out. 16.5 µl of 
purified EMP product was incubated at 37 
oC with 5 units of PNK kinase in 1x PNK 
kinase buffer to phosphorylate the 5’ end of the DNA. Ligation was carried out by 
adding 200 U of T4 DNA ligase and incubating at room temperature for one hour. 
To ensure no retransformation of original plasmid, DpnI treatment was then carried 
out at 37 
oC for 1-2 hours. 5 µl of the ligation mixture was transformed into NEB5α 
competent cells as described in 2.3.2, plating out all of the cells. 
2.4.6 DNA sequencing 
Plasmid DNA was sent away to the GATC sequencing service (GATC Biotech AG, 
Germany) for Sanger sequencing. Plasmids were typically sequenced using the T7 or 
T7 reverse primers available at the sequencing facility. Plasmid DNA was sent away 
at the concentration of 30-75 ng/µl in 30 µl aliquots. 
 
2.5 Protein expression 
2.5.1 Bacterial strains and storage 
Expression constructs were transformed into the BL21 (DE3) Gold expression strain 
of E. coli (Agilent Technologies). Single colonies from fresh transformation plates 
were used to prepare glycerol stocks as described in section 2.3.3. 
2.5.2 Small scale expression test 
A small flake from a glycerol stock was used to inoculate 10 ml LB containing the 
appropriate  antibiotics.  Cultures  were  grown  until  the  OD600  was  0.6  and  then 
induced with 0.5 mM isopropyl-β-D-thiogalactopyranoside (IPTG). Cultures were 
tested for expression at 37 
oC for four hours or at 22 
oC overnight. Four hour and 
overnight cultures were harvested by centrifugation at 4500G for ten minutes and 
resuspended in 1 ml of lysis buffer (50 mM Tris-HCl, 300 mM NaCl, pH 8) followed 
by cell lysis by sonication on ice. 15 µl of lysed cells were taken as a total protein 
sample while the rest of the sample was clarified by centrifugation at 13000 rpm in a 
micro centrifuge for 5 minutes; 15 µl of this was taken as the soluble protein sample.  81 
Samples  corresponding  to  total  and  soluble  protein  were  assayed  for  protein 
expression by SDS-PAGE. The expression level and amount of soluble protein was 
increased when expressed at 22 
oC overnight. If the construct was not adequately 
expressed the insert was subcloned into a vector containing an alternative solubility 
tag. 
2.5.3 Large scale protein expression 
2.5.3.1 Rich medium 
100  ml  LB  medium  containing  60  mg/ml  kanamycin  (LB-kanamycin)  were 
inoculated using a flake from a glycerol stock. The culture was grown overnight at 
37 
oC, cells harvested, the medium decanted and the pellet used to inoculate four 2-
litre flasks with 500 ml of LB-kanamycin each. Cultures were grown at 37 
oC and 
275 rpm until an OD600 of 0.6 was reached. Induction was initiated with 0.5 mM 
IPTG  and  cultures  were  grown  overnight  at  22 
oC.  Cells  were  harvested  by 
centrifugation at 6370G for 20 minutes using a Beckman Coulter ‘JSP F500’ rotor. 
2.5.3.2 PG minimal medium for 
15N and/or 
13C isotope labelling 
Recombinant 
15N-labelled  proteins  were  expressed  in  cells  grown  in  a  modified 
Studier PG medium
135 with 60 mg/ml kanamycin and (
15NH4)2SO4 and/or 
13C6-D 
glucose, as sole nitrogen and carbon sources respectively. 
10 ml of LB-kanamycin medium containing appropriate antibiotics were inoculated 
with a flake from a glycerol stock or a fresh well isolated colony and cultured by 
shaking  at  250  rpm  at  37 
oC.  After  6-8  hours,  the  cells  were  harvested  by 
centrifugation at 3000 rpm for ten minutes. The supernatant was discarded and the 
cell pellet resuspended into 100 ml of non-isotope labelled PG medium-kanamycin 
in a 500 ml flask. This seed culture was grown overnight at 37 
oC and 250 rpm. 
Overnight cultures were harvested by centrifugation at 3000 rpm for ten minutes and 
used to inoculate two 2-litre flasks containing 500 ml of isotopically labelled PG 
medium-kanamycin. Cultures were grown at 37 
oC and 275 rpm until an OD600 of 
0.7-0.8  was  reached,  they  were  then  induced  with  0.5  mM  IPTG  and  grown 
overnight at 22 
oC to allow for protein expression. 
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2.5.3.3 M9 minimal medium for 
15N/ 
13C-labelled Fas-DD 
The  recombinant 
15N/
13C-labelled  Fas-DD  construct  for  structural  data  collection 
was expressed in E. coli (DE3) Rosetta (Novagen). The expression protocol was the 
same as for the PG medium, but in this case the medium was modified M9
133 with 
13C6-D-glucose and (
15NH4)2SO4 as sole carbon and nitrogen sources. Modified M9 
minimal medium contains: Na2HPO4 6 g/l, KH2PO4 3g/l, NaCl 5 g/l, (
15NH4)2SO4 1 
g/l , 2 mM MgCl2, 0.1 mM CaCl2, 0.01 mM FeSO4, 0.2% 
13C6-D-glucose, 40 mM 
H3BO3, 3 mM CoCl2, 1 mM CuSO4, 0.8 mM MnCl2, 1 mM ZnSO4, 0.3 mM (NH4)6 
Mo7O24, 0.4 mg/l choline chloride, 0.5 mg/l folic acid, 0.5 mg/l pantothenic acid, 0.5 
mg/l nicotinamide, 1 mg/l myo-inositol, 0.5 mg/l pyridoxal HCl, 0.5 mg/l thiamine 
HCl, 0.05 mg/l riboflavin, 1 mg/l biotin. 
2.5.3.4 Large scale expression of 
2H/
15N-labelled protein  
Expression of 
2H-labelled protein was carried out as described in 2.5.3.2 with the 
addition of 20 mM sodium succinate and 




2.6 Protein purification for NMR and biophysical studies 
2.6.1 Cell lysis and clarification 
Cell pellets were resuspended in either IMAC lysis buffer (50 mM Tris-HCl, 300 
mM NaCl, pH 8) or GST lysis buffer (20 mM Tris-HCl, 100 mM NaCl, 1 mM 
EDTA, pH 8), containing Complete EDTA-free protease inhibitor tablet (Roche) and 
lysed on ice by sonication (Branson Sonifier 250, power output 50 W, 50% duty 
cycle, 2x 180 seconds). Lysed samples were clarified at 39,200G for 30 minutes 
using a Beckman Coulter ‘JA-20’ rotor. 
2.6.2 Immobilised metal affinity chromatography (IMAC) 
Hexahistidine-tagged  proteins  were  affinity  purified  using  Ni-IDA  metal  affinity 
resin (Generon). Per 1 litre of overnight cell culture, 4 ml of Ni-IDA metal affinity 
resin was packed into a gravity-driven column (BioRad Econopac) and equilibrated 
with 10 column volumes (CV) of lysis buffer. The supernatant of clarified cell lysate 83 
was applied to the resin and the flow-through loaded onto the column for a second 
time. The resin was washed with 5 CV of lysis buffer followed by 5 CV of wash 
buffer (20 mM Tris-HCl, 300 mM NaCl, 50 mM imidazole, pH 8) and eluted with 
elution buffer (20 mM Tris, 150 mM NaCl, 300 mM imidazole, pH 8). Elution was 
monitored  used  Bio-rad  Bradford  protein  assay.  Elution  buffer  was  applied  until 
protein was no longer detected. 15 µl of each step was collected and analysed by 
SDS-PAGE. 
2.6.3 Glutathione sepharose affinity chromatography 
GST-tagged proteins were purified by batch Glutathione sepharose (GE Healthcare) 
affinity  chromatography.  Beads  were  first  equilibrated  with  10  CV  of GST  lysis 
buffer (20 mM Tris-HCl, 100 mM NaCl, 1 mM EDTA, pH 8), added to the lysate 
and incubated with gentle stirring for one hour. The resin was then packed into a 
gravity driven column and washed with 5 CV GST lysis buffer and eluted with GST 
elution buffer (20 mM Tris-HCl, 100 mM NaCl, 1 mM EDTA, 50 mM reduced 
glutathione, pH 8).  
2.6.4 TEV protease cleavage 
All protein expression constructs contained the tobacco etch virus (TEV) protease 
recognition site ENLYFQ*S which was used to remove the tags from the constructs 
to yield as constructs with only an N-terminal extra serine. Recombinant H6-TEV 
protease was prepared in-house.  
TEV  protease  was  added  in  an  approximate  mass  ratio  of  1:100  to  the  eluate 
obtained from the IMAC purification. The eluate was then dialysed for sixteen hours 
at 18-22 
oC in Specta/Por Dialysis Membrane 3500 MWCO (Spectrum Laboratories) 
in 200x the sample volume of 20 mM Tris-HCl, 300 mM NaCl, 1 mM DTT pH 8. In 
order  to  be  able  to  use  IMAC  again  to  remove  the  H6-TEV  and  any  uncleaved 
protein, is necessary to remove the DTT. To achieve this removal the dialysis bag 
was then transferred into 200x the sample volume of 20 mM Tris-HCl, 150 mM 
NaCl, pH 8 and dialysed at 4 
oC for 4-16 hours. The TEV-cleaved sampled was then 
loaded into a pre-equilibrated the Ni-IDA column and washed with 5 CV of 20 mM 
Tris-HCl,  300  mM  NaCl,  pH  8.  Samples  of  the  flow-through  and  wash  were 
analysed by SDS-PAGE. 84 
2.6.5 Size exclusion chromatography (SEC) 
Samples from affinity chromatography were concentrated to 10 ml by centrifugal 
concentration  using  Vivaspin  concentrators  of  appropriate  MWCO  and  dialysed 
overnight in 2 litres of the corresponding NMR buffer. The buffer for NMR samples 
of Fas was 20 mM MES, 100 mM NaCl, 0.5 mM TCEP, 1 mM EDTA, 3 mM NaN3 
pH 6.2. The buffer for ezrin samples was 20 mM Tris-HCl, 150 mM NaCl, 1 mM 
TCEP, 1 mM EDTA, 3 mM NaN3, pH 7.4. Samples were finally concentrated again 
to less than 2 ml. 
Size  Exclusion  Chromatography  (SEC)  was  carried  out  using  an  AKTA  purifier 
chromatography system (GE Healthcare) with a prepacked 16/600 Superdex 200 or 
75  XK  column  (GE  Healthcare),  equilibrated  in  the  respective  NMR  buffer. 
Fractions  were  analysed  by  SDS-PAGE.  Fractions  containing  pure  protein  were 
pooled and concentrated by centrifugal concentration to the desired concentration.  
2.6.6 SDS-PAGE 
SDS-PAGE analysis was carried out using pre-cast Novex 4-12% 1.0 mm, 15 well 
Bis-Tris gels (Life Technologies) in an XCell SureLock (Invitrogen) gel tank and 
power source. Gels were run in 1x MES buffer (Life Technologies) at a constant 
current of 200 V for 35 minutes. Samples were prepared by mixing 15 µl protein 
sample with 5 µl NuPAGE LDS sample buffer (Life Technologies) and heating at 90 
oC for 5 minutes. A typical gel was loaded with 10 µl of each protein sample and 5 µl 
of Mark12 molecular markers (Life Technologies). Gels were stained in Coomassie 
stain (45% methanol, 10% acetic acid, 0.25% comassie blue R-250) for up to 2 hours 
and de-stained overnight in de-stain solution (20% methanol, 10% acetic acid). Gels 
were recorded using a GeneFlash gel documentation system (Syngene).  
2.6.7 Protein concentration for NMR, buffer exchange and storage 
Pure  protein  samples  were  concentrated  by  centrifugal  concentration.  Depending 
upon sample start volume, Vivaspin tubes of either 2 or 20 ml were used. Prior to 
sample  addition,  tubes  were  washed  with  2-10  ml  of  ddH2O  to  remove  storage 
additives.  Centrifugal  concentration  was  typically  carried  out  at  3800  rpm  for 
variable time intervals in order to minimise the concentration gradient that forms 
inside the tube.  85 
Buffer exchange was typically carried out by dialysis as described in section 2.6.5. 
When  buffer  exchange  was  required  into  D2O  buffer  for  NMR  side  chain 
experiments, samples were lyophilised at the correct concentration and volume and 
resuspended in the same volume of D2O. 
For long term storage, protein samples were aliquoted, snap frozen by immersion in 
dry ice/methanol, lyophilised and stored at -20 
oC until required. 
2.6.8 Protein concentration determination 
Protein  concentration  was  determined  using  a  Nanodrop2000  UV/Vis 
spectrophotometer (Thermo Scientific) recording protein absorbance at 280 nm. This 
is used to calculate protein con centration using the Beer-Lambert Law.  
A=εCL. 
A  is  the  absorbance  at  280nm,  C  is  the  protein  concentration,  ε  is  the  molar 
extinction coefficient and L is the path length. Molar extinction coefficients for each 
protein constructs were predicted using the Expasy ProtParam server.  
 
2.7 Biochemical and biophysical analysis  
2.7.1 Analytical size exclusion chromatography 
Analytical SEC was carried out in a Superdex 75 analytical size exclusion column 
(GE  Healthcare)  attached  to  an  AKTA  Purifier  chromatography  system  (GE 
Healthcare). The column was equilibrated in 20 mM Tris-HCl, 100 mM NaCl, 0.5 
mM TCEP, 1 mM EDTA, pH 7.4. Samples were injected in 100 µl volumes. Co-
injection of samples involved co-concentration of proteins in the ratio specified in 
each section. 
2.7.2 Co-precipitation assays 
 2.7.2.1 GST pulldown 
The binding buffer for GST-tagged ezrin (residues 1-365) experiments was 30 mM 
Tris-HCl,  pH  7.5,  150  mM  NaCl,  10%  glycerol,  1%  Triton  X-100.  Beads 
equilibrated in binding buffer were added to cleared GST-ezrin lysate and incubated 86 
for an hour. Beads were rinsed twice with binding buffer and the bead slurry was 
added to the solution of the expected binding partner and incubated overnight at 4 
oC 
with gentle rotation. After washing three times with binding buffer, pelleted beads 
were resuspended in LDS sample buffer and loaded onto an SDS-PAGE gel which 
was run and stained with Coomassie blue as described in 2.6.6. 
 2.7.2.2 Ni-NTA pulldown 
Hexa-histidine  tagged  Fas  and  untagged  ezrin  expression  lysates  were  separately 
incubated with cOmplete Ni-NTA beads (Roche) in IMAC binding buffer and the 
pull down carried out as described in 2.7.2.1. 
 2.7.2.3 Immunoprecipitation 
Hexa-histidine tagged Fas and untagged ezrin expression lysates were precleared by 
incubation with Protein G coated Dynabeads (Life Technologies) for one hour at 4 
oC. After preclearing the cell lysate, 5 µg/ml penta-His Mab (Abchem) was added to 
the lysate and incubated at 4 
oC for one hour. Untagged ezrin was then added and 
incubated overnight at 4 
oC. Protein G Dynabeads were then added and incubated for 
one hour at 4 
oC to pull down any potential binding partners. After three washes, the 
beads were resuspended in LDS sample buffer and loaded onto an SDS-PAGE gel 
which was run and stained with Coomassie blue as described in 2.6.6. 
2.7.3 Biolayer interferonmetry (BLI)  
Enzymatic in vitro biotinylation was carried out using the Avidity  Biotin-protein 
ligase kit. The kit consists of the BirA biotin ligase, and a two part 10x biotinylation 
buffer. the first containing 0.5 M bicine buffer, pH 8.3, and the second 100 mM 
ATP, 100 mM MgOAc, 500 µM d-biotin. The final biotinylation reaction had 40 mM 
protein, 50 mM bicine, 10 mM ATP, 10 mM magnesium acetate, 50 mM d-biotin and 
10 µg of BirA. The mix was incubated for two hours at 30 
oC.  
All experiments were carried out in PBS, 0.5  mM TCEP, 0.005% Tween20, 0.5 
mg/ml BSA, pH 7.4 on an Octet Red BLI instrument (ForteBio) operated at 25 
oC. 
Streptavidin-coated biosensors with immobilised biotinylated Fas (residues 202-335) 
or Fas (residues 194-335) were exposed to different concentrations of ezrin (residues 
1-365) [0-400 µM], ezrin (residues 1-297) [0-200 µM], and radixin [0.7-100 µM] 
and  readings  were  taken.  Positive  controls  of  immobilised  NHERF2  and 87 
FasDD+CTD were exposed to different concentrations of ezrin (residues 1-365) [0-
0.8  µM],  and  FADD  (residues  93-192)  respectively.  Dissociation  constants  were 
calculated by fitting the experimental data in SEDPHAT
55. 
2.7.4 Isothermal titration calorimetry (ITC) 
Complex  formation  was  measured  by  ITC  using  a  MicroCal  VP-ITC 
microcalorimeter. Fas (residues 194-335) and ezrin (residues 1-362) were dialysed 
overnight in the same buffer (20 mM Tris-HCl, 150 mM NaCl, 0.5 mM TCEP, pH 
8). The sample cell contained ezrin (1-362) [50 mM] and the syringe contained Fas 
(194-335) [500 mM]. Experiments were conducted at 10 
oC, 20 
oC and 25 
oC. Heat of 
dilution measurements were not taken as no heat of interaction was observed. 
2.7.5 Analytical ultracentrifugation (AUC) 
A  Beckman  Optima  XL-I  analytical  ultracentrifuge  was  used  to  perform 
sedimentation velocity measurements. Experiments were carried out in aluminium 
double sector sapphire cells using an AN50-Ti rotor at a speed of 35,000 rpm at 293 
K. Prior to the beginning of each run, the rotor temperature was equilibrated at 293 
K for 1-2 hours in the vacuum chamber. Interference images were collected every 60 
s during the sedimentation run. The recorded data was analysed using SEDFIT
54 in 
terms  of  discrete  species  and  continuous  distribution  function  of  sedimentation 
coefficient [c(s)]. 
The concentration of protein used with the experiments ranged from 0.5-2 mg/ml for 
Fas  (202-335)  and  ezrin  (1-365)  ran  in  isolation  and  mixed  together  at  equal 
concentrations of 20 µM, 50 µM, 100 µM. Prior to the experiments, samples were 
dialysed overnight against the experimental buffer blank solution, 20 mM Tris, 150 
mM NaCl, 0.5 mM TCEP, pH 7.4. 
2.7.6 Mass spectrometry (MS) 
2.7.6.1 Sample preparation 
Mass spectrometry samples were prepared using C4 Ziptips (Merck-Millipore) for 
desalting  and  concentration.  Ziptips  were  activated  with  5  CV  of  acetonitrile, 
equilibrated in 5 CV of 0.1% acetic acid which was followed by sample addition. 
This was followed by 5 CV 0.1% acetic acid wash, 5 CV 5% methanol, 0.1% acetic 88 
acid  wash,  0.1%  acetic  acid  wash  and  the  protein  sample  was  eluted  in  65% 
acetonitrile, 0.1% acetic acid.  
2.7.6.2 ESI-TOF 
Electrospray ionisation time of flight mass spectrometry was carried out in a Bruker 
Dalronics  MicroTOF  instrument.  Data  were  analysed  using  the  Bruker  Daltonics 
DataAnalysis program. 
2.7.6.3 MALDI-MS 
Analysis  by  Matrix-assisted  laser  desorption  ionisation  time  of  flight  mass 
spectrometry  (MALDI-TOF-MS),  (Bruker  Microflex)  was  carried  out  using  α-
cyano-4-hydroxycinnamic acid (CHCA) matrix. For all analysis, ion positive linear 
mode was used. Data were processed using FlexAnalysis program (Bruker). 
 
2.8 In vitro palmitoylation  
2.8.1 Palmitoylation of intracellular Fas 
The palmitoylation reaction was carried out by incubating intracellular Fas (residues 
194-335) in a final concentration of 200-300 µM, at 37 
oC with 1 mM palmitoyl Co-
A in acylation buffer (10 mM HEPES, pH 7, 1 mM EDTA, 1 mM MgCl2, 10 mM 
NaCl, 130 mM KCl, 1 mM DTT). Reactions were incubated for variable amounts of 
time. Reaction progression was monitored by ESI-TOF mass spectrometry with the 
samples prepared as described in 2.7.6.1. This method is based upon the acylation 
reaction carried out by Bano and collaborators
136.  
2.8.2 Tryptic digestion 
100 µg of protein samples were digested with 2 µg of trypsin overnight at 37 
oC. 
Reactions contained 10% acetonitrile and were prepared for mass spectrometry using 
C4 Ziptips as described in 2.7.6.1. 
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2.9 NMR spectroscopy 
2.9.1 Sample preparation, D2O addition/concentration 
NMR  protein  samples  were  prepared  by  protein  expression  in  minimal  medium 
followed by IMAC and SEC purification as described in 2.6. Samples were typically 
concentrated to between 100-700 µM (depending on the experiment) at a volume of 
550 µl by centrifugal concentration as described in 2.6.7. To obtain the lock signal 
on the instrument 10% of the final volume was 
2H2O. 
2.9.2 Spectrometers 
NMR spectra were recorded at the MRC Biomedical NMR Centre at the National 
Institute for Medical Research (NIMR), London, using Bruker Avance 600 and 700 
or Varian INOVA 600 and 800 MHz spectrometers with cryogenic probes. Pulse 
sequences had been adapted ‘in house’ by the staff of the MRC Biomedical NMR 
Centre.  HSQC  experiments  were  set  up  by  the  author  alone,  more  complex 
experiments were set up under the guidance of Dr Tom Frenkiel, Dr Geoff Kelly, Dr 
Diego Esposito or Dr TJ Ragan. 
2.9.3 NMR data processing 
NMR  data  processing  was  carried  out  using  NMRPipe
137  and  initially  visualised 
using NMRDraw
137 using processing scripts which had been developed within the 
Driscoll laboratory by Dr Diego Esposito or Dr TJ Ragan or supplied by the MRC 
Biomedical NMR Centre. Processed spectra were viewed and analysed using the 
CCPN Analysis software
138. 




139 experiments were recorded with 1024 complex 
points in the direct dimension and 128 complex points in the indirect dimension 
unless  otherwise  stated.  During  titration  experiments,  the  number  of  scans  per 
increment was kept constant for each point in the titration. 
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2.9.4.1 Titration experiments 
To avoid dilution effects, titration experiments were carried out using two separate 
550 µl NMR samples, one containing 100-300 µM of 
15N labelled protein (Sample 
A) and a second containing the same concentration of labelled protein with a higher 
molar  concentration  (usually  double)  of  the  unlabelled  putative  binding  partner 
(Sample  B). 
1H/
15N-HSQC  experiments  were  collected  for  both  sample  A  and 
sample B independently which would correspond to the first and last titration points. 
Following the initial HSQC experiments, equal volumes of samples A and B were 
simultaneously  swapped  between  sample  A  and  sample  B,  producing  two  new 
mixtures  still  containing  the  same  volume  of 
15N  labelled  protein  sample.  NMR 
spectra were then recorded for these new samples. This mutual swapping of aliquots 
between samples A and B was continued until an equimolar concentration of the 
unlabelled protein and the 
15N labelled protein was reached, which completed the 
titration series. Tracking the changes in chemical shift and intensity of cross peaks 
across the HSQC spectra of the labelled component of the samples determines the 
involvement of particular residues in any specific protein-protein interaction. 
2.9.5 Fas-DD backbone assignments 
2.9.5.1 NMR experiments for backbone resonance assignment 
For  sequence-specific  resonance  assignments,  a  number  of  two  and  three 
dimensional NMR experiments were carried out. A 2D 
1H/
15N-HSQC experiment 
was used as the basis and all other spectra referenced to this one. Three dimensional 






143.  All  spectra  were  recorded  with  600 
μM 
15N/
13C Fas-DD construct at 298 K, the magnetic field strength each experiment 
was collected at is shown in Table 2.15. Dr Diego Esposito collected the initial data 
and initialised the assignments on a sample expressed and purified prior to the author 
starting in the laboratory. 
2.9.5.2 Sequence specific backbone resonance assignments 
To assign the backbone resonances in a sequence-specific manner, intra-residue 
13C 
chemical  shifts  are  identified  for  a  particular  NH  group,  followed  by  sequential 
chemical  shifts  which  are  identified  from  a  different  NH  group.  The  three 91 
dimensional spectra recorded for the backbone assignments are rooted on the 
15N-
1H 
correlations.  Sequence  assignments  are  obtained  by  correlating  inter  and  intra-
residue resonances of Cα and Cβ chemical shifts and generating connected segments 
of sequential connected spin sub-systems using the CCPN Analysis software. 
Combined analysis of HNCA, HNCACB and CBCA(CO)NH spectra were used to 
designate the sequence specific resonance assignments for the Fas death domain. 
Table 2.15 contains the experimental details for these three dimensional experiments. 
Table  2.15  Experimental  details  for  the  3D  NMR  experiments  acquired  for  sequential 
backbone assignments  



















HSQC  800  926  9620  80  2757   
HNCA  800  1024  9620  40  2757  56  6036.3 
HN(CO)CA  700  1024  8427.5  20  2411.9  55  5636.9 
HNCACB  800  1024  9620  40  2757  112  14084.5 
CB(CACO)NH  600  1024  9620  40  2757  64  14084.5 
SW – sweep width 
2.9.6 NMR experiments for Fas-DD side-chain resonance assignments 
To assign the Fas-DD side-chain resonances, a number of two and three dimensional 
experiments were collected to detect through-bond and through-space interactions. 
15N-TOCSY
144  and  HCCH-TOCSY
145,146  experiments  were  collected  to  identify 
side-chain  proton  resonances.  The  HCCH-TOCSY  experiment  allows  correlation 
between 
13Cα,  Hα  with  aliphatic  side-chain  protons  and  carbon  nuclei  within  an 
individual residue. The 
15N-TOCSY correlates side chain protons with the amide 
proton and nitrogen. A 
13C-constant time HSQC was collected which correlated the 
resonances of each residue found using these experiments. Interproton NOEs arising 
from through-space dipolar interactions were identified by recording 
15N-NOESY 
and 
13C  aliphatic  and  aromatic  NOESY
144  experiments.  These  experiments  were 
carried out on a 
15N 
13C Fas-DD sample at 600 µM in 
2H2O, experimental details are 
shown in table 2.16 and table 2.17. 
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Table  2.16  Experimental  details  for 
13C  through-bond  and  through-space  side-chain 
experiments 



















13C HSQC  600  853  10000  388  14084   
HCCH-
TOCSY 
600  1024  7183  32  11314  64  7199  100 
13C - ali 
NOESY 
600  960  9600  60  14084  180  9600  100 
13C – aro 
NOESY 




600  838  8389  2  11636  3800  4201  32% 
13C-ali 
NOESY 
600  1120  8012  2  10204  5800  6024  41% 
13C -aro 
NOESY 
600    1561    1024    6024  41% 
 
Table  2.17  Experimental  details  for 
15N  through-bond  and  through-space  side-chain 
experiments 






1H- indirect  % 
sampled 
Points  SW 
(Hz) 
Points  SW 
(Hz) 
Points  SW 
(Hz) 
 
15N TOCSY  700  960  9615  32  2310.5  63  2310.5  100% 
700  1372  9803  3700  2483  120  8403  50% 
 
These  experiments  were  also  collected  using  a  non-uniform  sampling,  weighted 
Poisson disk sampling scheme to improve signal to noise under the guidance of Dr 
Tom  Frenkiel.  Experimental  information  is  detailed  in  table  2.16.  Spectra  were 
reconstructed using MDDnmr
147,148 under the guidance of Dr TJ Ragan. Through-
space NOE data was used for structural calculation. 
2.9.7 Residual dipolar couplings 
For  residual  dipolar  coupling  (RDC)  collection, 
15N  Fas-DD  was  aligned  in  Pf1 
bacteriophage  (ASLA  biotech  Pf1  co-solvent  P100-P)
149,  10  mg/ml  and  dialysed 
against  Fas  NMR  buffer.  For  NHH  couplings,  IPAP  (in-phase,  anti-phase)  type 
HSQC
150  experiments  and  for  HACA  couplings  HNCOCA  experiment  (with  no 93 
proton decoupling) were collected for aligned and non-aligned Fas samples. The 
1H-
15N residue dipolar coupling values (RDC) were calculated for each residue (using 
CCPN  Analysis
138)  by  subtracting  the  difference  between 
15N  frequencies  in  the 
spectra of the isotropic sample from the bacteriophage aligned sample. Module
151 
was  used  to  compare  experimental  RDC’s  with  simulated  RDC  values  from  the 
published Fas-DD solution structure (pdb:1DDF). RDC values were used within the 
structure calculation to help restrain the structure. 
2.9.8 Methyl-TROSY spectroscopy 
ILV-Fas-DD with Ile, Leu and Val residues specifically 
13CH3 labelled at one single 
methyl position was kindly provided by Dr Diego Esposito. NMR samples (110 µM) 
were prepared in buffer containing 20 mM Tris, 150 mM NaCl, 0.5 mM TCEP, 1 
mM EDTA, 3 mM NaN3 pH 6.2 in 
2H2O. Methyl-TROSY
152 spectra were recorded 
on a 800 MHz spectrometer. 
2.9.9 NMR relaxation experiments 
2.9.9.1 
15N Relaxation experiments 
T1,  T2  and  1H/15N  heteronuclear  NOE  data  was  collected  for  Fas-DD  in  three 
conditions: 
-  Fas-DD in NMR buffer (20 mM MES, 100 mM NaCl, 0.5 mM TCEP, 1 mM 
EDTA, 3 mM Sodium azide pH 6.2) 
-  Fas-DD  Y291E  in  NMR  buffer  (20  mM  MES,  100  mM  NaCl,  0.5  mM 
TCEP, 1 mM EDTA, 3 mM Sodium azide pH 6.2) 
-  Fas-DD in Crystal buffer (0.95 M citric acid, 1.9 M ammonium sulphate, pH 
4.0) 
 
T1, T2 and 1H/15N heteronuclear NOE data for Fas-DD construct was collected and 
analysed by Dr Diego Esposito prior to the author starting in the laboratory. Spectra 
were acquired at 25
oC. Relaxation delays are shown below in table 2.18. 
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Table 2.18 Parameters used in 





15N relaxation delay times (s) 
T1  10  0, 0.1, 0.2, 0.3, 0.4, 0.6, 0.8, 1, 1.25, 1.5 
T2  10  0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.08, 0.1, 0.125, 
0.15 
 




N  heteronuclear  NOE  data  were  recorded  at  600  MHz  using 
experiments  based  on  published  pulse  sequences
153,  but  optimised  by  the  MRC 
Biomedical NMR Centre, for Fas-DD Y275E and Fas-DD in crystal buffer. Spectra 
were acquired at 25 
oC using 1024 and 864 complex points in the direct and indirect 
dimensions. The spectral width in the direct and indirect dimensions was 9615.3 and 
2066.9 Hz. Relaxation delays are shown below in table 2.19. R1 and R2 values were 
determined for each residue by fitting an exponential decay (fitting function: Aexp(-
Bx)) to the peak intensity of data collected in an interleaved manner. In each case the 
error was determined from the fit according to a covariance procedure implemented 
in CCPN Analysis
138 assuming a normal distribution. Residues were excluded when 
overlap in the data precluded accurate measurement of peak intensity and where the 
chemical shift no longer matched the wild type assignment. 
Table 2.19 Parameters used in 
15N relaxation experiments at 600 MHz for Fas-DD Y275E 





15N relaxation delay times (s) 
T1  9  0.01, 0.05, 0.1, 0.3*, 0.6, 1, 1.5, 2, 
T2  9  0.008, 0.016, 0.024, 0.040*, 0.064, 0.096, 0.144, 0.2 
* - denotes repeated delay time 
2.9.9.2 Relaxation dispersion experiments 
CPMG based relaxation dispersion experiments were carried out upon Fas-DD, Fas-
DD Y275E and Fas-DD in crystallisation buffer. Spectra were acquired at 25
oC at 
600 MHz using 1024 and 600 complex points in the direct and indirect dimensions. 95 
The spectral width in the direct and indirect dimensions was 8417.5 and 2000 Hz. 
CPMG field strengths of 40, 100, 200, 400, 600, 800 and 1000 Hz (where one point 
was used for no relaxation) were applied during a 50 ms relaxation period. Peak 
intensities were extracted using CCPN Analysis
138 and fitted to a single exponential 
curve to look into the dispersion on a residue by residue basis. 
2.9.10 ARIA structural calculations for the Fas-DD 
Inter-proton distance restraints were derived from 3D 
15N-NOESY-HSQC and 
13C-
NOESY-HSQC spectra. A proportion of the resonances were successfully assigned 
in a manual fashion without ambiguity. Backbone φ and ψ torsion angle restraints 





15NH chemical shifts and 
extracted from CCPN Analysis
138. Hydrogen bond restraints for amide protons were 
derived from assessment of the helices of the protein from the current model (PDB: 
1DDF). RDCs were collected as described in 2.9.7. 
All structure calculations were carried out using the default settings from version 2.3 
of the ARIA (Ambiguous Restraints for Iterative Assignment) software package
154–
156.  Ambiguous  NOEs  were  calibrated  and  assigned  iteratively,  with  automatic 
assignments  being  checked  manually  throughout  the  refinement.  Per  calculation, 
nine  iterations  of  ARIA  were  carried  out,  with  20  structures  calculated  at  each 
iteration. After refinement of the 50 lowest-energy structures in explicit solvent, the 
final ensemble contained 20 structures with no distance restraint violations >0.5 Å 
and no dihedral angle restraint violation >5°. Figures were generated using PyMOL. 
 
2.10 Expressed protein ligation (EPL)  
2.10.1 Solid phase peptide synthesis (SPPS) 
The C-terminal phospho-tyrosine Fas peptide was synthesised by standard Fmoc (9-
fluorenylmethyoxycarbonyl) solid phase peptide synthesis (SPPS) techniques at a 
0.1 mmol scale using Rink Amide resin (0.1 mmol loading) (PL Rink Resin, 0.39 
mmol/g  loading).  The  first  32  amino  acids 
(DTLIKDLKKANLCTLAEKIQTIILKDITSDSE)  were  synthesised  on  a  CEM 
Liberty1  automated  microwave  peptide  synthesiser  with  DIC/HOBt  (1,3-96 
diisopropylcarbodiimide/hydroxybenzotriazole)  coupling  reagents,  with  a  ten-fold 
excess of Fmoc amino acids relative to the amount of resin. Amino acid deprotection 
was  carried  out  using  20%  piperidine  in  DMF.  To  reduce  secondary  structure 
formation  IT  (Fmoc-Ile-Thr(psiMe,Mepro)-OH)  and  QT  (Fmoc-Gln(Trt)-
Thr(psiMe,Mepro)-OH) pseudoproline amino acids (Novabiochem) were inserted at 
positions five and twelve (C to N-terminal) of the peptide respectively.  
Fmoc phosphotyrosine (Fmoc-Tyr(PO-(OBzl)OH)-OH, Novabiochem) and the final 
six  residues  (GKKEA)  were  incorporated  into  the  peptide  using  a  CS  Bio  336 
automated synthesiser with coupling reagents HBTU/DIEA (N-[(1H-benzotriazol-1-
yl)(dimethylamino)methylene]-N-methylmethanaminium  hexafluorophosphate  N-
oxide/N,N-diisopropylethylamine) with Fmoc amino acids at ten-fold excess relative 
to the resin. The reaction was followed by a final deprotection step to remove the N-
terminal Fmoc group. One equivalent of 2-hydroxy-3-thio-4-methoxy)benzyl (Htmb) 
auxiliary was coupled to the deprotected N-terminus of the peptide using microwave 
coupling, followed by treatment with sodium borohydride to reduce the peptide. 
The  peptide  was  cleaved  from  the  resin  in  trifluoroacetic  acid  (TFA)  with  5% 
trielthysilane, 5% H2O, 2% 1,2-ethanedithiol (EDT), for 1.5 hours. The TFA was 
filtered from the resin and sparged under nitrogen. The peptide was precipitated with 
sodium-dried diethyl ether and resuspended in 200 mM sodium phosphate pH 7.0-
7.5, 2 mM EDTA, 6 M guanidine-HCl, prior to freeze drying or preparation. 
Peptide  preparation  was  carried  out  by  semi-preparative  High  Pressure  Liquid 
Chromatography (HPLC), using a RP-C18 column (22x250 mm, Vydac) and the 
linear gradient, 15-35% B in 5 minutes, 35-70% B in thirty minutes at a flow rate of 
15 ml/min. Pure peptide fractions were pooled, lyophilised and stored at -20 
oC prior 
to deprotection. 
The auxiliary protecting group was removed from the full peptide in TFA with 2% 
thioanisole  and  0.167  mM  2,2′-Dithiobis(5-nitropyridine)  (DTNP)
157,158.  Each 
deprotection reaction consisted of 5 mg of lyophilised peptide was treated in 600 µl 
TFA. The deprotection reaction was incubated for one hour at room temperature; 
TFA was sparged away with nitrogen and precipitated using ice cold sodium-dried 
diethyl ether, resuspended in buffer A and prepared using semi-preparative HPLC as 97 
described above. Pure peptide fractions were pooled, lyophilised and stored at -20 
oC. 
At each stage of the synthesis, small aliquots of resin were removed and test cleaved 
(using  the  cleavage  conditions  described  above)  to  check  the  synthesis  was 
progressing correctly. Samples were analysed by RP-HPLC and MALDI-MS. 
2.10.2 Intein mediated protein preparation 
2.10.2.1 Expression, chitin purification and on-column cleavage 
Fas  N-terminal  constructs  were  expressed  in  BL21  (DE3)  Gold  as  described  in 
2.5.1.1. Protein expression was induced by the addition of 0.5 mM of IPTG once the 
cell density had reached an optical density of 0.6 at 600 nm. Optimal expression was 
achieved  when  expressed  overnight  at  20 
oC.  Cells  were  lysed  and  clarified  as 
described in 2.6.1. 
Per  1  litre  of  overnight  cell  culture,  7-10  ml  of  chitin  resin  (New  England 
Biosciences) was packed into a gravity-driven column and equilibrated in 10 CV of 
chitin  binding  buffer.  For  the  N-terminal  Fas  chitin  binding  buffer  was  20  mM 
sodium phosphate, pH 6, 0.5 M NaCl, 1 mM EDTA, 1.5 M urea; for the MBP-N-
terminal Fas chitin binding buffer was 20 mM sodium phosphate, pH 6, 0.5 M NaCl, 
1 mM EDTA. The supernatant of the clarified cell lysate was applied to the resin and 
the flow through was loaded a second time. The resin was washed with 5 CV of 
chitin binding buffer followed by 1 CV wash in chitin cleavage buffer, (degased 
chitin binding buffer containing 16.67 mM TCEP and 5 mM benzyl mercaptan). The 
column was incubated overnight in 1.5 CV of chitin buffer for on-column intein 
cleavage to occur. Following incubation, the column was washed in 5-10 CV of 
chitin buffer to elute cleaved product. 15 µl of each step was collected and analysed 
by SDS-PAGE. H269G mutant constructs were left incubating with chitin cleavage 
buffer for 72 hours to increase the yield of cleaved protein. 
2.10.2.2- N-terminal fragment preparation  
When  the  elution  from  the  chitin  column  contained  urea,  the  protein  was 
concentrated by centrifugal concentration to 5 ml. Final purification was achieved by 
semi-preparative  high  performance  HPLC  using  a  reverse  phase  C18  column 98 
(22x250 mm Vydac) with a linear gradient of A and B (15-35% in five minutes, 35-
75% in 30 minutes) at a flow rate of 15 ml/min. Fractions were analysed by MALDI-
MS. 
For  non-urea  containing  chitin  eluted  proteins,  fractions  were  lyophilised, 
resuspended  in  purified  water  and  desalted  using  PD10  desalting  columns  (GE 
Healthcare) equilibrated in 10 mM HCl. The final step of purification was using 
semi-preparative HPLC as described above. Fractions were analysed by ESI-TOF-
MS.  Pure  N-terminal  Fas  protein  was  lyophilised  and  stored  at  -20 
oC  prior  to 
ligation reactions. 
2.10.3 Expressed protein ligation of N and C terminal Fas 
The  ligation  of  pY291-Fas-DD  was  performed  as  follows:  200  mM  sodium 
phosphate buffer (pH 7.4) containing 2 mM EDTA and 6 M guanidine was degassed 
with argon for 20 min before use. 50 mM TCEP was added and the pH adjusted to 7. 
Protein  thioester  and  auxiliary  conjugated  peptide  were  dissolved  at  a  final 
concentration of 0.5 mM-5 mM. The ligation reaction was performed in a heating 
block at 30 
oC unless otherwise stated. Before analysis, 2 µl of the ligation reaction 
was quenched in 8 µl buffer A. The ligation was monitored by reverse phase HPLC 
with  a  C18  or  C4  column,  using  a  linear  gradient  of  (30-60%  and  30-50% 
respectively) of buffer B in buffer A over 30 minutes. Confirmation of HPLC peaks 
was carried out by MALDI-MS. 
2.10.4 RP-HPLC 
Analytical reverse phase HPLC was carried out using C4 (Vydac, 214TP C4 5 μM 
150  mmx4.6mm)  or  C18  columns  (Vydac,  218  TP  C18  5µ  150x4.6  mm)  in  an 
Agilent  1200  series,  or  Hitachi  elite  LaChrom  HPLC  machines.  Flow  rates  at  1 
ml/ml and thirty minute linear gradients were used as standard where buffer A was 
0.1% TFA and buffer B was 90% acetonitrile with 0.1% TFA. 99 
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Exploration of the propensity of the Fas death 




3.1.1 Death domain structures are inherently difficult to solve 
Solving the three dimensional structures of death domains has been used to inform 
our  understanding  of  the  basis  of  death  receptor  signalling.  The  classical  death 
domain fold is a bundle of six alpha helices in a Greek key topology: the nature of 
the domains surface features confer protein-protein signalling capabilities through 
homotypic interactions
159.  
The classical route of protein structure determination is to isolate the  domain of 
interest from a whole protein, then to solve the structure by NMR spectroscopy or X-
ray crystallography. However, as the native function of a death domain is to undergo 
oligomerisation and interact with other proteins, the isolation and study of death 
domains in vitro has proved challenging
160. Out of the 24 death domain structures 
deposited  in  the  Protein  Data  Bank  (both  isolated  domains  and  from  interacting 
complexes),  those  that  are  involved  in  apoptotic  signalling  were  only  able  to  be 
solved  under  non-physiological  conditions  or  with  the  presence  of  stabilising 
mutations  preventing  self-association  as  illustrated  in  Table  3.1.  For  example,  to 
obtain a monomeric Fas-DD at the concentrations needed to solve the structure by 
NMR, the solution structure was solved at the non-physiological pH 4. However the 
authors reported that the non-aggregating D260A mutant formed the same structure 
at a pH of 6
6. 
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Table 3.1 Conditions that death domain structures have been solved in 
 
Death domain  PDB code  Technique  Conditions  Complex 
(Y/N) 
Reference 
Ankryin  2YVI  X-Ray  200mNaCl, 
100mM Tris, 
pH8.5, 25% PEG 
3350 
N  N/A 2007 
Ankryin-1  2YQF  NMR  20mM Tris pH7, 
100mM NaCl, 
1mM DTT, 0.02% 
NaN3 
N  N/A 2007 




N  Berglund et al 
2000 
FADD  2GF5  NMR  50 mM potassium 
phosphate (pH 4), 
150mM NaCl, and 
1mM DTT - F25Y 
mutation 
Y  Carrington et al 
2006 
Fas  1DDF  NMR  pH4  N  Huang et al 1995 
Fas:FADD (4:4)  3EZQ  X-Ray  0.95M citric acid, 
1.9M ammonium 
sulphate, pH4 
Y  Scott et al 2009 













N  Lasker at al 2005 
IRAK-4  1WH4  NMR  20mM Tris pH7.5, 
100mM NaCl, 
1mM DTT, 0.02% 
NaN3 
N  N/A 2009 
mFADD  1FAD  NMR  50mM sodium 
acetate pH4 
N  Jeong at al 1999 
Myddosome 
(MyD88-IRAK4-
3MOP  X-Ray  50mM tris pH8.5, 
250mM MgCl2, 8-
Y  Wang at al 2012 101 
IRAK2)  15% ethanol 
NFkB p100 subunit  2D96  NMR  200mM Tris, pH7, 
100mM NaCl, 
1mM DTT, 0.02% 
NaN3 
N  N/A 2005 
NFkB p105 subunit  2DBF  NMR  200mM Tris, pH7, 
100mM NaCl, 
1mM DTT, 0.02% 
NaN3 
N  N/A 2005 
Nuclear matrix 
protein p84 
1WXP  NMR  20mM Tris pH7, 
100mM NaCl, 
1mM DTT 
N  N/A 2005 
p45  2IB1  NMR  PBS pH7  N  N/A 2005 
p75 Neurotrophin 
receptor 
1NGR  NMR  pH6 and pH7 
dependent on 
experiment 
N  Liepinsh et al 1997 





N  Moncrieffe et al 
2005 
Pelle and Tube 
complex 
1D22  X-Ray  20%–25% PEG 2K 
monomethyl ether, 
100 mM EPES at 
pH 7.2–8.4, 0–200 
mM NaCl 
Y  Xiao et al 1999 




Y  Park et al 2007 
RAIDD  2O71  X-Ray  20mM Tris pH8, 
150mM NaCl 
mixed 2M Na/K 
phosphate pH7 
  Park and Wu 2006 
TNFR1  1ICH  NMR  10mM sodium 
acetate pH4, 10mM 
DTT - R347K 
mutation 
N  Sukits et al 2001 
UNC5b  3G5B  X-Ray  0.1M MES, pH6.5    Wang et al 2009 
UNC5H2 (netrin1 
Receptor) 
1WMG  X-Ray  100mM MES 
pH6.4, 1.8M 
MgSO4 
Y  Handa et al 2006 102 
3.1.2  The  currently  available  Fas-DD  structures  show  diverse  polypeptide 
topologies, suggesting some plasticity in the domain 
The  solution  structure  of  the  Fas  death  domain  (Fas-DD)  was  solved  in  1996
6. 
However, only a single coordinate set was deposited in the Protein Data Bank, with 
no  resonance  assignments,  restraints  or  alternative  conformations  placed  in  the 
public  domain.  At  the  time  this  solution  structure  of  the  Fas-DD  was  the  first 
observation of the death domain fold. 
The  Fas-DD  is  made  up  of  six  antiparallel  amphipathic  helices,  containing  a 
disordered  C-terminal  tail  as  shown  in  Figure  3.1A.  This  conformation  will  be 
referred to as the ‘closed’ Fas formation. 
In recent years a debate has begun regarding the possibility that the Fas-DD could 
form  alternative  conformations  to  the  published  solution  structure.  In  part,  this 
debate  derives  from  the  publication  of  two  papers  detailing  different  oligomeric 
states  of  the  complex  formed  between  the  Fas  and  FADD  death  domains  which 
illustrate different formations of the Fas-DD
121,123,124.  
In 2009 the crystal structure of a complex containing four Fas and four FADD death 
domains  (4:4  complex)  indicated  that  the  interaction  was  dependent  upon  the 
remodelling  of  the  structure  of  Fas-DD.  This  crystal  structure  suggests  that  the 
interaction with FADD-DD causes a conformational change within the Fas death 
domain, in which the Fas α5 and α6 helices rearrange to form an elongated stem 
helix paired with a structured C terminus of the domain
121 (shown in Figure 3.1B). 
This remodelling formed the main interaction surface between Fas-DD and FADD-
DD in the 4:4 hetero-oligomer
121. The more open conformation of Fas-DD exposes 
the hydrophobic core of the domain enabling an interaction with a hydrophobic patch 
upon the surface of FADD-DD. Whereas the FADD-DD retains a six helical Greek 
key topology expected from a death domain. The elongation of Fas-DD helices 5 and 
6 form what the authors describe as a Fas-Fas bridge within the structure suggesting 
that  this  interaction  stabilises  the  more  open  conformation  and  could  act  in  a 
regulatory role in the formation of the DISC. Although this complex was formed by 
mixing cell lysates at physiological pH (pH 7.8) the crystallisation conditions were at 
pH 4. From this point onwards this will be described as the ‘open’ Fas conformation. 
Interestingly,  it  has  previously  been  reported  that  Fas-DD  was  unable  to  self-
associate at pH 4
6. 103 
In the Fas-DD solution structure also at pH 4, the C-terminus of Fas is unstructured, 
with no evidence of fusion of helix five and six.
6 (Figure 3.1A). In depth biophysical 
analysis has since shown that the C-terminal twelve residues of intracellular Fas are 
not required for the formation of the Fas:FADD complex in solution
122,123, with this 
C  terminus  remaining  in  a  disordered  formation  upon  interaction.  Sequence 
alignment  illustrated  that  the  C  terminus  of  Fas  is  not  conserved  between 
orthologues  suggesting  that  the  stem  loop  formation  at  helices  5  and  6  is  not  a 
universal  mechanism  for  DISC  formation
123.  In  solution,  the  predominant 
stoichiometry  observed  by  NMR  spectroscopy  and  ESI-MS  of  the  Fas:FADD 
complex was in a 5:5 ratio
123, as illustrated in in Figure 3.2C. 
The crystal structure of a 5:5 Fas:FADD complex (not involving the C terminal tail) 
has since been reported, shown in Figure 3.1D
124, corroborating the stoichiometry 
observed in solution
123. This crystal structure was solved in less harsh pH and salt 
conditions (0.1 M Tris pH 8.5, 100 mM MgCl2, 5% glycerol, 6-10% PEG 4000) 
compared  to  the  4:4  crystal  structure  perhaps  suggesting  this  is  a  more  relevant 
Fas:FADD oligomer. Within this complex, the Fas-DD formed a fold identical to 
that  reported  in  the  original  solution  structure.  Although  identified  in  both 
crystallographic and solution studies a 5:5 Fas complex also struggles to rationalise 
trimeric  Fas  interacting  with  FADD,  as  Fas  is  widely  accepted  to  exist  in  the 
membrane in a trimeric form. Ultimately none of the Fas:FADD complex models 
which are currently in existence fully explain the results from in vivo experimental 
observations upon the formation of the Fas DISC. 
A comparison of the three observed Fas-DD conformations is shown in Figure 3.2, 
illustrating  each  death  domain  using  a  ribbon  cartoon.  Although  the  4:4  crystal 
structure  was  obtained  in  non-physiologically  relevant  conditions  (pH  4)
121,  the 
variation in the Fas-DD structure highlights scope for conformational plasticity of 
the  domain,  which  may  be  relevant  to  further  aspects  of  DISC  formation  and 
downstream events. 
3.1.3  Post  translational  modifications  within  the  Fas-DD  may  infer  domain 
flexibility 
It has been reported that the Fas death domain is phosphorylated upon Tyr 291, 
resulting in Fas oligomerisation and non-apoptotic signalling
55. Tyr 291 is located 
within a suspected SH2 domain target site (a YxxL motif) which would suggest that 104 
upon phosphorylation Fas is able to recruit protein domains which are not involved 
with  the  usual  cell  death  pathways
62.  In  the  current  Fas-DD  solution  structure, 
Tyr291 and Leu294 have a relatively low surface accessibility which is illustrated in 
Figure 3.3A&B. The addition of a phosphate group upon Tyr291 would disrupt the 
structure of the Fas-DD both by adding steric bulk as well as changing the properties 
of the region. This could be taken as an indication that the Fas death domain is able 
to tolerate some level of flexibility in its structure. 
A rigid death domain would further be challenged by the recruitment of SH2 domain 
containing  signalling  proteins  as  in  the  canonical  model,  an  SH2  domain  would 
require  Leu  294  to  also  be  exposed,  which  in  this  conformation  would  not  be 
possible. The location of this post translational modification further highlights the 
scope for flexibility within the Fas death domain which was not observed in the 
previous solution studies. In the ‘open’ Fas death domain observed in the crystal 
structure, (had the domain not been in complex) Y291 and L294 would be positioned 
in a surface exposed location which could aid in phosphorylation and recruitment of 
alternative signalling proteins. A comparison of Y291 surface accessibility in both 
the  solution  death  domain  structure  and  the  ‘open’  crystal  structure  is  shown  in 
Figure 3.3 





Figure 3.1 The published structures of Fas-DD and Fas-DD:FADD-DD 
A, The solution structure of Fas-DD (PDB:1DDF) showing the classical 6 helical bundle with a disordered C 
terminal tail. B, The crystal structure of the 4:4 Fas:FADD complex (PDB:3EZQ). Fas is highlighted in blue 
shades and FADD in grey. An individual Fas-DD is also shown, highlighting elongation of a5 and a6 helices 
and an ordered C terminal tail. C, Schematic representation of the 5:5 Fas:FADD complex inferred from solution 
techniques by Esposito et al. D, Crystal structure of the 5:5 Fas:FADD, (PDB:3OQ9). Fas-DD in blue shades and 
FADD-DD shown in grey. An individual Fas-DD is shown in blue showing a similar domain organisation to that 





Figure 3.2 Comparison of the three published structures of Fas-DD  
A, NMR structure of the Fas-DD, PDB:1DDF. B, Structure of Fas-DD taken from the 4 Fas:4 FADD crystal 
structure, PDB: 3EZQ. C, Structure of mFas-DD taken from the 5 Fas: 5 FADD crystal structure, PDB: 3OQ9. 




Figure 3.3 Location of Y291 within the current Fas-DD models 
Cartoon (A) and surface (B) representations of Fas-DD in the closed conformation (PDB:1DDF).  Cartoon (C) 
and  surface  (D)  representations  of  Fas-DD  in  the  open  conformation  (PDB:3EZQ).    The  YxxL  motif  is 
highlighted, Y291 is highlighted in blue, D292 and T293 are highlighted in yellow and L294 in red. 
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3.1.4 Structural similarity between the known death domain structures 
The remodelling of the Fas death domain shown in the 4:4 crystal structure of Fas-
DD and FADD-DD appears to be unique throughout the known structures of death 
domain containing proteins.  
Sequence  analysis  published  by  Feinstein  and  Kimchi  described  two  different 
subtypes  of  death  domains,  relating  to  the  structures  predicted  through  sequence 
analysis. Death domain subtype 1 was described as having a less conserved α1 helix, 
and included the death domains involved in apoptosis and cytotoxic effects such as 
Fas, FADD, RIP and TRADD death domains
161. Subtype 2 was described as having 
longer  loop  regions  between  helices  α3-α4  and  α4-α5  and  conserved  prolines 
between helices, describing proteins DAP (death associated protein) kinase related 
proteins  and  the  NGFR  (nerve  growth  factor  receptor)  death  domain.  From  the 
eighteen isolated death domain structures deposited in the protein data bank, these 
differences  in  helix  conservation  and  loop  length  appear  to  be  the  only  major 
difference between the death domain structures. Examples of the similarity in the 
death domain structures are illustrated in Figure 3.4 in which the overall globular six 
helix shape is conserved with minimal differences between the globular structures.  
The structure of the FADD death domain has been published a number of times from 
both human
162 and murine
163 sources as well as in tandem with its death effector 
domain
27. Each structure shows an overall similarity to  Fas-DD even though the 
sequence similarity between human Fas and FADD death domains is only around 
14%. However in the other death domains, there are some subtle differences within 
their structures compared to Fas-DD. The death domain of TNFR shows an example 
of  some  rearrangement  in  that  helices  α2  and  α4  become  more  compact  when 
compared  to  Fas-DD
160  (Figure  3.4D).  This  has  also  been  shown  for  the  death 
domain of the p75 neurotrophin receptor which is involved in neuronal growth and 
migration. P75 death domain was categorised as a subtype 2 death domain, showing 
reorientation of helix one to be perpendicular to its equivalent location in the Fas-
DD, with the authors commenting that this is a large rearrangement for a conserved 
death domain
164. The crystal structure of IRAK4 (interleukin-1 receptor-associated 
kinase  4)  also  highlights  that  the  loop  regions  amongst  death  domains  can  be 
variable, with an eleven amino acid loop between helices two and three
165(Figure 109 
3.4E). Just to note, none of the known death domain structures other than Fas-DD 
describe any helical rearrangement between helices five and six either in isolation or 
when in a complex. Observed helical rearrangements have only been described to 
have occurred between helices α1 to α4. 
A number of death domain structures have been solved in their hetero-oligomeric 
form as well as in isolation, much like the known structural data for Fas-DD. The 
complex structures of both the Myddosome
166 (oligomeric complex containing death 
domains of MyD88, IRAK2 and IRAK4) and the Piddosome
79 (oligomeric complex 
containing  the  death  domains  of  PIDD  and  RAIDD)  showed  no  difference  in 
structure  of  the  death  domain  subunits  found  in  the  complexes  compared  to  the 
individual structures of the IRAK4
165 and RAIDD (RIP-associated Ich-1 protein with 
a death domain)
167 subunits respectively. However, there is one example of a death 
domain complex other than Fas and FADD which illustrates some level of structural 
rearrangement  between  crystal  and  solution  forms.  The  death  domain  complex 
containing Drosophilia proteins Pelle and Tube have been shown to be involved in 
the dorsal-ventral patterning of the Drosophilia embryo. The crystal structure of the 
complex  describes  the  three  dimensional  folds  of  the  proteins  involved  as  death 
domains,  highlighting  the  hydrophobic  core  which  is  preserved  throughout  the 
family of proteins. The complex contained a linear arrangement of four domains 
(two Pelle and two Tube) showing two distinct interaction sites with the authors 
describing  the  interaction  as  ‘plastic’
168.  Both  further  crystallographic  and  NMR 
spectroscopic analysis suggested some differences between the isolated Pelle domain 
to the one which had been crystallised. An attempt to crystallise Pelle resulted in the 
observation  of  a  non-classical  death  domain  shaped  protein,  with  the  domain 
rearranging  into  a  single  helix  which  formed  an  antiparallel  dimer.  However  in 
solution, results obtained from NMR spectroscopy still suggested the protein formed 
a six helical bundle. It was finally concluded that the single helical formation was 
possibly due to the conditions that the crystal was grown in
169, whereas in the NMR 
solution structure the structure of the Pelle death domain was similar to the death 
domain topology shown in the crystal complex. The authors went on to comment 
that they saw no evidence of the plastic nature of the interaction with Tube in the 
NMR, putting into doubt that the crystallographic tetramer was a suitable model for 
the  interaction  of  Pelle  and  Tube
170.  Parallels  between  this  example  of  a  death 110 
domain forming a different structure under different methodological conditions and 
the two known structural forms of Fas-DD could be drawn, as this is an example of 
another  death  domain  showing  some  level  of  structural  rearrangement  upon 
interacting with another death domain.  
3.1.5 Aims 
This chapter documents the approaches taken to validate whether the ‘open’ Fas-DD 
conformation  is  relevant  to  a  functioning  death  domain  in  solution.  Initial  NMR 
characterisation of the Fas-DD has previously been carried out within the laboratory, 
providing information about the Fas death domain in complex with FADD. This 
chapter expands on that work to investigate whether Fas-DD can exist in the reported 
open, crystal conformation in isolation, in a solution environment.  
This chapter describes (a) the collection and assignment of modern multidimensional 
NMR structural experiments for the Fas-DD to assess the intramolecular interactions 
within the domain and (b) the exploration of the dynamic properties of the Fas-DD in 
solution. Fas-DD dynamic properties were assessed using traditional spin-relaxation 
and  relaxation  dispersion  measurements  in  conditions  designed  to  mimic  the 
presence of a phosphorylated Y291 and in the crystal environment that the ‘open’ 
Fas structure was reported in. 
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Figure 3.4 Examples of Fas-DD structures 
A  and  B,  overlay  of  15  separately  determined  death  domain  structures,  PDB  accession  codes:  1DDF,  Fas-
DD;1FAD, 1E41, 1E3Y, FADD-DD; 1ICH, TNFR1-DD; 1NGR, p75 neutrotrophin receptor-DD; 1WH4, 2A9I, 
IRAK4-DD; 1WXP, nuclear matrix protein p84-DD; 2D95, NFkB p100-DD; 2DBF, NFkB p105-DD; 2IB1, P45-
DD; 2O21, RAIDD-DD; 2YQF, ankryin-1-DD; 2YVI, ankryin-DD. C, isolated DD of FADD, 1E3Y. D, isolated 
DD of TNFR1, 1ICH. E, isolated DD of IRAK4, 1WH4. F, isolated DD of RAIDD, 2O71. Helices are coloured 
from N to C termini. Helix 1, red; helix 2, orange; helix 3; yellow; helix 4, green; helix 5, cyan; helix 6, blue.112 
3.2 
15N 
13C Fas-DD expression and purification 
Vectors  expressing  Fas-DD  (residues  218-319)  and  Fas-DD+CTD  (residues  218-
335) with an N-terminal TEV cleavable hexa-histidine tag and GB1 solubility tag 
were  kindly  donated  by  Dr  Diego  Esposito.  These  constructs  were  used  for  the 
biophysical studies of Fas-DD published previously
123. 
BL21 (DE3) Gold E. coli expression strains were used for the expression of both Fas 
constructs. Expression had been previously optimised by Dr Diego Esposito. Both 
Fas constructs were expressed with 0.5 mM IPTG for sixteen hours at 22 
oC. These 
were the conditions used for large scale expression of the proteins. Isotopic labelling 




13C-labelled minimal medium as detailed in Section 2.5. 
Purification  was  carried  out  using  the  N-terminal  hexa-histidine  tag  for  Ni-NTA 
affinity  purification  which  was  followed  by  purification  tag  removal  using  TEV 
protease.  A  final  clean-up  of  the  preparation  was  carried  out  by  size  exclusion 
chromatography, as described in Section 2.6. Figure 3.5 shows SDS-PAGE analysis 




The  solubility  of  Fas  constructs  was  enhanced  by  the  presence  of  the  K263A 
mutation which has been shown to enable Fas-DD constructs to be concentrated up 
to 700 µM without aggregation occurring
6. This enabled preparation of protein at 
concentrations suitable for NMR samples. For NMR experiments, the protein was 
typically concentrated by centrifugal concentration to between 500 µM and 700 µM. 
The presence of the K263A mutation ensured that the constructs were monomeric 
and soluble at these concentrations. 
3.3 Backbone resonance assignments 
In  order  to  obtain  residue-specific  information  from  HSQC  based  experiments, 
assignment of the cross peaks in the 
15N/
1H-HSQC spectrum is required. This is 
traditionally the first step in NMR characterisation of a protein. The 
1H/
15N-HSQC 
spectrum  is  considered  the  fingerprint  of  a  protein,  with  each  peak  within  the 
spectrum corresponding to the NH of a single amino acid.   113 
 
Figure 3.5 Purification of Fas-DD 
SDS-PAGE analysis of the IMAC purification of 
15N
13C Fas-DD is shown in A. The elution was taken and TEV 
cleaved prior to running back over an IMAC column, SDS-PAGE analysis post TEV cleavage is shown in B. The 
flowthrough and wash from the post TEV IMAC purification was taken, concentrated to 5ml and loaded upon a 
Superdex 75 SEC column. The elution profile (monitored by UV absorbance at 280nm) and SDS-PAGE analysis 
of the peak are shown in C. The pure fractions were taken and concentrated for NMR. 
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Assignment  of  the  resonances  in  the 
1H/
15N-HSQC  corresponds  to  the  backbone 
resonance of the construct. Identification of the backbone NH cross peaks in the 
1H/
15N-HSQC spectrum was necessary for further assignment of the structure of Fas-
DD as well as analysis of the dynamic properties of Fas-DD. Throughout this thesis 
1H/
15N-HSQC based experiments of Fas-DD have been used to assay protein:protein 
interactions. The assignment of the backbone NH cross peaks of Fas-DD inferred 
binding information to these experiments as well. 
The backbone resonance assignment for Fas-DD+CTD had previously been carried 
out within the laboratory by Dr Diego Esposito. Due to the highly overlapped nature 
of the spectra, backbone assignment remained incomplete. As a basis for training in 
protein NMR and to attempt to complete backbone assignment for Fas-DD+CTD, I 
repeated the assignment process, starting from the raw data which had previously 
been collected by Dr Diego Esposito. 
Through-bond  triple  resonance  NMR  experiments  to  correlate  backbone  amide 
resonances  to  the  Cα,  Cβ  and  C’  atoms  of  the  same  and  previous  residues  were 
recorded to establish a stretch of sequential cross peak connections. Dr D. Esposito 
collected  HNCA,  HN(CA)CB,  HNCO,  HN(CA)CO  and  CBCACONH  3D 
heteronuclear experiments to enable these connections to be made. The details of 
these experiments are shown in Chapter 2. The experiments were recorded upon a 
15N 
13C-labelled  sample  at  25 
oC  at  600,  700  and  800  MHz.  Field  strength  and 
experimental parameters are detailed in Chapter 2, the raw data was processed using 
in house generated NMRPipe
137 scripts and analysed using CCPN-Analysis
138.  
Through  my  own  analysis  of  these  datasets  within  the  CCPN-Analysis  software 
package, I assigned 109 backbone NH resonances out of 117, corresponding to 93% 




15NH  frequencies  as  illustrated  in  Figure  3.6.  The  dotted  lines  represent  the 
correlation of the selected NH peak (the region of the spectrum the strip corresponds 
to) with the respective intra- (i) and inter-residue (i-1) 
13Cα and 
13Cβ atoms. The 
amide NH cross peak assignment is illustrated upon the 
1H/
15N-HSQC spectrum of 
Fas-DD+CTD shown in Figure 3.7. 
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Figure  3.6  Example  of  the  strategy  of  sequential  assignment  used  to  assign  the  backbone 
resonances of Fas-DD 




13C correlations from residues Asn 223 to Val 227 of Fas-DD. Cross peaks are labelled 
corresponding  to  whether  they  originate  from  Cα  or  Cβ  and  intra  (i)  or  inter  (i-1)  residue  carbon  atom 




Figure 3.7 Assigned 
1H/





15N-HSQC  spectrum.  Each  red  peak  corresponds  to  the  backbone  NH  from  one  amino  acid  in  the 
sequence. The centre of the spectrum is enlarged to highlight the peaks in this overlapped region. B, sequence of 
Fas-DD+CTD with the residues with backbone assignments highlighted in red. Buffer conditions: NMR buffer 
(20 mM MES, 100 mM NaCl, 20 mM MES, 100 mM NaCl, 0.5 mM TCEP, 1 mM EDTA, 3 mM Sodium azide 
pH 6.2). 
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The  reasons  for  less  than  complete  assignment  of  the  cross  peaks  shown  in  the 
1H/
15N-HSQC spectrum include unresolved NH cross peaks and lack of tractable 
HN(CA)CB correlations. In conjunction with the alpha helical nature of Fas-DD, the 
non-folded flexible N and C termini of the constructs resulted in regions of spectra 
which were impossible to fully resolve. 
 
3.4 The Fas-DD forms a compact structure in solution 
To  build  upon  the  possibility  that  Fas-DD  could  exist  in  alternative  forms  in 
solution, modern multidimensional NMR techniques were implemented to solve the 
solution structure of the Fas-DD. 
3.4.1 NMR structural experiment rationale 
The NMR experimental work flow used to get to the point of structure calculation is 
summarised in Figure 3.8. The backbone resonance assignment was carried out using 
HNCA, HNCACB and CBCAcoNH experiments as described in Section 2.9.5. As 
mentioned  above,  these  experiments  were  carried  out  upon  the  Fas-DD+CTD 
construct. These assignments were used as the basis for Fas-DD structure assignment 
as the cross peaks in the 
1H/
15N-HSQC spectrum of Fas-DD overlaid perfectly with 
the 
1H/
15N-HSQC  of  Fas-DD+CTD  making  for  facile  transfer  of  the  resonance 
assignments to the spectrum of the former construct.  
The next step was to assign resonances to the 
13C and 
1H atoms of the protein side 
chains. 
15N-TOCSY and HCCH-TOCSY experiments were used to assign side-chain 
proton atoms. This was achieved using the resonance of the NH peak in the 
1H/
15N-
HSQC  in  conjunction  with  the  location  of  the  Cα  and  Cβ  resonances  from  the 
backbone experiments to inform the location of the correct 
13C strips in the HCCH 
spectrum to yield the side chain proton connectivities.  
To obtain restraints for structure calculations, through-space 
15N- separated-NOESY 
and 
13C-separated aromatic and aliphatic NOESY spectra were collected. NOESY 
experiments show correlations between atoms that are relatively close in space, up to 
a separation of approximately 5Å. Figure 3.8 illustrates the magnetisation transfer 




















Figure 3.8 Flow chart for structural data collection of the Fas-DD 
Diagram showing the experiments used to collect atomic assignments for Fas-DD. Schematic diagrams show the 
transfer of magnetisation between atoms for each NMR experiment collected. Atom colour corresponds to how 




13C-NOESY) were repeated using both uniform and non-uniform sampling to obtain a better signal 
to noise for assignment. Information has been adapted from www.protein-nmr.org.uk. 119 
3.4.2 Fas-DD side chain resonance and through-space resonance assignment were 
greatly improved with the use of non-uniform sampling schemes 
Side  chain  resonance  assignments  were  initially  attempted  using  traditional 
uniformly sampled 
15N-TOSCY and 
13C-HCCH-TOCSY spectra in which all data 
points  in  the  indirect  dimensions  are  systematically  sampled,  and  the  data  is 
processed  using  standard  Fourier  transform  methods.  In  practice  assignment  was 
hampered due to low resolution within the HCCH-TOCSY spectrum combined with 
limited chemical shift dispersion resulting in peak overlap. 30% of the side chain 
resonances could be assigned using these spectra. 
The data was re-acquired for the same protein samples using non-uniform sampling 
as detailed in Section 2.9.6. Non uniform sampling (NUS) relies on the collection of 
a carefully selected subset of the indirect dimension data points of an experiment 
which  is  followed  by  the  reconstruction  of  the  full  experimental  dataset  using 
sophisticated  signal  processing  methods.  The  application  of  non-uniform  data 
sampling  allows  the  extension  of  the  effective  acquisition  time  in  the  indirect 
dimension(s),  without  extending  the  overall  measuring  time  of  the  experiment. 
Because the effective signal acquisition times are extended, NUS combined with 
non-standard signal processing results in a higher signal resolution in the indirect 
dimensions  than  is  achievable  by  traditional  methods.  The  Fas-DD  NMR  data 
recorded with NUS spectral reconstruction was carried out by Dr TJ Ragan using the 
IRLS function of MddNMR. The increased spectral resolution achieved through the 
NUS methods reduced peak overlap and facilitated the extension of the side chain 
assignments. This is illustrated for the resonances corresponding to Ile222 in the 
HCCH-TOCSY spectrum in Figure 3.9. To date the implementation of the NUS 
method of spectral sampling has enabled 91% of the side chain resonances to be 
assigned. 
Nuclear  Overhauser  effect  spectroscopy  (NOESY)  spectra  are  used  to  obtain 
distance  restraints.  In  a  NOESY  spectrum,  each  cross  peak  corresponds  to  the 
correlation of two (sets of) protons that are close in space. Due to the high number of 
cross peaks present in a NOESY spectrum there is often a high degree of overlap, 
leading  to  potential  for  ambiguity  in  the  assignment.  For  Fas-DD,  the  uniform 
sampled 
13C-NOESY  spectrum  was  particularly  crowded,  which  hindered  the 
assignment of 
1H resonances. 120 
 
Figure 3.9 Non-uniform sampling increases resolution in side-chain spectra which simplified 
side-chain proton assignments 
Strip plots from HCCH-TOCSY experiments which were uniform sampled (A) and non-uniform sampled (B) 
which  were  assigned  to  Ile  222.  Non-uniform  sampling  markedly  increased  the  resolution  of  peaks  in  the 
spectrum (B) allowing more assignments to be made. 121 
To  overcome  this  problem,  the  NOESY  data  was  also  re-acquired  using  NUS 
techniques and reconstructed by Dr TJ Ragan using the MDD function of mddNMR. 
The use of NUS again improved peak resolution, reducing overlap, which enabled an 
increased number of unambiguous NOE assignments to be made.  
3.4.3  Secondary  chemical  shift  index  (CSI)  infers  a  compact  death  domain 
structure 
Backbone resonance assignment of a protein assigns a 
13C and 
1H chemical shift to 
the Cα, Cβ and H atoms of the amino acids which make up the protein. Each amino 
acid has a known propensity to reside within a particular chemical shift window; a 
property that is exploited in the assignment of the backbone resonances. As is true 
throughout all protein NMR applications, the chemical shift of an atom is modulated 
by the chemical environment in which it resides, whether that is the external solution 
or the amino acids surrounding the residue of interest. Thus, the chemical shift of a 
particular atom of an amino acid is dependent upon the nature and character of the 
local secondary structure of the protein. Exploiting this observation, Wishart and 
Sykes described what they called the ‘chemical shift index’ (CSI) as a technique to 




171,172. CSI exploits the deviation in chemical shifts of certain nuclei 
relative  to  known  random  coil  chemical  shifts  as  a  method  to  detect  secondary 
structure, assigning an index value of 1 if the amino acid is in a position expected to 
form an α helix or -1 if in a β-strand. Using the CSI profile it is possible to assess the 
secondary  structure  content  of  a  protein  using  just  the  backbone  resonance 
assignments  and  no  NOESY  through  space  assignments.  Mapping  the  chemical 
shifts in such a manner is an accurate method to obtain a consensus estimate of the 
secondary structure of the molecule
171,172. 
Following backbone resonance assignment, the CCPNAnalysis program, was used to 
extract the chemical shifts of the 
13Cα, 
13Cβ and 
1H atoms and assign a chemical shift 
index score to each of the residues. The CCPNAnalysis readout of chemical shift 
perturbation and chemical shift index scores for Fas is shown in Figure 3.10. The 
carbonyl  chemical  shift  difference  (∆δ)  has  been  omitted  from  the  plot  as 
assignments were made using the HNCO and HNcaCO spectra. 



























































































































































































































































































































































































































































































































































































































































































































































































   123 
The chemical shift difference (∆δ) for Fas-DD in solution shows that the secondary 
structure contains six alpha helices in the locations expected from the previously 
published Fas-DD NMR structure. This suggests that the domain forms a compact 
death domain fold unlike the open Fas-DD reported in the 4:4 crystal structure. The 
secondary  structure  prediction  indicates  that  in  solution  helices  five  and  six  are 
separate helices. The results characterise a more flexible loop between helices five 
and six rather than an elongated helical shape as would be expected in the open 
conformation.  
3.4.4 
13C aromatic and aliphatic NOESY spectral analysis infers that Y291 is in a 
buried location  
NOESY  spectra  give  information  about  which  atoms  are  close  in  space.  The 
experiment takes advantage of the nuclear Overhauser effect (NOE) between nuclear 
spins during a mixing period to establish correlations between atoms corresponding 
to their distance apart in space. NOESY pulse sequences record the exchange of 
1H 
polarization (longitudinal magnetisation) as a result of dipolar coupling between 
1H 
nuclei in different regions of the protein structure. Thus the NOE depends upon a 
fundamentally different type of mechanism to that exploited in NMR experiments 
that  depend  upon  though-bond  J-coupling  dependent  transfer  of  antiphase  or  in-
phase  transverse  magnetisation.  The  magnitude  of  a  particular  NOE  cross  peaks 
depends upon the inverse-6
th power of the internuclear separation (1/r
6), the details 
of the reorientational dynamics of the internuclear vector, and the NOE build-up 
time. However for most globular proteins, it has been found that for short NOESY 
mixing times one can make a semi-quantitative estimate of the relative internuclear 
distances from the comparison of NOE cross peak intensities. The resulting NOESY 
spectra contain autocorrelation peaks along a diagonal and a number of cross peaks, 
each identifying atoms which are close to each other in space. The other cross peaks, 
(in a vertical line from the diagonal) correspond to atoms which are close to the atom 
identified upon the diagonal. The assignment of NOESY spectra is traditionally used 
to generate distance restraints between atoms within a protein to be used to generate 
a 3D model of the structure. To identify whether Y291 is in a buried or a solvent 
exposed location within the Fas-DD being used in this study, the NOEs which had 
been assigned to the 
1H atoms of Y291 were analysed.   124 
 
Figure  3.11  Strips  from 
13C  aromatic  and  aliphatic  NOESY-HSQC  spectra  showing  atoms 
which are close in space to Y291 
Each NOE strip corresponds to the nucleus highlighted at the top of the strip. Off diagonal peaks in the spectrum 
correspond to an NOE between two a nuclei which are close to each other in space. Strips corresponding to Y291 
Hδ and Hα are shown with assigned intra and inter-residue NOEs. Strips relating to interacting nuclei are also 
shown, confirming the NOE connectivity to Y291. Black lines represent NOE heteronuclei in Y291 which are 
close in space. NOEs to residues that are close in the primary sequence and in space are represented with green 
lines. NOEs to residues that are further away in the primary sequence and close in space are shown with blue 
lines.  125 
 
Figure 3.12 The location of the residues showing NOEs to Y291 
A, Fas solution structure (PDB:1DDF) and B, Fas-DD in ‘open’ structure from crystal structure (PDB:3ZQ) with 
Y291 highlighted in red. Residues containing short range NOE’s to Y291 illustrated in green. Residues showing 
long range NOE’s to Y291 shown in blue.  
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Strips from the 
13C aromatic and aliphatic NOESY spectra corresponding to Y291 
and those atoms showing NOE connectivity are shown in Figure 3.11. Each of the 
strips  shown  in  Figure  3.11  corresponds  to  a 
13C  plane  in  the  spectrum  (plane 
location highlighted within each strip) of the residue and atom shown at the top of 
the figure. Peaks on the diagonal line correspond to autocorrelations that correspond 
to  the  chemical  shifts  in  the  1D 
1H  NMR  spectrum;  vertical  lines  show  peaks 
corresponding to atoms which are close in space to the atom shown on the diagonal. 
NOE connectivity is considered when the cross peaks are at the same 
1H chemical 
shift but at different 
13C chemical shifts. The horizontal lines in Figure 3.11 highlight 
the  connectivity  between  different 
13C  planes  of  the 
13C-NOESY  spectrum, 
indicating the 
1H atoms which are close to each other in space. For example the 
I294Hδ strip, shows that the Hδ protons of I294 is close to both the Hα and the Hδ 
atoms of Y291.  
NOE cross peaks are present which show that the side chain of Y291 is close in 
space to residues I294 and I295, constituting medium range NOEs. This outcome 
would be expected as the latter residues are close in the primary sequence to Y291. 
NOE cross peaks are also present between Y291 and L224, L225 and I314, residues 
much further away from Y291 in the primary amino acid sequence constituting long 
range NOEs. The presence of NOE peaks between Y291 and these residues suggest 
that Y291 is in a buried/folded location within the domain. When the locations of 
these five residues are highlighted on the published ‘open’ and ‘closed’ Fas-DD 3D 
structures (Figure 3.12) the pattern of NOEs is clearly more consistent with the more 
buried ‘closed’ form of Fas-DD. The NOE data agrees with the residues which have 
been shown to be close to Y291 in the solution structure (PDB:1DDF). If Y291 was 
present in Fas in the ‘open’ conformation one would expect to observe fewer NOEs 
for this residue as it is predominantly solvent exposed. 
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3.5. Working towards a Fas-DD high resolution solution structure 
The  structure  calculations  presented  in  this  section  were  carried  out  with  equal 
contribution between the author and Dr Diego Esposito.  
3.5.1 Using ARIA to calculate the Fas-DD structure  
The  assignment  of  NOE  cross  peaks  is  the  critical  step  in  determining  the  3D 
structure  of  a  protein  using  NMR  data.  ARIA  (ambiguous  restraints  for  iterative 
assignment) is a program which can be used to inform NOE assignment through the 
process of iterative NMR structure calculations. It involves NOE assignment as an 
integral part of the structure calculation process. NMR structures are predominantly 
based upon the cross relaxation rates between nuclei which are close in space; these 
interactions  are  measured  through  NOESY  spectroscopy.  Traditionally  a  set  of 
unambiguously assigned NOE resonance assignments would be incorporated into a 
NMR calculation that comprising a combination of simulated annealing and energy 
minimisation  molecular  dynamics  protocols.  Using  the  ARIA  method,  the  whole 
NOESY spectrum is taken into account, in which the unambiguously assigned NOEs 
as well as unassigned and ambiguous cross peak assignments are included in the 
calculation. The core protocols of ARIA derive distance restraints from the NOESY 
spectra to define molecular conformations which are compatible with the cross peaks 
in the original data set. To do this, ARIA creates ambiguous distant restraints (ADR) 
from the chemical shift lists, in which the alternative possibilities for an NOE peak 
are combined into one restraint which impacts the generated structure. The use of 
ARIA  involves  an  iterative  process  in  which  each  ARIA  calculation  is  used  to 
inform the assignment of more ambiguous NOE cross peaks from the spectrum. This 
function is built into the CCPNAnalysis program to aid in NOE assignment
173.  
3.5.2 Residual dipolar couplings were collected in Pf1 bacteriophage alignment 
medium 
As well as the experiments described above, residual dipolar couplings (RDCs) were 
collected in magnetically-aligned Pf1 bacteriophage solution. The magnitudes of an 
RDC is dependent upon the distance and angle in which a bond vector is orientated 
relative to the applied magnetic field. When RDCs can be measured for a set of 
internuclear vectors within a molecule these data can provide information about the 128 
spatial arrangement of those vectors and aids the determination of the overall shape 
of that molecule. 
RDCs arise from the partial alignment of a macromolecule with a magnetic field. A 
molecule in solution undergoes isotropic tumbling, in this situation the RDC value 
averages  to  zero.  To  obtain  a  situation  in  which  the  sample  does  not  undergo 
isotropic tumbling and an RDC can be measured, the sample is introduced into a 
compatible  dilute  liquid  crystalline  environment  such  as  lipid  bicelles  or  in  the 
presence of filamentous bacteriophage. Solutions of filamentous pf1 bacteriophage 
spontaneously align in a magnetic field, due to the magnetic susceptibility anisotropy 
of  the  lipid  bilayer  head  groups.  Cosolute  macromolecules,  by  dint  of  random 
collisions with the aligned phage, are induced to undergo non-random reorientational 
(tumbling)  dynamics,  the  nature  of  which  is  dependent  on  the  overall  molecular 
shape. Thus in the presence of the dilute liquid crystalline environment provided by 
the phages, a co-dissolved protein will be, in effect, partially aligned (albeit very 
weakly) and give rise to non-zero dipolar couplings. In practice RDCs are detected 
as  a  contribution  (positive  or  negative,  depending  upon  the  direction  of  the 
internuclear  vector  relative  to  the  alignment  tensor)  to  the  measured  J-couplings 
between the nuclei involved.  In-phase anti-phase (IPAP) NMR experiments were 
acquired to extract N-H effective one-bond J-couplings and HNCOCA experiments 
with no proton decoupling were recorded to extract HA-CA one-bond J-couplings 
for  both  Fas-DD  in  isotropic  (unaligned)  and  anisotropic  (bacteriophage  aligned) 
environments. To determine the RDC values, the difference in 
15N frequency of the 
isotropic and anisotropic samples was measured. 64 RDC values were obtained for 
N-H couplings and 58 values for CA-HA couplings. RDC values were not obtained 
for every residue in the construct due to spectral overlap which meant that some of 
the peaks in the spectra overlapped too much to be able to identify which residue 
they corresponded to. 
The  calculated  RDC  values  were  analysed  prior  to  inclusion  in  the  structure 
calculation  using  the  program  Module.  Within  this  program  the  experimentally 
derived RDC values were compared to RDC values which had been predicted from 
the  published  Fas-DD  structure  (PDB:1DDF).  The  output  from  this  analysis  is 
shown in Figure 3.13. Both the experimentally derived HN-H and CA-HA couplings 
show a reasonable fit to those which were simulated by the program. 129 
 
 
Figure 3.13 Experimental RDC data showed a reasonable fit to the 1DDF structure of Fas-DD 
data 
RDC values collected for HN-N couplings using IPAP type HSQC experiments and HA-CA couplings collected 
using  HNCOCA  with  no  proton  decoupling  were  fitted  against  the  current published  model  of  the  Fas-DD 
(pdb:1DDF) using the program Module. A shows the fit of the NH couplings, which appear to follow the trend 
expected from the 1DDF structure more closely than the CA couplings shown in B. 
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3.5.3 Preliminary structural calculation 
The software ARIA
174 was used for automatic assignment of ambiguous NOEs and 
to obtain a starting set of restraints to use in a refinement protocol created for the 
program  XPLOR-NIH
175.  CCPN  data  were  input  directly  into  ARIA.  Initial 
interproton distance restraints lists were created by the software starting from the 
cross  peaks  picked  manually  in  the  3D 
1H-
13C  NOESY-HSQC, 
1H-
13C  aromatic 
NOESY-HSQC and 
1H-
15N NOESY-HSQC spectra. Backbone ϕ and ψ torsion angle 






shifts using the program DANGLE
176 in CCPN analysis. Hydrogen bond restraints 
for amide protons deriving from the assessment of the regular secondary structure 
helical segments in the available Fas-DD structure, coupled with the absence of the 
relative water cross peak in the 
1H-
15N NOESY-HSQC spectrum, were also used in 
the ARIA calculations.  
Unfortunately, due to the incomplete side chain resonance assignment the first set of 
conformers generated by ARIA did not converge to a single tertiary fold. In order to 
improve convergence in the final ARIA iteration we simulated a small subset (500) 
of NOE restraints from the available deposited coordinates of Fas-DD (PDB:1DDF). 
The insertion of simulated NOE restraints was used to calibrate the NOE distances 
used by ARIA to calculate NOE distances from the ambiguous peak lists. 
ARIA outputs, consisting of a set of unambiguous and ambiguous restraints were 
used,  together  with  the  hydrogen  bonds,  dihedral  and  experimental  HN  residual 
dipolar couplings, in a standard XPLOR-NIH refinement protocol. The subset of 500 
inserted  NOE  restraints  used  to  calibrate  ARIA  were  removed  prior  to  this 
calculation. The final structures were calculated using PARALLHDG
177 force field 
parameters, with PROLSQ non-bonded energy function
155. The dynamic simulated 
annealing protocol consisted of a high temperature (3000 K) torsion angle molecular 
dynamics followed by a Cartesian dynamics whilst cooling from 3000 K to 25 K in 
12.5  K  steps.  A  final  200  steps  Powell  minimization  followed  the  simulated 
annealing protocol. The axial and rhombic components of the molecular alignment 
tensor were left floating during the calculations. The final ensemble consisted of the 
20 lowest energy structures from the refinement protocol. Structural quality of was 
assessed with PROCHECK





Figure 3.14 NMR solution structure of Fas-DD at pH 6.4 and 298 K 
A, Backbone atoms of the ensemble of the twenty lowest energy conformers obtained after refinement in explicit 
water. B, Two orthogonal views of a ribbon representation of the structure of the lowest energy conformer of the 
ensemble. The helices are numbered from N  (red) to C terminal (blue).  132 
Table 3.2 Restraints and structural statistics for the Fas-DD ensemble 
 
  Ensemble (n=20)  Lowest energy conformer 
Number of experimental restraints   
Unambiguous distance restraints  1332 
Ambiguous distance restraints  130 
Dihedral angles  213 
Residual dipolar couplings  130 
Root mean square deviation from experimental data   
Unambiguous NOE distances (Å)  1.59 ±0.03  1.60 
Residual dipolar couplings  0.33 ±0.04  0.342 
R factor  0.48 ±0.06  0.485 
Average root mean square deviation to the mean structure   
Backbone atoms (residues 221-319)  1.75 ±0.66   
Root  mean  square  deviation  from  idealised  covalent 
geometry 
 
Bond (Å)  0.0206 ±0.0007  0.02 
Angle (
o)  1.723 ±0.07  1.647 
Improper (
o)  1.99 ±0.08  1.93 
Ramachandran plot statistics (PROCHECK)   
Residues in most favoured regions (%)  70.42±0.02  70.8 
Residues in additionally allowed regions 
(%) 
24.12±0.02  22.9 
Residues  in  generously  allowed  regions 
(%) 
2.92±0.01  3.1 
Residues in disallowed regions (%)  2.56±0.01  3.1 
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The  restraints  and  structural  statistics  for  our  preliminary  Fas-DD  structure  are 
shown  in  Table  3.2.  Our  preliminary  Fas-DD  structure  shows  the  canonical  six 
helical bundle death domain fold, with no major deviation from the six helix bundle 
presented in the 1DDF structure. Figure 3.14 illustrates the twenty lowest energy 
conformers obtained after refinement in explicit water and a ribbon representation of 
the lowest conformer of the ensemble. 
 
3.6 Dynamic investigation of Fas-DD using NMR relaxation experiments 
Secondary  chemical  shift/CSI  data  and  analysis  of  NOESY  through-space 
connectivity indicates that in our hands Fas-DD in solution forms the ‘closed’ death 
domain structure. However, it cannot be ignored that the Fas death domain would 
need to be able to form alternate conformations to enable non apoptotic signalling 
through  the  recruitment  of  adaptor  proteins  to  phosphorylated  Y291.  The  crystal 
structure  shows  that  Fas  can  exist  in  an  alternate  conformation  in  a  solid  state 
environment. We embarked upon an investigation of the dynamics of Fas-DD in 
solution in conditions which we hypothesised could induce the death domain to form 
different conformations. 
To  investigate  the  ability  of  Fas-DD  to  sample  the  alternate  conformations  in 
solution, two sets of NMR relaxation measurements were acquired for Fas-DD in 
three different conditions. Classical 
15N spin relaxation measurements were acquired 
to observe Fas-DD dynamics on the picosecond-nanosecond timescale and relaxation 
dispersion  (CPMG-based)  experiments  were  acquired  to  sample  whether  Fas-DD 
dynamics could be observed upon the microsecond-millisecond timescale. 
Experiments were initially acquired with a sample of Fas-DD in the same conditions 
used for the structural experiments; this was considered to be the equivalent of ‘wild-
type’ Fas-DD and used as a reference with which to compare other conditions. To 
investigate the effects of tyrosine phosphorylation upon the dynamics of Fas-DD, an 
Y291E phosphomimetic mutant Fas-DD+CTD construct was generated. 
15N nuclear 
relaxation measurements were also acquired for Fas-DD+CTD in the buffer used in 
the Fas;FADD crystal structure reported by Scott et al. (2009) (0.95 M citric acid, 
1.9M  ammonium  sulphate,  pH4  -  in  which  a  massive  rearrangement  of  Fas-DD 134 
helices five and six was observed) to see whether such dramatic effects might be 
observed in solution by NMR spectroscopy. These experimental conditions will be 
referred to throughout the chapter as Fas-DD, Fas-DD Y291E and Fas-DD in crystal 
buffer respectively.  
The theory that underpins the basis for extracting information concerning molecular 
dynamics from nuclear relaxation data is particularly challenging and beyond the 
scope  of  this  thesis.  It  should  suffice  to  note  that  many  of  the  experimental 
observables that relate to nuclear relaxation fundamentally depend upon the nature of 
fluctuating local magnetic fields that induce nuclear spin transitions. For a typical 
globular  macromolecule  the  fluctuations  arise  as  a  result  of  both  the  overall 
molecular motion (tumbling) and any ‘superposed’ internal motion that can either be 
faster or slower than the overall tumbling. Whilst in principle the relaxation of 
1H, 
13C and 
15N magnetisation can inform the researcher of the underlying dynamics, this 
is most readily teased out with measurements that focus upon 
15N nuclei, for which 
the  relaxation  is  dominated  by  the  influence  of  the  directly  attached  H
N  proton. 
‘Classical’  relaxation  measurements  comprise  pulse  sequences  designed  to  allow 
measurement of: a) the longitudinal 
15N relaxation rate constant R1; b) the transverve 
15N relaxation rate constant R2; and c) the {
1H}
15N heteronuclear NOE. The value of 
R1 characterises the rate of return of 
15N Z-magnetisation following a perturbation 
away  from  equilibrium  (e.g.  by  a 
15N  radiofrequency  pulse).  The  R2  value 
characterises  the  rate  of  decay  in  the  X-Y  plane  of  in  phase  transverse 
15N 
magnetisation,  following  excitation  (e.g.  by  a  90° 
15N  pulse).  Finally  the 
heteronuclear NOE (hNOE) measures the influence on the equilibrium polarisation 
of the 
15N Z-magnetisation of radiofrequency saturation of the NMR transitions for 
the directly bonded proton nucleus. It turns out that in each case the magnitude of the 
NMR observable (R1, R2, hNOE) is a sensitive function of the temporal dynamics of  
the NH bond vectors. Because spontaneous emission at NMR spectral frequencies is 
negligible, relaxation of spin-1/2 nuclei relies upon the influence of local magnetic 
field fluctuations operating through instantaneous dipole-dipole interactions or the 
motion of the nucleus within a non-spherically symmetric electronic environment 
(known  in  NMR  as  chemical  shift  anisotropy).  Thus  an  excited 
15N  nucleus 
experiences fluctuating magnetic fields, including at specific frequencies that can 
effect spin-state transitions, and thereby a return to equilibrium. It turns out that the 135 
dynamics  of  the  molecule  (more  strictly  the  NH  vectors)  can  be  related  to  the 
observed relaxation parameters via specific values of the so-called ‘spectral density 
function’  that  encodes  the  dynamics  in  terms  of  a  frequency-dependent  time 
correlation  function.  The  spectroscopist  can  choose  from  various  levels  of 
sophistication for the analysis of the relaxation data, from attempting to map out the 
complete spectral density function, to the adoption of simplified models, as in the 
‘model-free approach’ and its variants. Complicating factors in such analyses include 
rotational  anisotropy  of  the  molecular  system  under  investigation,  and  the 
contribution to R2 rates that arise from chemical exchange processes that modulate 
the chemical shift on a timescale that is long compared to the overall tumbling and 
are expressed in the theory as contributions to the spectral density at zero frequency. 
Properly disentangling these influences requires the application of a complex and 
time-consuming  series  of  NMR  experiments,  followed  by  detailed  data  analysis 
beyond  the  scope  of  the  work  presented  in  this  thesis.  However  the  presence  of 
chemical exchange, that might arise as a result of a low population of ligand bound 
protein molecules or from the existence of a low-lying excited state (i.e. alternate 
conformation) can be readily inferred from either: a) high outlier instances of 
15N R2 
values  in  an  otherwise  unremarkable  profile  across  the  protein  chain;  or  (more 
reliably) b) from the presence of 
15N ‘relaxation dispersion’ in experiments designed 
to measure the influence of radiofrequency fields on the effective R2 relaxation rate 
constant.  In  this  work  I  have  performed  preliminary 
15N  relaxation  dispersion 
measurements  for 
15N-labelled  Fas-DD  using  the  paradigm  of  Carr-Purcell-
Meiboom-Gill (CPMG) trains of 
15N 180° pulses. Dispersion is identified when the 
measured effective transverse relaxation rate R2
eff displays a characteristic non-zero 
dependence on the rate of application of CPMG pulses (the CPMG ‘field strength’).  
3.6.1 Sample preparation for relaxation studies 
The three conditions used for relaxation measurements were: 
-  Fas-DD in NMR buffer (20 mM MES, 100 mM NaCl, 0.5 mM TCEP, 1 mM 
EDTA, 3 mM Sodium azide pH 6.2). 
-  Fas-DD+CTD Y291E in NMR buffer (20 mM MES, 100 mM NaCl, 0.5 mM 
TCEP, 1 mM EDTA, 3 mM Sodium azide pH 6.2). 136 
-  Fas-DD+CTD  in  Crystal  buffer  (0.95  M  citric  acid,  1.9  M  ammonium 
sulphate, pH 4.0) in a 3mm diameter tube. 
 
Dr  Diego  Esposito  had  previously  collected  R1,  R2  and  Het  NOE  data  for 
15N 
labelled Fas-DD+CTD (218-335) construct, this was used as the wild-type control to 
compare the perturbed conditions to using classical relaxation measurements. The 
Fas-DD (residues 218-319) construct donated by Dr Diego Esposito was used for the 
remaining relaxation experiments, samples and experiments were prepared/executed 
by the author. Fas-DD was expressed in 
15N-labelled minimal medium and purified 
as described in Section 2.5. Protein from the same preparation of 
15N-Fas-DD was 
used  for  both  crystal  buffer  conditions  and  ‘wild-type’  conditions  for  relaxation 
dispersion experiments. The Y291E phosphomimetic mutation was generated from 
the Fas-DD plasmid using site directed mutagenesis methods as described in Section 
2.4.3  and  expressed  and  purified  as  described  in  Section  2.6.  All  samples  were 
concentrated  by  centrifugal  concentration  to  500μM  with  10% 
2H2O  for  field 
frequency lock.  
The Fas sample in crystal buffer conditions was achieved by dialysis of Fas-DD 
against crystal buffer overnight, as described in Section 2.6.7. Fas-DD was not as 
soluble in crystal buffer resulting in limited precipitation; the sample concentration 
was therefore lower and undetermined. Data was collected upon this sample using a 
glass NMR tube with a diameter of 3 mm. Using a tube with a diameter of 3 mm 
enhances the sensitivity of experiments collected in high salt conditions by reducing 
the concentration of salt present in the active sample. In doing this, the pulse length 
is reduced and the sensitivity of an experiment carried out on a sample containing up 
to 4 M salt is comparable to a sample in a conventional NMR buffer in a 5 mm 
diameter tube
179.  
The use of a Tyr-Glu phospho mimetic mutation is not fully representative of the 
addition of a phosphate group upon a tyrosine side chain. Glutamate mimics the 
negative charge incorporated upon a tyrosine when phosphorylated, but this does not 
take into account the steric bulk of the phosphate upon the surrounding structure. 
Therefore the tyrosine to glutamate mutation does not fully recapitulate the effects of 
phosphorylation  upon  a  protein.  Incorporation  of  a  phosphotyrosine  into  the  Fas 137 
death  domain  would  be  the  only  method  to  confirm  that  this  post  translational 




15N-HSQC projections of relaxation data for protein samples used for 
relaxation measurements show they are folded and suitable for relaxation analysis 
Both spin relaxation and relaxation dispersion experiments are on a 
1H/
15N-HSQC 
based format of experiment. Spectral analysis is carried out by the extraction of peak 
heights from the spectra collected at different 
15N internal relaxation delay times or 
CPMG field strengths. The relaxation of 
15N magnetisation is in effect projected onto 
the cross peak intensities of a 
1H/
15N-HSQC. Spectral analysis is carried out on a 
residue  by  residue  (peak  location)  basis  therefore,  cross  peak  assignments  are 
required. 
1H/
15N-HSQC spectrum assignments for Fas-DD were transferred from the 
structural  work  upon  Fas-DD  detailed  above,  however  the  other  two  Fas-DD 
conditions perturbed the spectra therefore tentative assignments were made in these 
conditions and in some cases cross peaks remained unassigned. 
Mutation of Tyr291 to Glu resulted in minimal changes to the overall 
1H/
15N-HQSC 
spectrum compared to Fas-DD (Figure 3.15), suggesting that the mutant Fas-DD is 
still folded. However a  number of the peaks which corresponded to the residues 
immediately proximal to Y291 shifted or disappeared. 84% of the assignments were 
transferred  from  Fas-DD  to  this  spectrum  to  enable  relaxation  analysis;                                      
the portion of the sequence confidently assigned is highlighted in Figure 3.15.  
As described above, upon dialysis into crystal buffer, Fas-DD partly precipitates. 
Due to this, the 
1H/
15N-HSQC projection for this sample showed poor signal to noise 
(Figure 3.16). Buffer conditions are well known to affect the 
1H/
15N-HSQC spectrum 
for a particular protein, therefore it was unsurprising to observe a number of peak 
shifts for Fas-DD in these conditions. It is possible to tell that Fas-DD was still 
folded as the spectrum still possesses a high degree of dispersion; for example the 
four  Gly  cross  peaks  are  still  notable  at  the  top  of  the  spectrum.  45%  of  the 
assignments  were  transferred  from  Fas-DD  to  this  spectrum  to  enable  relaxation 
analysis (highlighted in Figure 3.16). Having less than 50% of the protein assigned 
meant that only general trends could be observed in the relaxation data obtained for 





15N-HQSC projection of the T1 relaxation spectra for Fas-DD Y291E showing 
which assignments were transferred from Fas-DD+CTD 
There were some chemical shift differences caused by the Y291E mutation, resulting in peak shifts of a number 
of residues. 84% of assignments were transferred and relaxation analysis carried out upon these residues. The 




15N-HQSC projection of the T1 relaxation spectra for Fas-DD in crystal buffer 
showing which assignments were transferred from Fas-DD+CTD 
Fas-DD was less stable in crystal buffer compared to NMR buffer. There were a substantial number of peak 
shifts  and  a  significant  reduction  in  signal  to  noise of  the  spectra.  45%  of  the  resonance  assignments  were 
transferred  and  relaxation  analysis  carried  out  upon  these  residues.  The  residues  assignments  that  were 
transferred are highlighted in red upon the Fas sequence below the spectrum. 
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3.6.3 Classical 
15N spin relaxation measurements were acquired to explore Fas 
flexibility upon the picosecond-nanosecond timescale 
The 
15N  longitudinal  and  transverse  relaxation  rate  constants  (R1  and  R2 
respectively)  and  the 
1H/
15N  steady  state  heteronuclear  NOE  were  measured  to 
assess  the  overall  rotational  diffusion  and  internal  mobility  of  Fas-DD  in  the 
conditions  described  above.  The  measurements  were  made  at  600  MHz  with  a 
sample temperature of 25 
oC. The sample concentration was essentially identical for 
the Fas-DD and the Fas-DD Y291E samples at 500 μM.  
The 
15N relaxation experiments were recorded using standard pulse sequences as 
described by Kay, Bax, Torchia and colleagues
180,153. CCPN Analysis
138 was used to 
fit the R1, R2 and 
1H/
15N NOE values and their associated uncertainties. For the R1 
and R2 datasets, single exponential decays of the peak heights were assumed (Figure 
3.17). The fit of the exponential decay is then plotted as a function of residue number 
for both R1 and R2. 
1H/
15N NOE values obtained from the ratio of peak intensities in 
spectra measured with and without 
1H saturation are illustrated in a similar residue 
by  residue  manner.  Collectively,  from  these  data,  the  correlation  times  (τc, 
representative of the time it takes for a molecule to tumble through one radian in any 
arbitrary direction) for each Fas-DD sample was estimated from the mean trimmed 
R2/R1 ratios using in house software written by Dr Paul Driscoll. 
 
3.6.3.1 Fas-DD shows little flexibility throughout the whole death domain 
15N R1, R2 and 
1H
15N heteronuclear NOE data recorded for Fas-DD+CTD had been 
previously  recorded  at  600  MHz  by  Dr  Diego  Esposito.  This  data  was  used  for 
training purposes in the analysis of classical 
15N spin relaxation measurements. The 
quality of the spectra was excellent allowing for high quality fitting of the R1 and R2 
decay curves and a high precision estimation of the corresponding decay constants 
and the heteronuclear NOE. Figure 3.18 shows the derived values for R1, R2 and 
1H
15N heteronuclear NOE and Figure 3.21A shows the computed R2/R1 ratios on a 
per residue basis.  
The most part of the R2/R1 plot is flat which is consistent with a globular fold with 
relatively low rotational diffusion anisotropy. Preliminary estimates of the predicted 141 
isotropic rotational correlation time τc from the trimmed R2/R1 ratios was 8.2 ns. It is 
generally considered that for a globular protein the correlation time is approximately 
0.5 ns per kDa of atomic weight. Thus the estimated τc for Fas-DD (11 kDa) is on 
the high side for a monomeric protein and could indicate that the protein experiences 
some weak self-association, or possesses ‘rougher’ surface characteristics that lead 
to relatively slow tumbling. Resolution of the precise origin of this behaviour would 
require substantial additional experimentation and analysis.  
 
3.6.3.2 Fas-DD Y291E shows similar flexibility to Fas-DD  
15N R1, R2 and 
1H
15N heteronuclear NOE data were also recorded for Fas-DD Y291E 
as described above. The quality of the spectra was adequate for the fitting of the R1 
and  R2  decay  curves  (examples  shown  in  Figure  3.17)  and  estimation  of  the 
corresponding  decay  constants  and  heteronuclear  NOEs.  Figure  3.19  shows  the 
derived values for R1, R2 and 
1H
15N heteronuclear NOE and Figure 3.21B shows the 
computed R2/R1 ratios on a per residue basis.  
Due to having only 85% of the cross peak assignments for this construct there is not 
data for every residue throughout the construct, but there are sufficient to observe 
global trends. From the heteronuclear NOE it is observable that the mutation does 
not  destabilise  the  whole  protein.  The  profile  of  R1  and  R2  magnitudes  is  more 
dispersed compared to Fas-DD, with the R2/R1 values spread over a greater range. 
Assignments for the residues closest to the mutation were understandably the ones 
which could not be transferred with confidence. However, it is observable that values 
of relaxation parameters corresponding to residues within helix 5 (the location of 
Y291E  mutation)  are  more  perturbed  throughout  each  of  the  datasets  collected 
compared to Fas-DD, which may suggest some change in dynamics in this region. 
Preliminary estimates of the predicted isotropic rotational correlation time τc for the 
Fas-DD Y291E was 8.3 ns, which was similar to the wild type protein indicating no 
overall change in the shape of the protein. 
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3.6.3.3 Fas-DD in crystal buffer showed an increase in the range of R1, R2 and 
heteronuclear NOE values 
15N R1, R2 and {
1H}
15N heteronuclear NOE data was recorded for Fas-DD in crystal 
buffer as described above. Compared to the other samples, the quality of the spectra 
was poor due to a reduced level of signal to noise caused by the apparent instability 
of the construct under these conditions, witnessed as a tendency to precipitate. R1 
and R2 decay curves were fitted for the well resolved cross peaks in the spectrum and 
for which the assignments of Fas-DD could be transferred (45% of the residues), 
enabling  estimation  of  the  corresponding  decay  constants  and  fitting  of  the 
heteronuclear  NOE.  Figure  3.20  shows  the  derived  values  for  R1,  R2  and 
1H
15N 
heteronuclear  NOE and Figure 3.21C shows the computed R2/R1 ratios on a per 
residue basis. Fas-DD in crystal buffer showed elevated values of R2/R1 compared to 
the other Fas-DD conditions sampled suggesting some dynamics within the construct 
upon the nanosecond timescale.  
Preliminary estimates of the predicted isotropic rotational correlation time τc from 
the R2/R1 trimmed ratios was 12 ns. The distinctly higher value of τc for the protein 
under these conditions compared to standard NMR buffer is noteworthy and could 
result  from  a  number  of  factors  that  includes  the  adoption  of  an  expanded 
monomeric  conformation,  enhanced  self-association  and  possible  homodimer 
formation, a higher solvent viscosity due to the buffer conditions, or a combination 
of these influences. Further experiments would be required to specifically identify 
the origin(s) of the higher τc value. 
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Figure 3.17 Example of the relaxation decay graphs for Fas-DD Y291E used to extract values 
for R1 (A) and R2 (B) using CCPN analysis 
Delay curves used to extract the R1 (A) and R2 (B) for Serine 209 from Fas-DD Y291E. The relaxation data were 
collected at 600MHz at 25
oC. CCPN analysis was used to fit the data using the fitting function ‘A exp (-Bx)’. 
The extracted peak heights are shown in blue and the fitted values in red.  144 
 
Figure 3.18 Longitudinal, transverse and 
1H-
15N Heteronuclear NOE relaxation rates for Fas-
DD  
Secondary structural elements of Fas-DD (A) are represented by rectangles indicating alpha helices with loops 
and less structured regions shown by the dashed line.  Longitudinal 
15N relaxation rates R1 (B), Transverse 
15N 
relaxation rates R2 (C) and 
1H-
15N heteronuclear NOE values (D) for Fas-DD are plotted as a function of residue 
number. Values were extracted at 600MHz and fitted using CCPN Analysis. 145 
 
Figure 3.19 Longitudinal, transvers and 
1H-
15N Heteronuclear NOE relaxation rates for Fas-DD 
Y291E 
Secondary structural elements of Fas-DD (A) are represented by rectangles indicating alpha helices with loops 
and less structured regions shown by the dashed line. Longitudinal 
15N relaxation rates R1 (B), Transverse 
15N 
relaxation rates R2 (C) and 
1H-
15N heteronuclear NOE values (D) for Fas-DD Y291E are plotted as a function of 
residue  number.  Values  were  extracted  from  spectra  recorded  on  a  600MHz  spectrometer  and  fitted  using 
CCPNAnalysis. 146 
 
Figure 3.20 Longitudinal, transverse and 
1H-
15N Heteronuclear NOE relaxation rates for Fas-
DD in crystallisation buffer 
Secondary structural elements of Fas-DD (A) are represented by rectangles indicating alpha helices with loops 
and less structured regions shown by the dashed line.  Longitudinal 
15N relaxation rates R1 (B), Transverse 
15N 
relaxation rates R2 (C) and 
1H-
15N heteronuclear NOE values (D) for Fas-DD in crystallisation buffer are plotted 
as a function of residue number. Values were extracted from spectra recorded on a 600MHz spectrometer and 
fitted using CCPNAnalys 147 
 
Figure 3.21  R2/R1 for Fas-DD, Fas-DD Y291E and Fas-DD in crystal buffer 
Secondary structural elements of Fas-DD (A) are represented by rectangles indicating alpha helices with loops 
and less structured regions shown by the dashed line.  A plot of R2/R1 for A, Fas-DD; B, Fas-DD Y291E and C, 
Fas-DD in crystal buffer. 
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3.6.4 Relaxation dispersion measurements were acquired to explore Fas flexibility 
on the microsecond-millisecond timescale 
Relaxation dispersion data were acquired at seven CPMG field strengths (40, 100, 
200,  400,  600,  800  and  1000  Hz)  to  assess  the  potential  presence  of  possible 
intermediate  states  of  Fas-DD  which  cannot  be  detected  using  classical 
15N  spin 
relaxation  measurements.  The  data  was  acquired  at  600  MHz  with  a  sample 
temperature of 25 
oC upon the three Fas-DD conditions described above. A new 
sample  of 
15N-Fas-DD  was  expressed  and  purified  as  this  data  had  not  been 
previously collected by Dr Esposito. The samples used for the classical 
15N spin 
relaxation measurements described in Section 3.4.3 were the same as for Fas-DD 
Y291E and Fas-DD in Crystal buffer acquisition. 
The relaxation dispersion experiments were recorded using standard pulse sequences 
as described by Palmer and colleagues
181. CCPN Analysis was used to measure the 
peak heights in the 
1H-
15N correlation spectra as a function of the applied 
15N radio 
frequency (CPMG) field. The effective transverse relaxation rate constants R2
eff were 
calculated by measuring two point change in peak intensity between a dataset with 
no  CPMG  relaxation  period  and  another  data  set  with  a  40  relaxation  ms  delay 
comprising up to 1000 Hz of CPMG modulated transverse relaxation. Data were 
analysed for specific cross peaks corresponding to residues of interest either within 
close proximity to Y291 or at the boundary between helix 5 and helix 6. 
Relaxation  dispersion  experiments  interpret  the  classical  relaxation  experiments 
described above in terms of the overall rotational diffusion of the molecule. It is a 
measure of motions which are slower than the overall molecular tumbling of the 
whole molecule
182. Due to the readout relating to internal motion on relatively slow 
micro-to millisecond timescales, these types of experiments are commonly used to 
study protein refolding
183, the effects of mutations upon protein folding
184, and the 
allosteric transitions within proteins. The experiments themselves monitor the return 
of  transverse  magnetization  in  the  X-Y  plane  following  perturbation  by  and 
appropriate excitation train. In effect the observation of RF-field dependence of the 
effective transverse relaxation rate R2 in these experiments enables the detection of 
weakly-populated  alternate  states  of  the  protein  corresponding  to  either  ligand-
bound, or ‘excited’ conformational states
185.  149 
3.6.4.1 Selected residues in close proximity of Y291E mutation show increased 
flexibility compared to Fas-DD  
The effective transverse relaxation rate constants R2
eff were calculated for a subset of 
six cross peaks (Tyr232, Asp292, Leu294, Ile295, Ile310 and Ile314) from both the 
Fas-DD and the Fas-DD Y291E relaxation dispersion spectra. These residues were 
judged to be in the  closest proximity to  Y291  in the published  Fas-DD solution 
structure and therefore should be sensitive to the substitution of Tyr for Glu. The 
R2
eff was calculated for Glu261, as a control that the effects were localised to the 
region of interest, not a global change throughout the whole domain. This analysis in 
conjunction with an illustration of the location of the analysed residues upon the Fas-
DD structure is displayed in Figure 3.22, highlighting Tyr291 in black, with the 
other  analysed  residues  highlighted  in  colours  corresponding  to  the  associated 
dispersion profile.  
The dispersion profiles for residues extracted from experiments upon wild type Fas-
DD are flat: that is the difference between the effective transverse relaxation rates at 




(1000Hz) is close to zero. This result indicates 
that  this  construct  is  unlikely  to  be  undergoing  exchange  on  the  microsecond  to 
millisecond timescale with a significant population of an excited state. Mutation of 
Tyr291  to  glutamate  led  to  an  increased  R2
eff  at  low  CPMG  field  strengths  of 
residues in close proximity to Tyr291 (Tyr232, Asp292, Ile295). This observation is 
consistent  with  the  appearance  of  dynamics  on  the  microsecond  to  millisecond 
timescale for the mutant protein. However this effect is not a global one upon the 
whole protein. Glu261, which is not within the region of interest, exhibits a profile of 
R2
eff values similar to those obtained for wild type Fas-DD. 
3.6.4.2  Sub  microsecond  dynamics  are  observed  throughout  Fas-DD  in  crystal 
buffer 
The effective transverse relaxation rate constants R2
eff were calculated for a subset of 
five cross peaks (Ala301, Leu303, Cys304, Leu306, Ala307) from both the Fas-DD 
and  the  Fas-DD  in  crystal  buffer  relaxation  dispersion  spectra.  These  peaks 
correspond to the residues in the loop region between helices 5 and 6 in Fas-DD. The 
analysis  focused  upon  this  region  because  within  the  published  4:4  Fas:FADD 
crystal structure it is within this part of the structure that the polypeptide chain is 150 
reoriented to form an elongated helix. It would have been ideal to have been able to 
analyse  the  surrounding  helix  regions  of  this  loop,  however  assignments  for  this 
region  of  the  construct  were  not  transferrable  between  spectra,  as  highlighted  in 
Figure 3.16, which suggests that this region of the protein has been affected by the 
buffer conditions.  
The analysis of relaxation dispersion data for Fas-DD in crystal buffer is illustrated 
with the location of the analysed residues upon the Fas-DD structure in Figure 3.23. 
Fas-DD within the conditions used to crystallise Fas and FADD in a 4:4 complex 
exhibits a a globally higher value of R2
eff compared to wild type Fas-DD throughout 
all of the residues analysed. This result is consistent with the results of the classical 
relaxations analysis where the true 
15N R2 values were significantly higher than for 
the same protein in standard buffer conditions. However, the quality of the Fas-DD 
in crystal buffer relaxation dispersion data is not particularly high. The calculated 
experimental  error  is  larger  throughout  the  Fas-DD  in  crystal  buffer  samples 
compared to all of the rest of the Fas-DD acquisitions. This is due to the poor signal 
to noise within the spectra collected for these conditions, resulting in a drop off in 
peak height prior to reaching the longest CPMG value. The poor signal to noise is a 
consequence of the lower protein concentration coupled with the loss of signal due to 
dielectric losses associated with the high ionic strength of the buffer and aggregation 
of the sample. This greatly reduced the data that were available to analyse for this 
experiment. As a result it is essentially impossible to definitively infer the presence 
of relaxation dispersion for Fas-DD under these buffer conditions. 
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Figure 3.22 CPMG relaxation dispersion curves and the Fas-DD structure highlighting the six 
amino acids in the closest proximity to the Y291.  
Data extracted from relaxation dispersion experiments upon Fas-DD Y291E recorded at 600MHz and 25
oC, with 
the R2 effective measured relaxation rate and CMPG field strength applied indicated. Six residues were analysed for 
their proximity to Y291. Insert, published Fas-DD structure (PDB:1DDF) highlighting each of the residues for 
which dispersion curves were calculated by colour. The dispersion curve for E261 (grey) is included to illustrate 
that dispersion differences are specific to the location of the mutation rather than global effects upon the domain.  
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Figure  3.23  CPMG  relaxation  dispersion  curves  for  the  6  amino  acids  present  in  the  loop 
between helices five and six in the Fas-DD 
Dispersion  curves  for  Fas-DD  in  crystallisation  buffer  recorded  at  600MHz  and  25
oC,  with  the  R2  effective 
measured relaxation rate and CMPG field strength applied indicated. Data collected from Fas-DD shown as black 
curves, data collected for Fas-DD in crystallisation buffer shown as grey curves. A, Fas-DD published structure 
(pdb:1DDF) highlighting the residues for which dispersion curves were calculated. B, Fas-DD structure taken 
from Fas:FADD crystal structure (PDB:3EZQ) highlighting the same residues. The dispersion curve for G286 
(grey) is included as a representative of the dispersion differences to another area of the domain.. 153 
3.7 Discussion 
The Fas death domain structure was first described in 1996 by Haung and colleagues 
documenting a bundle of six antiparallel amphipathic helices. Since then a number of 
other death domain structures have been determined, all showing this now canonical 
death  domain  fold.  The  interaction  with  Fas  and  the  adaptor  protein  FADD  is 
mediated by a death domain-death domain interaction which provides the basis for 
the formation of the death inducing signalling complex and the onset of apoptosis. 
Much work has been carried out to elucidate the mechanism of interaction between 
the Fas and FADD death domains. Crystallisation of the Fas-DD and FADD-DD 
complex has elucidated two very different structures with different stoichiometry. In 
one of the structures (showing a 4:4 Fas:FADD complex), the Fas-DD is shown to 
undergo a rearrangement resulting in the fusion of helices α5 and α6, thus deviating 
from the classical death domain fold. Although this complex has been suggested to 
be an unfeasible mechanism of interaction between Fas and FADD in vivo, it does 
illustrate that the death domain may not be as rigid as was previously thought and 
rather  might  undergo  plastic  deformation  under  prescribed  circumstances.  A 
phosphorylation site has been documented within Fas-DD at Tyr291, an observation 
that provides additional support that the Fas death domain may have some level of 
flexibility in its shape. Due to the relatively buried location of Tyr291, the death 
domain may need to reorganise to accommodate the presence of a phosphate group. 
The  work  described  in  this  chapter  has  used  NMR  spectroscopy  to  explore  the 
propensity of the Fas-DD to form other structures in solution.  
Almost invariably the starting point for any protein NMR analysis is the assignment 
of  the  protein  backbone  resonances.  Backbone  assignment  initially  involves  the 
identification  of  which  cross  peak  in  the 
1H/
15N-HSQC  spectrum  corresponds  to 
which  amino  acid  in  the  protein’s  primary  sequence.  The  backbone  assignment 
forms the basis of all further side chain chemical shift and structural (NOE, RDC, 
etc.) assignments for the molecule. The assignment of the protein backbone signals 
was also required for the analysis of the polypeptide dynamics as the experiments 
used are all based on an HSQC-type readout which enables analysis of the data on a 
residue  by  residue  basis.  The  backbone  correlation  NMR  experiments  for  Fas-
DD+CTD had already been acquired within the laboratory by Dr Diego Esposito. I 
repeated the task of backbone assignment using the same raw data  as  a training 154 
exercise in protein NMR spectroscopy, assigning 93% of the backbone NH in the 
HSQC  spectrum.  Assignment  was  incomplete  due  to  unresolved  NH  cross  peak 
resulting  from  flexible  N  and  C-termini  of  the  construct  and  lack  of  a  tractable 
HN(CA)CB spectrum. 
Structural  restraints  which  are  used  in  the  calculation  of  solution  structures  are 
mainly derived from the collection and analysis of NOESY spectra. 
15N- and 
13C- 
NOESY  spectra  can  be  used  to  calculate  the  relative  distances  between  pairs  of 
protons which are close in space. To enable assignment of the NOESY spectrum the 
side chain 
1H resonances of the amino acids are required to be assigned. This task is 
usually achieved by acquisition of a 3D HCCH-TOCSY spectrum followed by 
13C-
aromatic  and  aliphatic  NOESY  spectra.  The  side  chain  spectra  recorded  using 
traditional methodology and parameters were highly crowded with poor signal-to-
noise. To overcome this problem experiments were re-acquired using a non-uniform 
sampling  schedule  which  significantly  improved  the  resolution  of  the  spectra 
enabling a more complete and efficient assignment. The application of non-uniform 
sampling (NUS) is rapidly becoming a more everyday occurrence throughout the 
NMR community. In the world of protein NMR the trade-off is consistently between 
the amount of instrument time available and the achievable signal to noise within a 
spectrum. An NUS sampled spectrum offers an increase in resolution (particularly in 
the indirect dimension) in a much shorter space of time than a traditionally sampled 
spectrum
186,  and  helps  to  overcome  the  traditional  bottleneck  of  NMR  data 
acquisition
187. In this study, NUS particularly improved the resolution in the 
13C 
NOESY  experiments.  NOESY  spectra  are  notorious  for  the  presence  of 
overcrowding of the peaks, due to the sheer number of correlations and the range of 
cross peak intensities which are within the aliphatic region of the spectrum. Often the 
weakest  cross  peaks  carry  a  disproportionate  amount  of  information  in  terms  of 
structural restraints. Therefore there is a premium on optimising the ability of the 
NOESY-type  spectra.  The  implementation  of  NUS  methods  has  been  shown  to 
enhance considerably the approach to extracting the maximum utility from NOESY 
data without compromising on experimental sensitivity
187, something that we were 
able to exploit throughout this work. 
Secondary chemical shift information taken from the chemical shifts of the 
13Cα, 
13Cβ and 
1H atoms point towards the domain forming six helices which are located 155 
in the equivalent positions as in the PDB:1DDF (Figure 3.10). NOE spectral analysis 
also highlighted that Tyr291 is in a buried location, with NOE correlations between 
itself  and  residues  which  have  been  shown  to  be  located  nearby  in  the  Fas-DD 
‘closed’ solution structure. Unfortunately we had an incomplete set of side chain 
resonance assignments and therefore pursued solving the structure with the aid of 
restraints from the deposited co-ordinates of Fas-DD (PDB:1DDF). Due to this we 
can  only  consider  our  structure  as  a  preliminary  representation  of  the  data  we 
collected  from  the  structural  NMR  experiments;  there  is  much  scope  for  further 
refinement of the NOE dataset which we used to calculate our structure in its current 
form. However, the preliminary structural results unambiguously indentify that in 
our  hands  in  solution  Fas-DD  forms  the  canonical  death  domain  fold,  almost 
identical to the Fas-DD structure published by Huang and colleagues in 1996. 
To test the likelihood that Fas-DD can exist in a more open conformation in solution 
within  different  environments,  the  dynamics  of  Fas-DD  containing  a  phospho-
mimetic mutation (Y291E) and in the buffer Fas was crystallised in were explored 
using NMR relaxation experiments. The problem with the introduction of a mutation 
or variation of the buffer environment of a protein is that it can disrupt the secondary 
structure of a protein, to this the NMR spectrum should be sensitive to such changes. 
The presence of the Y291E mutation resulted in a number of peak shifts within the 
Fas-DD 
1H/
15N-HSQC  spectrum,  preventing  full  transfer  of  backbone  resonance 
assignments. This could be considered to have limited the analysis of the relaxation 
data acquired in these conditions. Peak shifts in the 
1H/
15N-HSQC should have been 
expected due to the additional formal negative charge due to the mutation, Fas-DD 
backbone resonance assignments should be repeated with this mutant construct to be 
able to fully analyse the effect of this mutation on the relaxation properties of Fas-
DD. The Fas-DD construct, once dialysed into crystallisation buffer (0.95 M citric 
acid, 1.9 M ammonium sulphate, pH 4) showed, signs of instability. Upon dialysis a 
proportion of the protein partly precipitated resulting in a lower concentration of 
protein  and  a  knock-on  effect  upon  the  achievable  quality  of  the  NMR  data. 
Changing the buffer conditions of a protein also has a large effect upon the local 
environment of each NMR active nucleus and a global effect on the chemical shifts; 
again  for  these  conditions  only  a  subset  of  the  resonance  assignments  could  be 
transferred. As these experiments were designed to recapitulate the conditions the 156 
death domain was exposed during crystallisation, there is little improvement to the 
quality of this sample that could be made.  
Despite  the  difficulties  posed  by  the  constructs  used  to  look  at  Fas  dynamics,  a 
number of observations were able to be made. The overall rotational diffusion and 
internal mobility of Fas-DD in these three different conditions were assessed using 
the standardised set of NMR spin relaxationion experiments: 
15N R1, 
15N R2 and 
{
1H}
15N  heteronuclear  NOE.  These  ‘classical’  experiments  are  most  useful  for 
assessing the overall dynamic characteristics of the target protein. In particular for 
the globular part of a folded protein the ratio of R2/R1 values relates directly to the 
overall  rotational  correlation  time  τc.  Outlier  low  values  of  the  hNOE  (<~  0.6) 
combined with small values of R2 typically indicate regions of the protein that are 
more flexible on the nano-to-picosecond timescale. And outlier high values of R2 
may  indicate  the  presence  of  an  exchange  contribution  to  the 
15N  linewidth  and 
thereby the presence of multiple states (conformations) that fluctuate on the milli- to 
microsecond timescale.  
Chemical  exchange  is  more  reliably  identified  in  CPMG  relaxation  dispersion 
measurements. Such experiments were performed for all three Fas-DD conditions 
described above. The data was analysed on a residue by residue basis for each of the 
conditions,  focusing  upon  residues  which  are  in  suspected  areas  of  increased 
flexibility/rearrangement.  The  effective  transverse  relaxation  rate,  R2
eff,  of  the 
residues of interest was plotted against the CPMG frequency. These were plotted in 
conjunction with the same analysis from peaks corresponding to the Fas-DD data to 
make a comparison between the conditions and what was considered globular Fas-
DD. Of note, each of the dispersion curves shown in Figure 3.21 and 3.22 show an 
initial dip in the R2
eff values. This is considered to have been an unexplained and 
unresolved artefact of the pulse sequence used when the experiments were acquired, 
similar  effects  were  observed  using 
15N  ubiquitin  as  a  control  protein  (Dr  Tom 
Frienkel, personal communication). 
The R1, R2 and heteronuclear NOE analysis of Fas-DD+CTD all showed essentially 
flat  dynamic  profiles.  This  pattern  of  relaxation  and  dynamic  parameters  is 
characteristic of a stable, globular protein fold, coupled with the estimate of τc (8.2 
ns) determined from the trimmed average R2/R1 ratio these results are in line with 157 
Fas-DD  forming  a  globular  structure  consistent  with  the  canonical  death  domain 
fold. In conjunction with the structural results observed for Fas-DD in solution in our 
hands, these conditions were considered wild type or Fas in a closed conformation. 
This categorisation was to aid in the analysis of the other conditions tested to act as a 
comparison. 
The profiles of R1, R2 and heternonuclear NOE of Fas-DD Y291E are mostly flat, 
indicating  that  this  mutant  Fas-DD  maintained  the  globular  fold.  The  R2  values 
throughout the protein were significantly more dispersed than both the R1 and NOE 
profiles. The dynamic profiles indicate that there are some localised differences in all 
three parameters around helix five and the loop between helix five and six which 
may  suggest  some  flexibility  in  this  region.  This  is  the  location  of  the  Y291E 
mutation and could therefore indicate local rearrangement of Fas-DD, however there 
is not a continued stretch of residues affected. The classical readout for a region of a 
protein with increased flexibility would be an increase/decrease in the parameters of 
all three experiments for a contiguous stretch of amino acids. Complete assignment 
of Fas-DD Y291E would give a clearer picture as to whether these anomalies are due 
to local unfolding or plasticity. For Fas-DD Y291E, the assignments for six of the 
peaks in the closest proximity to Y291 were available. The R2
eff of these peaks and 
the  associated  peaks  for  Fas-DD  in  NMR  buffer  calculated  from  relaxation 
dispersion measurements were compared. The Y291E mutation increased the R2
eff at 
the lowest CPMG frequencies of residues in the closest proximity to residue 291 
(Tyr232, Asp292, Ile295). This effect is consistent with the presence of dynamics in 
the micro- to millisecond timescale for these residues. However, for the residues 
slightly further away and a ‘control’ residue (Glu261) which is in a region distinct 
from that containing Tyr291, the R2
eff values were essentially indistinguishable from 
those  obtained  for  the  wild  type  protein.  These  results  are  consistent  with  the 
presence of local dynamic refolding or orientation of the domain close to the location 
of  the  mutation,  suggesting  that  the  Fas-DD  Y291E  is  capable  of  some  level  of 
deformation or rearrangement. The experiments with this mutant were carried out 
with a view to  crudely  model the effect of phosphorylation of the side chain of 
Tyr291. At face value the results for Fas-DD Y291E suggest that the introduction of 
a negative charge at that position can be accommodated without very significant 
disruption of the overall fold of the protein as evidenced by the overall high level of 158 
conservation of chemical shifts, the essentially identical rotational correlation time, 
and  only  limited  evidence  of 
15N  relaxation  dispersion  patterns.  Rather  it  seems 
probable that, given the larger dimensions of the Tyr side chain compared to Glu 
residue, and the fact that the putative phosphoryl group would be appended onto the 
solvent exposed extremity of the former, the modification would have very limited 
influence on the stability and folded-ness of the Fas death domain.  
It is well known that buffer conditions can have a large effect upon the position of 
NH peaks observed in a 
1H/
15N-HQSC spectrum. The high salt conditions of the 
crystal buffer resulted in a number of dramatic peak shifts throughout the 
1H/
15N-
HQSC spectrum which resulted in only 45% of the backbone resonance assignments 
being able to be transferred for the spectrum. This dramatically reduced the number 
of data points which could easily be sampled. As observed from the formation of the 
‘open’  Fas  conformation,  the  crystal  conditions  (if  this  is  what  caused  the 
rearrangement) could encourage helical rearrangement of the Fas-DD. Analysis of 
the R1, R2 and heteronuclear NOE showed dispersed, ‘non flat’ dynamic profiles, 
suggesting  that  Fas-DD  in  crystal  buffer  is  more  flexible  upon  the  nanosecond 
timescale than Fas-DD in NMR buffer. Interestingly, the estimated value of τc (12 
ns) is significantly higher for Fas-DD in crystal buffer when compared to wild type 
(8.2 ns) and the Y291E mutant (8.3 ns). This could be an indication that in crystal 
buffer,  Fas-DD  tends  to  strongly  self-associate  and  possibly  forms  a  dimer,  or 
tumbles more slowly as a result of the heightened viscosity of the buffer conditions, 
or a combination of these effects. Both the observed 
15N R2 and R2
eff values for Fas-
DD  in  crystal  buffer  were  all  significantly  higher  than  the  corresponding  values 
obtained in standard NMR buffer. Unfortunately it is difficult to make definitive 
conclusions from the relaxation dispersion data from the experiments collected in 
crystal buffer. The lower solubility of Fas-DD in these conditions is consistent with 
the use of these conditions to crystallise the protein. However, it is noteworthy that a 
number of the cross peaks remained essentially unshifted compared to Fas-DD in 
standard NMR buffer. Those cross peaks which could be assigned were distributed 
throughout the length of the protein which would indicate that the overall fold of the 
construct  in  the  crystal  buffer  conditions  is  essentially  that  of  a  canonical  death 
domain fold. Taken as a whole we have not obtained any substantive evidence that 
Fas-DD can rearrange in these conditions, although an exhaustive investigation for a 159 
conclusive  outcome  is  warranted.  Unfortunately,  due  to  the  time  and  resource 
commitment applied towards the other strands of activity described in this thesis, at 
the time of writing it has not proved possible to devote further effort towards this 
objective.  
In summary, this chapter has given a clear indication that in our hands, the Fas-DD 
does in fact form a six helical, compact bundle like the reported solution structure. 
Dynamic analysis of Fas-DD in conditions to induce alternative conformations has 
on the whole proved inconclusive, with some local rearrangements possible with the 
introduction  of  a  phosphomimetic  mutation  and  global  changes  in  crystallisation 
conditions. In general there was no definitive evidence for the spontaneous formation 
of any significantly different structures similar to those observed in crystallo. Further 
work would focus upon the possibility of generating a phosphorylated Fas-DD to test 
whether this post translational modification confers structural rearrangement to the 
death domain. 
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                                                                     Chapter 4 
Semi-synthesis of pY Fas Death Domain using 




4.1.1 Phosphorylation of the death domain of Fas could alter the structure and 
dynamics of the domain 
The  death  domain  of  Fas  (Fas-DD)  has  been  reported  to  be  phosphorylated  on 
tyrosine  291.
54  It  has  been  proposed  that  this  phosphorylation  is  crucial  for  Fas 
oligomerisation and the commitment to apoptotic signalling
55. Furthermore, reports 
have  suggested  that  Fas  phosphorylation  triggers  a  variety  of  non-apoptotic 
signalling pathways, including the PI3 kinase and ERK pathways
63.  
Y291 is present within a region with homology to the known SH2 domain target 
sites (YxxL). Co-precipitation of SH2-domain containing phosphatases SHP1/2 and 
SHIP
45 and the activation of PI3K through its SH2 domain containing regulatory 
subunit
62 further implicate the phosphorylation of the death domain to have a role 
within cellular signalling. The kinase(s) able to phosphorylate Fas have not been 
unambiguously identified, but the src family YES kinase has been implicated, at 
least as part of the PI3K activation pathway
62.  
Two,  highly  divergent,  3D  structures  of  Fas-DD  have  been  reported,  exhibiting 
different degrees of solvent accessibility for Y291
6,121. As described in Chapter 3, 
NMR studies with wild type and a phospho-mimetic mutation of Fas-DD indicated 
that, at least in solution, both constructs behave in a manner compatible with the 
structure  in  which  Y291  is  buried.  This  fact  prompts  a  plethora  of  questions 
regarding how this tyrosine can be phosphorylated and the consequences this might 
have  on  the  structure  of  the  domain.  The  addition  of  a  phosphate  group  would 
certainly disrupt the compact structure of the death domain possibly having ‘knock-
on’ effects upon the functional interactions of Fas.  161 
The implementation of a methodology for the semi-synthetic preparation of a Tyr-
phosphorylated death domain would have merits in its own right. Development of 
novel  chemical-biology  based  methods  would  generate  transferrable  protocols  to 
introduce post translational modifications into other proteins within the laboratory. 
Moreover, the introduction of pY291 into Fas-DD might reveal interesting structural 
and dynamical information about death domains and their ability to modulate their 
interaction with other proteins. 
4.1.2 The use of expressed protein ligation to generate a Tyr291 phosphorylated 
Fas construct in vitro 
It is extremely challenging to synthesise peptides longer than 60 residues in length 
using standard methods due to the formation of secondary structure (primarily β-
sheets)  within  the  peptide  chain.  Regular  secondary  structure  elements  normally 
cause aggregation, reducing the efficiency of the amino acid coupling reaction
188. A 
common method to overcome this problem is the insertion of pseudo proline (ψP) 
units  into  the  peptide  sequence  throughout  synthesis.  A  ψP  is  a  dipeptide  unit 
constituted of any amino acid followed by a serine, threonine or cysteine derivatised 
as an oxazolidine. This derivatisation creates an amino acid with a similar structure 
to proline, resulting in a kink in the backbone of the peptide preventing any ordered 
structure from forming. Acid treatment following peptide synthesis, converts the ψY 
into the two native amino acid structures, leaving no trace in the peptide chain. ψY 
are  routinely  used  to  enable  the  synthesis  of  long  peptides  thus  allowing  the 
synthesis of longer peptides by solid phase peptide synthesis
188,189. Fas-DD itself has 
previously been fully synthesised with the use of eight pseudo proline (ψP) units
190. 
Although very interesting, syntheses based on using multiple pseudo proline units 
are laborious, resulting in a low yield of peptide and, at least for the present time, are 
not suitable to be used for preparative purposes in structural biology laboratories.  
Expressed  protein  ligation  (EPL)  is  a  technique  which  merges  the  biochemical 
techniques  of  recombinant  protein  expression  and  purification  with  the  organic 
chemistry  techniques  of  peptide  synthesis.  EPL  overcomes  the  peptide  length 
limitation in peptide synthesis by the ligating a protein, or a fragment of a protein, 
expressed in E. coli with a synthesised peptide. It is a powerful method, enabling the 
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post  translational  modifications,  as  well  as  fluorescent  and  isotopic  site-specific 
protein  labelling  for  NMR,  of  the  type  that  are  either  difficult  or  impossible  to 
achieve with peptide synthesis or protein expression alone
191. 
Established technologies of EPL are currently limited by the need to have a cysteine 
residue at the N-terminus on the second C-terminal fragment in the ligation junction. 
This  is  because  the  ligation  occurs  via  a  thioester  exchange  reaction.  The  work 
described here includes the validation of a novel Na auxiliary ((2-hydroxy-3-thio-4-
methoxy)benzyl; Htmb) that bypasses the requirement for a cysteine at the ligation 
junction
192.  
The strategy used to generate a pY Fas Death Domain by expressed protein ligation 
was carried out in three steps. First, the N-terminal fragment (residues 218-285) of 
Fas-DD (Nt-Fas-DD) was expressed in E. coli in a form that contained a reactive C-
terminal thioester. Then, the C-terminal fragment (Ct-Fas-DD residues 286-323) was 
synthesised  by  Fmoc  solid  phase  peptide  synthesis  (SPPS)  to  include  a 
phosphorylated tyrosine at position 291 (pY-Ct-Fas-DD) and a novel auxiliary group 
(Htmb)  attached  at  the  N-terminus.  The  N-  and  C-termini  were  then  ligated  by 
thioester exchange. The following sections will extend on the principles of each of 
these stages of generating pY291 Fas-DD in vitro.  
The phospho-tyrosine of interest is in the C-terminal part of the death domain thus, 
the peptide forms the C-terminus of the construct. The location of the ligation site 
within the protein is crucial for the yield of the ligation, as the rate of the thioester 
exchange reaction depends on factors such as the nucleophilicity of the C-terminal 
reactive thioester, which is the attacking nucleophile, and the steric hindrance at the 
site. It has been shown that the rate of exchange of C-terminal glycine or histidine 
thioesters is enhanced compared to that for other natural amino acids
193,194. Also, it is 
thought that the presence of a  glycine at the N-terminus of the second fragment 
optimises  the  ligation  yield  because  it  minimises  the  steric  hindrance  due  to  the 
absence of a side chain. Residues 285 and 286 in the Fas death domain are His and 
Gly respectively, so this peptide bond was the chosen location to be the ligation 
junction. The decided Fas-DD construct designs for EPL are shown in Figure 4.1. 




Figure 4.1 Schematic representation of the division of the Fas-DD for expressed protein ligation 
A, Schematic representation of the full Fas Death domain, to be recreated using expressed protein ligation. The 
sequence of the N-terminal construct is highlighted in blue and the C-terminal peptide is highlighted in orange. 
The  N-terminal  methionine  will  be  left  over  from  E  coli  expression.  B,  Representation  of  the  Nt-Fas-DD 
construct  cloned  using  the  NEB  IMPACT  system.  C,  The  Nt-Fas-DD  benzyl  mercaptan  thioester  produced 
following on column cleavage. (CBD – chitin binding domain.) D, representation of protected Htmb- Ct-Fas-DD. 
E,  Representation  of  deprotected  Htmb-pY-Ct-Fas-DD.  The  numbers  below  illustrations  correspond  to  the 
residue number of Fas. F, Cartoon representation of Fas-DD (pdb:1DDF) highlighting the N-terminal (blue), C-
terminal (orange) and Tyr291 (green) 
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4.1.3 The Nt-Fas-DD fragment with a C-terminal reactive thioester is produced by 
intein excision 
An intein is a self-splicing protein. Protein splicing is a post translational processing 
event  in  which  the  intein  domain  catalyses  its  own  excision  from  a  larger 
polypeptide. The excision is followed by the ligation of the two flanking regions 
(termed exteins) via the formation of a native peptide bond between them (Figure 
4.2). Protein self-splicing enables the formation of two distinct proteins from one 
gene transcript
195. Although inteins have been identified in all domains of life, there 
is little sequence similarity, other than a conserved N-terminal cysteine residue (or 
Serine) and a C-terminal asparagine followed by a cysteine, threonine or serine
196. 
Intein-mediated protein splicing is initiated at the N-terminus of the intein, with an 
N-S (or N-O) acyl  rearrangement that replaces  the peptide bond between the N-
terminal extein and the intein with a thioester (or ester) linkage. The next step is a 
transesterification  reaction  in  which  the  C-terminal  Cys,  Thr  or  Ser  attacks  the 
carbonyl group of the newly formed thioester (or ester) cleaving the bond between 
the N-terminal extein and the intein, yielding a branched intermediate. Then, the side 
chain nitrogen of the C-terminal Asn residue undergoes cyclisation by attacking its 
own backbone carbonyl group, which breaks the peptide bond between the intein and 
the C-terminal extein, releasing the intein and leaving a thioester (or ester) bond 
between the exteins. Finally, the exteins undergo an spontaneous S–N (or O–N) acyl 
shift to form a native peptide bond (Figure 4.2A) 
197,198. 
In  order  to  use  inteins  for  the  generation  of  proteins  with  a  C-terminal  reactive 
thioester, the intein needs to be located C-terminal to the protein of interest. Also, the 
C-terminal Asn of the intein must be mutated to Alanine. This mutation halts the 
intein cleavage at the level of the formation of the thioester between the protein of 
interest and the intein. The reaction is carried out in the presence of a thiol reagent 
such at 2-mercaptoethanesulfonic acid (MESNA), DTT or thiophenol
199,200. The thiol 
reagent attacks the carbonyl group in the newly formed thioester, releasing the target 
protein  from  the  intein  and  resulting  in  the  formation  of  a  polypeptide  product 
containing a C-terminal thioester (Figure 4.2B).  






Figure 4.2 Comparison of standard intein cleavage and modified intein cleavage used within the 
IMPACT system 
A, Standard intein mechanism. 1, N-S acyl shift between the side chain of a cysteine residue and the carbonyl of 
the C-terminal amino acid of the N-extein, which is followed by, (2) transesterification to shift the N-extein to the 
side chain cysteine in position +1. 3, Succinimide formation caused by the presence of the Asn at position -1 
releases the intein, this is followed by a S-N acyl shift which recapitulates the native peptide bond and the side 
chain of the cysteine in the +1 position. B, Modified intein mechanism. 1, undergoes S-N acyl shift like a native 
intein. 2, benzyl mercaptan thiol attacks the carbonyl in the newly formed thioester, releasing the target protein 
from the intein and results in the formation of a protein construct containing a C-terminal thioester. Due to there 
being no Asn in the -1 position, succinimide formation and intein excision is prevented causing the intein to 
remain bound to the C-terminal CBD and chitin bead. More information on this process is shown in Figure 4.3. 
Adapted from Southworth and Perler 2004. 166 
 
 
Figure  4.3  Schematic  diagram  illustrating  the  protocol  used  for  Nt-Fas-DD  purification, 
including the mechanism for intein cleavage  
Schematic diagram showing benzyl mercaptan induced on column intein cleavage of the Nt-Fas-DD construct 
from the intein and chitin binding domain. Nt-Fas-DD is shown in blue, the intein in brown and the chitin 
binding domain (CBD) in green. Briefly, after E. coli expression (2), the lysate is clarified and the construct is 
affinity purified using chitin beads (3). Upon the beads, intein cleavage is induced by the presence of benzyl 
mercaptan. This induces thiol mediated cleavage via a N-S acyl shift (4), allowing the freed Fas-DD thioester to 
be eluted from the column (5). (adapted from NEB Biolabs literature on the IMPACT system). 
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The  thiol  chosen  for  this  study  was  benzyl  mercaptan.  The  benzyl  thioester  is 
considered  a  robust  group  which  is  less  susceptible  to  hydrolysis  than  other 
thioesters  therefore  has  advantages  for  the  storage  of  the  prepared  protein 
thioester
201. 
New England Biolabs incorporated the intein-mediated cleavage technology in their 
IMPACT (intein mediated purification with an affinity chitin binding tag) system of 
products, in which an intein is fused to the chitin binding domain (CBD) of chitinase 
A1 from Bacillus circulans
202 . The DNA insert of the protein of interest can then be 
cloned either N or C-terminal to the intein-CBD to exploit these properties
203. The 
vector chosen to prepare the Nt-Fas-DD thioester contains the coding sequence for 
the naturally occurring Mxe GyrA mini intein which was originally isolated from 
Mycobacterium  xenopi.  This  intein  is  198  residues  in  length.  When  it  was 
discovered,  this  was  the  smallest  naturally  occurring  protein  splicing  element 
identified
204. The presence of the CBD in the expressed protein not only enables 
affinity purification using chitin beads, but also on-column cleavage of the target 
protein.  The  released  protein  of  interest  (containing  the  reactive  thioester)  elutes 
from the column, while the intein and CBD remain on the beads. This procedure 
aims  to  yield  a  purified  protein  containing  a  C-terminal  thioester  and  no  vector 
derived  amino  acids
199,205.  The  process  and  mechanism  of  thiol  mediated  intein 
cleavage which was used to generate Nt-Fas-DD is illustrated in Figure 4.3. 
4.1.4  The  C-terminal  Y-phosphorylated  fragment  was  synthesised  using  Nα  9-
fluorenylmethylozycarbonyl solid phase peptide synthesis 
Nα 9-Fluorenylmethylozycarbonyl (Fmoc) solid phase peptide synthesis (SPPS) is a 
widely used methodology for the generation of peptide fragments from amino acid 
constituents  on  a  solid  support.  It  builds  upon  the  SPPS  technique  originally 
described  by  Merrifield  in  1963
206,  in  which  Na-derivatised  amino  acids  are 
sequentially coupled to form the peptide of interest. Following each coupling, the 
reagents and by-products are removed by filtration as the peptide is built up from the 
C to the N terminus. A schematic of the Fmoc-SPPS process used to synthesise pY-
Ct-Fas-DD is shown in Figure 4.4.  
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Figure 4.4 Synthesis of pY-Ct-Fas-DD peptide 
Schematic representation of the process used to make the Ct-Fas-DD phosphopeptide by Fmoc-SPPS, followed 
by auxiliary addition and deprotection. Briefly, Rink resin, containing a free amide group is swelled in DMF. The 
first Fmoc protected amino acid is coupled to the resin using DIC/HOBt coupling methods (HBTU/DIEA for the 
phosphotyrosine and last five amino acids) (1), followed by the removal of the Fmoc protecting group using 20% 
piperidine in DMF (2). The amino acid coupling and deprotection is repeated sequentially to build up the target 
protein sequence (3). This is followed by the chemical addition of the auxiliary by a 1, 2 addition, elimination 
reaction (4) The phosphopeptide was cleaved from the resin using TFA and appropriate side-chain protecting 
group scavengers (5). Following preparation the auxiliary deprotecting group was removed using DTNP (6), re-




Figure 4.5 Chemical mechanisms involved in solid phase peptide synthesis 
The three main reactions involved in solid phase peptide synthesis. A, Activation of Fmoc protected amino acid 
using DIC/HOBt coupling. Carboxylic acid needs activating to enable coupling. DIC converts the amino acid to 
O-acylisourea  which  is  spontaneously  converted  to  the  reactive  1-hydroxybenzotriazole  ester  by  HOBt.  B, 
Activation of Fmoc amino acids using DIEA/HBTU coupling works along a similar mechanism. C, Coupling 
reaction to form an amide bond. D, Fmoc deprotection. The Nα-Fmoc protecting group is removed through a β-
elimination reaction with piperidine. More in depth description of the reaction is found in the main text. 
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Amino  acids  used  for  SPPS  contain  side  chain  and  N-terminal  modifications 
designed  to  protect  the  functional  groups  and  limit  side  reactions.  Side-chain 
protecting groups are designed to prevent the peptide chain growing through side-
chain linkages whereas the N-terminus is protected by an Fmoc group which ensures 
that only one amino acid is incorporated to the chain in a given reaction cycle. To 
enable amide (peptide) bond formation between the resin-linker and the carbonyl 
group of the amino acid to be coupled, the carbonyl of the amino acid needs to be 
activated. The activity of the activated species is one of the most important factors to 
affect the coupling yield. One of the most common ‘activators’ is a combination of 
N,N-diisopropylcarbodiimide  (DIC)  and  the  catalytic  auxiliary  N-hydroxy-
benzotriazole (HOBt). The HOBt presence is primarily to reduce the occurance of 
side reactions, especially racemisation. DIC reacts with the carboxylic acid of the 
amino acid to form a highly reactive O-acyl isourea. The O-acyl isourea reacts with 
HOBt to form an activated benzotriazolyl ester of the amino acid which can readily 
react with the deprotected amine in the existing peptide chain to form an amide 
bond (Figure 4.5A). 
Other activation chemistries exist, one of them using O-(benzotriazol-1-yl)-1,1,3,3-
tetramethyl-uronium hexafluorophosphate (HBTU) and N,N-diisopropylethylamme 
(DIEA). HBTU does not require the generation of the O-acyl isourea in order to 
form  the  benzotriazolyl  ester  of  the  amino  acid.  The  incorporation  of  benzyl 
protected  phosphoamino  acids  using  DIC/HOBt  results  in  incomplete 
incorporation
207, so HBTU was used for the activation of Fmoc protected phosphor-
tyrosine used to synthesise Ct-pY-Fas-DD. The mechanism of amino acid activation 
is shown in Figure 4.5B. Once the amino acid is activated, the first coupling reaction 
can be carried out.  
The  very  first  coupling  reaction  in  Fmoc  SPPS  is  the  coupling  of  the  most  C-
terminal  amino  acid  to  an  insoluble  support  (resin)  which  contains  a  specific 
functional  group  such  as  free  acids,  amides  or  hydrazide
208.  For  Ct-Fas-DD 
synthesis, a PL-Rink amide resin, containing an amide functional group was chosen 
in  order  to  create  generate  a  natural  amino  C-terminus  following  synthesis.  The 
coupling reaction is shown in Figure 4.5C. The amide group upon the resin attacks 
the carbonyl  group of the activated benzotriazolyl ester forming an amide bond 171 
between the resin and the amino acid. Prior to the second amino acid coupling, the 
Nα Fmoc group is removed in a process known as deprotection. This is carried out 
by washing the resin/solid support in the weak base, piperidine, thus exposing the N-
terminus of the amino acid that has just been incorporated. The basic properties of 
piperidine abstracts the acidic proton from the Fmoc fluorenyl ring system resulting 
in β-elimintation of the Fmoc group from the peptide chain (Figure 4.5D). The next 
Fmoc protected amino acid is then activated and coupled to this new N-terminus 
using  the  same  series  of  reactions
208,209.  The  cycle  of  amino  acid  coupling  and 
deprotection is repeated until the desired amino acid sequence has been synthesised.  
In the case of pY-Ct-Fas-DD, the N-terminal auxiliary group Htmb was additionally 
coupled to the most N-terminal residue in order to allow for ligation without the 
requirement for a cysteine at the C-terminus of the junction. For all Fmoc-SPPS 
resin  supports,  the  resin-peptide  link  is  acid  labile.  This  property  enables 
simultaneous cleavage of the full peptide from the support and removal of side chain 
protecting groups. This process is done by the addition of trifluoroacetic acid (TFA) 
supplemented with scavengers such as H2O and phenol. Scavengers trap and prevent 
reactive  co-products  from  reacting  with  the  synthesised  peptide
208,210.  Following 
cleavage,  the  peptide  is  purified  using  reverse  phase  high  pressure  liquid 
chromatography (RP-HPLC).  
4.1.5 The Htmb auxiliary group enables the ligation of fragments without an N-
terminal cysteine at the junction 
Native  chemical  ligation  (NCL)  refers  to  the  general  method  of  coupling  large 
unprotected peptides to form a natural amide bond at the reaction site. This reaction 
is  illustrated  in  Figure  4.6.  In  NCL  a  thioester-containing  peptide  reacts  with  a 
second peptide that has a cysteine residue at its N-terminus. In an analogous manner 
to the N-S acyl shift reaction that occurs during intein cleavage, the side chain thiol 
of the cysteine attacks the carbonyl group of the C-terminal thioester, forming a new 
thioester-linked intermediate. The thiol moiety can then spontaneously rearrange to 
form an amide bond
211. 
The development of NCL has revolutionised the field of peptide chemistry, greatly 
extending the size of the peptides which could be generated by SPPS alone. The 172 
reaction is also advantageous as it is a ‘one pot’ reaction in which the formation of 
the natural amide bond occurs both in neutral and denaturing aqueous conditions. 
The  ability  to  carry  out  the  reaction  in  a  denaturing  environment  permits  an 
increased  concentration  of  reactants  to  be  used  and  increases  the  overall  rate  of 
reaction
211. However the requirement for a cysteine residue at the ligation junction is 
a  significant  drawback  to  the  technique.  Cysteine  is  the  second  lowest  abundant 
amino acid in native proteins. Therefore a protein may not have an adequate number 
of cysteine  residues, or they might be located  at an inconvenient location in the 
peptide  chain,  this  greatly  limits  the  application  of  NCL  to  native  sequences. 
Moreover, NCL does not perform well when certain amino acid residues are present 
at  the  ligation  junction.  For  example  β-branched  amino  acids  result  in  steric 
hindrance
212 and Asp and Glu cause ligation to occur between side chains rather than 
in the peptide backbone
213. In this context it is estimated that only half of the natural 
amino acids are suitable for efficient NCL
127. 
To overcome this problem, the method of auxiliary-mediated NCL was developed. 
The general strategy is to include at the N-terminus of the C-terminal peptide, a 
chemical auxiliary that is able to undergo the same reactions as the side chain thiol 
group of cysteine, but that can be removed from the protein after the ligation. This 
strategy  was  initially  mentioned  by  Canne  at  al
193,  highlighting  X-Gly  or  Gly-X 
ligation sites, and then put into practice by Low et al.
214 and Offer et al.
192,215 who 
respectively  synthesised  cytochrome  b562  and  SH3  domains  using  an  auxiliary-
mediated ligation approach. The auxiliary used in this study, 2-hydroxy-3-thio-4-
metoxy-benzaldehyde  (Htmb)  acid,  and  the  mechanism  of  auxiliary-mediated 
ligation using this compound are illustrated in Figure 4.7. The adoption of Nα-linked 
auxiliary  has  two  advantages:  first  it  might,  in  principle,  expand  the  number  of 
amino  acids  that  can  be  used  at  the  ligation  junction  and  second,  it  is  broadly 
compatible with SPPS techniques
214. 
A number of different auxiliaries have been developed to improve the yield of the 
ligation reaction between different combinations of amino acids. When designing an 
auxiliary,  there  are  two  desirable  features:  first,  following  addition  to  a  peptide 
which is still attached to the resin, an auxiliary is required to be able to withstand the 
strong acid treatment used to finally  cleave the synthetic peptide  from the resin; 173 
second, it needs to be acid labile to enable successful removal following the ligation 
reaction.  Auxiliaries  have  been  designed  around  substituted  derivatives  of 
benzaldehyde because this framework fits these requirements
192.  
The auxiliary used in this study, Htmb, is illustrated in Figure 4.7B. Due to its high 
reactivity, and in a similar manner to the side chains of natural amino acids, the thiol 
group  of  Htmb  needs  to  be  protected  during  peptide  synthesis
216.  The  protected 
Htmb,  2-hydroxy-3-[(4-methoxyphenyl)thio]-4-metoxy-benzaldehyde,  is  shown  in 
Figure 4.7A. The protected Htmb was coupled to the N-terminus of the pY-Ct-Fas-
DD  peptide  prior  to  the  peptide  being  cleaved  from  the  resin.  The  first  step  of 
auxiliary coupling to the peptide is a nucleophilic addition to give a carbinolamine 
intermediate that dehydrates to form an imine. Next, sodium borohydride is added to 
reduce the imine to an amine (Figure 4.8).  
The 4-methoxyphenyl protecting group has to be removed from the auxiliary prior to 
the ligation reaction taking place. The removal (deprotection) of this group prior to 
ligation adds another step after the elution of the peptide from the solid support. The 
mechanism of DTNP (2,2’-dithiobis(5-nitropyridine)) deprotection used within this 
study is shown in Figure 4.9
157. The first step in the reaction is the formation of a 
highly reactive DTNP-thioanisole conjugate. The conjugate reacts with the protected 
sulphur of Htmb to form an unstable sulphonium intermediate that is resolved by the 
removal  of  the  4-methoxyphenyl  group,  while  the  disulphide  bond  between  the 
sulphur  of  Htmb  and  2-(5-nitropyridyl)  (5  Npys)  intermediate  group  remains. 
Finally, TCEP is added in excess to reduce the disulphide bond. 
Once the peptide is cleaved from the resin and the auxiliary is deprotected, the NCL 
between the Nt-Fas-DD thioester and Hmb-pY-Ct-Fas-DD can be carried out. As 
illustrated in Figure 4.7, there are three basic steps in auxiliary-mediated NCL: (1) an 
initial  capture  step  in  which  the  protein  and  peptide  undergo  thioester  exchange 
which links the two peptide chains together via the auxiliary; (2) the intermediate 
then  undergoes  two  acyl  transfer  steps,  in  which  the  N-terminal  fragment  is 
transferred  from  the  auxiliary  to  the  C-terminal  fragment  forming  a  terminal 
secondary amine; (3) the release of the auxiliary by acid treatment generates the 
native peptide bond
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4.1.6 Aims 
This part of the thesis documents the semi-synthesis of phosphorylated Y291 Fas-
DD using expressed protein ligation (EPL). Our aim was to investigate whether it 
was  feasible  to  use  this  methodology  to  produce  samples  for  structural  biology 
studies, as well as to validate a novel native chemical ligation auxiliary which avoids 
the  need  for  a  cysteine  at  the  ligation  junction.  Death  domains  prepared  by  this 
method  could  then  be  used  to  investigate  the  effect  of  post  translational 
modifications on the structure, dynamics and binding. This work was performed in 
collaboration  with  the  laboratory  of  Dr  John  Offer  in  the  Division  of  Physical 
Biochemistry, to exploit the novel methods of peptide ligation which they are aiming 
to develop. 
 
4.2  N-terminal  Fas-DD  can  be  expressed  with  a  good  yield  but  can  only  be 
purified after cleavage using denaturing conditions 
4.2.1 Cloning of the Nt-Fas-DD-Mxe intein-chitin binding domain construct 
To generate a protein construct suitable to undergo expressed protein ligation, the 
first  67  residues  of  the  Fas-DD  (residues  218-285)  were  cloned  into  the  NEB 
pTWIN1  expression  vector  as  described  in  Section  2.4.  The  DNA  template  was 
kindly provided by Dr Diego Esposito and contained the K263A mutation which has 
been shown to enhance the solubility of Fas-DD constructs. The pTWIN1 vector 
allows either an N-terminal chitin binding domain and Ssp intein or a C-terminal 
Mxe intein (or both) and chitin binding domain (CBD).  
In order to insert the N-terminal Fas-DD (Nt-Fas-DD) sequence, the N-terminal Ssp 
intein-CBD  was  excised  from  the  vector  resulting  in  an  Nt-Fas-DD  construct 
containing a C-terminal Mxe intein and CBD (Nt-Fas-DD-Mxe-CBD). The molecular 
weight and extinction coefficient of the different protein products that were obtained 
with this construct were calculated using the EXPASY Protparam server, as shown 
in Table 4.1. 
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Nt-Fas-DD-Mxe-CBD  218-285  35593  42650 
Nt-Fas-DD 
(with active thioester) 
218-285  7852  6990 
Nt-Fas-DD 
(without active thioester) 
218-285  7752  6990 
Mxe-CBD  -  27858  35660 
 
4.2.2 Expression and purification of N-terminal Fas-DD with a reactive thioester 
at the C-terminus 
E. coli BL21(DE3) Gold expression strain was used for the expression of Nt-Fas-
DD-Mxe-CBD. Small scale expression tests were performed as described in Section 
2.5  assaying  expression  by  SDS-PAGE.  Optimal  expression  was  obtained  when 
induced with 0.5 mM IPTG for sixteen hours at 20 
oC. These were the conditions 
used for large scale expression of the proteins, carried out as described in Section 
2.10.2. 
Expressed Nt-Fas-DD-Mxe-CBD was affinity purified using chitin beads which bind 
to  the  C-terminal  CBD.  Elution  of  the  Nt-Fas-DD  thioester  from  the  beads  was 
achieved by benzyl mercaptan-induced intein cleavage (as described in Section 4.1. 
and Figure 4.3). Column incubation in cleavage buffer was optimal after 16 hours at 
room  temperature.  Following  this  time  little  uncleaved  Nt-Fas-DD-Mxe-CBD 
remained, as assessed by resuspending the chitin beads in SDS-PAGE loading buffer 
before SDS-PAGE analysis, however only a minimal amount of Nt-Fas-DD eluted 
from the column.  
The most plausible explanation of the minimal elution of cleaved Nt-Fas-DD is that 
Nt-Fas-DD was binding to the beads. Due to the construct being a truncation of the 
death domain we would presume that it is unable to fold properly, possibly exposing 
hydrophobic residues to the solvent and rendering the construct insoluble and/or able 
to interact strongly with the bead matrix once the Mxe intein and CBD had been 
removed. In order to elute Nt-Fas-DD from the chitin column, cleavage was carried 
out  in  denaturing  conditions  (1.5  M  urea  for  cleavage,  and  8  M  urea  washes 180 
following  cleavage).  Denaturation  enabled  the  elution  of  the  Nt-Fas-DD  benzyl 
mercaptan thioester from the column. SDS-PAGE analysis of optimised Nt-Fas-DD 
purification is shown in Figure 4.10A. The presence of the thioester was confirmed 
by QTOF mass spectrometry as shown in Figure 4.10B.  
The elution and washes from the chitin column were pooled and concentrated by 
centrifugal concentration. A final clean-up step was done by semi-preparative C18-
RP-HPLC,  the  chromatogram  is  shown  in  Figure  4.10C.  The  mass  spectrum  of 
purified Nt-Fas-DD benzyl mercaptan thioester is shown in Figure 4.10D. Between 3 
and 5 mg of Nt-Fas-DD thioester was purified for each litre of bacterial culture. 
 
4.3 The C-terminal pY-Fas-DD peptide was synthesised by SPPS 
The 38-mer phospho-tyrosine 291 containing C-terminal Fas-DD (Ct-pY-Fas-DD) 
peptide (residues 286-323) was synthesised by FMOC-SPPS on a PL-Rink amide 
solid support as described in Section 2.10.1. The synthesis was carried out in five 
stages. At each stage a small portion of resin was cleaved and analysed by C18-RP-
HPLC  and  MALDI-MS  in  order  to  confirm  that  the  correct  peptide  had  been 
obtained; this is illustrated in Figure 4.11. In order to reduce the formation of regular 
secondary structure elements, two pseudo-proline units were incorporated into the 
peptide. The location of the amino acids substituted with pseudo-proline dipeptides 
are highlighted in bold in the peptide sequences shown in Figure 4.11J. The initial 
32-mer was synthesised with microwave coupling using DIC/HOBt. The most N-
terminal  six  amino  acids  were  incorporated  onto  the  chain  using  HBTU/DIEA 
coupling. DIC activation results in incomplete incorporation of benzyl-protected pY 
as discussed in Section 4.1.4. 
The Htmb auxiliary was coupled to the deprotected N-terminus of the full-length 
peptide using microwave coupling, followed by sodium borohydride treatment to 
reduce the imine group formed during the coupling reaction (Figure 4.8 and Figure 
4.9). After auxiliary coupling, the peptide was cleaved from the resin and the side 
chain protecting groups removed using TFA plus scavengers. Finally, the peptide 
was  purified  by  semi-preparative  C18-RP-HPLC  as  described  in  Section  2.10.1. 181 
Fractions containing pure Ct-pY-Fas-DD peptide were pooled and lyophilised prior 
to auxiliary deprotection. 
Deprotection of the Htmb auxiliary (Figure 4.9) was obtained by incubation with 
DTNP as described in Section 2.10.2 and assayed by C18-RP-HPLC (Figure 4.11G-
I). The deprotected product could be detected after reduction with TCEP (Figure 
4.11H and I). It should be noted that the MALDI-MS of the final product shows two 
species corresponding to the predicted masses of peptides both with and without the 
auxiliary, despite appearing pure judging by the RP-HPLC profile; we believe this is 
due  to  the  auxiliary  coming  off  the  peptide  during  ionisation.  The  deprotected 
peptide  was  purified  by  semi-preparative  C18-HPLC.  Fractions  containing  one 
species of peptide were pooled and lyophilised. The C18-RP-HPLC chromatogram 
and ESI-QTOF mass spectrum of the pure Htmb-Ct- pY-Fas-DD peptide is shown in 
Figure 4.12. Following deprotection, the overall peptide yield was 1.5%. 
 
4.4  pY-Fas-DD  can  be  obtained  by  auxiliary  mediated  expressed  protein 
ligation 
4.4.1 pY-Fas-DD is produced by auxiliary mediated EPL at low yield 
To perform the ligation, Nt-Fas-DD thioester and Htmb-Ct-pY-Fas-DD peptide were 
mixed to a final concentration of 2 mM each in pH 7 ligation buffer, as detailed in 
Section 2.10.3. The ligation reaction was monitored over time using analytical RP-
HPLC. Product peaks were identified by MALDI-TOF-MS as illustrated in Figure 
4.13. A peak (peak labelled 4) corresponding to the ligated pY-Fas-DD began to 
form within two hours of the reaction and marginally increased up until the eight 
hour time point. As can be seen from Figure 4.13, a peak (peak labelled 3) which is 
not  the  desired  product  begins  to  form.  This  peak  corresponds  to  the  hydrolysis 
product of the Nt-Fas-DD thioester, showing that the thioester start material for the 
ligation is being depleted by hydrolysis.  



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 4.11 Sequential Ct-Fas-DD synthesis and auxiliary addition 
A, C, F, G, H show C18 RP-HPLC profiles from each step in the C-terminal peptide synthesis. A gradient of 20-
70%B over thirty minutes was used with the absorbance recorded at 214nm. The step of the synthesis is indicated 
above the HPLC profile. B, D, F, I, MALDI-TOF-MS results for each of the HPLC profiles.* denotes the HPLC 
peak corresponding to the mass spectrometry result illustrated. J, shows the peptide sequence and expected mass 
at each step in the synthesis. Amino acids in bold were coupled as Fmoc pseudo-proline amino acids to reduce 
secondary structure. During the mass spectrometry analysis, the auxiliary comes off the peptide, therefore the 
non- auxiliary and or deprotected mass of the peptide and auxiliary is observed in F and I 





Figure 4.12 Pure preparation of Htmb-pY-Ct-Fas-DD C-terminal phosphopeptide. 
A. A typical C18 RP-HPLC profile of pure Htmb-pY-Ct-Fas-DD. A gradient of 20-70%B over thirty minutes 
was  used  with  the  absorbance  recorded  at  214nm.  B,  QTOF  mass  spectrum  showing  the  pure  mass  of  the 
phosphopeptide (4500) as well as a peak corresponding to the loss of the auxiliary in the instrument (4331).  
 185 
 
Figure 4.13 pY291-Fas-DD can be obtained using auxiliary mediated EPL although a lot of N-
terminal start material is lost to hydrolysis 
A, Analytical C18 HPLC of the time-course for a ligation reaction between 1mM N-terminal Fas-DD and 1mM 
C-terminal Fas-DD phosphopeptide with TCEP in degassed 200 mM NaH2PO4 and 6 M Guanidine chloride at 
pH 7.5. Peaks are numbered corresponding to the species that were present; 1, hydrolysed N-terminal Fas-DD 
thioester, 2, N-terminal Fas-DD thioester, 3, C-terminal Fas-DD phosphopeptide, 4, ligated phospho-Y291-Fas-
DD product B, MALDI-TOF MS of the product. 1
+ and 2
+ ions can be observed, 12,252 and 6122 respectively. 186 
4.4.2 Attempts to optimise the ligation reaction were not successful  
The initially selected ligation conditions led to the formation of the product, but 
considerable  hydrolysis  of  the  N-terminal  Fas-DD  thioester  as  well.  In  order  to 
minimise hydrolysis I performed the reaction in an organic solvent and explored 
variation of the pH. 
It  has  previously  been  reported  that  ligation  reactions  can  be  carried  out  in  the 
presence of high concentrations of organic solvents
217–219, and that this could reduce 
the level of hydrolysis observed. To perform the ligation in organic solvent, Nt-Fas-
DD thioester and Htmb-Ct-pY-Fas-DD were mixed to a final concentration of 4 mM 
each in a ligation buffer consisting of 80% N-methyl-2-pyrrolidone (NMP) and 20% 
ligation buffer v/v. The N and C termini were solubilised and mixed in the 20% 
ligation buffer prior to combing with the NMP. The reaction was monitored over 
time by analytical RP-HPLC. As can be seen from Figure 4.14, no ligation occurred 
in high solvent conditions. After six hours, the ligation reaction was diluted 1:2 with 
ligation buffer at pH 7, reducing the NMP concentration to 40% v/v. Reduction of 
the NMP concentration did not result in ligation either, however by 24 hours, a peak 
corresponding to hydrolysed N-terminal thioester could be observed. 
The  ligation  reactions  discussed  above  were  all  at  pH  7.  We  hypothesised  that 
increasing the pH might slow the hydrolysis. A ligation was carried out in which 2 
mM Nt-Fas-DD was mixed with 2 mM Htmb-Ct-pY-Fas-DD in ligation buffer at pH 
8 as described in Section 2.10.3. The reaction was monitored over a time course in 
which the ligation was followed by analytical RP-HPLC and products analysed by 
MALDI-TOF-MS. Increasing the pH of the reaction did not improve either product 
formation  or  decrease  the  amount  of  hydrolysis  observed  when  compared  to  the 
same reaction at pH 7 (data not shown). Although this observation suggests that the 
thioester  hydrolysis  maybe  base-catalysed,  the  pH  of  the  ligation  could  not  be 
reduced  below  pH  7  as  this  value  is  below  the  pKa  of  the  auxiliary.  Ligation 
reactions from this point were maintained at pH 7. 




Figure 4.14 Hydrolysis is prevented by carrying out the ligation in the solvent NMP however the 
ligation reaction does not occur.  
Analytical C18 HPLC of the time-course for a ligation reaction between 4mM N-terminal Fas-DD and 4mM C-
terminal  Fas-DD  phosphopeptide  in  80%  NMP  (N-methyl-2-pyrrolidone)  with  TCEP  in  degassed  200  mM 
NaH2PO4 and 6 M Guanidine chloride at pH 7.5 and 30
oC. Due to lack of ligation, reaction was diluted to 40% 
NMP using phosphate buffer at 6hours. This only encouraged hydrolysis. Peaks are numbered corresponding to 
the  species  that  were  present:  1,  N-terminal  Fas-DD  thioester,  2,  C-terminal  Fas-DD  phosphopeptide,  3, 
hydrolysed N-terminal Fas-DD thioester. #, buffer/NMP peak 
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4.5 Introduction of a solubility tag in Nt-Fas-DD simplifies purification and a 
mutation increases ligation yield 
4.5.1 Fusion of maltose binding protein to Nt-Fas-DD makes the protein soluble 
after cleavage, increasing purification yield 
4.5.1.1 Cloning of MBP- Nt-Fas-DD-Mxe-CBD construct 
With the aim of increasing the solubility of the Nt-Fas-DD thioester, maltose binding 
protein (MBP) was inserted at the N-terminus of the Nt-Fas-DD construct. MBP is 
well known for its ability to make protein constructs soluble in solution
220. Therefore 
the aim was to create a soluble Nt-Fas-DD construct which would increase the yield 
of the protein purified from the chitin beads and simplify the purification protocol.  
MBP was amplified from the pNIC-MBP vector developed at the Oxford site of the 
Structural  Genomics  Consortium
221.  The  construct  contains  an  N-terminal  hexa-
histidine tag, MBP and a tobacco-etch virus protease cleavage site, all these features 
were inserted into pTWIN-Nt-Fas-DD using the exponential megaprimer technique 
followed  by  DNA  ligation  as  described  in  section  2.4.5.  The  protein  construct 
generated is illustrated in Figure 4.15 with the predicted properties shown in Table 
4.2. Inserting the H6-tag and TEV protease site along with the solubility tag would 
enable the MBP tag to be removed from the ligated pY-Fas-DD product following in 
vitro  protein  folding  after  ligation  using  the  TEV  cleavage  protocol  outlined  in 
Section 2.6.4. 
Table 4.2 Properties of H6-MBP-TEVp-Nt-Fas-DD-Mxe-CBD expressed protein products  











218-285  78362  110490 
MBP-Nt-Fas-DD (with 
active thioester) 
218-285  50610  74830 
MBP-Nt-Fas-DD (without 
active thioester) 
218-285  50510  74830 
Mxe -CBD  -  27858  35660 
 
   189 
4.5.1.2 MBP-Nt-Fas-DD can be purified in non-denaturing buffer with good yield 
E. coli BL21(DE3) Gold cells were used for the expression of MBP-Nt-Fas-DD-
Mxe-CBD.  An  expression  test  was  carried  out  and  assayed  by  SDS-PAGE  as 
described in Section 2.5.1. The addition of the MBP solubility tag did not alter the 
expression  profile  observed  for  Nt-Fas-DD-Mxe-CBD.  Optimal  expression 
continued to be achieved with induction using 0.5 mM IPTG for sixteen hours at 20 
oC. 
Expressed  MBP-Nt-Fas-DD-Mxe-CBD  was  affinity  purified  using  chitin  beads. 
Intein-mediated cleavage of the construct was induced by incubation of the column 
in cleavage buffer. The addition of MBP to the construct did not affect the rate of 
intein-mediated  cleavage  of  the  construct  (shown  in  Figure  4.16A).  SDS-PAGE 
analysis of the elution of MBP-Nt-Fas-DD after overnight cleavage (Figure 4.16B) 
shows a great improvement compared to a similar sample with the initial Nt-Fas-DD 
construct (Figure 4.10A). The MBP tag had therefore improved the solubility of Nt-
Fas-DD and reduced its affinity for the bead matrix.  
As  MBP-Nt-Fas-DD  was  no  longer  eluted  from  the  chitin  column  in  buffer 
containing  urea,  pooled  elution  and  wash  fractions  could  be  concentrated  by 
lyophilisation.  To  mitigate  problems  with  semi-preparative  RP-HPLC,  such  as 
construct aggregation and buffer salt crystallisation, the lyophilised MBP-NT-Fas-
DD  was  resuspended  in  H2O  and  desalted  using  a  PD10  size-exclusion  column 
equilibrated in 10 mM HCl. The final clean up step after desalting was carried out 
using  semi-preparative  C18-RP-HPLC.  The  chromatogram  and  ESI-QTOF-MS 
analysis of a pure fraction are shown in Figure 4.16C and D. As a result of the 
introduction of the desalting step, the resolution of the peaks in the RP-HPLC was 
improved,  allowing  the  separation  of  the  MBP-Nt-Fas-DD  thioester  from  the 
uncleaved  MBP-Nt-Fas-DD-Mxe-CBD.  13  mg  of  MBP-Nt-Fas-DD  thioester  was 
purified per litre of E.coli culture, thereby the insertion of the MBP tag had improved 











Figure 4.15 – Schematic representation of MBP-Nt-Fas-DD construct. 
The MBP solubility tag was cloned N-terminal to Nt-Fas-DD to improve solubility. A and B; represent the MBP-
Nt-Fas-DD construct cloned using the NEB pTWIN1 vector and the benzyl mercaptan thioester of this construct 
produced  following  on  column  cleavage.  H6  –  hexahistidine  tag,  MBP  –  maltose  binding  protein,  TEV  – 
recognition sequence for TEV protease, CBD – chitin binding domain. 191 
 
Figure 4.16 Purification of MBP-Nt-Fas-DD 
A, SDS-PAGE analysis of samples corresponding to bead samples taken at hour (hr) timepoints (t) once chitin 
cleavage buffer had been put onto the column and following elution and washes of the column, illustrating there 
was still protein on the beads. 15µl samples of the chitin beads were taken and denatured. B, SDS-PAGE analysis 
of  MBP-Nt-Fas-DD  chitin  purification,  the  three  resulting  species  are  highlighted.  Overnight  flowthrough 
corresponds to the elution of buffer incubated upon the column overnight. W1-W3 corresponds to buffer washes 
(W) to collect the rest of the sample. C, semi-preparative C18 RP-HPLC of desalted chitin column pooled elution 
and wash. The elution profile was monitored by UV absorbance at 214nm, using a method 15-35%B in 5minutes, 
followed by 35-70%B in thirty minutes. SDS-PAGE analysis of fractions (F) corresponding to the peaks is 
shown above the elution profile. D, Q-TOF mass spectrum of fraction 76. 192 
 
Figure 4.17 MBP-N-terminal Fas-DD construct does not sufficiently improve the ligation but 
causes solubility problems 
Analytical C4 HPLC (gradient: 30-60% B in 30 minutes) of the time-course for a ligation reaction between 1mM 
N-terminal MBP-Fas-DD and 1mM C-terminal Fas phosphopeptide with TCEP in degassed 200mM NaH2PO4 
and 6 M Guanidine chloride at pH7. Peaks are numbered corresponding to the species that were present; 1, 
Htmb-pY-Ct-Fas-DD, 2, Nt-MBP-Fas-DD, 3, Ligated pY291 MBP-Fas-DD product, 4, hydrolysed Nt- MBP-
Fas-DD 
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4.5.2 MBP-Nt-Fas-DD also undergoes hydrolysis during ligation 
To  perform  the  ligation,  MBP-Nt-Fas-DD  thioester  and  Htmb-Ct-pY-Fas-DD 
peptide were mixed to a final concentration of 1 mM each in pH 7 ligation buffer, as 
detailed in Section 2.10.3. The reaction was monitored over time by analytical RP-
HPLC and product peaks identified by QTOF-MS, as illustrated in Figure 4.17. A 
peak corresponding to the ligated phospho-Y291-Fas-DD product began to form by 
two hours but after this time the MBP-Nt-Fas-DD thioester started hydrolysing and 
the ligation did not proceed further. 
It is relevant to notice that the relative intensity of the peaks in Figure 4.17 at 0 hours 
is very different to the one observed in Figure 4.12. This difference shows that I 
inadvertently  added  a  lower  amount  of  Htmb-Ct-pY-Fas-DD  in  the  former  case. 
According  to  Le  Chatelier's  Principle,  the  lower  loading  should  have  shifted  the 
equilibrium  towards  hydrolysis  instead  of  ligation,  so  perhaps  at  equimolar 
concentrations the outcome might have been better. Nevertheless, it is possible to 
conclude that whilst the presence of MBP greatly improves the yield of N-terminal 
fragment,  the  ligation  reaction  does  not  proceed  to  completion  and  the  thioester 
readily undergoes hydrolysis limiting the reaction yield. 
4.5.3 The H285G mutation improves the yield of the ligation reaction 
Previous studies report that peptides with histidine or glycine thioesters show better 
ligation yields than other amino acids
193,194,222. As our ligation using the histidine 
thioester had demonstrated limited success, we decided to attempt the ligation with a 
glycine thioester instead. Histidine 285 is located in the loop between helices α4 and 
α5,  and  it  is  not  conserved  in  other  death  domains,  suggesting  that  a  His-Gly 
substitution should not cause major disruption in the folding of the domain. 
4.5.3.1 MBP-Nt-Fas-H285G-Mxe-CBD has very slow intein cleavage kinetics 
The  H285G  mutation  was  introduced  into  the  MBP-Nt-Fas-DD-Mxe-CBD 
expression  vector  by  linear  cyclic  amplification  as  described  in  Section  2.4.5. 
Properties of the new construct are shown in Table 4.3. BL21 (DE3) Gold E. coli 
cells were used for the expression of MBP-NT-Fas-DD-H285G. An expression test 
assayed by SDS-PAGE was carried out as described in Section 2.5.2. The insertion 
of  the  H285G  mutation  did  not  alter  the  expression  profile  of  MBP-Nt-Fas-DD 194 
construct,  optimal  expression  still  being  observed  when  expressed  with  0.5  mM 
IPTG for sixteen hours at 20 
oC. 
 
Table  4.3  Properties  of  H6-MBP-TEVp-Nt-Fas-DDH285G-Mxe-CBD  expressed  protein 
products  










218-285  78285  110490 
MBP-Nt-Fas-DD 
H285G (with active 
thioester) 
218-285  50530  74830 
MBP-Nt-Fas-DD 
H285G (without active 
thioester) 
218-285  50430  74830 
Mxe -CBD  -  27858  35660 
 
Although expression of the protein was not affected by the H285G mutation, the 
performance of intein-mediated cleavage was extremely poor. Figure 4.18A shows 
SDS-PAGE analysis of the fractions taken from chitin column purification following 
overnight incubation with chitin cleavage buffer. Reports show that glycine at this 
position  reduces  the  rate  of  intein  cleavage.  NEB  literature  documents  that  after 
sixteen  hours  incubation  at  room  temperature,  only  40%  of  a  protein  with  a  C-
terminal  glycine  was  cleaved,  compared  to  80-95%  cleavage  with  a  C-terminal 
histidine. However, cleavage of up to 60% of the glycine C-terminal construct can be 
achieved with incubation times of over 40 hours
223.  
To  optimise  the  on-column  cleavage  of  MBP-Nt-Fas-DD-H285G-Mxe-CBD,  a 
chitin  column  loaded  with  MBP-Nt-Fas-DD-H285G-Mxe-CBD  was  incubated  in 
chitin cleavage buffer for 60 hours with samples of the beads being taken at specified 
time points. SDS-PAGE analysis of these samples is shown in Figure 4.18B. By 60 
hours, a large proportion of the loaded MBP-Nt-Fas-DD H285G thioester had been 
formed.  SDS-PAGE  analysis  of  fractions  from  the  optimal  chitin  purification  of 
MBP-Nt-Fas-DD-H285G-Mxe-CBD  is  shown  in  Figure  4.18C.  Incubation  of  the 195 
column for 72 hours resulted in an equivalent amount of reactive thioester as was 
observed  for  the  corresponding  wild  type  construct  during  overnight  cleavage. 
Elution and wash fractions were pooled, lyophilised, desalted and purified by semi-
preparative C18-RP-HPLC in the same manner as for the wild type construct. The 
RP-HPLC chromatogram and QTOF-MS spectra for purified fractions are shown in 
Figure  4.18D-F.  The  fractions  and  mass  spectra  make  apparent  the  difficulty 
separating cleaved and non-cleaved MBP-Fas-DD-H285G constructs using a C18 
column,  which  was  apparent  for  the  wild  type  construct  also.  It  is  possible  that 
columns with lower hydrophobicity would be more suitable for this purpose due to 
the less hydrophobic properties of this construct. Only the fractions containing the 
desired thioester species were used for the ligation reactions. 7 mg of active MBP-
Nt-Fas-H285G thioester were purified per litre of E.coli culture. 
4.5.3.2  Ligation  of  MBP-Nt-Fas-DD-H285G,  increases  yield  but  hydrolysis  still 
competes 
To perform the ligation reaction, MBP-Nt-Fas-DD H285G thioester and Htmb-Ct-
pY-Fas-DD peptide were mixed to a concentration of 1 mM each in ligation buffer at 
pH  7,  as  detailed  in  Section  2.10.3.  The  reaction  was  monitored  over  time  by 
analytical RP-HPLC and the product peaks identified by QTOF-MS, as illustrated in 
Figure  4.19.  A  peak  corresponding  to  the  ligated  MBP-pY291-Fas-DD  product 
began to form much more rapidly than in the previous ligation reactions. A product 
peak more than half the area of that corresponding to the MBP-Nt-Fas-DD H285G 
thioester had formed by two hours. The amount of ligated product increased until 
four hours, after this point thioester hydrolysis became the predominant reaction.  
To confirm that the MBP-pY291-Fas-DD product was ligated by an amide bond and 
not a thioester, an aliquot of the four hour time point was taken and reduced with 
hydroxylamine. This test confirmed that the product peak was the final product and 
not  an  intermediate  species  (shown  in  Figure  4.7C).  Hydroxylamine  is  a  strong 
reducing  agent,  therefore  would  reduce  and  non-covalently  bonded  product  or 
unreacted  thioester.  By  analytical  RP-HPLC,  the  pY291  product  peak  remained 
unchanged  following  reduction  however  the  remaining  MBP-Nt-Fas-DD  H285G 
thioester had all been converted into the hydrolysed product. These RP-HPLC traces 
can be seen in the appendix.    196 
 
Figure 4.18 Purification Optimisation of MBP-N-terminal Fas-DD-H285G 
A, SDS-PAGE analysis of initial MBP-Nt-Fas-DD-H285G chitin purification, when incubated overnight in chitin 
cleavage buffer. B, SDS-PAGE analysis of samples corresponding to bead samples taken at hour (hr) timepoints 
during chitin column incubation in chitin cleavage buffer (left) and flow through samples following chitin elution 
(right).  C,  SDS-PAGE  analysis  of  optimised  incubation  time  for  MBP-Nt-Fas-DD-H285G  chitin  column 
cleavage. Overnight flowthrough corresponds to the buffer left incubating on the column overnight. D, semi-
preparative RP-HPLC of  desalted chitin column pooled elution and wash. The elution profile was monitored by 
UV absorbance at 214nm. SDS-PAGE analysis of fractions corresponding to the peaks is SHOWN. E, Q-TOF 
mass spectrum of F75 showing both MBP-Nt-Fas-DD-H285G thioester and hydrolysed product. F, Q-TOF mass 
spectrum of F76 showing both MBP-Nt-Fas-DD-H285G thioester as well as the uncleaved MBP-Nt-Fas-DD-
H285G-Mxe intein-CBD 197 
 
 
Figure 4.19 Ligation between MBP-Nt-Fas-DD-H285G and Htmb-pY-Ct-Fas-DD at equimolar 
concentrations  
Analytical C4 HPLC (gradient: 30-60% B in 30 minutes) of the time-course for a ligation reaction between 1mM 
N-terminal MBP-Nt-Fas-DD-H285G and 1mM Htmb-pY-Ct-Fas-DD with TCEP in degassed 200mM NaH2PO4 
and 6 M Guanidine chloride at pH 7. Peaks are numbered corresponding to the species that were present; 1, 
Htmb-pY-Ct-Fas-DD, 2, MBP-Nt-Fas-DD-H285G thioester, 3, Ligated pY291-MBP-Fas-DD-H285G product, 4, 
hydrolysed MBP-Nt-Fas-DD-H285G. 
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Although  the  kinetics  and  yield  of  the  ligation  of  the  MBP-Nt-Fas-DD  H285G 
thioester were much improved compared to the corresponding wild-type construct, 
this construct still underwent undesirable side reactions under the standard ligation 
conditions. 
 
4.6 Dissection of the ligation reaction variables gave little clue as to the origin of 
thioester hydrolysis 
The mutation H285G at the site of the ligation greatly improved the yield of the 
ligation reaction, but the hydrolysis side reaction was still prevalent under standard 
ligation conditions. A variety of conditions were changed in an attempt to reduce 
hydrolysis and understand the underlying causes. 
4.6.1 Increasing the ratio of C to N-terminal Fas-DD increases the rate of the 
ligation reaction but still results in hydrolysis 
The ligation reactions described above were limited by the breakdown of the N-
terminal Fas-DD thioester construct by hydrolysis over time. If the ligation reaction 
could be engineered to progress faster, it would enable more pY291-Fas-DD product 
to form. Ligation reactions were performed in which the ratio of Htmb-pY-Ct-Fas-
DD to MBP-Nt-Fas-DD H285G was increased. The rationale being that this would 
shift the equilibrium towards forming product and outcompete hydrolysis. Ligation 
reactions containing the concentration ratios of 1:2 and 1:10 of MBP-Nt-Fas-DD 
H285G  and  Htmb-Ct-pY-Fas-DD  were  performed  at  pH  7  in  ligation  buffer  as 
described  in  Section  2.10.3.  The  time  course  of  these  ligations  monitored  by 
analytical RP-HPLC is shown in Figures 4.20 and 4.21 respectively. 




Figure  4.20  Ligation  between  MBP-Nt-Fas-DD-H285G  and  Htmb-pY-Ct-Fas-DD  at  a  1:2 
concentration ratio  
Analytical C4 HPLC (gradient: of 30-50%B in 30 minutes) of the time-course for a ligation reaction between 
0.5mM  N-terminal  MBP-Fas-DD-H285G  and  1mM  C-terminal  Fas  phosphopeptide  with  TCEP  in  degassed 
200mM NaH2PO4 and 6 M Guanidine chloride at pH 7. Peaks are numbered corresponding to the species that 
were present; 1, Htmb-pY-Ct-Fas-DD, 2, MBP-Nt-Fas-DD-H285G thioester, 3, hydrolysed MBP-Nt-Fas-DD-
H285G, 4, ligated pY291 MBP-Fas-DD-H285G product 
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Figure  4.21  Ligation  between  MBP-Nt-Fas-DD-H285G  and  Htmb-pY-Ct-Fas-DD 
phosphopeptide at a 1:10 concentration ratio  
Analytical C4 HPLC (gradient: of 30-50%B in 30 minutes) of the time-course for a ligation reaction between 
0.1mM  N-terminal  MBP-Fas-DD-H285G  and  1mM  C-terminal  Fas  phosphopeptide  with  TCEP  in  degassed 
200mM NaH2PO4 and 6 M Guanidine chloride at pH 7. Peaks are numbered corresponding to the species that 
were present; 1, Htmb-pY-Ct-Fas-DD, 2, MBP-Nt-Fas-DD-H285G thioester, 3, hydrolysed MBP-Nt-Fas-DD-
H285G, 4, ligated pY291 MBP-Fas-DD-H285G product. 
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As before, the ligations result in a similar distribution of peaks corresponding to the 
N  and  C  termini  of  Fas  as  well  as  the  ligation  product  and  hydrolysis  peaks. 
However it is possible to see that the ligation reaction occurs at an increased rate 
when there is more C-terminal than N-terminal Fas. For example, by the two hour 
time point in the 1:10 ligation (Figure 4.21) the analytical RP-HPLC chromatogram 
shows the hydrolysis of MBP-Nt-Fas-DD H285G and product peaks to be of similar 
height. However in the reactions containing the concentration ratios of 1:2 (Figure 
4.20) and 1:1 (Figure 4.19), this species distribution was not observed until four, 
possibly eight hours. This suggests that at a lower concentration of MBP-Nt-Fas-DD 
H285G  more  ligation  product  is  made  in  a  shorter  period  of  time.  What  is  also 
notable when comparing these three ligations (Figure 4.19-4.21) is that once this 
1:1:1  distribution  of  peaks  is  established,  there  in  no  further  increase  in  product 
formation,  as  if  there  were  no  more  reagents  available.  After  this  point  only  N-
terminal thioester hydrolysis is observed. This observation suggests that one of the 
reagents is undergoing a change and becoming inactive during the experiment.  
A possibility was that the reactive thiol group of Htmb was oxidising during the 
ligation. If so, this would have prevented the ligation reaction from occurring. To test 
this, an aliquot of Htmb-Ct-pY-Fas-DD was assayed by analytical HPLC and the 
chromatogram  overlaid  with  the  corresponding  chromatogram  from  the  ligation 
reaction. If Htmb-Ct-pY-Fas-DD had oxidised, the peak observed by HPLC would 
have shifted. No peak shift was observed for the peptide (data not shown) so Htmb 
oxidation appear to not be the cause of the unexpected lack of ligation activity. 
4.6.2 Neither the N nor C terminus are a limiting factor to the reaction 
To test whether either the MBP-Nt-Fas-DD H285G thioester or the Htmb-Ct-pY-
Fas-DD peptide were limiting the progression of the ligation, two ligations were 
prepared as described in Section 2.10.3, both containing 0.5 mM MBP-Nt-Fas-DD 
H285G thioester and 1 mM Htmb-pY-Fas-DD peptide. To one of them, fresh MBP-
Nt-Fas-DD H285G thioester was added into the reaction at several time points, and 
to the other fresh Htmb-pY-Fas-DD peptide was added. In order to minimise the 
change in the concentration of reagents, this was done by removing an aliquot of the 
reaction and replacing it with equivalent volume of the fresh reagent at the same 
concentration. These ligations are shown in Figures 4.22 and 4.23, respectively. 202 
 
 
Figure 4.22 The readdition of MBP-Nt-Fas-DD-H285G protein, increases the amount of product 
from the ligation but does not reduce the amount of hydrolysis occurring 
Analytical C4 HPLC (gradient: of 30-50%B in 30 minutes) of the time-course for a ligation reaction between 
0.5mM MBP-Nt-Fas-DD-H285G and 1mM Htmb-pY-Ct-Fas-DD with TCEP in degassed 200mM NaH2PO4 and 
6 M Guanidine chloride at pH 7. N-terminal Fas protein was added at the same 0.5mM concentration at time 
points 2hr, 3hr and 4hr, this is illustrated by the *. Peaks are numbered corresponding to the species that were 
present; 1, Htmb-pY-Ct-Fas-DD, 2, MBP-Nt-Fas-DD-H285G thioester, 3, hydrolysed MBP-Nt-Fas-DD-H285G, 
4, ligated pY291 MBP-Fas-DD-H285G product. 
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Figure 4.23 The readdition of Htmb-pY-Ct-Fas-DD, increases the rate of the ligation but does 
not reduce the amount of hydrolysis occurring 
Analytical C4 HPLC (gradient: of 30-50%B in 30 minutes) of the time-course for a ligation reaction between 
0.5mM  N-terminal  MBP-Fas-DD-H285G  and  1mM  C-terminal  Fas  phosphopeptide  with  TCEP  in  degassed 
200mM NaH2PO4 and 6 M Guanidine chloride at pH 7. Peptide was added to the same 1mM concentration at 
time points 1hr and 2hr, this is illustrated by the *. Peaks are numbered corresponding to the species that were 
present; 1, C-terminal Fas-DD phosphopeptide, 2, N-terminal MBP-Fas-DD-H285G, 3, hydrolysed N-terminal 
MBP-Fas-DD-H285G, 4, ligated phospho-Y291 MBP-Fas-DD-H285G product. 
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When fresh MBP-Nt-Fas-DD H285G thioester was added into the ligation (shown in 
Figure  4.22)  at  the  two,  three  and  four  hour  time  points,  the  addition  of  extra 
thioester increased the amount of product formed. However, this had no effect on the 
onset of hydrolysis, the distribution 1:1:1 was achieved once more and if anything, 
we observed even more hydrolysis than in the previous cases. When fresh Htmb-pY-
Fas-DD peptide was added into the ligation at one and two hours (shown in Figure 
4.23), there was less of an effect on product formation when compared to the re-
addition of the MBP-Nt-Fas-DD H285G thioester. The overall progression of the 
ligation was similar to the 1:10 concentration ratio ligation shown in Figure 4.21. 
Together with the hydroxylamine result discussed above, this outcome shows that 
lack  of  Htmb-pY-Fas-DD  peptide  is  not  what  is  causing  the  ligation  reaction  to 
falter. 
4.6.3 Optimisation of the reaction conditions using traditional NCL procedures 
does not reduce hydrolysis  
Thiol additives are commonly included within a NCL reaction, to enhance the rate of 
ligation by catalysing in situ transthioesterification. One of the most common thiol 
additives is mercaptophenulacetic acid (MPAA)
224. A ligation was performed with 
0.5 mM MBP-Nt-Fas-DD H285G and 1 mM Htmb-Ct-pY-Fas-DD peptide in pH 7 
ligation  buffer,  containing  5  mg/ml  MPAA.  The  aim  of  this  experiment  was  to 
increase the rate of ligation so that it would take place quicker than the hydrolysis. 
The reaction was monitored over a time course in which the ligation was followed by 
analytical HPLC, as illustrated in Figure 4.24.  
The addition of MPAA to the ligation did speed up the rate of the ligation but also 
the rate of hydrolysis. All of the MBP-Nt-Fas-DD H285G thioester had been either 
hydrolysed or reacted to form pY291-Fas-DD product within an hour. There was no 
change in the HPLC chromatogram for the ligation time points after two hours. The 
ratio of peak heights of hydrolysed MBP-Nt-Fas-DD H285G to the product was even 
greater  than  was  observed  when  all  of  the  thioester  has  been  hydrolysed  in  the 
previous ligations. The addition of MPAA and elevated temperature did not mitigate 
the hydrolysis problem within this ligation. 




Figure  4.24  Addition  of  the  cofactor  MPAA  and  elevating  the  temperature  of  the  ligation 
reaction speeds up the ligation as well as the hydrolysis. 
Analytical C4 HPLC (gradient: of 30-50%B in 30 minutes) of the time-course for a ligation reaction between 
0.5mM  MBP-Nt-Fas-DD-H285G  and  1mM  Htmb-pY-Ct-Fas-DD  with  TCEP,  5mg/ml  MPAA 
(mercaptophenylacetic acid) in degassed 200mM NaH2PO4 and 6 M Guanidine chloride at pH 7, incubated at 
40
oC. # identifies the MPAA in the injection peak. Peaks are numbered corresponding to the species that were 
present; 1, Htmb-pY-Ct-Fas-DD, 2, MBP-Nt-Fas-DD-H285G thioester, 3, ligated pY291 MBP-Fas-DD-H285G 
product, 4, hydrolysed  MBP-Nt-Fas-DD-H285G..   206 
 
 
Figure 4.25 Reducing the phosphate buffer concentration reduces the rate of the ligation and 
appears to not affect the solubility of the reaction components. 
Analytical C4 HPLC (gradient: of 30-50%B in 30 minutes) of the time-course for a ligation reaction between 
0.5mM MBP-Nt-Fas-DD-H285G and 1mM Htmb-pY-Ct-Fas-DD with TCEP, in degassed 20mM NaH2PO4 and 
6 M Guanidine chloride at pH 7, incubated at 30
oC. # identifies the guanidine in the buffer to halt the reaction in 
the injection peak. Peaks are numbered corresponding to the species that were present; 1, Htmb-pY-Ct-Fas-DD, 
2, MBP-Nt-Fas-DD-H285G thioester, 3, ligated pY291 MBP-Fas-DD-H285G product, 4, hydrolysed  MBP-Nt-
Fas-DD-H285G. 
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It  was  suggested  that  high  concentrations  of  phosphate  can  adversely  affect  the 
ligation efficiency of NCL reactions. To test whether this was the case I set up a 
ligaton with 0.5 mM MBP-Nt-Fas-DD and 1 mM Htmb-pY-Ct-Fas-DD in a buffer 
containing 20 mM NaH2PO4 50 mMTCEP and 6 M guanidinium hydrochloride at 
pH 7. The ligation reaction was followed over time by analytical RP-HPLC as can be 
seen in Figure 4.25. This had an interesting effect, in that although compared to other 
cases the same amount of ligation product was observed, the rate of hydrolysis was 
somehow reduced. Even after 24 hours we could still detect the peak corresponding 
to the thioester. However, this new result did not offer sensible clues as to explain 
why the side reaction takes place. 
 
4.7 Optimised ligation conditions for phosphorylated-Y291-Fas-DD 
From  the  experiments  outlined  above,  the  conditions  which  the  greatest  yield  of 
ligation product could be obtained were 0.5 mM MBP-Nt-Fas-DD and 1 mM Htmb-
Ct-pY-Fas-DD in ligation buffer at pH 7 for two hours. The analytical RP-HPLC 
chromatograms of the ligation reactions of MBP-Nt-Fas-DD and MBP-Nt-Fas-DD 
H285G are shown in Figure 4.26. It is evident when seeing these traces side by side 
that the yield with the H285G mutant is higher compared to the wild type construct. 
However, due to the lack of resolution between the product and the NT-Fas-DD 
thioester peaks, the reaction yield could not be properly quantified, as attempts to 
separate  this  species  using  different  flow  rates  and  solvent  gradients  were 
unsuccessful  (data  not  discussed).  QTOF-MS  spectra  confirmed  that  the  mass  of 
these  peaks  correspond  to  fully  ligated  MBP-Nt-Fas-DD  and  MBP-Nt-Fas-DD 
H285G (Figure 4.27). Table 4.3 shows a comparison of the predicted and observed 
masses for the ligation products. 
Table 4.4 Predicted and observed masses of ligation products 
N-terminal Fas construct  Predicted ligation 
product mass (Da) 
Observed ligation 
product mass (Da) 
Nt-Fas-DD  12352  12252 
MBP-Nt-Fas-DD  55252  55189 
MBP-Nt-Fas-DD H285G  55170  55108 




Figure 4.26 ‘Optimal’ MBP-Nt-Fas-DD and Htmb-Ct-pY-Fas-DD ligation 
Analytical C4 HPLC (gradient: of 30-50%B in 30 minutes) of the time-course for a ligation reaction between 
0.5mM MBP-Nt-Fas-DD-H285G and 1mM Htmb-pY-Ct-Fas-DD with TCEP, in degassed 20mM NaH2PO4 and 
6 M Guanidine chloride at pH7, incubated at 30
oC for two hours. # identifies the guanidine in the buffer to halt 
the reaction in the injection peak. A, shows optimal HPLC trace for WT MBP-Nt-Fas-DD, B, shows optimal 
HPLC trace for MBP-Nt-Fas-DD- H285G. Peaks are numbered corresponding to the species that were present; 1, 
Htmb-pY-Ct-Fas-DD, 2, MBP-Nt-Fas-DD thioester, 3, ligated pY291 MBP-Fas-DD product 
.   209 
 
 
Figure 4.27 ESI-MS results from the products formed from the ‘optimal’ reaction conditions.  
Low resolution ESI-MS for the product peaks shown in Figure 4.26. A. mass spectrum of the product from the 
ligation of MBP-Nt-Fas-DD and Htmb-pY-Ct-Fas-DD. B, Mass spectrum of ligated product from the ligation of 
MBP-Nt-Fas-DD H285G and Htmb-pY-Ct-Fas-DD. 
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4.8 Discussion 
Expressed  protein  ligation  is  becoming  widely  used  to  semi-synthesise  proteins 
containing post translational modifications and site-specific labelling. I report here 
the development of an EPL technique to prepare a Fas death domain containing a pY 
at position 291. An Nα auxiliary cysteine mimic (developed in the Offer laboratory 
at  NIMR)  was  used  to  bypass  the  usual  for  a  cysteine  at  the  N-terminus  of  the 
ligation junction. If successful, this technique could be the platform on which to 
begin in vitro structural, functional and dynamic studies to further probe the effects 
of this post translational modification on the death domain of Fas in particular, but 
also in death domains in general. 
The approach that was selected to produce Fas-DD pY291 was to generate an N-
terminal  recombinant  Fas-DD  thioester  and  a  C-terminal  synthetic  Fas  phospho-
peptide. The ligation junction was chosen to be between residues H285 and G286. 
This position was considered the most promising in terms of previous knowledge of 
success rate of the occurrence of different amino acids at the ligation junction.  
The  Nt-Fas-DD  thioester  was  generated  using  the  NEB-IMPACT  system.  A 
construct was cloned and expressed containing the Mxe intein followed by a chitin 
binding domain at the C-terminus. The expression yield of this construct was good 
and no in vivo proteolysis of the construct was observed. Intein cleavage had to be 
induced in denaturing conditions, because otherwise the Nt-Fas-DD thioester did not 
elute  from  the  chitin  beads,  presumably  because  it  is  very  hydrophobic  and/or 
insoluble.  
The pY-Ct-Fas-DD peptide was successfully synthesised by SPPS in four stages. 
Two pseudo-proline dipeptide units were incorporated to prevent aggregation of the 
growing peptide chain. The novel Htmb auxiliary was coupled to the N-terminus of 
the peptide to act as a cysteine mimic necessary for the ligation reaction to occur. 
The auxiliary can be removed at the end of the ligation leaving no chemical scars in 
the created semi-synthetic protein.  
The initial ligation of Nt-Fas-DD thioester and Htmb-Ct-pY-Fas-DD was successful 
in that it generated a fragment of the anticipated molecular weight for pY291-Fas-
DD. However, only a small amount of product was formed and most of the thioester 211 
was  degraded  by  hydrolysis.  To  try  to  discourage  hydrolysis  of  the  Nt-Fas-DD 
thioester, the ligation buffer conditions were carried out at higher pH and in the 
presence of a high concentration of organic solvent. Increasing the pH of the ligation 
buffer to pH 8 did not have any effect on thioester hydrolysis, suggesting it is being 
catalysed by bases. Unfortunately it was not possible to reduce the pH below 7 due 
to the auxiliary being incompatible with a lower ligation reaction pH (John Offer, 
personal communication).  
Dittman et al. (2010)
217 have previously reported the use of organic solvents for 
native chemical ligation of hydrophobic peptides. We predicted that an environment 
with  a  high  concentration  of  organic  solvent  would  prevent  hydrolysis  and  also 
improve the solubility of the N and C-terminal components. A ligation was set up in 
80%  NMP  v/v,  conditions  similar  to  those  described  by  Payne  et  al.  (2007)  for 
sugar-assisted ligation (SAL) reactions
219. None of the previously observed reactions 
(hydrolysis or ligation) occurred within the reaction carried out in organic solvent 
(NMP) until the concentration of NMP was reduced to 40% (v/v) at which thioester 
hydrolysis was observed. It is believed that a base additive is required to ensure thiol 
reduction  and  enable  thioester  exchange  in  an  organic  solvent  environment
217. 
Dittman  et  al.  (2010)  used  the  base  triethyamine  as  well  as  a  thiol  additive  to 
catalyse  a  ligation  reaction  in  DMF,  this  is  because  thiol  additives  catalyse  the 
ligation reaction by in situ transesterification
224. Perhaps the lack of base additive 
was the reason I did not observe a Fas-DD ligation in these conditions.  
At this point, it was clear that not only the ligation had to be optimised, but also that 
the yield of Nt-Fas-DD thioester needed to be improved. I decided to try to make a 
more  soluble  construct  by  insertion  of  maltose  binding  protein  (MBP)  at  the  N-
terminus of the Nt-Fas-DD construct. This strategy was successful in that the fusion 
construct  eluted  from  the  chitin  beads  under  non-denaturing  conditions  both 
increasing yield and simplifying the preparation. However, the behaviour of MBP-
Nt-Fas-DD thioester during ligation was not different and if anything a little worse 
than that of untagged Nt-Fas-DD thioester. An unexpected precipitate was formed 
during  the  reaction  and  the  quenched  aliquots  gellified  on  addition  of  TFA, 
presumably  because  the  quenching  reduces  the  concentration  of  guanidinium 
hydrochloride, and/or because the acid precipitated the protein. Several other death 212 
domain  polypeptides  also  create  gels  in  various  situations  (TJ  Ragan,  Lily 
Nematollahi, Christine Richter, personal communications), and we believe this is a 
consequence of the domains’ inability to fold efficiently leaving the hydrophobic 
core exposed. Of course, in this case results are too preliminary to assess whether 
precipitation was related to the prevalence of the hydrolysis reaction or not. 
Another strategy that could increase the ligation rate and in this way outcompete 
hydrolysis  was  to  replace  the  His  at  the  ligation  junction  for  Gly.  A  C-terminal 
glycine thioester results in slower thioester rearrangements
193 but there is less steric 
hindrance, therefore potentially increasing the rate and yield of ligation. In a review 
of published Na auxiliary-mediated NCL reactions
127, it was highlighted that the 
most  frequently  used  ligation  junction  is  glycine-glycine  for  this  reason.  This 
mutation  might  favour  ligation,  but  it  also  disfavours  intein-mediated  cleavage. 
Glycine  is  the  least  favourable  amino  acid  to  have  positioned  immediately  N-
terminal to the Mxe intein
223, greatly reducing the speed of the cleavage reaction. 
The overnight cleavage protocol had to be extended to 72 hours in order to obtain 
comparable  amounts  of  MBP-Nt-Fas-DD  H285G  thioester.  Despite  this 
unanticipated hiccup, incorporation of the H285G mutation did increase the rate and 
yield of product formed in the ligation reaction, although the formation of product 
was still being outcompeted by the hydrolysis reaction. 
Ligation  reactions,  in  which  the  concentration  of  MBP-Nt-Fas-DD  was  reduced 
while that of Htmb-Ct-pY-Fas-DD was kept constant, made clear that the reaction 
always reached a point in which no more product was formed and only thioester 
hydrolysis occurred. Reducing the concentration of MBP-Nt-Fas-DD resulted in the 
reaction reaching this point a lot quicker than in the previous ligations. This posed 
the question of whether one of the components was losing its ability to react over 
time. To investigate this, ligations in which fresh MBP-Nt-Fas-DD or Htmb-Ct-pY-
Fas-DD were added into the ligation at different time points were carried out. As 
expected, the addition of fresh MBP-Nt-Fas-DD thioester increased the amount of 
product, for as long as more fresh thioester was added. Whereas the addition of fresh 
Htmb-Ct-pY-Fas-DD peptide made no difference to the distribution of the reaction 
species visible in the RP-HPLC chromatogram. This outcome also suggests that the 
lack of reactive Ct fragment is not what is leading to thioester hydrolysis. It was also 213 
confirmed  that  the  Htmb  auxiliary  was  not  oxidising  and  thereby  becoming 
unreactive  over  time.  Each  of  these  ligation  conditions  displayed  the  same 
behaviour; namely, a ligation product started forming, but when reaching a certain 
concentration the ligation halted and the hydrolysis became dominant. It is important 
to point out that the only evidence (we have at this point) that this is a hydrolysed 
thioester are previous observations in the Offer lab, and the fact that the retention 
time  is  not  very  different  to  that  of  the  N-terminal  fragment,  only  slightly  less 
hydrophobic. More detailed analysis of this peak would need to be carried out to 
really understand what is the side reaction that is taking place. 
After  identifying  that  neither  the  N-  nor  C-terminal  components  were  a  limiting 
factor in the decay of product formation, the addition of additives was tested. It is 
common to include a thiol additive during NCL reactions, but we discovered that the 
addition of MPAA was able to both increase the rate of hydrolysis and of ligation. 
Johnson and Kent (2006) also observed this effect upon ligations when using MPAA 
as a catalyst
224.  
Despite being unable to prevent hydrolysis using several strategies, I regarded that it 
was important to generate enough sample to characterise the peaks by MS. The best 
conditions found were to be incubating 0.5 mM MBP-Nt-Fas-DD and 1 mM Htmb-
pY-Fas-DD for two hours at 30 
oC in ligation buffer at pH 7. From side-to-side 
comparison under these conditions it was clear that the H285G mutant performed 
better than the wild type thioester.  
The next possible strategy to tackle the hydrolysis problem, would be to vary the 
thiol used to prepare the thioester, as perhaps the benzyl mercaptan thioester is not 
stable under these conditions. Benzyl mercaptan has been found to perform poorly 
during ligation reactions. This is thought to be the case because under the conditions 
of the reactions the benzyl group is a non-optimal leaving group
224. Johnson and 
Kent  (2006)  suggested  that  the  MPAA  thioesters  would  outperform  others  in 
expressed protein ligation reactions, because of their superior stability and ease of 
storage
224.  
More data would have to be obtained using other systems to validate Htmb for EPL 
applications.  It  could  well  be  that  the  Htmb  auxiliary  is  suitable  for  NCL  using 
peptides,  however  proteins  are  more  challenging  in  terms  of  the  possible 214 
conformations present, steric hindrance, and solubility limitations. Whether Htmb is 
the  cause  or  not  of  the  poor  yields  and  hydrolysis  that  I  observed,  it  could  be 
assessed by attempting the ligation without the use of an auxiliary, by synthesising a 
peptide with a cysteine at the G286 position. It could also be that the ligation is 
inhibited by changes in pH or the presence of other products. This could be tackled 
by doing the ligation in an open system in which the buffer was constantly being 
replenished and small molecules would diffuse rapidly, e.g. a microdialysis chamber. 
Other alternatives include carrying out the reaction in organic solvents, addition of 
alternative additives and attempting ligations in other sites within the domain and/or 
other death domains.  
In  summary,  this  chapter  has  demonstrated  that  a  55  kDa  MBP-tagged 
phosphorylated Fas-DD can be generated by expressed protein ligation. Although 
attempts to optimise the ligation reaction yield and limit hydrolysis of the thioester 
were made, I was unable to satisfactorily overcome these limitations. However, the 
results have set the basis to further optimise conditions to be able to perform this 
reaction at a preparative scale in the future.  
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5.1 Introduction  
The first step of Fas-mediated apoptosis is the aggregation of Fas upon activation by 
its  ligand.  Fas  clusters  trigger  the  formation  of  the  Death  Inducing  Signalling 
Complex  (DISC)  by  recruitment  of  Fas-associated  protein  with  death  domain 
(FADD), procaspase-8 and cellular-FLICE inhibitory protein (c-FLIP). 
There is controversy about the nature of the involvement of the cytoskeleton in the 
formation of the DISC. Actin interacts with membrane proteins via the linker protein 
ezrin or other members of the ERM family of proteins (ezrin, radixin and moesin). 
Early reports suggested that ezrin was required for the Fas apoptotic pathways to be 
initiated
114, this was further supported by the observation that Fas ligation stimulated 
ezrin  recruitment
225.  However,  others  have  observed  that  siRNA-mediated 
knockdown of ezrin facilitates DISC formation, increasing the level of apoptosis
116. 
An interaction between Fas and ezrin has been observed mainly in mammalian cells 
and  lysates  by  co-localisation  and  co-immunoprecipitation.  However,  two 
independent groups have reported a specific direct interaction between recombinant 
Fas  and  recombinant  ezrin  using  GST  pull  down  assays
116,117.  Luzopone  and 
collaborators mapped the interaction to a nineteen amino acid region in the central 
lobe of the FERM domain of ezrin (residues 149-168)
117. Using different constructs 
of recombinant Fas and mammalian cell lysates, Ruan et al. mapped the interaction 
site in Fas to a region, predicted to be unstructured, between the transmembrane 
domain  and  the  death  domain  (residues  191-204);  they  named  this  region  the 
membrane proximal domain (MPD)
118. Moreover, ezrin and other ERM proteins are 216 
known to recognise twenty to thirty amino acid stretches with little regular secondary 
structure
110,111, a description that could be applied to the MPD of Fas. 
In this chapter I describe the development of methodologies for biophysical studies 
of the putative interaction between the cytoplasmic region of Fas and the FERM 
domain of ezrin. This involved the cloning, expression and purification of constructs 
of Fas and ezrin, followed by the characterisation of the interaction using pull-down 
assays, isothermal titration calorimetry (ITC), analytical ultracentrifugation (AUC) 
biolayer interferometry (BLI), and nuclear magnetic resonance (NMR). Particular 
attention was paid to confirmation of ‘non-specific’ ezrin interactions and to verify 
NMR spectroscopy results.  
5.1.2 Biophysical techniques used to characterise the Fas-ezrin interaction 
5.1.2.1 Isothermal titration calorimetry - ITC 
Isothermal titration calorimetry is a physical technique which is used to characterise 
the thermodynamics of a binding event in solution. The method provides a direct 
measurement  of  the  binding  energies  of  biological  processes  that  is  widely 
implemented  to  characterise  protein:protein,  protein:ligand,  protein:DNA  and 
antigen:antibody interactions. ITC measures the heat which is produced (exothermic) 
or taken (endothermic) from the environment as an interaction occurs, exploiting the 
fact that the production or absorption of heat is an intrinsic property of virtually all 
biochemical  reactions.  The  change  in  enthalpy  (∆H)  can  be  used  to  precisely 
calculate the changes of Gibbs free energy (∆G), entropy (∆S) and heat capacity 
upon  macromolecules  binding.  These  parameters  are  then  used  to  determine  the 
stoichiometry and binding affinity of the interaction being studied. ITC is carried out 
in a matrix free environment requiring no immobilisation or modification of binding 
partners which are only required at low concentrations. Experiments can be carried 
out in a range of salt concentrations, pHs and temperatures, making ITC a robust 
assay for any interaction. 
ITC analysis is carried  out using a heat flux calorimeter which operates under a 
dynamic  power  compensation  principle.  The  calorimeter  itself  is  made  up  of  a 
syringe to enable binding partner titration and two cells, one for the sample and one 
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the cells are  constantly  monitored and upon temperature changes in the cell, the 
calorimeter implements a feedback control system to maintain the same temperature 
between  cells.  The  instrument  output  is  a  measure  of  the  amount  of  power  (in 
μcal/sec) which is required to maintain a constant temperature between the two cells 
(dynamic power compensation). Temperature control is monitored by the presence 
of  a  semiconductor  sensor  which  is  sandwiched  between  the  cells.  A  schematic 
diagram of an isothermal calorimeter is shown in Figure 5.1A. 
For the experiment, one reactant is placed within the sample cell, whereas the other 
is placed in the syringe. The reference cell only contains the buffer that the reaction 
is being carried out in, which acts as the temperature reference. Over the course of 
the experiment, known aliquots of the reactant from the syringe are titrated into the 
sample cell and the reaction is mixed. If a complex is formed, the extent of binding is 
dependent  upon  the  concentration  and  binding  affinity  of  the  reactants.  Upon 
complex  formation,  heat  is  either  released  (exothermic  reaction)  or  absorbed 
(endothermic reaction) resulting in a temperature difference between the reference 
and  the  sample  cells.  The  feedback  system  within  the  instrument  increases  or 
decreases the thermal power deposition to the sample cell to restore the temperature 
balance between the two cells following each injection. The deflection in the power 
input to the sample cell to maintain a constant temperature constitutes the reported 
signal. This is plotted as a series of peaks against the concentration of reactant added 
from the syringe. An example of raw ITC data is illustrated in Figure 5.1B. Titration 
of the reactant from the syringe into the sample cell is continued until the binding is 
observed  as saturated. Saturation is achieved when the heat signal diminishes so 
much so that only the background heat from dilution or unspecific buffer factors are 
detectable. 
To analyse the raw data, the area under each of the peaks of instrument power is 
calculated and normalised to the quantity of the ligand injected in each step of the 
titration. This is plotted against the molar ratio of the reaction components as an 
integrated heat plot, as illustrated in Figure 5.1B (bottom panel). From this graph, 
thermodynamic  parameters  such  as  binding  affinity  and  stoichiometry  of  the 
complex can then be extracted by applying a specific analytical model. The analysis 
and fitting functions of the raw data are usually carried out within the control and 
analysis software of the calorimeter.
226–228 219 
5.1.2.2 Analytical ultracentrifugation – AUC  
Analytical  ultracentrifugation  is  a  useful  tool  for  the  study  of  protein:protein 
interactions. AUC monitors the sedimentation of macromolecules through a solvent 
over  time  within  a  centrifugal  field.  It  is  a  technique  which  enables  the 
hydrodynamic  and  thermodynamic  characterisation  of  a  macromolecule  (or 
complex) in solution without the interference or interaction with a matrix. In general 
terms, during AUC, a sample is spun (encased in a transparent cell) at a very high 
speed in which real time monitoring is carried out by an optical detection system. 
The concentration of a sample is observed verses the distance it is from the axis of 
the  centrifugal  field.  Real  time  detection  can  take  the  form  of  UV/visible 
spectrophotometric  absorption  or  collection  by  an  interference  optical  refraction 
index  (RI)  system.  There  are  two  main  types  of  AUC  experiment  which  can  be 
carried out to study macromolecules in solution, sedimentation velocity (SV) and 
sedimentation equilibrium (SE) experiments. 
Within sedimentation velocity  experiments, high speed centrifugation results in a 
centrifugal force which depletes macromolecules at the meniscus of the sample cell 
resulting  in  a  concentration  boundary  which  moves  to  the  base  of  the  cell  as  a 
function of time. The recording of this process is illustrated by a response spectrum 
(Figure 5.2) which plots the variation in concentration of the macromolecule that is 
formed throughout the axis of the cell during centrifugation as a function of time. 
The concentration is plotted in units of ‘fringe displacement’ which is taken from the 
interference optical system and translates into a specific analyte concentration value 
per  unit.  With  this  response  spectrum  it  is  then  possible  to  determine  the 
sedimentation  coefficient  (S)  of  a  molecule.  The  sedimentation  coefficient  (S)  is 
used  as  a  parameter  that  characterises  the  molecules  translated  hydrodynamic 
behaviour during the sedimentation process. S is defined as the ratio of a particles 
sedimentation velocity to the force of acceleration applied to it. With the molecules S 
value  it  is  possible  to  begin  to  model  the  hydrodynamic  shape,  including  the 
oligomeric  state  and  if  a  heterogeneous  interaction  the  stoichiometry  of  the 
macromolecules under investigation.  
In sedimentation equilibrium (SE) AUC experiments, the absolute molecular weight 
and stoichiometry of a complex mixture can be obtained. SE-AUC experiments are 220 
carried out at a lower rotor speed establishing an equilibrium across the cell in which 
sedimentation diffusion  can be monitored. These experiments are run  for several 
days during which the distribution of molecules along the cell reaches an equilibrium 
state. The distribution formed is sensitive only to the molecular mass and not the 
shape.  To  study  the  interaction  between  Fas  and  ezrin  described  in  this  chapter, 
sedimentation velocity experiments were carried out. 
As mentioned above, the molecular sedimentation coefficient (S) can be obtained 
from the SV-AUC experimental data. Another parameter, the translational diffusion 
coefficient (DT) can also be calculated. DT gives an estimate of the molecular weight 
of a macromolecule independent of its shape. These parameters are calculated using 
the Svedberg equation, which takes into account the buoyant force (Fb), the frictional 
force (Ff) and the centrifugal force (Fc) which the macromolecule experiences, along 
with the mass of the displaced solution and the density of the solution itself. The 
Svedberg equation to calculate S is shown in Equation 1 below: 
M(1-ṽρ)/NAf = v/ω
2r = S      Equation 5.1 
The diffusion coefficient (DT) can be determined using Equation 5.2.  
DT = RT/ NA f       Equation 5.2 
Where v is the radial velocity, ω is the angular velocity, M is the molar mass, ρ is 
the solvent density, f is the frictional coefficient, R is the gas constant, r is the radial 
position,  ω
2r  is  the  centrifugal  field,  ṽ  is  the  partial  specific  volume,  NA  is 
Avagadro’s constant and DT is the diffusion coefficient. 
At  the  beginning  of  a  SV-AUC  experiment,  the  analyte  macromolecules  are 
positioned  at  a  uniform  concentration  throughout  the  solvent.  As  the  sample  is 
centrifuged, macromolecules sediment leading to the formation of a concentration 
boundary in which there is a depletion of the macromolecules between the boundary 
and the meniscus of the cell. The concentration boundary moves through the cell as a 
function of time; it is the position of this boundary which is recorded in the response 
spectrum.  The  data  from  the  entire  SV-AUC  experiment  is  fitted  to  the  Lamm 
equation (Equation 5.3) to obtain values for DT and S.  221 
 
￿￿










           Equation 5.3 
The Lamm equation takes into account the variation in the rate of concentration of 
the particles along the radius of the cell in conjunction with the movement of the 
components in the sample. In a multicomponent system a range of sedimentation 
coefficients contribute to the observed behaviour.  
In these circumstances the correct analysis involves the calculation of the continuous 
size distribution factor C(s) which allows for the sedimentation coefficient to vary 
within  a  defined  range.  The  C(s)  value  is  plotted  against  the  sedimentation 
coefficient resulting in the formation of a peak for each of the components present in 
the sample. 
The frictional coefficient (fo) gives information about the shape of the protein within 
a sample, which can be used to calculate the molecular weight of the macromolecule 
using  the  Stokes  equation  (Equation  5.4),  which  for  a  spherical  object  takes  the 
following form: 
fo = 6πŋR0        Equation 5.4 
Where fo is the frictional coefficient of a spherical particle, ŋ is the viscosity of the 
solution  and  R0  is  the  radius  of  the  spherical  particle.  Shape  anisotropy  of  the 
macromolecule causes the measured friction coefficient (f) to be different from fo. 
Hence, the frictional ratio f/fo which is obtained during fitting of the SV-AUC data 
can provide an indication of the shape of the investigated protein.
229,230 Within this 
study,  the  AUC  data  analysis  program  Sedfit  was  employed  to  calculate  the 
sedimentation  coefficient  (S)  and  associated  parameters  using  the  observed 
sedimentation boundary measurements at a specific centrifugal field by fitting the 
data to the Lamm equation 









Figure 5.2 Schematic representation of the experimental output from a sedimentation velocity-
analytical ultracentrifugation experiment.  
The absorbance boundaries across fifteen consecutive time points (denoted t1-t15) are illustrated as a function of 
the radial distance in the cell. Colour of the boundary is representative of the first fifteen time points of the 
experiments from t1 in blue to t15 in red. 
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5.1.2.3 Biolayer interferometry – BLI 
Biolayer interferometry (BLI) is a label free technique for real time monitoring of 
molecular interactions based upon the interference of reflected white light in a form 
of interference spectroscopy/reflectomeric interferometry spectroscopy (RIfS). It can 
be  used  to  measure  several  aspects  of  biomolecular  interactions  such  as  binding 
kinetics, concentration and affinity. BLI involves the use of proprietary technology 
in  the  form  of  disposable  detector  tips  (biosensors)  developed  by  ForteBio  that 
enable a binding reaction to be analysed in real time upon the Octet instrumentation. 
The  tip  of  a  biosensor  is  the  location  for  the  binding  reaction  to  be  monitored. 
Biosensors have an optical coating with a biocompatible matrix which enables the 
immobilisation of a variety of different biomolecules. A range of standard surface 
chemistries are available to enable sample immobilisation, such as protein A and 
protein  G  for  antibody  binding  and  glutathione  biosensors  to  bind  the  GST  tag. 
Within this study, streptavidin sensors were used to immobilise biotinylated proteins.  
BLI is carried out upon the Octet system in which up to eight biosensors can be used 
to analyse eight samples in parallel in an automated manner. This enables multiple 
conditions, proteins or concentrations to be analysed at one time. Experiments/assays 
are  carried  out  across  the  columns  of  a  standard  96  well  plate  in  which  the 
instrument moves the biosensors across and into separate wells for each step of the 
binding assay. Bringing the biosensor to the sample of interest removes the need for 
microfluidics systems which is common in other known real time binding assays 
such as Biacore/surface plasmon resonance instruments. To remove the effects of 
diffusion,  the  sample  plate  is  maintained  on  a  shaker  throughout  the  experiment 
which can be set to oscillate between 100-1500 rpm. 
BLI  measurements  are  carried  out  in  real  time,  as  binding  is  monitored  by  the 
building  up  of  a  protein  layer  upon  the  surface  of  the  biosensor  (schematic 
illustration shown in Figure 5.3A). During an assay, white light is shone down the 
long axis of the biosensor, with the instrument collecting the light which is reflected 
back  from  the  end  of  the  sensor.  Protein  binding  to  the  biosensor  tip,  shifts  the 
interference pattern of white light. The instrument measures and reports the change 
in wavelength as a function of time, with the wavelength shift (∆λ) being a direct 
measurement of the optical thickness of the biological layer. Therefore only if one or 224 
more species are binding to the biosensor tip it affects the trace from the instrument. 
The observed interference pattern is analysed as a comparison between two surfaces: 
the immobilised protein layer upon the biosensor, and an internal reference layer 
within the tip itself, illustrated in Figure 5.4. This interference data create a unique 
spectral signal within the visible spectrum which is reported in  relative intensity 
units (nm). 
231,232 In this study, BLI was utilised as a kinetic binding study to monitor 
protein:protein interactions and to calculate dissociation constants between putative 
binding partners. To  enable this calculation,  each step of the binding  assay (e.g. 
loading, association, dissociation) was carried out across five columns of a 96 well 
plate, with seven different concentrations of binding partner. The traditional steps of 
the experiment, the status of the biosensor tip and example data read outs are shown 
in Figure 5.3. 
The experimental assay was initiated with the establishment of a buffer baseline in 
which the sensors are equilibrated in the buffer solution which is used throughout the 
whole experiment (Step 1). Biosensors are then moved to the next column of the 
plate containing the tagged protein which is immobilised upon the biosensor until 
a.new baseline optical readout has been achieved (Step 2). The bait-loaded sensor is 
then equilibrated in the buffer used in the experiment to establish an experimental 
baseline (Step 3). The association step is initiated by shifting the biosensors into 
wells containing the binding partner of interest (Step 4) which is followed by moving 
the sensor into buffer enabling dissociation to occur (Step 5). The association and 
dissociation events are observed by a change in the optical readout. To calculate the 
dissociation constant from the relative intensity units, serial dilutions of the protein 
binding partner were tested in parallel by aliquoting them down a column of wells in 
the plate. Following subtraction of the baseline reading (Figure 5.3C), the change in 
relative  intensity  units  for  each  analyte  concentration  were  extracted  and  a 
dissociation constant (Kd) calculated by fitting the data to a one to one binding model 
using the program Sedfit    225 
 
Figure 5.3 Schematic representations of the steps involved in the biolayer interferometry assays. 
A, Schematic representation of streptavidin biosensors throughout the course of one binding experiment. Briefly, 
the sensor is equilibrated (1) followed by loading of the sensor with the tagged protein of interest (2). The loaded 
sensor is equilibrated in the buffer to be used throughout the experiment (3), prior to association with the protein 
of interest (4) which is followed by a dissociation step (5). B, Experimental binding assay raw data taken from 
the Octet instrument. Steps in the experiment are indicated by the numbers above the trace. C, An example of  
processed  BLI  data.  The  raw  data  has  been  truncated  to  just  include  the  binding  events  and  the  baseline 
normalised to the absorbance of the loaded biosensor.  
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5.1.2.4 NMR titrations with 
15N-labelled protein samples  
The most common method of studying protein:protein interactions by NMR is to 
monitor  the  two  dimensional 
1H/
15N-HSQC  spectrum  of  a  labelled  protein  as  an 
(unlabelled)  putative  binding  partner  is  titrated  into  the  sample.  This  method  is 
known  as  a  ‘
15N  titration’  experiment.  A 
15N  titration  enables  the  monitoring  of 
resonance  frequencies  and  line  widths  of  the  spectrum  upon  addition  of  binding 
partners. If the chemical shift assignments are known for the 
15N-labelled protein, the 
effect of the addition of an unlabelled binding partner upon the cross peaks in the 
spectrum  can  be  related  to  the  protein  structure.  This  approach  is  referred  to  as 
‘chemical shift mapping’, in which the affected cross peaks can be used to map a 
putative binding site upon the structure of the protein of interest. 
A change in the chemical environment of the nuclei that give rise to a cross peak 
typically results in chemical shift perturbation. Perturbation reflects a change in the 
atoms which are in close proximity to the nuclei which gave rise to the cross peak, 
which could be caused by a change in the local atomic configuration, an induced 
conformational change which has been brought about by the presence of a binding 
partner, at a more or less remote site or a combination of the two. The protein surface 
which corresponds to the location of perturbed cross peaks is commonly interpreted 
as revealing the binding site of an interaction partner but the effects upon a 
1H/
15N-
HSQC can radiate beyond the contact surface upon the labelled protein
233. 
Chemical  shift  mapping  is  a  method  which  can  also  be  used  to  characterise  the 
kinetic process of two site exchange between two molecules. Two site exchange is 
characterised  by  an  exchange  rate  constant  (kex),  which  is  sum  of  the  forward 
(binding) and reverse (unbinding) of a reaction. A simple ligand two-site exchange 
binding can be considered as: 
kon 
P+L   ￿  PL       Equation 5.5 
koff 
P represents the free protein, L is the ligand (or protein binding partner) and PL is 
the bound form of the protein, ligand complex. kon represents the binding of the 
ligand  to  the  protein  as  a  biomolecular  second  order  rate  constant,  whereas  koff 228 
represents dissociation of the complex as a first order rate constant. Therefore kex is 
characterised as: 
kex = kon + koff        Equation 5.6 
Within  the  NMR  spectrum,  both  the  free  and  bound  forms  of  the  protein  have 
resonance frequencies, represented as ⱴP and ⱴPL, which result in a chemical shift 
difference, reported in angular frequency units – s
-1. 
∆ⱴ = ⱴP-ⱴPL        Equation 5.7 
The  appearance  of  the  corresponding  features  in  the 
1H/
15N-HSQC  spectrum  is 
dependent upon the populations of each state, the magnitude of the exchange rate 
constant and the chemical shift difference ∆ⱴ. The exchange rate corresponds to the 
average number of exchange events per unit time which enables comparison with 
∆ⱴ.  The  nature  of  the  observed  chemical  exchange  is  typically  characterised  as 
belonging to one of three exchange regimes, slow exchange (kex < ∆ⱴ), fast exchange 
(kex > ∆ⱴ) and intermediate exchange (kex ~ ∆ⱴ). Each regime is associated with a 
pattern  of  ligand  concentration  dependent  effects  on  the  appearance  of  the 
corresponding NMR resonances (and cross peaks). 
When  an  interaction  is  undergoing  slow  exchange,  separate  signals  are  observed 
which represent both the free and bound states of the protein (and/or ligand). This is 
due  to  the  exchange  rate  being  lower  than  the  frequency  differences  within  the 
spectrum. The linewidth of each resonance/cross peak is not materially affected by 
exchange in this case. In this instance, a bound state spectrum may need its own set 
of assignments to be carried out. Peaks undergoing fast exchange are the easiest to 
follow when implementing chemical shift mapping as only a single peak is observed. 
The chemical shifts of the affected spectral features  change as a  function of the 
concentration of the binding partner. The behaviour enables the affected peaks to be 
easily followed and mapped back to the original peaks in the free state spectrum and 
then onto the three dimensional structure of the protein. This occurs because the 
exchange rate constant kex is greater than then chemical shift difference between the 
two  states.  Binary  systems  interacting  in  intermediate  exchange  regimes  are 
characterised by the observation of overall line broadening of the affected peaks and 
dependent on ligand concentration, the broadening of spectral lines, resulting in loss 229 
of signals within the spectrum. In these circumstances, the exchange rate constant is 
within the same order as the chemical shift differences. Assignment is more or less 
straight  forward  depending  upon  the  overall  effect  of  signal  loss,  the  extent  of 
binding and spectral overlap. 
Throughout a 
15N-titration, the cross peak intensity can be affected by any one of 
these exchange regimes, which is ultimately dependent upon the binding properties 
(Kon/Koff) of the ligand to the 
15N-labelled protein. In principle it is possible for all 
three exchange mechanisms to occur within the same experiment, through different 
binding  sites  on  the  molecule  undergoing  different  exchange  regimes.  However 




5.2 DNA cloning of constructs of intracellular Fas and ezrin FERM domain into 
E. coli protein expression vectors 
The expression constructs of Fas Death Domain (DD) (residues 218-319) and Fas 
DD+C-terminal region (CTD) (residues 218-335) were kindly provided by Dr Diego 
Esposito.  All  other  constructs  were  made  by  cloning  into  pNIC-NTH  vectors 
(detailed  methodology  in  Section  2.4.2).  pNIC-NTH  are  vectors  for  ligation 
independent  cloning  developed  at  the  Oxford  site  of  the  Structural  Genomics 
Consortium
221. They encode the introduction of an N-terminal hexa-histidine tag for 
affinity purification, either a GB1 or a GST fusion tag for immobilisation and/or 
solubility enhancement and a tobacco-etch virus (TEV) protease cleavage site. The 
pNIC-NTH vector with a GB1 tag was developed in our laboratory.  
Fas  constructs  were  subcloned  from  existing  plasmid  vectors  available  in  our 
laboratory. Ezrin was cloned from human neural cDNA (DV Biologics). The ezrin 
FERM-truncated coiled  coil (tCC) construct (residues 1-362) is equivalent to the 
construct used in the pull-down experiments carried out by Louzepone et al. (2004).  
A schematic diagram illustrating the protein constructs used throughout this chapter 
are shown in Figure 5.5. The molecular weight and extinction coefficient for each 
construct was estimated using the EXPASY ProtParam server, this information is 
shown in Table 5.1 below. Throughout this chapter, different constructs are referred 230 
to by the construct names listed in Table 5.1. Fas residues are numbered according to 
UniProt:P25445.  
Table 5.1 Properties of Fas and ezrin constructs 









GST  GB1  H6Avi 
Fas-DD  218-319  13315  8480       
Fas-DD+CTD  218-335    8480      ￿ 
Fas-JM(-MPD)-
DD+CTD 
208-335  14335  8480  ￿  ￿   
Fas 
JM+DD+CTD 
194-335  16101  8480  ￿  ￿  ￿ 
Fas-TM+IC  185-335  17221  13980  ￿  ￿   
Ezrin 
FERM+tCC 
1-362  43170  53860  ￿  ￿   
Ezrin FERM  1-297  35026  52370    ￿   
DD, death domain; CTD, C-terminal domain; JM juxtamembrane; MPD, membrane-
proximal domain; IC intracellular, tCC, truncated coiled coil domain; FERM, four 
point one ezrin radixin moesin domain 
* following removal of the affinity tag by TEV protease cleavage 





Figure 5.5 Schematic representation of Fas and ezrin proteins and construct design. 
A,  Full  length  Fas  indicating  the  domain  architecture  and  numbering  used  throughout  this  chapter.  The 
extracellular  region  is  present  to  illustrate  the  shape  of  the  whole  molecule  and  is  not  to  scale.  TM  -, 
transmembrane domain, JM - juxtamembrane domain, MPD - membrane proximal domain, CTD - C-terminal 
domain.  Shorter  Fas  truncation  constructs  are  shown  below  the  full  length  diagram.  B,  Full  length  ezrin 
indicating the domain orientation and numbering used throughout this chapter. FERM - band four point one ezrin 
radixin moesin, tCC – truncated coiled coil domain, CTD – C-terminal domain. Ezrin truncation constructs are 
shown below the full length diagram. 
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5.3 Expression and purification of Fas and ezrin constructs 
The E. coli strain BL21 (DE3) Gold was used for the expression of all Fas and ezrin 
constructs.  An  expression  test  for  each  construct  was  performed  as  described  in 
Section 2.5.2, assaying expression by SDS-PAGE. Expression for all constructs was 
optimal when cells were induced with 0.5 mM IPTG for sixteen hours at 22 
oC. 
These  were  the  conditions  used  for  large  scale  expression  of  the  proteins,  as 
described in Section 2.5.3. 
When fused to an N-terminal hexa-histidine tag, expressed proteins were initially 
purified by immobilised metal affinity chromatography  (Ni-IDA, Generon). Then 
solubility and purification tags were removed by cleavage with TEV protease. A 
final purification step was carried out using size exclusion chromatography (SEC; 
Superdex75,  GE  Healthcare)  (Section  2.6).  SDS-PAGE  analysis  and  SEC 
chromatograms of typical Fas and ezrin preparations are shown in Figures 5.6 and 
5.7. 
When fused to an N-terminal GST tag, expressed proteins were initially purified by 
glutathione sepharose (GE healthcare) affinity chromatography using a batch binding 
method to load the beads. Then solubility and purification tags were removed by 
treatment with TEV protease. A final purification step was carried out using size 
exclusion chromatography (SEC; Superdex75, GE Healthcare) (Section 2.6).  
The  solubility  of  Fas  constructs  was  enhanced  by  the  presence  of  the  K263A 
mutation which has been shown to enable Fas-DD constructs to be concentrated up 
to 800 µM without aggregation. This enabled preparation of protein at concentrations 
suitable for NMR samples. The Fas constructs containing more of the intracellular 
and transmembrane domain were less stable and could not be concentrated to such a 
high concentration due to protein precipitation. Ezrin constructs were stable up to 
600  µM  with  no  solubility  problems.  The  FERM-tCC  construct  formed  a  dimer 
observable upon a SDS-PAGE gel as well as by SEC. This limited concentration to 
~400 µM. 
   233 
 
Figure 5.6 Fas 185-335 purification 
A, SDS-PAGE analysis of the IMAC purification of  Fas-TM+IC. B, SDS-PAGE analysis post TEV cleavage. C, 
The elution profile (monitored by UV absorbance at 280nm) and SDS-PAGE analysis of Superdex 75 SEC.  
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Figure 5.7 Ezrin 1-362 purification 
A,  SDS-PAGE  analysis  of  the  IMAC  purification  of    Ezrin-FERM+tcc.  B,  SDS-PAGE  analysis  post  TEV 
cleavage. C, The elution profile (monitored by UV absorbance at 280nm) and SDS-PAGE analysis of Superdex 
75 SEC. The red line indicates the fractions that were pooled. 
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5.4  An  interaction  between  intracellular  Fas  and  ezrin  is  not  observed  in  a 
number of conventional biophysical assays 
5.4.1 A variety of pull-down assays with Fas-JM+DD+CTD and ezrin FERM+tCC 
failed to detect an specific interaction 
In an attempt to replicate the GST pull-down assay carried out by Lozupone et al. 
(2004)
117,  GST-tagged  ezrin  FERM+tCC  was  immobilised  onto  glutathione 
sepharose  beads  as  bait  and  Fas-JM+DD+CTD  was  used  as  prey.  Lozupone  and 
coworkers used a variety of ezrin constructs to map the binding site, but because the 
purpose of this study was to validate the fundamental result of their study, only the 
longest ezrin construct in their assay (FERM+tCC) was tested.  
Preliminary  GST-pull  down  experiments  were  attempted  with  these  two  protein 
constructs but they failed to show a Fas and ezrin interaction (data not shown). To 
ensure that the expressed and purified Fas and ezrin constructs were correctly folded, 
a number of controls were added to the experiment. As a positive control for Fas 
binding, the GST-FADD:Fas pull down previously published by our laboratory
123 
was used. As a positive control for ezrin binding, we selected an 18 amino acid 
sequence  corresponding  to  the  region  of  Na
+/H
+  exchange  regulatory  factor  2 
(NHERF2) that has been crystallised bound to the radixin FERM domain
111. The 
sequence of the peptide was introduced into the pNIC-GB1 vector, and the GB1-
NHERF2 (residues 320-337) fusion protein expressed and purified. To control for 
Fas binding to GST as opposed to ezrin, a stop codon was inserted into the pNIC-
GST  vector  to  enable  the  expression  and  purification  of  GST  alone.  Fas-
JM+DD+CTD was also incubated with the glutathione sepharose beads on its own to 
control for non-specific binding. GST-tagged proteins were incubated with 50 µg of 
their  respective  binding  partner  for  sixteen  hours.  Beads  were  equilibrated  and 
washed in 20 mM MES, 100 mM NaCl, 1 mM EDTA, 0.5 mM TCEP, pH 6.2 and 
then  added  to  the  protein  mix.  Pull  downs  were  then  analysed  by  SDS-PAGE 
analysis followed by Coomassie Blue or silver staining (Figure 5.8). 
Evidence of a productive interaction was detected for both positive controls GST-
FADD:Fas  and  GST-Ezrin:GB1-NHERF2  (residues  320-337).  This  pull  down 
confirmed that the conditions of the assay were appropriate to detect protein:protein 
interactions and that both Fas and ezrin were in a suitable conformation to be able to 236 
bind their well-documented binding partners. However, Fas was also pulled down by 
GST and by the gluthatione sepharose beads. To try and reduce this non-specific 
binding, the assay was repeated with the addition of 0.1% NP40 detergent and 1 
mg/ml BSA, but this did not prevent this non-specific binding (data not shown). 
Due  to  Fas  binding  to  the  gluthatione  sepharose  beads,  an  alternative  pull  down 
using  immobilised  hexahistidine-tagged  Fas-JM+DD+CTD  was  tested.  Lysate  of 
cells which express H6-GB1-Fas-JM+DD+CTD was used to load the Ni-NTA beads 
which were then incubated with 25 μM of purified ezrin FERM domain for sixteen 
hours. Beads were equilibrated and washed in 30 mM Tris-HCl, 150 mM NaCl, 10% 
glycerol, 1% Triton, 1 mM EDTA, 10 mM imidazole, pH 7.5. The results can be 
seen in Figure 5.9. Fas was successfully loaded onto the beads and appeared to have 
pulled down ezrin. However, the unloaded bead control had also pulled down ezrin, 
suggesting  that  this  untagged  ezrin  construct  can  bind  to  these  beads  in  a  non-
specific manner. These pull down conditions were not further optimised as the buffer 
conditions already contained additives to reduce non-specific binding. 
As a third option, co-immunoprecipitation of H6-GB1-Fas ezrin was attempted with 
an  anti-H6  antibody.  Cell  lysate  containing  H6-GB1-Fas-JM+DD+CTD  was 
precleared  by  incubation  with  Protein  G  magnetic  beads  for  one  hour.  After 
preclearing, anti-H6 antibody (5 μg/ml) was added to the lysate and the mixture was 
incubated overnight with ezrin (25 μM). Following ezrin incubation, the conjugate 
was incubated with Protein G magnetic beads for one hour, the beads were then 
washed with PBS and finally analysed by SDS-PAGE and silver staining (Figure 
5.10). Unfortunately, like the two previous pull downs detailed above, ezrin bound to 
the beads with or without Fas, so presumably in a non-specific manner. Furthermore, 
it  was  not  possible  to  observe  a  band  on  the  gel  corresponding  to  H6-GB1-Fas-
JM+DD+CTD. Perhaps the light chain of the antibody and the tagged Fas construct 
migrate on the gel at a similar rate. Being unable to observe Fas is sub-optimal for a 
pull down because it would be impossible to prove that it was the Fas that gave rise 
to the pull down of a binding partner rather than the antibody and due to this the 
immunoprecipitation approach was not further explored.  





Figure  5.8  Silver  stained  pull  down  using  Glutathione  sepharose  beads  to  immobilise  GST-
ezrin-FERM+tCC to pull down Fas-TM+IC 
GST ezrin-FERM+tCC was immobilised upon glutathione sepharose beads and incubated with Fas or a number 
of binding partners to control for whether Fas and ezrin were able to bind to known binding partners (GST-
FADD to ensure the Fas construct bound and GB1-NHERF2 to ensure GST-ezrin could pull down protein) as 
well as whether Fas bound to the beads or the GST tag upon the ezrin construct. Beads were equilibrated and 
washed in 20mM MES, 100mM NaCl, 1mM EDTA, 0.5mM TCEP, pH6.2. 50µg of each protein partner was 
incubated for sixteen hours prior to washing and analysis. 
 
 








Figure  5.9  Silver  stained  pull  down  using  Ni-NTA  beads  to  immobilise  H6-GB1-Fas-
JM+DD+CTD to pull down ezrin-FERM 
H6-GB1-Fas-JM+DD+CTD was immobilised upon Complete Ni-NTA beads and incubated with 25µM ezrin-
FERM for sixteen hours. Beads were equilibrated and washed in 30mM Tris-HCl, 150mM NaCl, 10% glycerol, 
1% Triton, 1mM EDTA, 10mM imidazole, pH7.5. Unfortunately ezrin was observed to bind to the Ni-NTA 
beads therefore this would not be a suitable method for observing any interactions. Bands which are unlabelled 
are non-specific binding from the H6-GB1-Fas cell lysate used to load the beads. 
 







Figure  5.10  Silver  stained  immunoprecipitation  using  H6  antibody  coupled  to  protein  G 
magnetic beads to pull down ezrin FERM with H6-GB1-Fas-JM+DD+CTD 
H6-GB1-Fas-JM+DD+CTD was immobilised upon Complete Ni-NTA beads and incubated with 25µM ezrin-
FERM for sixteen hours. Beads were equilibrated and washed in 30mM Tris-HCl, 150mM NaCl, 10% glycerol, 
1% Triton, 1mM EDTA, 10mM imidazole, pH7.5. Unfortunately ezrin was observed to bind to the Ni-NTA 
beads therefore this would not be a suitable method for observing any interactions. Bands which are unlabelled 
are non-specific binding from the H6-GB1-Fas cell lysate used to load the beads. 
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5.4.2  Size  exclusion  chromatography  does  not  show  co-elution  of  Fas-
JM+DD+CTD and ezrin FERM 
To assess the ability of intracellular Fas and ezrin to form a higher molecular weight 
complex, purified Fas-JM+DD+CTD and ezrin FERM were combined with a molar 
excess of the Fas construct and loaded into an analytical SEC column (Superdex 75 
10/300GL; GE Healthcare) that had been calibrated using the following molecular 
weight standards: lysozyme (15 kDa), RNase (25 kDa), cytochrome C (29 kDa), 
ovalbumin (45 kDa) and BSA (66 kDa) (Figure 5.11). 
Purified ezrin-FERM and Fas-JM+DD+CTD constructs, both in 20 mM Tris, pH 7.4, 
150 mM NaCl, 1 mM EDTA, 1 mM TCEP, 3 mM NaN3, were mixed in a 1:4 ratio 
and concentrated to a final protein concentration of 1 mM (200 µM ezrin:800 µM 
Fas). A hundred µl of the solution were injected onto the analytical SEC column 
previously  equilibrated  in  the  same  buffer.  As  shown  in  Figure  5.4,  the  co-
concentrated Fas and ezrin sample eluted as two separate peaks with no indication of 
a higher molecular weight complex being formed. The elution volumes of the two 
peaks in the mixed protein sample overlaid perfectly with the elution volumes of the 
proteins obtained when they were individually injected (at 10.18 ml and 12.05 ml). 
This behaviour suggests that Fas and ezrin do not form a high molecular weight 
complex when mixed at this concentration or that the association constant for any 
such complex formation is too low to be observed by analytical SEC. 
 
5.4.3 Isothermal titration calorimetry measures no heat of exchange upon mixing 
Fas-JM+DD+CTD with ezrin FERM+tCC 




oC. The sample cell contained ezrin FERM+tCC (50 μM) and the syringe 
contained  Fas-JM+DD+CTD  (500  μM).  No  heat  of  interaction  was  observed 
suggesting  that  if  an  interaction  occurs,  it  does  not  absorb  or  emit  a  significant 
amount  of  any  heat.  Interestingly,  other  confirmed  protein-protein  interactions 
involving  death  domains  do  not  have  any  observable  heat  exchange  (Dr  Diego 





Figure 5.11 Fas and ezrin do not co-elute from an analytical size exclusion column suggesting a 
weak interaction 
Ezrin-FERM and Fas-JM+DD+CTD were co-injected onto an analytical Superdex 75 size exclusion column (in 
ezrin NMR buffer) to see whether an interaction could be observed by the presence of co-elution. The three runs 
are overlaid, with Fas (750µM) in blue, ezrin (200µM) in red and the co-concentrated ezrin:fas (200µM:800µM) 
in green. 
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5.4.4  Sedimentation  velocity  analytical  ultracentrifugation  experiments  of  Fas-
DD+CTD  with  ezrin  FERM+tCC  gives  no  definitive  suggestion  of  complex 
formation 
Sedimentation velocity  analytical ultracentrifugation (SV-AUC) experiments were 
carried out as described in Section 2.7.5, with all samples dialysed overnight into 20 
mM Tris, 150 mM NaCl, 0.5 mM TCEP, pH 7.4. Initially, data for Fas and ezrin 
samples alone were collected at concentrations ranging from 0.5 mg/ml to 2 mg/ml. 
Figures 5.12 and 5.13 show representative data analyses for Fas (0.5 mg/ml) and 
ezrin (1 mg/ml), showing the experimental time-dependent sedimentation profiles, 
the residuals and the derived sedimentation coefficient distributions c(S) (graph in B) 
obtained after fitting the data with the program SEDFIT. These data show the Fas-
DD+CTD and ezrin FERM+tCC are both monomeric when alone in solution and 
have a sedimentation coefficient (S value) of 1.6 S and 2.8 S, respectively. These 
sedimentation coefficients were reproducible across all concentrations tested. The 
Fas experiments predicted the molecular weight to be ~18 kDa, about 6 kDa larger 
than the expected mass for this construct. The predicted molecular weight for ezrin 
was ~43 kDa which is around the expected monomeric weight for this construct. 
Table  5.2  lists  the  ultracentrifugation  experiments  carried  out  and  the  results 
obtained. 
Table 5.2 Summary of the SV-AUC experiments for Fas and ezrin 
Concentration 
(mg/ml) 





0.5  1.62  1.32  18.2  0.003 
2.0  1.61  1.41  18.2  0.004 
Ezrin-FERM+tCC 
0.5  2.88  1.38  44.9  0.008 
1.0  2.83  1.36  43.9  0.006 
2.0  2.89  1.31  42.7  0.010 
S, sedimentation coefficient; MW, molecular weight in kDa; %, % of that species 
present;, f/f0, frictional ratio. 
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SV-AUC experiments were also carried out for Fas and ezrin mixed at equimolar 
concentrations of 20 μM, 50 μM and 100 μM. Figure 5.14A shows a representative 
experiment  including  experimental  time-dependent  sedimentation  profiles,  the 
residuals and the derived sedimentation coefficient distribution c(S). A summary of 
the SV-AUC experiments of mixed Fas and ezrin can be seen in Table 5.3. As can be 
seen from Figure 5.14B and Table 5.3, the majority of the Fas and ezrin within the 
sample appeared to remain in its monomeric form at all three concentrations with 
~20% sample being monomeric Fas and ~76% of the sample being monomeric ezrin. 
Sedfit  estimates  the  contribution  that  each  species  has  on  the  total  absorbance 
observed. Therefore this distribution of components would be expected if there was 
no interaction as ezrin has a molecular weight approximately three times that of Fas, 
therefore there would be approximately three times as much present at an equi-molar 
concentration.  A  third  species  was  shown  to  have  formed,  with  a  sedimentation 
coefficient of ~5, however this only makes up around 2% of the species present for 
each experiment. This new species has an estimated molecular weight close to 100 
kDa which would suggest that a number of ezrin monomers would be involved or a 
high molecular weight platform of Fas could have formed. However as it is such a 
small proportion of the sample it is difficult to say whether it has any bearing on Fas 
and ezrin interacting as the majority of the sample is still made up of Fas and ezrin in 
a monomeric form, at all three concentrations.  






Oligomer  f/f0  Fit 
(RMSD) 
S  MW  %  S  MW  %  S  MW  % 
20  1.4  13.0  21  2.8  37.5  76  5.3  97.3  1.3  1.226  0.009 
50  1.4  13.2  20  2.9  38.9  76  5.8  110.3  2.3  1.211  0.016 
100  1.5  14.1  15  3  42  80  5.3  95.3  2.2  1.211  0.018 
S, sedimentation coefficient, MW, molecular weight in kDa, %, % of that species 
present, f/f0, frictional ratio. 




Figure 5.12  Sedimentation velocity profiles, c(S) distribution and residuals for Fas-DD+CTD 
Sedimentation  velocity  measurements  were  performed  on  Fas-DD+CTD  at  concentrations  of  0.5mg/ml  and 
2mg/ml  in  buffer  containing  20mM  Tris,  150mM  NaCl,  0.5mM  TCEP  at  pH7.4.  A,  Time-dependent 
sedimentation velocity profiles and the fit residuals. The meniscus (red line) and fitted data range (between the 
green lines) are highlighted. B, The c(S) distribution plot showing that Fas is monomeric and sediments with the 
sedimentation coefficient of 1.6S at the two concentrations of 0.5mg/ml (blue line) and 2mg/ml (green line). 




Figure  5.13  Sedimentation  velocity  profiles,  c(S)  distribution  and  residuals  for  ezrin-
FERM+tCC 
Sedimentation  velocity  measurements  were  performed  on  ezrin-FERM+tCC  at  concentrations  of  0.5mg/ml, 
1mg/ml and 2mg/ml in a buffer containing 20mM Tris, 150mM NaCl, 0.5mM TCEP at  pH7.4. Time-dependent 
sedimentation velocity profiles and the fit residuals are shown in A. The meniscus (red line) and fitted data range 
(between  the  green  lines)  are  highlighted.  The  c(S)  distribution  plot  showing  that  ezrin  is  monomeric  and 
sediments with the sedimentation coefficient of 2.8S at the three concentrations of 0.5mg/ml (blue line), 1mg/ml 
(red line) and 2mg/ml (green line) as shown in B. 




Figure  5.14  Sedimentation  velocity  profiles,  c(S)  distribution  and  residuals  for  Fas:ezrin 
complex 
Sedimentation velocity measurements were performed on Fas-DD+CTD and ezrin-FERM+tCC mixed at a 1:1 
ratio at concentrations of 20µM, 50µM and 100µM, in buffer containing 20mM Tris, 150mM NaCl, 0.5mM 
TCEP  at  pH7.4.  Time-dependent  sedimentation  velocity  profiles  and  the  fit  residuals  is  shown  in  A.  The 
meniscus (red line) and fitted data range (between the green lines) are highlighted. The c(S) distribution plot 
showing the Fas and ezrin monomers at 1.6S and 2.8S respectively, as well as the formation of a larger species 
between  4  and  5S  is  shown  in  B.  The  third  species  was  more  prominent  at  the  higher  concentrations. 
Concentrations represented as, 20µM, blue line, 50µM, red line and 100µM, green line. 
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5.5 An interaction between Fas constructs and ezrin is observed by BLI 
Biolayer  Inteferometry  (BLI)  measures  molecular  interactions  indirectly  through 
changes in the interference pattern of white light between an immobilised protein 
and an internal reference
231. Proteins can be immobilised using several chemistries, 
we were advised to use streptavidin-biotin chemistry due to its robust non covalent 
immobilisation  properties.  Because  the  intensity  of  the  signal  depends  on  the 
thickness of the biolayer upon binding, it is better to immobilise the smallest protein 
to the sensor, in this case, Fas. To obtain biotinylated Fas, the Fas-DD+CTD and 
Fas-JM+DD+CTD  DNA  constructs  were  cloned  into  a  vector  constructed  in  our 
laboratory to allow the expression of proteins with an N-terminal hexa-histidine tag 
followed  by  the  E.  coli  biotin  ligase  (BirA)  recognition  sequence 
(GLNDIFEAQK*IEWHE - * denotes site of biotin attachment), commonly named 
by its commercial name Avi-tag. After purification of the protein, the lysine in the 
recognition sequence can be biotinylated in vitro by incubation of the recombinant 
protein  with  BirA,  biotin  and  ATP,  as  described  in  Section  2.7.3.  From  here 
onwards,  the  tag  H6-linker-TEV-Avi  (MKHHHHHHPMSDYDIPTT  ENLYFQ 
GLNDIFEAQKIEWHE  GSGSGA),  will  be  referred  to  as  H6Avi  without  biotin 
attached and H6Avi*, when biotin-labelled.  
The  setting  of  a  typical  BLI  experiment  was  as  follows:  First,  the  H6Avi*  Fas 
constructs are immobilised onto the surface of the sensors using streptavidin. Next 
the sensors are equilibrated in binding buffer, and then immersed in buffer with the 
potential binding partner. Finally the sensors are dipped into buffer again in order to 
measure  the  dissociation  kinetics.  The  experiment  was  repeated  using  different 
concentrations of ezrin FERM+tCC (from 3.1 to 400 µM) in the plate wells, and also 
FADD as a positive control, as in the pull down experiments. The interaction was 
recorded over time and is shown in Figure 5.15. The time-dependent BLI profiles 
(Figure 5.15A and 5.15C) show that  Fas and ezrin associate  and dissociate very 
quickly. The initial baseline in the profile is obtained when the biotinylated protein is 
being  equilibrated  in  the  binding  buffer.  When  the  sensor  is  immersed  into  the 
solution with the potential binding partner, the response increases as more protein is 
bound to the sensor. Finally the response decreases during the dissociation step. The 
effective dissociation constant was calculated by fitting the experimental data to an 






Figure 5.15 Biolayer interferometry show that the Fas:ezrin interaction has a Kd around 100μM 
BLI analysis was used to see if different immobilised Fas constructs associated to ezrin. The colours used in the 
time response data (A and C) corresponds to the concentrations illustrated below the graphs. Experimental data is 
shown as the red points, fitted trend as a black line (B and D). 
A, Bio-Fas-DD+CTD interaction with ezrin-FERM-tCC background corrected time response data. B, Bio-Fas-
DD+CTD interaction with ezrin-FERM+tCC data fitted to A + B heterodimerisation model using SEDPHAT, 
giving a Kd of 87µM. C, Bio-Fas-JM+DD+CTD interaction with ezrin-FERM+tCC background corrected time 
response  data.  D,  Bio-Fas-JM+DD+CTD  interaction  with  ezrin-FERM+tCC  data  fitted  to  A  +  B 
heterodimerisation model using SEDPHAT, giving a Kd of 75µM.  
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Figure 5.16 Biolayer interferometry shows that Fas immobilisation onto the sensor does not 
affect the observation of the interaction 
The colours used in the time response data (A) corresponds to the concentrations illustrated below the graphs. 
Experimental data is shown as the red points, fitted trend as a black line (B).a) low loaded Bio-Fas(202-335) 
interaction  with  ezrin  (1-297)  background  corrected  time  response  data.  b)  low  loaded  Bio-Fas-202-335 
interaction with ezrin (1-297) data fitted to A + B heterodimerisation model using SEDPHAT, giving a Kd of 
60µM.
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The fitted Kd for the interaction with H6Avi*-Fas-DD-CTD was predicted to be 87 
µM (Figure 5.15B) and with H6Avi*-Fas-JM+DD+CTD at 75 μM (Figure 5.15D). 
These  results  indicate  that  the  Fas  death  domain  interacts  with  ezrin  with  little 
dependence on the presence of the juxtamembrane/membrane proximal domain upon 
the apparent dissociation constant.  
The  experiment  using  H6Avi*-Fas-DD+CTD  was  repeated  with  a  shorter 
immobilisation time in order to verify that the amount of loaded Fas did not affect 
the results. With a reduced amount of Fas on the sensor surface, the derived ezrin 
dissociation constant was 60 µM, which is of the same order of magnitude as the 
other experiments (Figure 5.16). 
 
5.6  Ezrin  interaction  observed  by  Biolayer  Interferometry  is  mapped  to  the 
purification/biotinylation tag 
5.6.1 Fas-DD+CTD surface mutants all show similar dissociation constants 
Having detected an apparent interaction between Fas and ezrin which did not include 
the Fas juxtamembrane region, we thought it important to map the binding site in the 
Fas death domain. Six solvent exposed residues located across the whole surface of 
the death domain surface were chosen for mutation. These residues were identified 
from the published structure of the Fas death domain (PDB code 1DDF) using the 
program  MOLMOL.  Mutations  were  introduced  in  the  H6Avi-Fas-DD+CTD 
construct by site directed mutagenesis, as described in Section 2.4.3.  
BLI  experiments were carried out  as with the  wild-type  Fas constructs, with the 
H6Avi*-Fas mutants immobilised onto streptavidin sensors. Sensors were immersed 
in samples containing different concentrations of ezrin (FERM+tCC), (from 3.1 to 
400 µM). The interactions were recorded over time and the effective dissociation 
constant  was  calculated  by  fitting  the  experimental  data  to  an  A  +  B 
heterodimerisation model in SEDPHAT. As can be seen from Figure 5.17 and Table 
5.4, the dissociation constants for each of the mutants (except K231D) were within 
the same range as the initial wild-type Fas BLI experiments shown in Figure 5.11. 
The K231D mutant showed a much higher predicted dissociation constant which 
could have suggested that Fas K231 was in the ezrin interaction site. However, the 251 
time-dependent signal, shown in Figure 5.17A, shows that the 400 μM and 200 μM 
ezrin binding curves do not follow the trend of the other six concentrations assayed 
suggesting that an experimental artifact was the source of the anomalous behaviour. 
Table 5.4 BLI calculated dissociation constants for Fas surface mutants. 
Fas surface mutant  Dissociation constant Kd (μM) 
K231D  240* 
D260K  64 
Q268K  85 
E272K  79 
K287Q  80 
K309D  74 
*Unreliable result, see main text. 
5.6.2 Ezrin interacts with a variety of unrelated proteins with only the H6Avi tag in 
common 
Having obtained little variance with Fas surface mutants and due to the non-specific 
binding observed during pull-down experiments, it was decided to conduct more 
detailed control BLI experiments. The following H6Avi biotinylated proteins were 
used as negative controls: (a) the death domain of the protein PIDD (kindly provided 
by  Dr  Lily  Nematollahi);  (b)  the  glycogen  binding  domain  of  AMPK  (kindly 
provided by Dr Matthew Sanders) and; (c) E. coli frataxin (CyaY), (kindly provided 
by Dr Clara Iannuzzi). 
A  full  dilution  series  of  ezrin  (0-400  µM)  was  assayed  for  H6Avi*-PIDD  which 
showed  a  similar  association/dissociation  profile  (Figure  5.18A,  B)  to  the  Fas 
constructs with a calculated dissociation constant of 80 µM. Ezrin also bound to 
H6Avi*-AMPK-GBD  and  H6Avi*-CyaY  at  the  assayed  concentrations  (Figure 
5.18C-F  and  Table  5.5).  It  could  be  concluded  that  ezrin  is  a  very  promiscuous 
binding partner, however, all of the constructs being assayed had the H6Avi tag in 
common. The higher dissociation constants for H6Avi*-CyaY and H6Avi*-AMPK-
GBD could indicate that, being of higher molecular weight, these proteins hinder the 
interaction between ezrin and the H6Avi* to a greater extent. 
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Figure 5.17 Biolayer interferometry shows that ezrin interacts with a variety of Fas surface 
mutants with similar dissociation constants 
BLI analysis was used to see if immobilised Fas constructs with different surface mutations associate to ezrin-
FERM+tCC with different affinities. The colours used in the time response data (A and C) corresponds to the 
concentrations illustrated below the graphs. Experimental data is shown as the red points, fitted trend as a black 
line (B and D). The ezrin construct was kept constant throughout these experiments. 
A,C,E,  G,  I  and  K  show  the  time  response  data  (background  corrected)  for  varying  Fas-DD+CTD  mutants 
interaction with ezrin. The mutation being tested is shown above the graph. B, D, F, H, J, and L, show the data 
collected for each mutant fitted to an A + B heterodimerisation model using SEDPHAT. Dissociation constants 
and the mutant Fas tested are shown above each of the curves. 








Figure 5.17 (continued) Biolayer interferometry shows that ezrin interacts with a variety of Fas 





Figure 5.18 Ezrin shows binding to unrelated proteins by biolayer interferonmetry 
A  and  B,  show  the  time  response  data  (background  corrected)  (A)  and  the  data  fitted  to  a  A  +  B 
heterodimerisation model using SEDPHAT (B) for immobilised Biotinylated-PIDD and ezrin-FERM+tCC. C 
and D show the time response data (background corrected) (C) and the data fitted to a A + B heterodimerisation 
model using SEDPHAT (D) for immobilised Biotinylated-AMPK-GBD and ezrin-FERM+tCC. E, F show the 
time response data (background corrected) (E) and the data fitted to a A + B heterodimerisation model using 
SEDPHAT (F) for immobilised Biotinylated-CyaY and ezrin-FERM+tCC. 
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The  next  section  describes  how  the  association  of  ezrin  and  H6Avi  was  further 
confirmed  by  both  BLI  and  NMR  and  can  also  be  observed  by  GST  pull  down 
assays. 
Table  5.5  BLI  calculated  dissociation  constants  for  ezrin-FERM+tCC  and  alternative 
binding partners. 
Binding partner  Dissociation constant Kd (μM) 
H6Avi*-PIDD  80 
H6Avi*-AMPK-GBD  101 
H6Avi*-CyaY  237 
 
5.7  BLI,  NMR  and  GST  pull-down  assays  show  that  ezrin  recognises  the 
purification tag  
5.7.1 H6Avi tagged proteins compete ezrin off the BLI sensor 
To test the hypothesis that ezrin could be interacting with the H6Avi tag and not with 
the proteins themselves, a competition assay was designed in order to see whether 
mixing  free  non-biotinylated  H6Avi-Fas  with  ezrin  in  the  association  step  would 
compete with the H6Avi*-Fas immobilised in the streptavidin sensor. 
Figure 5.19 shows the time dependent binding profile for the ezrin and H6Avi*- Fas-
DD+CTD  competition  assay.  The  binding  profile  shows  four  steps  of  the  assay 
separated by dashed lines. After being loaded with biotinylated protein, the sensors 
were moved into wells containing only binding buffer (step 1). Next, the sensors 
were moved into wells containing 50 μM ezrin FERM+tCC (step 2), causing an 
increase in the optical response due to the ezrin binding. The sensors  were then 
transferred into wells containing a fixed concentration of ezrin with a serial dilution 
of either non-biotinylated H6Avi-Fas (bottom panel) or un-tagged Fas-DD+CTD (top 
panel) (step 3). The final step was to dissociate ezrin from the sensors by moving the 
sensors into wells containing only buffer (step 4).  





Figure 5.19 Biolayer interferometry competition assay, competing ezrin off the biosensor using 
H6Avi-tagged Fas-DD+CTD 
BLI was used to see whether H6Avi-tagged proteins could compete ezrin-FERM+tCC off the streptavidin sensors 
it was already bound to. There were five steps to the experiment, loading the sensor with biotinylated Fas (not 
shown),  equilibrating  a  baseline  with  the  loaded  sensor  (1),  associating  ezrin  to  the  Fas  on  the  sensor  (2), 
competition  (3)  in  which  the  sensor  was  moved  into  a  well  containing  the  Avi  or  untagged  protein  and 
dissociation (4) where the sensor was moved into a well containing buffer to dissociate the remaining ezrin from 
the sensor. These steps are separated by the dashed yellow lines. The top panel is the time response data for 
untagged Fas being used to compete ezrin from the sensors. The bottom panel shows the time response data when 
H6Avi-tagged  Fas  was  used  to  compete  ezrin  form  the  sensor.  Each  competition  was  carried  out  at  four 
concentrations, 200µM (blue line), 50 µM (red line), 12.5µM (green line) and a buffer blank (purple line).  
 




Figure 5.20 Biolayer interferometry competition assay, competing ezrin off the biosensor using 
H6Avi-tagged PIDD 
BLI was used to see whether H6Avi-tagged PIDD could compete ezrin FERM+tCC off the streptavidin 
sensors  it  was  already  bound  to.  There  were  five  steps  to  the  experiment,  loading  the  sensor  with 
biotinylated Fas (not shown), equilibrating a baseline with the loaded sensor (1), associating ezrin to the 
PIDD on the sensor (2), competition (3) in which the sensor was moved into a well containing the avi or 
untagged  protein  and  dissociation  (4)  where  the  sensor  was  moved  into  a  well  containing  buffer  to 
dissociate the remaining ezrin from the sensor. These steps are  separated by the dashed yellow lines. The 
top panel is the time response data for untagged PIDD being used to compete ezrin from the sensors. The 
bottom panel shows the time response data when H6Avi-tagged PIDD was used to compete ezrin from the 
sensor. Each competition was carried out at four concentrations, 200µM (blue line), 50 µM (red line), 
25µM  (orange line) 12.5µM (green line) and a buffer blank (purple line).  
 
   258 
The time response data show that as the concentration of H6Avi-Fas in the well 
increases,  ezrin  detaches  from  sensor,  presumably  because  the  free  H6Avi  tag 
outcompetes  the  immobilised  H6Avi*  tag  for  ezrin  binding.  Only  the  highest 
concentration of un-tagged Fas seems to be able to show some competition but not to 
the same extent as the H6Avi-Fas protein. The competition assay was also repeated 
with immobilised H6Avi*-Fas-DD+CTD using H6Avi-PIDD and un-tagged PIDD to 
compete. This assay showed the same behaviour between the H6Avi tagged protein 
competing and removing ezrin from the sensor and the un-tagged protein not being 
able  to  do  so,  shown  in  Figure  5.20.  This  competition  assay  confirms  that  the 
previous BLI results are not detecting ezrin interacting with Fas, but ezrin interacting 
with the H6Avi tag. 
5.7.2  A  variety  of  proteins  with  H6Avi  tags  perturbed  the 
2H




To verify whether the H6Avi interaction with ezrin could be monitored using other 
techniques, a number of NMR titration end points were collected for 
2H
15N labelled 
ezrin mixed with non-isotope labelled proteins with and without H6Avi tags. 
The ezrin FERM construct is 35 kDa and non-deuterated samples show a 
1H/
15N-
HSQC spectrum of very poor quality (shown in appendix), most probably because of 
signal broadening due to slow tumbling. To enable suitable visualisation of ezrin 
FERM by NMR, the construct was expressed in 
2H/
15N labelled minimal medium as 
described  in  Section  2.5.3.  Following  expression  in 
2H2O-labelled  medium, 
purification was carried out in the same manner as for the other H6-tagged proteins 
as described in Section 2.5.3. 
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Figure 5.21 H6Avi-tagged proteins perturb the 
1H/
15N-HSQC spectrum of 
2H/
15N ezrin-FERM 
whereas non H6Avi-tagged proteins do not 
1H/
15N-HSQC spectra of 200µM 
2H/
15N ezrin-FERM mixed with 400µM of binding partners stated upon each 
spectra. The left side of the figure shows ezrin spectra mixed with untagged proteins, whereas the right side of 
the figure shows ezrin spectra when mixed with tagged proteins. A, 200µM 
2H/
15N ezrin-FERM; B, 200 µM 
2H/
15N  ezrin-FERM  with  400µM  Fas-DD+CTD;  C,  200µM 
2H/
15N  ezrin-FERM  with  400µM  H6Avi-Fas-
DD+CTD; D, 200µM 
2H/
15N ezrin-FERM with 400µM Fas-JM+DD+CTD; E, 200µM 
2H/
15N ezrin-FERM with 
400µM H6Avi-Fas-JM+DD+CTD; F, 200µM 
2H/
15N ezrin-FERM with H6Avi-D;1G, 200µM 
2H/
15N ezrin-FERM 
with 400µM Rab-GFP; H, 200µM 
2H/
15N ezrin-FERM with 400µM H6-GFP. All of the spectra were recorded at 
25
oC at 800MHz. 






Figure 5.21 (continued) H6Avi-tagged proteins perturb the 
1H/
15N-HSQC spectrum of 
2H/
15N 
ezrin-FERM whereas non H6Avi-tagged proteins do not 
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Each sample contained 200 µM 
2H
15N ezrin FERM and 400 µM of the test protein. 
The samples were prepared by co-concentrating both proteins to 500 µl. 
1H/
15N-
HSQC spectra were  collected at 25 
oC  at 800 MHz as described in Section 2.9. 
Figure 5.21 shows the 
1H/
15N-HSQC spectrum of 200 µM 
2H
15N ezrin on its own 
(panel A) as well as mixed with a variety of proteins with and without the H6Avi tag 
(panels B-H). Panel A shows a well dispersed spectrum consistent with globular 
structure, as expected from the crystal structure. The overall trend observed is that, 
irrespective of the nature of the protein, the presence of the H6Avi tag broadens the 
cross peaks resulting in an overall reduction in the intensity of the spectrum (panels 
C, E and F).  
These  effects  are  indicative  of  an  interaction  occurring  in  a  millisecond,  slow, 
timescale  (kex  <<  ∆υ).  The 
1H/
15N-HSQC  spectra  of  ezrin  in  the  presence  of 
untagged proteins (panels B and D) also show broadening, but to a lesser extent. 
Although the longer H6Avi-Fas-JM+DD+CTD (panel D) construct appears to show 
more line broadening than the shorter H6Avi-Fas-DD+CTD construct (panel B), the 
unrelated  protein  H6Avi-DI  (DI  is  the  N-terminal  sushi  domain  of  beta-2 
glycoprotein 1, kindly provided by Lucy Murfitt) affects the spectrum to a similar 
extent, so the line-broadening effect cannot be solely attributed to the presence of 
Fas (Figure 5.21F). 
In an effort to find a possible biological significance of ezrin biding the H6Avi tag a 
BLAST search was carried out, which highlighted that the Avi peptide, the BirA 
recognition sequence  LNDIFEAQKIEWHE, shares 50% identity with  a fragment 
(LNDIFEDKQRRTE) of the protein Rab11fip2 (Rab11 family-interacting protein 2; 
UniProt:  Q7L804),  a  protein  involved  in  receptor-mediated  endocytosis  and 
membrane trafficking of recycling endosomes. A construct of GFP containing the 
Rab11bp (residues 105-118) fragment instead of the Avi tag was generated by site-
directed  mutagenesis  of  an  H6Avi-Green  Fluorescent  Protein  (GFP)  construct 
available in our laboratory. However when titrated into ezrin, the presence of this 
construct had no effect on the ezrin spectrum (Figure 5.21G) suggesting that it did 
not interact with ezrin. To test for the effect of the hexa histidine tag, 
2H
15N ezrin 
was  mixed  with  H6-GFP  as  shown  in  Figure  5.21  (panel  H).  Surprisingly,  this 
construct perturbed the ezrin NMR spectrum more than the constructs containing the 
H6Avi tags, showing a larger number of peaks broadening to the noise level and 262 
essentially disappearing. This result led us to conclude that the interaction between 
ezrin and the H6Avi tag would be restricted to the hexa histidine purification tag. 
To quantify these observations (and for a more visual representation of the result), 
the decrease in peak intensity was assessed for each of the end point spectra (Figure 
5.21 panels B-H) relative to the intensity of the starting spectrum (Figure 5.21 panel 
A). A set of 60 well-resolved peaks was selected and the decrease in intensity in the 
spectra recorded for these peaks in each of the spectra is shown in Figure 5.21. This 
change  in  peak  intensity  is  represented  in  Figure  5.22  as  a  bar  chart  illustrating 
which binding partner had induced the greatest relative decrease in peak intensity 
compared to the starting spectra. The bar chart representation highlights the trends 
described  above,  showing  that  H6-GFP  and  H6Avi-Fas-JM+DD+CTD  had  the 
greatest  effect  on  the  spectrum  with  90%  and  80%  loss  of  peak  intensity, 
respectively.  
5.7.3 The H6Avi tag ezrin interaction is also observed by GST pull down assays  
In order to verify that the results obtained by NMR, GST-tagged ezrin was used as 
bait and the same protein constructs used in the NMR experiments were used as prey 
in  a  GST  pull  down  assay  (Figure  5.23).  The  results  of  this  pull  down  were  in 
agreement  with  the  NMR  results.  The  most  intense  band,  suggesting  stronger 
binding, was that of H6Avi-Fas-JM+DD+CTD, followed by H6-GFP.  
Intriguingly,  the  pull  down  assay  also  shows  GST  tagged  ezrin  interacting  with 
untagged  Fas-JM+DD+CTD,  in  agreement  with  the 
1H/
15N  HSQC  spectrum  in 
Figure 5.21 (panel E). Although more controls are needed at this point, these two 
results still suggest that ezrin and Fas were capable of binding, but that, until this 
moment, this interaction was being masked by that of ezrin and the hexa histidine 
tag. Therefore, I set out to test this hypothesis by NMR using only untagged proteins 





Figure 5.22 Percentage decrease in peak height across the spectra shown in 5.15 when 
2H/
15N 
ezrin-FERM is mixed with alternatively tagged proteins. 
Bar chart showing the decrease in percentage of peak height (for a selection of 60 well resolved peaks) for each 
of the binding partners added to 
2H/
15N ezrin-FERM and recorded by 
1H/
15N HSQC shown in Figure 5.15. 








Figure 5.23 Ezrin: H6Avi-tagged protein interaction can also be observed by GST-ezrin pull 
down  
To verify the effects seen by 
1H/
15N HSQC, the same protein combinations were used in a GST-pull down. GST-
ezrin-FERM+tCC  was  immobilised  upon  glutathione beads  and  incubated  overnight  with between  5µM  and 
50µM of possible ezrin binding partners (all pre-purified, lanes labelled above the gel). Following three washes 
beads were denatured in SDS-loading buffer and visualised upon a SDS-PAGE gel with comassie staining. Pull 
down was only observed for the H6Avi-tagged constructs and the GFP containing constructs. The buffer used to 
equilibrate and wash the beads was 30mM Tris-HCl, 150mM NaCl, 10% glycerol, 1% triton, 1mM EDTA, pH 
7.5. Proteins pulled down by GST-ezrin are highlighted with coloured boxes. The colours reflect the colours used 
for each construct in the NMR spectra in Figure 5.21. 
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 5.8 A weak and unspecific interaction between intracellular Fas and ezrin is 
observed by NMR 
5.8.1 The presence of ezrin FERM+tCC broadens the signals in the 
1H/
15N HSQC 
spectrum of all constructs of intracellular Fas 
Signal  broadening  due  to  the  presence  of  untagged  Fas  in  the 
1H/
15N  HSQC 
spectrum of 
2H
15N ezrin FERM was observed during the investigation of the H6Avi 
tag: ezrin interaction (Figure 5.21 panels D and F). To investigate this further, I 
performed the inverse experiment, to test the effect of unlabelled ezrin FERM+tCC 
on the 
1H/
15N HSQC spectrum of Fas. 
The four 
15N-labelled Fas intracellular domain truncation constructs were expressed 
and purified as described in Section 2.5. For each of the Fas constructs, two NMR 
samples were prepared: one with 200 µM 
15N-labelled Fas only, and the second with 
200 µM 
15N-labelled Fas mixed with 300 µM ezrin FERM+tCC. Figure 5.24 shows 
the  eight 
1H/
15N-HSQC  spectra  corresponding  to  four  different  Fas  intracellular 
domain constructs (panels A, C, E and G) on their own and the same proteins mixed 
with ezrin FERM+tCC (panels B, D, F and H). 
All untagged Fas intracellular domain constructs show a reduction in the intensity of 
the peaks across the spectrum when mixed with untagged ezrin. The majority of the 
cross peaks were broadened to the noise level and effectively disappeared. The only 
remaining cross peaks correspond to the flexible N- and C- termini of the molecule, 
based on known assignments and the characteristic chemical shifts of Fas-DD. The 
most  straightforward  interpretation  of  this  behaviour  is  that  untagged  ezrin  does 
interact  with  untagged  Fas,  forming  a  protein  complex  which  tumbles  slowly  in 
solution leading to an overall increase in the line widths of all peaks except those 
corresponding to atoms located in regions that retain high internal mobility in the 
complex. However, the fact that the effect of ezrin is observed irrespective of the 
precise nature of the Fas construct used is in disagreement with the observations by 
Ruan and coworkers, who mapped the ezrin binding site to the so-called membrane 
proximal domain in the juxtamembrane region
118. Although there is a possibility that 
the interaction is happening elsewhere within the intracellular region of Fas, given 
our previous experience with the promiscuous binding tendency’s for ezrin FERM 
proteins, leads us to interpret this result as a non-specific binding event.  266 
5.8.2 ICAM2 peptide counteracts the effect of ezrin FERM+tCC on the 
1H/
15N 
HSQC of Fas DD+CTD 
To test the hypothesis that ezrin interaction with Fas was non-specific, we designed a 
competition experiment using a peptide we hypothesised will bind ezrin with high 
affinity. Some of the interactions of the FERM domain (residues 1-297) of ERM 
proteins are well characterised, as a number of FERM domains have successfully co-
crystallised  with  a  variety  of  binding  partners.  For  example,  the  radixin  FERM 
domain  has  been  crystallised  with  peptides  from  NHERF2,  ICAM2  and 
CD44,
111,112,235 each showing  a strong binding affinity. Specifically, a 26 residue 
peptide  of  ICAM2  (QHLRQQRMGTYGVRAAWRRLPQAFRP)  has  been 
previously shown to interact with the radixin FERM domain (PDB: 1J19) with a 
dissociation constant of 3.3 µM
235. As the level of sequence identity between radixin 
and ezrin in the region of the interaction with the ICAM2 peptide is very high, we 
hypothesised that the interaction would also be observed with ezrin. 
To test the interaction between the ezrin FERM and the ICAM2 peptide, a NMR 
titration was carried out in which two samples were made, one containing 100 µM 
2H
15N ezrin (sample A) and one containing 100 µM 
2H
15N ezrin and 100 µM of the 
ICAM2 peptide (sample B). To obtain the intermediate points of the titration without 
dilution, samples of intermediate concentrations were prepared by simultaneously 
swapping equivalent volumes between sample A and sample B. This was followed 
by the recording of a 
1H/
15N HSQC spectrum for each of the sample tubes. As the 
concentration of the  ICAM2 peptide was increased, signals form the cross peaks 
became broader, resulting in an overall reduction in intensity of the spectrum, which 
is indicative of an interaction occurring. This is shown in the appendix. 
Once the interaction between ezrin and the ICAM2 peptide was confirmed, three 
NMR samples were prepared. One contained 135 µM 
15N Fas-DD+CTD (sample C). 
The second and third samples were prepared in the same way: two aliquots of 135 
µM Fas-DD+CTD and 270 µM ezrin FERM+tCC were concentrated to 400 µl by 
centrifugal concentration. To one sample 100 µl of buffer were added (sample D) 
and to the other ICAM2 peptide and buffer were added to make the final volume 500 
µl with 270 µM of peptide (sample E).
 1H/
15N-HSQC experiments were recorded at 
800 MHz and 25 
oC for each sample, illustrated in Figure 5.25. As before, sample D, 267 
containing only unlabelled ezrin showed a decrease in the intensity of the majority of 
the folded peaks in the spectrum in the presence of Fas-DD+CTD only. However, in 
sample  E  with  Fas,  ezrin  and  ICAM2  peptide  a  number  of  Fas  cross-peaks  are 
recovered  in  the  spectrum.  These  features  are  highlighted  by  residue  type  and 
number in Figure 5.25C. The recovery of peaks suggests that the binding observed 
between Fas and ezrin was not a strong interaction and that a significant fraction of 
Fas was being displaced by the small peptide at equimolar concentration. When the 
residues whose peaks are recovered are plotted on the Fas structure, these residues 
do  not  cluster  to  suggest  a  binding  site  (data  not  shown)  which  could  also  be 
interpreted as arising from non-specific interactions with ezrin. 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.8.3 Addition of ezrin does not perturb the 
13CH3-ILV-labelled Fas-DD methyl-
TROSY spectrum  
The addition of unlabelled ezrin to 
15N Fas results in the decrease in intensity of 
cross peaks throughout the 
1H/
15N-HSQC spectrum. Irrespective of the nature of this 
interaction, this behaviour could be indicative of the formation of a high molecular 
weight complex. Even a 1:1 complex of aproximately 47 kDa might be invisible in a 
1H/
15N-HQSC experiment due to signal broadening as a result of slow tumbling. The 
combination of novel NMR experiments such as TROSY (Transverse Relaxation- 
Optimised Spectroscopy) pulse sequences combined with specific labelling of atoms 
within a construct are technologies which allow information about high molecular 
weight macromolecular complexes to be elucidated by NMR
236. Previous work in 
our laboratory has used TROSY-based experiments to analyse the formation of the 
Fas:FADD death domain complex
123. This was achieved using a Fas death domain 
construct  which  had  been  specifically 
13C-labelled  on  the  methyl  groups  of  the 
isoleucine, leucine and valine (ILV) residues in an otherwise uniformly deuterated 
background.  As  the 
13CH3  ILV-labelling  and  methyl-TROSY  experiments  have 
already been optimised for the Fas system in our lab, probing the possible Fas:ezrin 
interaction in this way was relatively straightforward.  
Dr Diego Esposito kindly provided some ILV-labelled Fas-DD to be used for this 
work. To prepare samples for this experiment, the ILV-labelled Fas and unlabelled 
ezrin were buffer exchanged into ezrin NMR buffer prepared in 99% 
2H2O, as the 
experiment requires a fully deuterated background for optimal performance. Two 
samples were prepared: one containing 125 µM ILV-Fas-DD (sample A) and one 
containing 125 µM ILV-Fas-DD with 125 µM unlabelled ezrin-FERM (sample B). 
Methyl-TROSY  spectra  were  recorded  for  these  two  samples,  shown  in  Figure 
5.26A and B. As can be seen, there was no change in the spectrum containing both 
ezrin and Fas. Due to no difference being observed, sample B was modified by the 
addition of more unlabelled ezrin and re-concentrated to 500 µl so that the sample 
then  contained  450  µM  ezrin,  shown  in  Figure  5.26C.  Even  at  the  higher 
concentration of ezrin, it had no effect upon the spectrum suggesting that no higher 







































































































































































































































































































































































































































































































































































































5.8.4 Addition of Fas-JM+DD+CTD does not perturb the 
1H/




Section 5.7.2 shows the presence of Fas constructs has a moderate effect on the 
15N 
HSQC spectrum of 
2H
15N ezrin. This experiment was revisited with the addition of 
twice  as  much  unlabelled  Fas  to  the 
2H
15N  ezrin  in  an  attempt  to  encourage  a 
stronger effect on the spectrum compared to that observed in Section 5.7.2. 
As in the previous NMR titration end point experiments, two samples were prepared, 
one containing 200 µM 
2H
15N ezrin (sample A) and one containing 200 µM 
2H
15N 
ezrin mixed with 800 µM Fas-JM+DD+CTD (sample B). A 
1H/
15N-HSQC spectrum 
was collected for each sample at 25 
oC at a field strength of 800 MHz. The resulting 
spectra are shown in Figure 5.27. Unfortunately, in this case, the effect was minimal 
compared to that observed previously. It could be argued that these results are not 
comparable, as in this experiment the signal to noise ratio in not as good as the one 
obtained in Figure 5.21, this is possibly due to less efficient deuterium exchange 
between the solvent and the protein during expression in E.coli. 
5.9 Different pH or presence of other proteins does not have the same effect as 
ezrin on the 
1H/
15N-HSQC of Fas 
The  results  of  the  previous  section  suggest  that  the  effect  of  ezrin  on  the  NMR 
spectra of Fas is reproducible, but weak and non-specific and that the intensity of 
such effect is variable. A couple of experiments were devised to test whether this 
effect could be due to a failure of the experimental design or a result of molecular 
crowding at high protein concentration and/or a viscosity effect. 
5.9.1 Increasing the sample pH does not fully re-create the ezrin effect on the 15N 
Fas 1H/15N-HSQC 
Samples in solution NMR spectra of proteins are particularly sensitive to changes in 
the sample buffer, particularly pH. For example when working on a new protein 
construct, some of the parameters to assay for an optimal NMR spectrum (in terms 
of line widths, peak dispersion and resolution) is the pH of the sample, temperature 
and salt concentration. It could have been possible that slight variations in the pH of 
ezrin samples might have a strong effect on the 
15N Fas 
1H/
15N-HSQC spectrum.  273 
 
 
Figure  5.27   
1H/
15N-HSQC  spectra  of 
2H/
15N  ezrin-FERM  mixed  with  800µM  Fas-
JM+DD+CTD. 
As no effect upon the ezrin spectra had been observed with the addition of double the concentration of Fas, four 
times the concentration of Fas 194-335 was added to 
2H/
15N ezrin. A, 
1H/





15N-HSQC spectrum of 200µM 
2H/
15N ezrin-FERM with 800µM Fas-JM+DD+CTD. All of 
the spectra were recorded at 25
oC at 800MHz.  





Figure 5.28 Superimposed 
1H/
15N HSQC spectra of Fas-DD+CTD at pH7 and pH8 
1H/
15N HSQC spectrum of 200µM 
15N Fas-DD+CTD at pH7 is shown in black and the
1H/
15N HSQC spectrum of 
200µM 
15N Fas-DD+CTD at  pH8 is overlaid in red. 
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To test whether the variation of the pH of the sample could induce the same effects 
as ezrin addition upon the 
15N Fas HSQC spectrum, two 
1H/
15N-HSQC datasets were 
recorded for the same sample. Initially, a 
1H/
15N-HSQC spectrum of 200 μM Fas-
DD+CTD in ezrin NMR buffer at pH 7 was recorded, shown in black contours in 
Figure 5.28. This sample was then dialysed into ezrin NMR buffer  at pH 8 and 
another 
1H/
15N-HSQC spectrum was recorded, overlaid in red contours in Figure 
5.28. When comparing these two NMR spectra at different pH it is notable that some 
peaks are not present in the pH 8 spectrum compared to the pH 7 spectrum. However 
these effects upon the spectrum are quite minor compared to the effect when ezrin 
was added. The effect of pH variation cannot explain the effects seen for the 
1H/
15N-
HSQC spectrum of Fas after ezrin addition.  
 
5.9.2 Addition of high molecular weight proteins does not fully re-create the ezrin 




In general one might expect that the 
1H/
15N-HQSC spectrum of a protein is sensitive 
to the viscosity of a sample. High viscosity slows the tumbling time of the observed 
protein, which would translate to broadening of the signals. Adding ezrin did not 
cause  any  effect  on  the  methyl-TROSY  spectrum  of 
13CH3  ILV-labelled  Fas, 
suggesting that there was no complex formation, but the addition of ezrin could have 
caused  an  increase  in  the  viscosity  and/or  crowding  of  the  samples  observed  by 
1H/
15N-HSQC experiments, therefore perturbing the spectra of interactions assayed 
in  this  manner.  To  test  for  this  effect,  two  NMR  samples  were  prepared,  one 
containing 200 µM 
15N Fas-DD+CTD and one which contained 200 µM 
15N Fas-
DD+CTD and 400 µM bovine serum albumin (BSA). The two 
1H/
15N-HSQC spectra 
are shown overlaid in Figure 5.29 with an equivalent spectrum which was recorded 
for a sample containing Fas-DD+CTD and ezrin FERM+tCC. As can be seen in 
Figure 5.29, a number of the peaks which are not present in the ezrin spectrum are 
also  not  present  in  the  spectrum  containing  BSA,  however  the  effect  is  not  as 
extensive as it is with ezrin. Therefore the addition of a large protein to 
15N Fas does 
not fully explain the changes induced in the spectrum by the presence of ezrin. 




Figure 5.29 Superimposed 1H/15N HSQC spectra of 200µM 15N Fas-DD+CTD, 200µM 15N Fas-
DD+CTD and 400µM ezrin-FERM+tCC and 200µM 15N Fas-DD+CTD and 400µM BSA 
To see whether the effects of ezrin upon the Fas 
1H/
15N HSQC could be due to the addition of a larger protein to 
the sample, thus changing the viscosity and the environment of the protein rather than showing an interaction, 
400µM BSA was added to 200µM 
15N Fas 202-335.  
200µM 
15N  Fas-DD+CTD  spectrum  in  red,  with  200µM 
15N  Fas-DD+CTD,  200µM 
15N  Fas-DD+CTD  and 
400µM BSA spectrum overlaid in green and 400µM ezrin-FERM+tCC overlaid in black. All spectra are shown at 
a low contour level at which you recover the majority of the Fas HSQC spectrum when ezrin is present. The 
addition of BSA to the sample alters the spectrum in a similar manner to the addition of ezrin does, however not 
as many peaks disappear. 
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5.10 Discussion 
An interaction between Fas and ezrin has been highly documented in the literature 
with conflicting opinions of its involvement in the positive or negative regulation of 
apoptosis. The interaction has mainly been observed in vivo by co-localisation and in 
vitro by co-immunoprecipitation
114 or by using GST tagged recombinant proteins as 
bait  and  mammalian  cell  lysates  as  prey
117,118.  GST  pull  downs  using  only 
recombinant proteins have been reported by two different groups. In both cases, the 
construct of Fas was roughly equivalent to Fas-JM+DD+CTD, but while Kuo and 
coworkers  used  full-length  ezrin,  Lozupone  et  al.  (2004)  used  a  variety  of  ezrin 
constructs with the  aim of mapping the  Fas binding site. They concluded that it 
consisted of a nineteen-amino acid region of the ezrin FERM domain (residues 149-
168).  However  no  structural,  thermodynamic  or  kinetic  binding  data  have  been 
published regarding this interaction. 
The first step towards  attempting to characterise the Fas:ezrin interaction was to 
express and purify truncations of the intracellular region of Fas as well as the ezrin 
FERM domain and the coiled coil region. Fas constructs were loosely based around 
those used previously within the laboratory in the work published by Esposito et al. 
(2010). The Fas protein constructs contained a K263A mutation which increases the 
solubility  and  stability  of  the  constructs.  The  ezrin  FERM  domain  construct 
consisting of residues 1-362 was based on the longest construct used by Lozupone 
and  collaborators.  The  ezrin  FERM  domain  has  been  highly  characterised  and  a 
crystal structure has been solved
97, therefore  expression and purification was not 
expected  or  observed  to  be  problematic.  The  analysis  of  the  analytical  SEC 
chromatograms of both proteins at concentrations similar to those used in the NMR 
experiments, show that both proteins exist in a monomeric state in solution, as has 
been previously reported from other biophysical investigations of these proteins
96,122. 
Within this study it was not been possible to fully recapitulate the pull-down results 
obtained by Lozupone and collaborators. Although it appeared at first glance that 
both GST-ezrin could pull down Fas and immobilised H6-GB1-Fas could pull down 
ezrin,  in  both  of  these  assays,  the  un-tagged  binding  partner  was  observed  to 
associate  with  the  beads  in  a  non-specific  manner.  The  non-specific  interaction 
observed  in  the  negative  control  could  be  caused  by  the  addition  of  high,  non-278 
physiological, concentrations of un-tagged protein resulting in non-specific binding 
to the beads. However the conditions used within the binding assays in this study and 
those  used  by  Lozupone  et  al.  are  very  similar.  It  is  possible  that  what  these 
researchers interpreted as an interaction was a result of non-specific binding. This 
possibility cannot be discarded  as the authors  failed to show the results of ezrin 
binding to the glutathione-sepharose beads in the absence of Fas. 
Likewise, Fas and ezrin were not found to co-elute from an analytical SEC column 
which suggested the corresponding dissociation  constant is too high for complex 
formation to be observable by this technique. However, the SEC results were also 
supported by analytical  ultracentrifugation measurements which can  access lower 
affinity protein protein complex formation. The SV-AUC experiments also showed 
that both Fas and ezrin were monomeric in solution and that the majority of the 
sample maintained the dissociated monomeric forms after mixing the two proteins.  
Biolayer interferometry (BLI) is an optical analytical technique which offers a real 
time binding assay in which you can detect the build-up of a protein complex on the 
sensor  by  analysing  the  interference  pattern  of  white  light  with  an  internal 
reference
231.  Initial  BLI  experiments  were  very  encouraging,  suggesting  that  the 
dissociation constant between Fas and ezrin was between 70 µM and 90 µM. The 
first doubts about this conclusion were cast with the realisation that similar binding 
constants were obtained with or without the juxtamembrane region of Fas, which has 
previously been reported by Ruan et al. (2008) to be crucial for binding. In an effort 
to map the ezrin binding site, BLI experiments were also conducted with six mutants 
of Fas with conservative point mutations that spanned the solvent exposed surface of 
the death domain. Derived dissociation constants for the mutants were also between 
60 µM and 90 µM, suggesting that the interaction did not map to the Fas death 
domain. To test for binding to the purification/biotinylation tag (H6Avi), which was 
common to all constructs, a variety of H6-Avi tagged proteins unrelated to Fas were 
also tested and they all interacted with ezrin, adding further support to the idea that 
ezrin was recognising the H6Avi region of the constructs. Ezrin binding to the H6Avi 
tag was further investigated by a number of NMR titration experiments and by a 
GST-pull down assay of the corresponding proteins (Figures 5.21 and 5.23). The 
results of these assays also supported the hypothesis that ezrin recognises the H6Avi 
tag. Because the same effect on the 
1H/
15N-HSQC spectrum of 
2H
15N ezrin occurred 279 
with H6-GFP, the conclusion is that ezrin is able to bind the hexa histidine tag alone. 
The possibility that it also binds some region of GFP cannot be excluded but it was 
decided not to pursue this avenue any further. 
The fact that ezrin may be able to recognise a variety of targets with different levels 
of affinity as well as in a non-specific manner may be a feature of the FERM domain 
family binding, as their role is to bind a wide variety of proteins in the membrane to 
actin.  Even  the  well-documented  FERM  binding  ligands  of  ICAM2,  CD44, 
NHERF2 and EBP50 do not share a common binding motif.
 Results obtained so far 
did  not  exclude  the  possibility  that  ezrin  and  Fas  were  interacting  but  that  this 
interaction was masked by the binding to the H6Avi tag, so that further experiments 
would  have  to  be  done  with  fully  untagged  proteins  to  prevent  further  non-
physiological interference. 
 
NMR  is  a  powerful  technique  to  observe  protein-protein  interactions  in  solution 
because, in principle, it can permit analysis of interactions at the residue level. The 
requirement for high protein concentrations to observe sufficient signal enables the 
study of weak binding events. 
1H/
15N-HSQC experiments recorded with 
15N-labelled 
Fas in the presence or absence of non-isotopically labelled ezrin initially appeared to 
indicate that an interaction was taking place, as addition of ezrin caused broadening 
of the Fas signals consistent with the formation of a high molecular weight complex. 
Because NMR cross peaks corresponding to the structured death domain were also 
affected, this putative interaction did not seem to be limited to the MPD of Fas. 
Unfortunately, the inverse NMR experiment using 
2H
15N ezrin and non-isotopically 
labelled  Fas  was  not  successful  as  the  spectrum  remained  unperturbed  on  the 
addition of Fas. 
So far, I could not exclude the possibility that a Fas-ezrin interaction was occurring 
but  was  not  being  detected  using  the  HSQC  experiment  due  to  the  size  of  the 
complex  formed.  This  was  addressed  by  recording  a  methyl-TROSY  experiment 
with 
13CH3 ILV-labelled Fas and non-labelled ezrin. The advantage of collecting a 
methyl-TROSY  spectrum  over  a 
1H/
15N  spectrum  is  that  the  methyl-TROSY 
experiment is less sensitive to the tumbling time of the molecule; therefore if a large 
complex is formed which tumbles slowly, an interaction between the two interaction 
partners  would  still  be  observable.  The  resulting  spectra  (shown  in  Figure  5.26) 280 
showed  no  indication  of  a  decrease  in  cross  peak  intensity  or  chemical  shift 
perturbation  allowing  us  to  conclude  that  in  our  experimental  setting  no  high 
molecular weight complex was being formed between Fas and ezrin. In light of these 
results, sample pH and the addition of BSA to increase viscosity were explored as 
possible  causative  agents  of  the  signal  broadening  of  the 
15N-Fas  signals  in  the 
1H/
15N-HSQC, but this did not seem to be the case. 
In summary, exhaustive exploration of a possible direct binding interaction between 
a variety of intracellular Fas constructs and the FERM domain of ezrin has revealed 
that  there  is  no  strong  evidence  for  an  interaction  occurring  in  these  conditions. 
Instead, ezrin has shown promiscuous interactions with a number of different solid 
supports used for pull down assays as well as the H6Avi tag, most probably the hexa 
histidine  region.  These  results  have  led  us  to  the  conclusion  that  the  Fas,  ezrin 
interaction that has been observed by  co-localisation and  co-immunoprecipitation 
experiments
114 cannot be reliably reproduced in vitro using recombinant proteins. It 
is essentially impossible to reconcile my findings with all reports in the literature. 
However it is possible that productive Fas ezrin interaction of the type claimed by 
multiple research groups for in-cell type experiments may require an element that my 
experimental approach could not straightforwardly take into account. Such as  (a) the 
requirement of other regions of ezrin besides the FERM domain; (b) the involvement 
of  a  third  interaction  partner  and/or;  (c)  the  requirement  of  a  post  translational 
modification of Fas. It has previously been reported that Fas is palmitoylated prior to 
the binding of ezrin
25. It is possible that this lipid modification upon Fas could be the 
missing aspect within this interaction study. 
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6.1.1 Palmitoylation functions as a switch to modulate protein association with cell 
membranes 
S-palmitoylation  is  the  addition  of  palmitate,  the  sixteen  carbon  fatty  acid,  by 
thioesterification of a cysteine residue side chain within a protein
237. More accurately 
it should be referred to as protein S-acylation, as depending on availability, other 
fatty acids can also be attached to a protein in this fashion and with similar results
238. 
Throughout this chapter acylation and palmitoylation will be used interchangeably to 
refer to palmitoylation – the covalent addition of a palmitate fatty acid to a protein 
via a cysteine residue side chain.  
Post translational palmitoylation is a reversible modification that is used as a switch-
like mechanism, much like other, better understood, post translational modifications 
such as ubiquitinylation and phosphorylation
239,47. In humans, protein palmitoylation 
is  widespread  throughout  a  number  of  cell  types,  with  more  than  1000  human 
proteins showing some evidence of palmitoylation
240, this is approximately 10% of 
the human proteome
241. The substrate for palmitoylation is the activated form of the 
palmitate fatty acid, palmitoyl-coenzyme A (CoA); the structure of both palmitate 
and  its  activated  form  are  shown  in  Figure  6.1.  In  vivo,  the  palmitoyl  group  is 
transferred from the palmitoyl-CoA to the target cysteine by  a class of enzymes 
known as palmitoyl transferases (PAT). It had been known for a long time that an 
enzyme  existed  carry  out  this  role,  but  the  first  PAT  were  not  identified  until 
2002
242,243 possibly due to their membrane association. Depalmitoylaton is catalysed 
by the protein palmitoyl thioesterases/acyl protein thioesterases (PPT/APT), which 
hydrolyse the thioester bond to generate a cysteine thiol and palmitate
244. 282 
The addition of a palmitoyl group to a protein increases its hydrophobicity which 
mainly  functions  as  a  protein  trafficking  mechanism.  Both  soluble  and  integral 
membrane proteins have been shown to be palmitoylated in vivo. Palmitoylation of a 
soluble protein targets the protein to membrane environments inside the cell
238. It 
acts as a temporary transmembrane domain, tethering the protein to the cytoplasmic 
side of the cell membrane, or to other membrane compartments such as the Golgi 
apparatus or endosomes. The consequences of adding palmitoyl groups to integral 
membrane proteins are less obvious, but it seems that palmitoylation can regulate 
recruitment of proteins to lipid rafts or to other cholesterol-rich membrane regions 
such as tetraspanin-rich microdomains
245. Driving palmitoylated proteins into lipid 
rafts  has  been  suggested  to  be  necessary  for  events  such  as  endocytosis
38  and 
massive endocytosis (MEND)
246. Palmitoylation can also alter protein conformation, 
for example by ‘tilting’ the transmembrane domain which in turn can affect the local 
shape of the membrane and/or promote the formation of protein complexes
47.  
Protein  palmitoylation  also  influences  protein:protein  interactions.  A  number  of 
studies have identified an increased affinity between both tetraspanins and integrin 
subunits  upon  palmitoylation  as  a  mode  of  regulating  their  interactions
48,247. 
Palmitoylation  of  GPCR  components  has  also  been  shown  to  maintain  receptor 
signalling. For example, palmitoylation prevents desensitisation of the β2-adrenergic 
receptor, which is involved in the production of cyclic adenosine monophosphate 
(cAMP), by maintaining subunit interaction
248. Other studies have highlighted a role 
for palmitoylation in protein signalling and ion transport into the cell
241.  
6.1.2  Protein  palmitoylation  can  take  place  both  enzymatically  and  non-
enzymatically depending on the concentration of the activated fatty acid 
There  is  not  a  specific  consensus  sequence  which  targets  specific  cysteines  for 
palmitoylation by PAT. Bizzozero et al. (2001) found that stretches of basic amino 
acids, similar to those commonly found close to the membrane, were preferentially 
palmitoylated in vitro. The same sequences that could be chemically palmitoylated in 
vitro were found to be palmitoylated in vivo, suggesting that it is not the protein 
structure that is recognised by the PAT, but the environment in which the cysteine is 
located
249. Prior to the identification of PAT a number of in vitro autoacylation/in 
vitro palmitoylation (IVP) assays were used to look into the possible mechanisms of 283 
palmitoylation.  This  section  serves  as  a  brief  review  of  both  in  vitro 
palmitoylation/autoacylation as well as some background about the PAT enzymes. 
6.1.2.1 Autoacylation only takes place at millimolar concentrations of activated fatty 
acid 
The autoacylation reaction is the spontaneous addition of a palmitoyl group to a 
cysteine within a protein or a peptide when incubated with the activated form of the 
acid: palmitoyl-CoA
49. It has been shown to be an effective method to palmitoylate 
both  short  peptides  and  proteins  in  vitro.  It  was  primarily  used  to  study 
palmitoylation prior to the identification of the PAT enzymes, both to elucidate the 
mechanism of the reaction and to identify palmitoylation sites within proteins. 
The first autoacylation reaction was carried out by Bizzozero and colleagues in 1987. 
In this experiment they observed that a peptide corresponding to a region of myelin 
proteolipid  protein  was  acylated  on  the  correct  cysteine  when  incubated  with 
palmitoyl-CoA.  They  hypothesised  that  the  mechanism  with  which  the  reaction 
occurred by could be physiological and therefore an enzyme may not be necessary 
for  the  reaction  to  occur
250.  Building  upon  this,  a  number  of  different  groups 
successfully  used  IVP  on  peptides  corresponding  to  palmitoylated  regions  of 
proteins, furthering debate over the need for an enzyme for palmitoylation to occur at 
all
136,249. Interestingly, a number of these peptides could only be palmitoylated when 
they had been previously lipid modified with a myristoyl group
136,250–252. IVP was 
also used to develop a fluorescence-based assay to identify palmitoylated peptides in 
vitro
252 as well as a method to correctly acylate full proteins such as the Giα1 subunit 
of a GPCR
251 and SNAP-25
253 in vitro.  
By  using  autoacylation  reactions  on  short  peptides  corresponding  to  know 
palmitoylation sites, the basic mechanism of palmitoylation was elucidated. There is 
limited sequence similarity between the locations that proteins are palmitoylated. 
Bizzozero and colleagues
254 used the  IVP assay to identify the specificity of the 
amino acids surrounding the palmitoylation site and the role which this would play 
within the process of palmitoylation. They identified that in close proximity to or 
surrounding the cysteine there were always a number of basic amino acids, it was 
unclear  whether  these  were  the  same  basic  residues  usually  observed  in  near 
proximity to the cell membrane. The sulfhydryl group of a free cysteine has a pKa of 284 
7.2-7.4 rendering it unable to react with palmitoyl-CoA at physiological pH. The 
presence of the basic amino acids in close proximity to the cysteine results in the 
reduction in the pKa of the thiol to around 3
254. Therefore, palmitoylation targets 
exist as thiolates in physiological conditions. The thiolate ion can then attack the 
carbonyl  of  the  thioester  between  CoA  and  the  palmitoyl  group  resulting  in  the 
formation of a new thioester bond between the cysteine of interest and the palmitoyl 
group and the release of HSCoA
49. This reaction is shown in figure 6.2, illustrated 
using IC-Fas-DD as the target protein. 
The spontaneous acylation of proteins is an unlikely mechanism of palmitoylation in 
vivo due to the presence of acyl-CoA binding protein (ACBP). This 10 kDa protein 
sequesters  activated  fatty  acids  (such  as  palmitoyl-CoA)  to  prevent  them  from 
reacting.  ACBP  has  a  strong  affinity  for  activated  fatty  acids  and  the  ability  to 
remove  them  from  the  cell  membrane.  The  presence  of  ACBP  maintains  the 
concentration of free acyl-CoA within a cell at the nanomolar concentration range, 
ACBP itself is present at micromolar range of concentrations inside cells
255,256. In the 
assays  described  above,  the  palmitoyl-CoA  was  always  present  at  an  excess 
concentration to the peptide or protein to be palmitoylated; in vivo, the autoacylation 
reaction could take days to occur and would not be a viable mechanism. Despite this, 
it  has  been  suggested  that  autoacylation  could  play  a  role  in  the  modulation  of 
mitochondrial  metabolic  enzymes,  because  there  are  no  known  PAT  in  the 
mitochondria. For example, it is known that substrate binding in methylmalonate 
semialdehyde dehydrogenase is controlled by S-acylation
239 . 
6.1.2.2 Palmitoylation is catalysed by the DHHC family of transmembrane proteins 
The first PAT, Akr1p
242 and Erf2
243 were discovered using classical genetic screens 
in yeast. By now, seven yeast and twenty three metazoan PAT have been identified 
and a sufficient number of studies on these enzymes have been reported in order to 
draw some generalisations. PAT are multipass alpha helical proteins containing four 
or six transmembrane helices. Through cell based tests of both  yeast and human 
PAT, a large number were shown to localise to the endoplasmic reticulum or the 
Golgi body, with very few locating to the plasma membrane
257. This could further 
suggest that following protein synthesis, palmitoylation can act to target the protein 






Figure 6.1 Structures of the small molecules used throughout chapter 6 
A, Palmitate/palmitic acid. B, coenzyme A. C, palmitoyl-coenzyme A 
 










































































































































































































































































































































































































































































































































































Figure 6.3 DHHC palmitoyl transferase mechanism of palmitoylation  
A, Schematic representation of a palmitoyl transferase enzyme. B, Schematic representation of the suggested 
DHHC mechanism of palmitoylation. The palmitoyltransferase enzyme (yellow) forms a thioester intermediate 
with palmitate.A target protein can bind to the pamlitoyltransferase, which then catalyses the transfer of palmitate 
onto the target protein.  
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PATs  are  characterised  by  the  presence,  in  the  cytoplasmic-facing  site  of  the 
molecule,  of a highly conserved 50-residue cysteine rich domain referred to as the 
DHHC (Asp-His-His-Cys)
258,241,237. The DHHC sequence is very hydrophobic and 
folds forming a zinc finger thought to be able to co-ordinate two Zn
2+ ions. The 
hydrophobicity of the DHHC is necessary in order to be able to exclude H2O, thus 
preventing side reactions from occurring during palmitoyl transfer
237. Three other 
conserved motifs, all facing the cytoplasm, are present in known PAT, a Thr-Thr-X-
Glu  (TTxE  motif);  a  Asp-Pro-Gly  (DPG  motif)  and  a  16-residue  motif  named 
palmitoyl  transferase  conserved  C-terminal  (PaCCT)
259.  The  human  PATs  are 
referred to by a number following the DHHC name, e.g. DHHC17. 
The  role  of  a  PAT  is  to  recognise  the  target  cysteine  on  the  protein  to  be 
palmitoylated and then to catalyse the acyl transfer
49. The mechanism of action has 
been  described  as  ‘ping  pong’  kinetics
260,  in  which  the  enzyme  first  becomes 
autoacylated by palmitoyl-CoA, and then transfers the palmitoyl group to the protein 
of interest
260 (Figure 6.3). This site of autoacylation is still unknown. 
Although  the  DHHC  domain  and  the  other  motifs  are  relatively  well  conserved 
between all known PATs, there is a high level of substrate specificity between the 
enzyme and the protein targets. This substrate specificity is conferred by regions of 
the protein distinct from the DHHC domain. N- and C- terminal extensions of the 
DHHC have been shown to contain a variety of distinct protein-protein interaction 
domains; evidence has been found to suggest that it is these domains which recruit 
the  protein  to  be  acylated.  For  example,  the  C-terminal  extension  of  DHHC3 
contains a Src homology 3 (SH3) domain
261 and in the same region of DHHC13 and 
DHHC17 ankirn repeats have been predicted
262. However, it is not just the protein 
sequence  which  modulates  the  activity  of  DHHC-PAT,  but  also  protein-protein 
interactions between different DHHCs themselves. It has been shown that DHHC2 
and  DHHC3  can  homodimerise,  affecting  the  reactivity  of  each  of  the  enzymes. 
When  dimers,  these  enzymes  are  catalytically  inactive,  suggesting  that 
oligomerisation  could  be  a  mechanism  of  self-regulation  for  DHHC  protein 
activity
263. DHHC proteins have not only been reported to self-associate, but there 
are  also  reports  that  DHHC  activity  is  modified  through  interactions  with  other 
proteins in regions which are not being palmitoylated, for example the cysteine rich 289 
domain of SNAP25 which is not palmitoylated is important for the recruitment of 
DHHC15 at the membrane, enabling palmitoylation to occur
261. 
6.1.3  Palmitoylation  is  required  for  the  activity  of  Fas  and  many  other  pro-
apoptotic proteins 
Palmitoylation has a prominent role in both intrinsic and extrinsic apoptosis. BCL-2-
associated  X  (BAX)  protein  is  recruited  to  the  membrane  of  mitochondria  by 
palmitoylation where it permeabilises the mitochondrial outer membrane and leads 
to the release of cytochrome C into the cytoplasm
264. The netrin receptor UNC5H, 
which induces apoptosis when netrin is not available, also requires palmitoylation 
and  lipid  raft  localisation  in  order  to  induce  caspase  activation  and  apoptosis
265. 
Palmitoylation is also essential for Fas ligand (FasL) activity, as the addition of a 
palmitoyl group is required for recruitment to lipid rafts prior to proteolysis
52. The 
death  receptor  DR4,  but  not  DR5  or  TNFR1,  requires  palmitoylation  for  DISC 
formation and commitment to cell death
51. 
Initiation of Fas-mediated apoptosis occurs by receptor oligomerisation and lipid raft 
recruitment followed by DISC internalisation
38. The palmitoylation of the membrane 
proximal  cysteine  (Cys199)  is  believed  to  be  the  targeting  signal  for  Fas  to  be 
directed into lipid rafts
266. Lipid raft recruitment of activated Fas has been observed 
prior to the internalisation of the DISC
50. It has been reported that Fas palmitoylation 
is a requirement for the formation of the ezrin-mediated cytoskeleton association of 
the  DISC.  Without  such  association,  internalisation  does  not  occur  reducing  the 
onset of the caspase cascade
25.  
This  chapter  documents  an  approach  to  in  vitro  palmitoylate  a  recombinant 
intracellular  Fas  construct  and  to  characterise  it  using  biophysical  and  binding 
studies. Furthermore, I present my attempts to validate the location of the palmitoyl 
group by NMR spectroscopy, site-directed mutagenesis and mass spectrometry (MS) 
techniques. The development of these techniques was in line with efforts in our lab 
to set the methodology  for studying transmembrane domains in lipid bilayers by 
solution NMR. 
Furthermore,  the  previous  chapter  detailed  comprehensive  in  vitro  studies  of  the 
interaction between Fas and ezrin, all of which did not give evidence of a specific 290 
interaction, suggesting that something could be missing in our in vitro system which 
would allow this interaction to occur. As palmitoylation is one of the first events that 
take place before receptor clustering, we hypothesised that Fas might need to be 
palmitoylated in order to interact with ezrin. 
6.2 Palmitoyl-Coenzyme A palmitoylates Fas-JM+DD+CTD on Cys 199 
6.2.1 Fas-JM-DD+CTD preparation 
Fas-JM+DD+CTD  (residues  194-335)  was  prepared  using  the  H6-GB1-Fas-JM-
DD+CTD construct introduced in Chapter 5. The construct was expressed in either 
LB or 
15N-labelled minimal medium (as described in Section 2.5), purified by IMAC 
and cleaved with TEV protease. The tag was then removed by a second IMAC step 
and a final purification step was carried out by SEC. SDS-PAGE analysis and the 
SEC chromatogram of a typical purification is shown in Figure 6.4. Table 6.1 shows 
the predicted properties of Fas-JM+DD+CTD.  
6.2.2 Palmitoyl-CoA incubation causes broadening of the 
1H/
15N-HSQC signals 
due to the formation of two products 
In vitro palmitoylation of Fas-JM+DD+CTD was initially carried out using a 
15N-
labelled protein in an attempt to track the reaction using a 
1H/
15N-HSQC experiment.  
Two NMR samples were prepared, each containing 200 µM 
15N Fas-JM+DD+CTD 
in acylation buffer (10 mM HEPES, pH 7, 1m M EDTA, 1 mM MgCl2, 10 mM 
NaCl, 130 mM KCl, 1 mM DTT) at a volume of 550 µl (containing 10% 
2H2O). 
Palmitoylation  was  initiated  in  one  of  the  samples  by  addition  of  a  final 
concentration of 1 mM palmitoyl-CoA dissolved in acylation buffer. The equivalent 
volume of acylation buffer was added to the other sample  (Section 2.8).
  1H/
15N-
HSQC spectra were collected periodically over five hours for 
15N Fas-JM+DD+CTD 
mixed with palmitoyl-CoA. By the time it took from adding the palmitoyl-CoA to 
inserting the sample in the spectrometer, the changes in the 
1H/
15N-HSQC had been 
quite dramatic, there was no further change to the spectra in subsequent time points, 
suggesting that the reaction was occurring very fast. The comparison of the 
1H/
15N-
HSQC  spectra  before  and  after  palmitoyl-CoA  addition  (Figure  6.5  A  and  B, 
respectively) reveals that addition of palmitoyl-CoA causes significant broadening of 
the cross peaks corresponding to the folded regions of the protein. 291 
 
Figure 6.4  Fas-JM+DD+CTD purification 
A, SDS-PAGE analysis of the IMAC purification of  Fas-JM+DD+CTD (residues 194-335). Wash 2 corresponds 
to the high imidazole wash. The elution was taken and TEV cleaved prior to running back over an IMAC 
column. B, SDS-PAGE analysis post TEV cleavage. C, The elution profile (monitored by UV absorbance at 
280nm) and SDS-PAGE analysis of post TEV flowthrough and washes from Superdex 75 size exclusion column. 
The red line indicates the fractions that were pooled and concentrated to be used throughout these experiments. 

























































































































































































































































































































































































































Figure 6.6 The Fas species invisible to NMR is confirmed to be palmitoylated Fas-JM+DD+CTD 
by ESI-TOF-MS 
Mass spectra of samples of NMR samples shown in Figure 6.5. A, QTOF mass spectra of unreacted 
15N Fas-
JM+DD+CTD.  B,  QTOF  mass  spectra  of 
15N  Fas-JM+DD+CTD  with  1mM  Palmitoyl  CoA.  Masses 
corresponding to the addition of a palmitoyl group or coenzyme A to Fas-JM+DD+CTD were observed. N.B. 
15N 
Fas-JM+DD+CTD shown in this spectrum yields a higher molecular weight than previously noted within this 
study. This is due to the 
15N labelling used for NMR spectroscopy. 
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This was not observed in the sample containing no palmitoyl-CoA (Figure 6.5A). 
The observed broadening of 
1H/
15N-HSQC peaks can be a result of the formation of 
a  high  molecular-weight  Fas  oligomer,  conformation  exchange  and/or  protein 
denaturation. 
To test whether the effect of adding palmitoyl CoA to Fas-JM+DD+CTD on the 
1H/
15N HSQC was the result of a specific palmitoylation event or palmitoyl-CoA 
aggregating around Fas, a third set of conditions were tested. 
1H/
15N-HSQC spectra 
were collected for 
15N-Fas-JM+DD+CTD (200 μM) samples mixed with 1 mM or 5 
mM free palmitic acid. It was expected that if aggregation was occurring it would be 
due to the lipid component. Therefore the addition of the fatty acid should control for 
this effect. The 
1H/
15N-HSQC spectra recorded for these samples looked identical to 
when no palmitoyl-CoA was present (Figure 6.5C). This suggested that the effects 
observed were specific to the addition of palmitoyl-CoA reacting with Fas and not 
just the presence of a hydrophobic group in the sample. 
The samples were left at room temperature for sixteen hours to assess the stability of 
the newly produced construct compared to an unmodified Fas-JM+DD+CTD. After 
this time, a precipitate formed in the sample containing palmitoyl-CoA but not in the 
sample  without  the  lipid  additive.  Lipid  modified  proteins  are  known  to  be  less 
soluble in aqueous conditions and require detergent or other lipid micelles to stay in 
solution.  The  acylation  buffer  used  contained  no  detergent  additives  to  increase 
solubility. Therefore, this is a separate indication that a lipid modified product is 
being generated over time. 
To confirm that palmitoylation of Fas-JM+DD+CTD had taken place, aliquots of the 
NMR  samples  were  analysed  by  ESI-QTOF  MS.  The  mass  spectra  for 
15N  Fas-
JM+DD+CTD  and 
15N  Fas-JM+DD+CTD,  which  had  been  incubated  with 
palmitoyl-CoA, are shown in Figure 6.6 and the predicted masses of the constructs 
are shown in Table 6.1. The incubation with palmitoyl-CoA resulted in the formation 
of two additional masses different from the free Fas-JM+DD+CTD. The mass of 
16702  is  consistent  with  the  addition  of  a  single  palmitoyl  group  (which  has  a 
molecular  weight  of  240)  to  Fas-JM+DD+CTD.  The  mass  of  17229  would  be 
consistent with the addition of coenzyme A (molecular weight 766.5) or the addition 
of more than one palmitoyl group to the construct; due to the presence of a second 295 
cysteine (C304) in the Fas construct, it was possible that at least one other palmitoyl 
group could be added to Fas-JM+DD+CTD. 
 As can be seen from Figure 6.6B, the 16702 peak is very weak, compared to the 
others, suggesting that the proportion of palmitoylated Fas-JM+DD+CTD was quite 
low. However, this is probably just an artefact of the sample preparation for mass 
spectrometry. Samples have to be desalted and concentrated using a ziptip - a tip 
packed with C4 resin, and there is a high probablility that being more hydrophobic, 
the palmitoylated protein binds quite strongly to the C4 tips. Another possibility is 
that  the  palmitoylated  Fas  could  be  less  soluble  than  non-palmitoylated  Fas  and 
could have precipitated prior to desalting. This way there would be less present for 
the mass spectrometry analysis. 
6.2.3  Limited  digestion  of  palmitoylated  Fas-JM+DD+CTD  does  not  enable 
mapping of the palmitoylation site due to heterogeneity 
In order to map the location and number of palmitoyl groups which had been added 
to  Fas-JM+DD+CTD  on  incubation  with  palmitoyl-CoA,  a  limited  trypsin 
proteolysis was carried out on both palmitoyl-CoA reacted and unreacted samples. In 
vitro  palmitoylation  had  to  be  repeated  using  an  unlabelled  sample  to  enable 
identification of peptide masses. The trypsin digested samples were analysed by ESI-
QTOF MS. The theoretical peptide masses of Fas-JM+DD+CTD were calculated 
using  ‘Peptidemass’  in  the  Expasy  server.  A  coverage  of  85%  of  the  Fas-
JM+DD+CTD sequence was achieved. An alignment of the peptides corresponding 
to the masses observed by MS is shown in Figure 6.7.  
Cys199 is the residue that is palmitoylated in vivo
30. Two peptides were detected for 
this region in the non-palmitoylated Fas-JM+DD+CTD (corresponding to masses of 
927.5 and 1501.7).  In the palmitoylated sample, both of these peptide  fragments 
were no longer detectable which could suggest  that there was  a palmitoyl  group 
attached to this peptide.  
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A different peptide corresponding to the region containing Cys199 was identified: 
TCRK with a molecular weight of 506, suggesting that the digestion had not gone to 
completion; an expected result given that the mass spectrum had already shown that 
there  are  at  least  three  species  in  the  sample.  Unfortunately,  all  my  attempts  to 
separate the three species using RP-HPLC had been unsuccessful (data not shown). 
The non-palmitoylated peptides may also be positively selected for during desalting 
following  limited  proteolysis  due  to  the  hydrophobic  nature  of  palmitoylated 
peptides as described in Section 6.2.2. 
To detect whether or where CoA could be reacting with Fas-JM+DD+CTD, the mass 
of CoA (677.5) was added to the mass of the peptide fragments observed in the 
control sample and the palmitoylated peptide fragments analysed for these masses. 
Three  peptide  fragments  were  identified  as  possible  peptides  with  a  CoA 
modification; these are illustrated in Figure 6.7C. These peptide fragments span a 
large proportion of the protein and do not highlight one specific location which CoA 
is reacting with.  
In the control sample (Figure 6.7A) two regions of the protein were not detected, one 
of  which  contained  the  second  possible  palmitoylation  site,  Cys304.  A  peptide 
corresponding to this region was detected in the sample which had been incubated 
with palmitoyl-CoA (Figure 6.7B), suggesting that at least part of the protein had not 
been palmitoylated on Cys304. 
6.2.4 Site-directed mutagenesis confirms palmitoylation occurs on Cys199 
Given  that  the  results  of  limited  proteolysis  of  palmitoyl-CoA  treated  Fas-
JM+DD+CTD were inconclusive, I turned to site directed mutagenesis to further 
characterise the reaction. Both Cys199 and Cys304 were mutated to serine using the 
method  described  in  Section  2.4.3.  The  cysteine  to  serine  mutation  removes  the 
reactive thiol of cysteine while maintaining the size and polar character of the amino 
acid, it is a conservative mutation that is not expected to have a significant effect on 
the 3D structure of the domain. A C199S/C304S double mutant was also generated 
to investigate whether palmitoylation could occur elsewhere in the construct. These 
mutants behave the same as the original construct during expression and purification, 
and have a very similar 
1H/
15N-HSQC spectra. Table 6.1 shows the properties of 
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Figure 6.9 QTOF mass spectra of JM-Fas-DD+TD cysteine mutants which had been incubated 
with palmitoyl-CoA 
Mass spectra of the samples shown in Figure 6.8. A, QTOF mass spectra of Fas-JM+DD+CTD C199S incubated 
with  pamitoyl-CoA.  B,  QTOF  mass  spectra  of  Fas-JM+DD+CTD  C304S  incubated  with  pamitoyl-CoA.  C, 
QTOF mass spectra of Fas-JM+DD+CTD C199S, C304S incubated with pamitoyl-CoA.  
15N Fas-JM+DD+CTD 
constructs shown in this spectrum yield a higher molecular weight than previously noted within this study, see 
Table 6.1. 300 
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16230  16432  8480 
*
15N averaged molecular weight calculated using the Scripps Mass calculator 
Three NMR samples were made in acylation buffer, each containing 200 µM of the 
cysteine mutants of Fas-JM+DD+CTD and 500 µM palmitoyl-CoA at a volume of 
550  µl  (containing  10% 
2H2O).  For  each  sample,  a 
1H/
15N-HSQC  spectrum  was 
recorded,  shown  in  Figure  6.8.  C199S  and  C199S/C304S  show  no  effect  after 
incubation with palmitoyl-CoA on the 
1H/
15N-HSQC spectrum (Figure 6.8A,C). On 
the other hand, when incubated with palmitoyl-CoA, the 
1H/
15N-HSQC spectrum of 
Fas-JM+DD+CTD  C304S  showed  the  same  behaviour  as  the  one  seen  for  the 
original construct (Figure 6.5). In both cases the spectrum showed line broadening, 
resulting in a marked decrease in intensity of the peaks corresponding to the folded 
region of the protein.  
Aliquots of these NMR samples were desalted and analysed by ESI-QTOF MS. The 
mass spectra for 
15N Fas-JM+DD+CTD cysteine mutants incubated with palmitoyl-
CoA are shown in Figure 6.9. In agreement with the 
1H/
15N-HSQC spectra, both 
samples  which  contained  a  C199S  mutation  showed  no  chemical  modifications, 
whereas in the mass spectrum for the sample containing the C304S mutation the 
main product peak observed contained a peak corresponding to the mass of 17229. 
This mass would correspond to the addition of 780Da that, as previously mentioned, 
could correspond to the addition of coenzyme-A to Fas. Its occurrence in the C304S 
mutant, and not in the C199S mutants, may suggest this is a reaction that takes place 301 
after the thioesterification of Cys199, when HS-Co-A is released, so it might involve 
the thiol group. Altogether, the effects on the 
1H/
15H-HSQC spectra and the mass 
spectra for the Fas-JM+DD+CTD cysteine mutants suggest that palmitoylation is 
occurring at the predicted site of Cys199. However, and perhaps not surprisingly, the 
palmitoylated Fas is not tractable by NMR in aqueous buffers lacking detergents. 
 
6.3 Discussion 
The  process  of  palmitoylation  is  crucial  for  a  number  of  different  pro-apoptotic 
pathways. Palmitoylation of Cys199 in the intracellular region of Fas is necessary for 
the recruitment of Fas to lipid rafts and clustering of the receptors, an event that is 
necessary for the initiation of the caspase cascade
266,25,50. This chapter documents the 
development  of  a  protocol  to  palmitoylate  Fas  in  vitro  suitable  for  biophysical 
characterisation and protein-protein interaction studies. In vitro palmitoylation takes 
place spontaneously by incubating the protein of interest with the activated form of 
palmitate, palmitoyl-CoA. Not all cysteines can be palmitoylated using this method, 
as the pKa of the side chain thiol needs to be acidic for the reaction to occur
254. 
Comparison  of  known  palmitoylation  sites  indicate  that  the  low  pKa  of 
palmitoylated  cysteines  is  due  to  the  presence  of  several  basic  residues  in  the 
vicinity, and this is the case for Fas Cys199, which is close to lysines at positions 
194, 201 and 204 and arginines at position 200 and 203. 
On  addition  of  palmitoyl-CoA,  the 
1H/
15N-HSQC  of 
15N  Fas-JM+DD+CTD 
immediately  showed  a  dramatic  change.  The  majority  of  folded  peaks  became 
significantly broader, suggesting that a much larger species had been formed. MS 
detected the addition of at least one palmitoyl group to Fas-JM+DD+CTD, but also 
the  presence  of  a  second  product  corresponding  to  the  addition  of  CoA  to  Fas-
JM+DD+CTD;  unreacted  Fas-JM+DD+CTD  was  also  detected.  The  amount  of 
palmitoylated product detected by ESI-MS probably underestimates the actual yield 
of the reaction. To enable MS analysis the sample was desalted using a tip with C4 
hydrophobic resin fixed inside (ZipTip). For ZipTip purification, the proteins are 
bound to the resin in aqueous solution and then eluted with 65% acetonitrile, 0.1% 
acetic acid. Given the hydrophobicity of palmitoylated Fas, it seems likely that these 
conditions  may  not  have  been  sufficient  to  elute  palmitoylated  protein  from  the 302 
ZipTip; more hydrophobic solvents may improve the recovery from the C4 resin or 
other methods of preparation of the sample for MS would have had to be explored. 
As a first approach to map the palmitoylation site I carried out a limited trypsin 
digestion of Fas-JM+DD+CTD incubated with and without palmitoyl-CoA. A good 
coverage of the whole protein sequence was achieved following digestion, proving 
that the palmitoyl  group was not being  added to Cys304. However, results were 
ambiguous as to whether Cys199 was being palmitoylated. Although long peptides 
corresponding  to  the  region  containing  this  cysteine  were  not  present  in  the 
palmitoylated sample, a short peptide including Cys199 was recovered. However, 
this peptide could have been derived from the unreacted Fas present in the sample. In 
order to overcome this problem, separation of palmitoylated and non palmitoylated 
Fas  by  RP-HPLC  was  briefly  explored  using  a  C18  column  and  an 
acetonitrile/0.1%TFA gradient (data not shown). The addition of the palmitoyl group 
increases the hydrophobicity of Fas, therefore the retention time of the palmitoylated 
construct in reverse phase chromatography would have been longer compared to the 
non palmitoylated protein. Unfortunately, there  was little change in the retention 
time between the two species of Fas resulting in poor separation. The components of 
the acylation buffer absorb quite strongly at 220 nm, making it difficult to identify 
the protein components in the chromatogram. Further optimisation of the conditions 
used  for  RP-HPLC  would  be  necessary  for  any  further  studies,  for  example  by 
changing the hydrophobicity of the stationary phase, the ion pairing agent and/or the 
composition of the buffers
267.  
Given  the  ambiguity  of  the  peptide  mapping  experiment,  the  limitations  of  the 
detection methods and the intriguing fact that there seem to be two reaction products, 
I decided to tackle the problem using site directed mutagenesis experiments. Three 
mutants were generated; two single mutants with each one of the cysteines mutated 
to serine and a double mutant without any cysteines. Once the thiol group is absent 
the in vitro palmitoylation reaction should not take place. When the Cys199 was 
mutated  to  Ser,  either  on  its  own  or  in  the  double  mutant,  no  changes  to  Fas-
JM+DD+CTD  were  observed  by  NMR  or  MS.  Only  the  C304S  mutant  showed 
similar behaviour as wild type Fas-JM+DD+CTD, i.e. a small peak corresponding to 
palmitoyl  Fas-JM+DD+CTD, a peak corresponding to unreacted  Fas and another 
peak corresponding to the added mass of Fas and CoA. This result suggests that only 303 
Cys199 is being modified and that the formation of a CoA-protein adduct is either 
dependent on the breakage of the thioester bond between CoA and the palmitoyl 
group or competing with the acylation reaction for the Cys199 thiol. The pKa of HS-
CoA is ~9.6, so that the expected species in solution would be the oxidised CoA-S-
S-CoA  dimer,  but  perhaps  the  presence  of  DTT  in  the  buffer  allows  for  some 
reactivity. It would be interesting to test whether this adduct can be obtained by 
incubating the protein with CoA-SH in the absence of acyl groups. This result was 
quite surprising, as the formation of a CoA-protein by-product has not been reported 
during in vitro palmitoylation reactions. Perhaps this is because in most studies in 
vitro palmitoylation has been assayed by reacting CoA with [H
3] or [
14C] palmitic 
acid before acylation and then tracking the product by scintillation or fluorography, a 
possible protein-CoA adduct would not be detectable by these methods. In 1996, 
Huth  and  coworkers  reported  the  existence  of  CoA-modified  proteins  in  the 
mitochondria,  but  there  has  not  been  any  follow-up  to  this  work
268.  To  my 
knowledge this is the first report of the detection of CoA modified proteins produced 
by in vitro palmitoylation. 
 The increase in hydrophobicity of palmitoylated Fas-JM+DD+CTD would offer an 
explanation for protein precipitation when the samples were left at room temperature 
overnight. The IVP assay used within this study (adapted from Bano et al. (1998))
136 
was carried out in aqueous solution, and although this seems to be  adequate for 
peptides, it would not be surprising that a palmitoylated protein is not able to stay in 
solution.  Reported  IVP  experiments  using  full  proteins  were  carried  out  in  the 
presence  of  detergent;  IVP  of  GPCR  Gα  subunits  was  carried  out  in  7.5  mM 
CHAPS
251,  and  in  the  case  of  SNAP-25  IVP  was  initiated  in  0.005%  Triton  X-
100
253. However, in both of these cases the palmitoylated samples were not used for 
any other assay in solution, in the case of the Gα subunit the protein was precipitated 
and assayed by scintillation and in the case of SNAP-25 it was analysed by western 
blot  and  fluorography.  Therefore  it  could  well  be  that  these  proteins  were  also 
insoluble. 
The addition of detergent before palmitoylation was briefly tested. Three detergents 
(CHAPS, n-dodecyl-β-D-maltoside (DDM) and sodium cholate) were screened at 
both 20% above and below their critical micelle concentration (CMC) to see whether 
this would affect the 
1H/
15N HSQC spectrum observed on addition of palmitoyl-CoA 304 
to 
15N  Fas-JM+DD+CTD.  Unfortunately,  the  HSQC  spectrum  of  samples  with 
detergent did not change at all after addition of palmitoyl-CoA (data not shown) and 
these detergent-containing samples could not be analysed by MS because a suitable 
protocol for detergent removal was not in place. It is possible that the concentration 
of detergent was inhibiting the reaction. During the palmitoylation of SNAP-25 0.1% 
Triton X-100 inhibited the reaction
253, also 0.1% Triton was enough to inhibit the 
acylation of rhodopsin
269. On the other hand Bano and collaborators observed an 
increase in the yield of palmitoylated myristoylated Yes-peptides in the presence of 
0.1% Triton X-100
136. So it is difficult to draw any conclusions based on so few 
experiences. Detergent conditions were not further screened as at the time there was 
no feasible way to analyse them. Avoiding detergent contamination in MS samples is 
another reason why the development of a suitable HPLC method for the separation 
of the reaction products is necessary. 
In light of these findings, it is possible that the only feasible method of preparing 
palmitoylated proteins for structural studies is to avoid the use of detergents during 
the reaction, and to further induce the palmitoylated protein precipitation in order to 
facilitate its recovery, purification and analysis. Once pure, the palmitoylated protein 
can  then  be  resuspended  in  lipid  bilayers
270,271  or  detergent  micelles
272.  Once 
solubilised  palmitoylated  Fas  can  be  obtained,  circular  dichroism  and  NMR 
spectroscopy could be used to investigate the effects of the lipid modification on the 
folding of the cytoplasmic region of Fas and its interaction with the lipid phase. 
Binding experiments with ezrin and other better characterised Fas binding partners 
could also be assayed with a similar methodology as used in Chapter 5. 
In retrospect, owing to these additional complications that arise from working with 
full protein domains instead of peptides, it would have been a better starting point to 
first assay palmitoylation of short peptides comprising Cys199 and Cys304. Peptides 
allow  for  greater  flexibility  regarding  reaction  conditions.  For  example,  Yousefi-
Sakakdeh et al., reported 80% S-palmitoylation of a 17- residue peptide after 10 
minute  incubation  with  palmitoyl  chloride  in  100%  TFA
273,  and  Vogt  and 
collaborators palmitoylated a 14-residue peptide in benzene
274, and in a subsequent 
paper reconstituted the lyophilised acyl-peptide in lipid bilayers for NMR studies
275.  305 
In  summary,  this  chapter  has  illustrated  that  palmitoylation  of  Cys199  can  be 
accomplished in sufficient amounts for structural studies, but that two problems need 
to be overcome before putting into practice this technique; first, separation of the 
palmitoylated  product,  and  second  the  solubility  of  the  palmitoylated  product  in 
aqueous  conditions.  It  is  almost  certainly  possible  to  separate  the  palmitoylated 
protein from the unreacted protein  and CoA modified by-product by  reversed or 
normal phase liquid chromatography. Solubility could be achieved by purification 
under  denaturing  conditions  and  subsequent  reconstitution  in  lipid  bilayers  or 
micelles.  306 
                                                         Chapter 7 
Concluding remarks and perspectives 
 
 
Death  domains  are  protein:protein  recognition  platforms  that  enable  specific  and 
controlled modes of oligomerisation (aggregation) to allow the proximity activation 
of enzymes such as proteases and kinases. Although structures of members of the 
death domain family have been solved, many in isolation and some in oligomeric 
form, the molecular bases of their patterns of recognition have only just begun to be 
understood.  Of  particular  interest  for  our  laboratory  was  to  develop  methods  to 
enable the biophysical characterisation of their dynamic behaviour and of the effects 
of post translational modifications on structure, dynamics and binding modes. This 
thesis describes my efforts to tackle some of these challenges using the cytoplasmic 
domain of the death receptor Fas as a test case.  
In  retrospect,  it  is  precisely  the  ability  of  death  domains  to  undergo  organised 
aggregation  that  made  progress  so  difficult.  By  developing  these  biophysical 
techniques in a more tractable system before applying them to death domains, it 
would have enabled the capabilities and reliability of the techniques to be established 
first, and clarified the questions of whether the problems encountered were inherent 
to the technique or the specific protein at hand. Nevertheless, I believe I have been 
able to improve the characterisation of the Fas death domain in solution and lay the 
foundations  for  future  progress  in  the  understanding  of  phosphorylated  and 
palmitoylated proteins through the semi-synthetic methods that I have established for 
their production. I conclude by presenting my observations, general conclusions and 
perspectives of each chapter independently. 
 
   307 
7.1 The Fas-DD adopts a compact configuration in solution with inconclusive 
evidence that it can also form an open conformation in the tested conditions 
The canonical death domain (DD) fold is formed by a bundle of six alpha helices 
arranged in a Greek key motif. The structure of the 90 residue Fas death domain was 
published in 1996, it was the first of the DD structures to be solved and has formed 
the basis of a number of Fas and FADD protein-protein interaction studies
6,121–124. 
The Fas-FADD interaction is of interest due to its role in the initiation of apoptotic 
pathways through the formation of the death inducing signalling complex (DISC).  
In  2009  a  crystal  structure  of  the  Fas-FADD  complex  was  published  which 
contained  four  Fas-DD  and  four  FADD-DD  subunits.  In  this  structure  the  death 
domain of Fas showed an open conformation exposing the hydrophobic core of the 
domain to form the main interaction surface with FADD. Although this has since 
been  shown  to  be  a  non-physiological  arrangement  of  Fas  and  FADD-DD
123,124, 
probably  induced  by  the  crystallisation  conditions  (0.95  M  citric  acid,  1.9  M 
ammonium sulphate, pH 4), this non-canonical form fuels the debate over the ability 
of the Fas-DD to form alternative structures. A more open DD conformation would 
help rationalise the proposed phosphorylation site (Tyr291) and the recruitment of 
SH2  domain  containing  proteins  to  a  region  which  is  particularly  buried  in  the 
current  compact  Fas-DD  structure.  Furthermore,  structures  of  calmodulin  with 
peptide  corresponding  to  the  death  domains  of  some  death  receptors  have  been 
published
125,276. If proven biologically relevant, the formation of these calmodulin 
complexes, both with Fas and with the neurotrophin receptor death domains, would 
require the opening of the death domain. 
The Fas-DD structure presented in this thesis was calculated using data obtained 
from modern multidimensional NMR pulse programs. Due to the fact what I have 
yet to complete the assignment of all NOE peaks present for the residues in helices 
five and six, I am not yet in a position to calculate the structure without any input 
from prior structural information. However, by priming the calculation using a small 
subset of NOEs derived from the compact Fas-DD structure, a structural ensemble of 
twenty conformers is obtained, which shows a six helical canonical death domain 
type structure. While it could be argued that this protocol forced the structure into 
the  canonical  death  domain  fold,  both  the  secondary  structure  predicted  from 308 
chemical shifts and the presence of NOEs between residues expected to be close in 
the compact structure indicate that, in our hands, Fas-DD forms the canonical fold in 
solution.  
Fas-DD is not the only death domain that has been reported to experience a radical 
conformational change.  The death domain of Pelle, a protein involved  in dorsal-
ventral  patterning  in  Drosophila  development,  has  also  been  seen  to  undergo 
structural rearrangement when crystallised. By crystallography methods, the death 
domain alone, formed an elongated helical structure
169 whereas in complex with its 
binding partner Tube
168, and when isolated in solution
170 it formed the expected six 
helical bundle. The authors of the crystal structure of isolated Pelle discuss how the 
cosolvent conditions (45% 2-methyl-2,4-pentanediol, MPD) could be responsible for 
the induction of the structural change. This change may illustrate the susceptibility of 
the death domains to rearrange when present in some conditions, perhaps because 
the hydrophobic core is quite minimal. In addition, this behaviour might provide 
some evidence that the death domains can be made to change their arrangement of 
alpha helices in certain physiologically relevant conditions as well.  
Of the death domain structures that are deposited in the Protein Data Bank, there are 
examples of the DD undergoing small rearrangements. This is illustrated reasonably 
well  by  the  alignment  of  a  subset  of  the  known  DD  structures  (Figure  3.4).  In 
particular for Fas, the lymphoproliferation mutation V254N is well known to disrupt 
the binding interface between Fas and FADD which when present in vivo results in 
the accumulation of autoreactive T cells characteristic of ALPS. Analysis of NMR 
chemical shifts and heteronuclear NOEs highlighted that the V254N mutation results 
in local destabilisation with possible unfolding of Fas-DD helix 3; the cause of the 
loss of FADD binding
277. The mutation did not appear to rearrange the rest of the 
death domain in a similar manner; it could be possible that the death domain is able 
to  tolerate  some  level  of  local  rearrangement  to  its  structure.  This  could  be  the 
mechanism  used  to  enable  the  reported  interaction  with  Fas  and  SH2  domain 
containing proteins. Perhaps once full assignments have been collected for Fas-DD 
Y291E and Fas-DD in crystallisation buffer the chemical shift mapping will enable 
us to draw further conclusions from the relaxation data; much like Eberstadt and 
colleagues did for the Fas V254N mutation. 309 
In  attempts  to  encourage  conformational  changes  and  probe  the  effects  of 
phosphorylation upon the death domain we collected NMR relaxation data on Fas-
DD, both with a phosphomimetic mutation and in the same buffer conditions used 
for  crystallisation  of  the  open  conformation.  In  the  case  of  the  phosphomimetic 
Y291E mutation, considerable chemical shift changes were observed in the mutant 
compared to the wild type death domain and I was unable to transfer my assignments 
from wild type to Y291E HSQC. Lacking assignments, I can only make general 
observations of the differences between both HSQCs. Fas-DD Y291E appears to 
show localised changes in dynamics around the site of the mutation. From this we 
can  infer  that  a  phosphorylation  event  may  encourage  a  local  rearrangement  to 
enable other proteins to bind. A more in depth study would be required to study the 
extent and the causes of this rearrangement. Chapter four documents an expressed 
protein ligation approach to generate a phosphorylated Fas-DD that would enable 
building upon this matter. 
Relaxation measurements of Fas-DD in crystal buffer were significantly hampered 
by the poor signal to noise ratio caused by the partial precipitation of the protein. It is 
not surprising that the  buffer used to crystallise Fas-DD induced precipitation in 
solution, as that is precisely the aim of such a buffer. However, even from the low 
quality data obtained, some tangible observations could be made. In all relaxation 
experiments  an  increased  level  of  exchange  was  observed  in  these  conditions, 
compared to the one observed in the NMR buffer (20 mM MES, 100 mM NaCl, pH 
6.2).  This  increase  could  indicate  that  Fas-DD  was  opening,  oligomerising,  or 
affected by the viscosity of the solution, or a combination of these three possibilities. 
However, it is clear that the shape of the molecule is not particularly perturbed, as 
assignments  could  be  transferred  from  those  obtained  in  NMR  buffer  along  the 
whole length of the construct. 
It is possible that the Fas-DD does not undergo rearrangement unless in the presence 
of  a  specific  binding  partner.  There  are  two  schools  of  thought  regarding  the 
mechanisms and structural changes that can occur upon protein or ligand binding to 
its interaction partner: induced to fit and conformational selection. Proteins exist in 
more than one conformation in solution and conformational selection type binding 
occurs when a ligand binds to a sparsely populated/minor species of the protein, 
immediately forming the structure of the protein:ligand complex. In an induced fit 310 
mechanism  of  binding  a  ligand  binds  to  a  protein,  forming  a  weak  intermediate 
complex  that  induces  a  conformational  change  to  the  whole  protein
278.  However 
binding events may not be so straightforward, with more recent analysis suggesting 
an  extended  conformational  selection  model  which  encompasses  selection  and 
adjustment of protein structures in sites distinct from the binding site. For example 
an interaction may result in allosteric propagation throughout the molecule. Models 
of protein interactions increase in complexity when more than two binding partners 
are  involved  resulting  in  a  large  number  of  conditional  steps  that  can  affect  the 
processing of the interaction
279. It is possible that the open Fas conformation could 
form through the conformational selection process, in which only a small population 
of the death domain is in an alternative conformation at any given time. It is possible 
that the conditions used in the experiments presented in this thesis were not suitable 
for the detection of such minor alternative conformation of the Fas-DD. The addition 
of a binding partner could therefore be the trigger to cause global opening of the 
death domain.  
Studies of the transient structures of proteins that exist prior to ligand binding are 
inherently difficult due to their low population and the fluctuations of such species. 
Transient protein conformations can be characterised using paramagnetic relaxation 
enhancement experiments (PRE), in which a paramagnetic spin label is incorporated 
onto an engineered or native cysteine and the relaxation rate is collected between the 
label and nuclei of interest. By NOE measurements only effects occurring within 6 Å 
can be observed, while PRE experiments, due to the fact that an unpaired electron 
has a very large magnetic moment, changes within 25-35 Å of the paramagnetic 
group can be observed. Because the increase in relaxation rate is strong but decays 
rapidly  as  the  distance  increases,  in  a  case  where  there  is  a  very  low  populated 
conformation in which a nucleus is closer to the paramagnetic group than in the main 
species, the presence of the rare conformation can be detected via the unusually fast 
relaxation of the nucleus
278. PRE analysis of Fas-DD could be a good method to 
detect the possible existence of open conformations in solution that may provide 
more conclusive evidence about the plasticity of the domain. 
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7.2  Auxiliary  mediated  EPL  is  a  viable  platform  for  the  preparation  of 
phosphorylated death domains by semi-synthesis 
Production of post translational modified proteins in bacterial expression systems in 
sufficient  quantity  for  structural  and  functional  studies  is  not  a  straightforward 
process. Protein post translational modifications are not genetically encoded but arise 
from sequence or structural motifs present in the protein itself. Bacterial expression 
systems such as E. coli often do not possess the necessary machinery to perform the 
desired modifications to an exogenous protein. To overcome these limitations, post 
translational  modifications  are  usually  performed  in  vitro  during  or  after  protein 
purification.  In  the  specific  case  of  phosphorylation,  phosphorylated  proteins  are 
often prepared by the incubation of the purified protein with a suitable kinase and 
ATP. It not uncommon to find that the substrate recognition is highly specific, so 
that phosphorylation requires the use of a kinase that might not be commercially 
available, requiring additional cloning, expression and purification. Moreover, the in 
vitro phosphorylation reaction often results in low yields o product and it is difficult 
to control the specific site of phosphorylation without introducing mutations
280.  
Expressed protein ligation (EPL) enables the production of phosphorylated proteins 
by semi synthesis. EPL produces a chemically defined protein construct which can 
contain a phosphate group on the amino acid residue of interest. This methodology 
has been successfully used to generate a number of phosphorylated proteins in vitro. 
For example, the molecular mechanism of Smad2 activation by type I transforming 
growth  factor  β  receptor  (TGFβR)  was  probed  using  a  tetraphosphorylated  EPL 
generated  TGFβR  construct
281,282.  The  same  research  group  also  generated  a 
phosphorylated Smad2 showing that upon phosphorylation the transcription factor 
induces the formation of a stable trimer
283. In an unrelated study, the use of EPL to 
generate a phosphorylated fork head associated (FHA) domain of check point kinase 
2  (Chk2)  was  used  to  illustrate  that  phosphorylation  stabilises  the  FHA  domain 
interactions in vitro
284. 
Although  EPL  is  a  well-established  technique  proved  to  be  amenable  to  the 
production  of  phosphorylated  proteins  for  biophysical  studies,  it  has  one  main 
limitation: the fragment at the C-terminus of the ligation junction needs to start with 
a  cysteine.  Cysteine  is  the  second  lowest  abundant  amino  acid  in  cytoplasmic 312 
proteins, it is unlikely that, if a cysteine is present, it will be in a convenient location 
in the polypeptide chain to constitute a suitable ligation junction. It is common for 
researchers to either mutate an amino acid to or insert a cysteine into the protein of 
interest to overcome this limitation, for example, to enable EPL using Chk2, Ser73 
was mutated to Cys
284. Insertion of a cysteine is not always feasible or could have 
knock on effects on the properties of the protein under investigation, and this is why 
the development of Nα-auxiliary technologies is a promising area of research. An 
Nα-auxiliary is a molecule able to mimic the function of the cysteine thiol, but after 
ligation  can  be  removed  by  an  acid  treatment  step,  leaving  no  trace  in  the  final 
protein construct
127. The Nα-auxiliary tested in this study, Htmb, has been developed 
by the laboratory of Dr John Offer at the NIMR and is currently under investigation 
for performance and yield in different systems. The Offer group was particularly 
interested in assessing the performance of Htmb in systems of biological relevance, 
as their focus is traditional peptide chemistry ligation strategies. 
My aim was to develop a protocol to semi-synthesise phosphorylated death domain 
constructs in order to probe the structural and functional effect of the presence of a 
phosphate group on the death domain of Fas. The Htmb-mediated expressed protein 
ligation  approach  was  used  to  successfully  generate  a  55kDa  MBP-tagged 
phosphorylated Fas-DD, but the methodology will requires substantial optimisation 
to enable the reaction to be performed on a preparative scale. The main problem 
observed  during  synthesis  was  the  ongoing  occurrence  of  N-terminal  thioester 
hydrolysis and protein precipitation, both of which hampered the yield of ligated 
protein which was generated. Li and co-authors observed some thioester hydrolysis 
in the production of a phosphorylated semi synthesised Chk2, but not to an extent 
which  impaired  the  ligation  reaction  itself  such  as  we  observed
284.  To overcome 
thioester  hydrolysis,  the  influence  of  several  parameters  needs  to  be  assessed. 
Reports show that native chemical ligation reaction (EPL between two peptides) can 
greatly be improved by performing the experiment in a solvent environment. In the 
case of our Fas-DD ELP this strategy was tested with little success, but the effect of 
base  additives  for  catalysis  in  these  conditions  has  not  been  tested.  Protein 
precipitation  has  also  been  observed  in  the  EPL  reaction  used  to  make  a 
tetraphosphorylated TGFβR, which upon optimisation was overcome by the use of 
1,6 hexanediol
281, solvent conditions may also aid to improve this difficulty. Another 313 
important  parameter  that  could  have  a  great  effect  on  hydrolysis  is  the  use  of 
thioesters different than benzyl mercaptan.  
Unfortunately, given that Htmb has not been tested in a variety of systems, at this 
stage it is not possible to conclude if the problems encountered could be attributed to 
the auxiliary, or were an effect of the specific peptide sequence in the vicinity of the 
ligation junction or of the aggregation tendencies of the DDs. These effects will have 
to be studied independently to assess their importance. In order to test the limitations 
of the auxiliary, it would prove valuable to attempt a traditional EPL reaction by 
inserting a cysteine at the C-terminus of the junction. The effect of the residues at the 
ligation  junction  has  been  briefly  explored  by  mutating  the  histidine  at  the  N-
terminus of the junction to glycine. The use of glycine as the preceding amino acid to 
the thioester is a popular choice throughout both NCL and EPL as it reduces the 
steric bulk which can interfere with the thioester exchange
193,194. Indeed, the ligation 
yields of this mutant were better than in the wild type, however, the introduction of 
unnecessary mutations could have a great effect in the behaviour of the domain, and 
this is not a solution that we are keen to pursue. Another more suitable solution 
would be to explore other sites within the polypeptide chain that would perform 
better as ligation junctions. Whether the poor yields are due to the general behaviour 
of death domains could be assessed by attempting ligation of other death domain 
superfamily  members,  for  example,  the  death  domain  of  PIDD,  which  has  been 
extensively  characterised  in  our  lab,  has  been  reported  to  be  Threonine 
phosphorylated
285. 
EPL  technologies  have  roots  in  native  chemical  ligation  (NCL)  of  peptides  to 
generate larger proteins than are unable to be synthesised using solid phase peptide 
synthesis  alone.  Protein  based  systems  are  more  challenging  to  work  with  than 
peptides  due  to  the  increased  size,  steric  hindrance,  greater  conformational 
variability  and  limitations  on  solubility  observed  in  the  larger  molecules.  For 
peptides,  these  problems  are  traditionally  overcome  by  keeping  peptides  in  a 
denaturing acidic environment, conditions that might not be suitable for a protein 
based system. However, EPL is not inherently unsuitable for large proteins, dimers 
of  Hsp90  (heat  shock  protein  90)  of  approximately  80kDa,  have  been  made  by 
EPL
286. Although the size of this construct is an attribute of having both the N and C 314 
termini  purified  from  bacteria,  it  shows  that  in  principle  the  thioester  exchange 
reaction mechanisms should not be limited by protein size. 
The semi-synthesis of a protein is a laborious process that involves many steps. As 
with any multi-step protocol, the accumulating loss of material at each purification 
step  results  in  low  yields  of  ligation  product
287.  To  compound  this  challenge, 
millimolar  concentrations  of  reactants  are  required  to  obtain  suitable  ligation 
yields
191.  For  this  multi-step  process  to  be  worthwhile  for  the  production  of  a 
phosphorylated Fas-DD at a preparative scale, better yields at each step and/or fewer 
purification steps are necessary. It is not unreasonable to expect yields of several 
milligrams  for  ligated  Fas-DD.  The  semi  synthesised  phosphorylated  Chk2  and 
Smad2  proteins  were  generated  at  high  enough  yields  to  carry  out  analytical 
ultraentrifugation,  surface  plasmon  resonance  and  size  exclusion  chromatography 
with multiangle laser light scattering analysis
283,284. In the case of the semi-synthesis 
of TGFβ required much optimisation to reduce a side reaction and the non-specific 
aggregation observed when the ligation was initially carried out
282. But following 
optimisation the authors reported a 16% yield of ligated product in the milligram 
quantities,  enough  to  enable  the  implementation  of  kinase  activity  assays
281. 
Expression  levels  of  the  Nt-Fas-DD  intein  conjugate  were  adequate,  however 
purification from the chitin column was inefficient due to protein aggregation. The 
purification  of  Nt-Fas-DD  was  greatly  improved  by  the  presence  of  the  MBP-
solubility tag, but the introduction of the His to Gly mutation greatly reduced the 
yield  of  cleaved  protein.  The  scaling  up  of  Ct-pY-Fas-DD  synthesis  would  also 
require optimisation, current yields are in the order of 5 mg on a 0.1 mmol scale 
reaction. With further handling practice and synthesis at a larger scale it should be 
possible to prepare the peptide in greater amounts. The ligation itself would require 
some  optimisation  primarily  to  avoid  hydrolysis,  but  also  to  develop  a  suitable 
method  for  the  efficient  separation  of  the  ligation  product  from  the  N-terminal 
fragment. There is no reason to believe that by implementing some of these changes 
pY-Fas-DD could not be produced in the hundreds of micromolar quantities required 
for assays such as circular dichroism and binding assays such as BLI.  
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7.3 The reported Fas ezrin interaction is unlikely to be direct or does not occur 
in the juxtamembrane region or the DD of Fas 
It  cannot  be  disputed  that  Fas  and  ezrin  interact,  as  it  has  been  observed 
independently  by  several  groups  using  colocalisation  or  coprecipitation 
experiments
50,113–115. Unfortunately, throughout the work carried out for this thesis, 
we  have  been  unable  to  detect  a  direct  Fas  and  ezrin  interaction  in  vitro  using 
purified recombinant proteins. In light of these results, either this interaction may not 
be direct, or it does not occur at the juxtamembrane region of Fas as suggested by 
Ruan and collaborators
118, or through the death domain.  
Most  previously  reported  co-immunoprecipitation  and  colocalisation  experiments 
were carried out using mammalian cell extracts. Unlike the recombinant proteins 
used in our in vitro assays, the use of mammalian cell extracts allows for proteins 
being post translationally  modified and/or for the presence of additional proteins 
from the ones being detected. All previous reports used antibody-based detection 
methods  to  analyse  Western  blots  and/or  co-immunoprecipitation  experiments. 
These methods are targeted for the detection of what the researchers wish to observe, 
leaving them unaware of any other constituents that may have been present in their 
samples. It is conceivable that the interaction between Fas and ezrin could not have 
been reproduced in vitro because it is mediated by another protein, or because it 
requires a change in configuration as a result of a posttranslational modification. 
The recombinant Fas and ezrin constructs in this study focused around the ezrin 
FERM domain and the Fas death domain with a proportion of the juxtamembrane 
region. Another possibility is that one or both of these constructs did not contain the 
region of interaction. Kuo and coworkers.
116 reported a direct interaction by pulling 
down recombinant full-length His-tagged ezrin with a recombinant GST-tagged Fas 
construct containing the transmembrane region and cytoplasmic domain (residues 
185-328), and used anti-His and anti-GST antibodies for detection. Perhaps using 
these much longer constructs would have been sufficient to detect binding. However 
this  reasoning  does  not  fully  justify  why  in  our  hands  no  direct  interaction  was 
detected,  as  Lozupone  and  coworkers
117  reported  a  successful  pull  down  of 
cytoplasmic  Fas  construct  (residues  191-335,  three  residues  longer  than  the  Fas-
JM+DD+CTD  (194-335)  used  in  this  study)  by  short  truncations  of  GST-tagged 316 
ezrin  and  using  an  anti-Fas  antibody  for  detection.  It  is  feasible  that  these  three 
residues are necessary for binding. Another, more interesting, possibility is that, by 
using short truncations of the FERM domain, surfaces that are not exposed in the full 
length FERM are available for binding.  
Crucially, neither Kuo nor Luzopone and collaborators included a negative control 
showing that ezrin is not associating with the bead matrix, and the possibility exists 
that they are only observing an artefact. In our hands, ezrin binding in a not specific 
manner was a substantial problem when using a number of matrixes and proteins. If 
is very unfortunate that a significant proportion of the literature regarding the direct 
interaction between Fas and ezrin has been published from the same research group, 
as  it  is  possible  that  others  have  attempted  to  recreate  these  results  and  have 
stumbled across similar issues to those we encountered. 
FERM  domains  are  known  to  either  directly  interact  with  membrane  proteins  or 
indirectly  interact  via  adaptor  proteins  of  the  NHERF  family.  NHERF  (Na
+/H
+ 
exchanger regulatory factor) 1 and 2 (also known as ERM binding phosphoprotein 
50 (EBP50) and E3KARP (NHE3 kinase A regulatory protein)) have been identified  
as a linker between the cytoplasmic tail of transmembrane proteins and the FERM 
domain  of  ERM  proteins
288,107.  NHERFs  are  composed  of  a  a  C-terminal  ERM 
binding domain, which has been shown to bind the F3 lobe of ezrin
289 and two PDZ 
domains, a protein:protein interaction fold that recognises short regions at the C-
terminus of its targets. Upon scaffold protein binding, the FERM domain reduces its 
affinity for known direct membrane protein interactions which is suggested as a role 
for scaffold proteins in the regulation of the formation of ERM related signalling 
complexes
111. Diverse transmembrane proteins such as the β2 adrenergic receptor
108, 
cystic  fibrosis  transmembrane  conductance  regulator  (CFTR)
290,  platelet  derived 
growth factor receptor (PDGFR)
291 and EGFR
292 associate by EBP50 in this manner. 
Fas associated phosphatase-1 (FAP-1) is a PDZ domain containing enzyme that has 
been identified to bind to the C-terminal tail of Fas
293. The PDZ domain of FAP-1 
shows 49% similarity to the N-terminal PDZ domain of EBP50 and 45% similarity 
to its C-terminal PDZ domain, therefore it would not be surprising that EBP50 can 
also bind to the C-terminus of Fas. This mechanism of interaction would account for 
our inability to confidently observe a direct Fas and ezrin interaction in vitro.  317 
Fas is not the only death receptor that has been shown to require a link to the actin 
cytoskeleton for DISC progression to apoptosis. A recent study has reported that the 
apoptotic pathways of the death receptors DR4 and DR5 can be regulated by an E-
cadherin mediated link to the actin cytoskeleton. E-cadherin is known to be involved 
in the formation of adherens junctions, promoting cell adhesion and providing a link 
to cytoskeleton dynamics via the formation of a cadherin-catenin complex with β 
and α-catenin binding to actin. The authors report that, upon receptor ligation, E-
cadherin links DR4/DR5 to the actin cytoskeleton, facilitating receptor clustering 
and  efficient  DISC  formation.  This  effect  was  not  observed  on  Fas  receptor 
activation
294. Parallels can be drawn between effects on a cytoskeletal link during 
DR4/DR5 activation and the DISC forming events involving Fas and ezrin. This new 
study  shows  that  death  receptors  other  than  Fas  require  an  association  to  the 
cytoskeleton to initiate apoptosis and that this link is not a direct link. 
Ezrin is not the only protein with has been reported to mediate a linkage between Fas 
and the cytoskeleton. Del Rio and coworkers
295 observed that the death domain of 
ANKG190, a kidney ankyrin, interacts with the Fas death domain. Akyrins are a 
conserved family of proteins, known to link integral membrane proteins to the actin 
cytoskeleton. They are modular in structure, containing a number of ankyrin repeats, 
a spectrin domain and a C terminal death domain. In the renal cell line MDCK, 
ANKG190 overexpression resulted in an increase in cells undergoing apoptosis. A 
mutation  in  ANKG190,  R1496  (similar  to  the FADD  R234  mutation on  the  Fas 
binding  surface)  resulted  in  loss  of  the  interaction
295.  This  study  illustrates  an 
alternative mechanism of Fas linkage to the actin cytoskeleton that does not involve 
ezrin but exploits a death domain mediated interaction to reach the same ends. Like 
many  other  apoptotic  related  observations  this  is  perhaps  a  cell  type  specific 
interaction and therefore may not be generally applied to the Fas apoptotic system. 
However it is an illustration that DISC formation can be flexible with the possibility 
of a variety of adaptor proteins being involved in the internalisation of the DISC. 
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7.4 In vitro palmitoylation of full length proteins proved more challenging than 
expected, but raises interesting possibilities  
Much like the addition of a phosphate group to a protein, protein lipid modifications 
are  not  genetically  encoded  or  easily  obtainable  through  the  use  of  bacterial 
expression systems. Unlike the phosphorylation of proteins, in vitro study of protein 
lipid  modifications,  particularly  palmitoylation  are  highly  underrepresented 
throughout the literature. The confirmation of the identity of palmitoyl transferase 
enzymes is a relatively recent discovery
242, the specificity and the transmembrane 
form
49 of these enzymes makes the use of enzymes to palmitoylate a protein in vitro 
almost impossible.  
We hypothesised that one of the possible scenarios for an undetectable Fas and ezrin 
interaction  in  vitro  was  that  our  recombinant  expressed  Fas  constructs  were  not 
palmitoylated.  Fas  palmitoylation  upon  Cys  199  is  reported  to  redistribute  and 
partition  Fas  into  lipid  raft  regions  of  the  cell  membrane  prior  to  receptor 
internalisation. Feig and colleagues reported that prior to Fas internalisation ezrin 
was recruited to Fas in a palmitoylation dependent manner, therefore we embarked 
on a method to try and recreate this process in vitro
30.  
In  vitro  palmitoylation  or  autoacylation  exploits  the  local  sequence  environment 
surrounding a cysteine to enable transfer of the lipid group from palmitoyl CoA (an 
activated fatty acid form) to the cysteine of interest
254. It is a method which was 
favoured to study the mechanism of palmitoylation using primarily peptide targets 
prior to the discovery of the palmitoyl transferase enzymes. Our aim was to transfer 
this  technique  to  a  whole  protein  target  which  could  be  scaled  up  and  used  for 
structural and biophysical characterisation and interaction studies. Palmitoylation of 
Fas-DD  at  Cys  199  was  indeed  achieved  using  this  in  vitro  palmitoylation 
technology.  However,  we  also  observed  a  side  reaction  with  coenzyme  A  and 
significant precipitation of the presumably palmitoylated protein. 
Many  of  the  reported  autoacylation  studies  of  both  peptides  and  recombinant 
proteins  did  not  go  onto  use  the  palmitoylated  target  for  anything  other  than 
identification  of  the  palmitoylated  target.  Peptide  targets  were  assayed  using 
scintillation  counting  and  HPLC  based  assays  to  confirm  the  incorporation  of 
radiolabelled palmitate
252,254. In the case of the G protein alpha subunit and SNAP-319 
25, the proteins were assayed for palmitoylation by precipitation in trichloroacetic 
acid  or  chloroform/methanol  and  assayed  by  western  blot  and  scintillation 
counting
251,253.  At the  time  of  their  publication,  these  studies  were  focused  upon 
characterising  the  mechanism  of  palmitoylation  rather  than  in  developing  a 
preparative method, and no observations were made on the effects on the solubility 
of the proteins or other effects of the modification. This is why, perhaps, we were so 
naïve when we decided to follow their steps.  
Although  limited,  there  are  examples  of  proteins  that  have  been  in  vitro 
palmitoylated  on  a  preparative  scale  and  used  for  some  other  purpose.  These 
experiences might prove more valuable in order to put our results in perspective. 
Robert  and  colleagues  demonstrated  that  palmitoylation  of  proteins  could  be  a 
method of enabling proteins to cross the blood brain barrier (BBB) by preparing in 
vitro N-palmitoylated RNase A and testing it in a BBB mimicking system 
296,297. 
Along  similar  lines,  a  palmitoylated  gramicidin  (a  membrane  channel-forming 
polypeptide) has been investigated using solution NMR spectroscopy to observe the 
effect  of  acylation  on  the  position  of  specific  side  chain  residues  in  a  lipid 
bilayer
274,275.  Notable  from  these  studies  is  that  they  both  use  a  non-aqueous 
environment to palmitoylate and throughout analysis of the palmitoylated protein. 
Palmitoylated  RNase  A  was  prepared  within  reverse  micelles,  (small  aqueous 
droplets in an apolar medium) followed by protein precipitation and resuspension 
prior to the assay
296. In the case of gramicidin, the peptide was palmitoylated in a 
solvent environment containing free fatty acid, benzene, PPY (4, pyrolidinopyridine) 
and DDC (N,N,dicyclohexylcarbodiimide), precipitated, purified
274 and resuspended 
in  SDS  micelles  or  DPMC  detergent  bilayers  for  NMR  experiments
275.  These 
examples highlight the requirement for a hydrophobic environment to be present to 
make lipidated proteins tractable for biophysical study. However in the autoacylation 
reaction used in this thesis, detergents were shown to inhibit the lipid transfer
253.  
Ultimately,  it  would  be  interesting  to  see  what  palmitoylation  would  do  to  the 
structure and the interactions of intracellular Fas. A search of the Protein Data Bank 
for protein structures which contain a covalent palmitic acid modification showed 
that there is an abundance of structures of acyl binding proteins, acyltransferases and 
thioesterases in complex with palmitic acid, but there seem to be few structures that 
contained the fatty acid covalently linked to a protein chain. Acyl binding protein 320 
and acyl transferase structures are of less interest in this analysis as these proteins 
tend to contain a hydrophobic binding cleft, that isolates the lipid from the aqueous 
environment.  For  example,  the  crystal  structure  of  an  atypical  acetyltransferase 
domain from mycobacterial polyketide synthase Pks13 was solved showing palmitic 
acid present. This orientation was achieved by cocrystallision or crystals soaking 
with palmitoyl CoA to get the resulting complex
298. This could illustrate a much 
easier structural methodology than a reaction such as the one we were attempting to 
optimise if our protein had such mode of binding to the fatty acid.  
Of the structures deposited in the PDB which contained covalently linked palmitate, 
lipidation  was  either  synthetic  or  unexpected.  The  structure  of  a  lipidated  thirty 
amino acid glucan analogue has been reported using solution NMR and characterised 
by circular dichroism, to investigate lipidation of peptides which could be used to 
stimulate  weight  loss
299.  Whereas  another  group  reported  the  crystal  structure  of 
EVF, a Virulence Factor Produced by the Drosophila Pathogen Erwinia carotovora 
observing S-palmitoylation which was unexpectedly added to the protein during its 
expression in E. coli
300. These examples highlight that structural studies containing 
covalently linked S-palmitoylation appear to be rarely approached in a way in which 
palmitoyl  groups  are  added  to  a  recombinant  expressed  protein  that  may  further 
highlight the difficulties observed throughout chapter six.  
Another approach that could be utilised to palmitoylate Fas would be the generation 
of a palmitoylated protein by expressed protein ligation. The lipidation of the GTP 
binding protein Ras has been studied in an S-palmitoylated and farnesylated form in 
which the lipidated C terminus of the protein was synthesised as a short lipidated 
peptide and ligated to the expressed N-terminus. The resulting construct was used in 
biophysical assays in which it was inserted into artificial lipid bilayers and assayed 
using  surface  plasmon  resonance  or  utilised  in  cell  based  assays
301.  A  similar 
technique was used to solve the structure of a prenylated Ras protein
302, illustrating 
that this is a possible technique to generate lipidated proteins at yields which are 
suitable for biophysical analysis 
In  light  of  these  observations  and  the  challenges  of  working  with  palmitoylated 
proteins, to progress with the palmitoylation of Fas in vitro, in vitro palmitoylation 
could be carried out using a Fas construct with solubility fusion proteins N and C-321 
termini, perhaps this could encourage the protein to remain in solution following 
palmitoylation. Also, as discussed at the end of chapter six, a feasible strategy would 
be to perform the reaction in aqueous buffer, induce precipitation, purify and finally 
encourage  the  protein  to  solubilise  in  the  presence  of  a  membrane  mimicking 
environment such as lipid bilayers
270,271 or detergent micelles
272.  
One of the grander aims of our laboratory is to work towards the full reconstitution 
of  the  Fas  DISC  in  a  membrane  mimicking  environment.  Organisation  of  a 
membrane-confined DISC would constrain oligomerisation in an arrangement more 
similar to the one found in vivo. This extra level of constraint would possibly affect 
the structure of the DISC and shed light into some of the many mysteries that still 
puzzle  the  apoptosis  community.  In  recent  times  the  use  of  highly  deuterated 
phospholipid bilayer nanodiscs has been presented as a promising tool for studying 
membrane proteins by solution NMR. A nanodisc is a small patch of phospholipid 
bilayer of defined size, held in place with apolipoprotein-1, into which membrane 
proteins  of  interest  can  be  inserted.  The  use  of  nanodiscs  avoids  the  associated 
problems of using detergents to mimic a membrane environment as detergents are 
well known to disrupt protein folding and protein interactions, making a detergent 
environment  far  from  optimal  for  the  study  of  protein  complexes
303.  Nanodiscs 
would be an attractive system to study the effects of Fas palmitoylation on DISC 
formation, and  I hope  my work will be the first step towards such a fascinating 
achievement.  
7.5 Final summary 
In summary, this thesis demonstrates the implementation of a variety of structural 
and  biophysical  techniques,  exploring  aspects  of  the  3D-structure,  dynamics, 
chemical  modification  and  possible  interactions  of  the  cytoplasmic  region  of  the 
death receptor Fas.This work has paved the way for the routine production of E. coli-
expressed  death  domains  with  modifications  incorporating  the  use  of  chemical 
biology methodologies. This approach constitutes an exciting development towards 
the  in-depth  biophysical  study  of  the  effect  of  post-translational  modifications. 
Milligram amounts of post-translationally modified death domains would facilitate 
the understanding of new aspects in the behaviour of this intriguing protein family 
and its ability to initiate the dissimilar signalling events of cell survival and apoptosis 322 
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Appendix  A  -    Hydoxylamine  treatment  of  L11  t4  to  prove  the  product  is  product  not 
unrearranged intermediate 
Chromatograms showing the four hour timepoint from the ligation in which 1mM MBP-Nt-Fas-DD  H285G 
thioester was incubated with1mM Hmb-pY-Ct-Fas-DD peptide at pH 7 in ligation buffer. A, shows with no 
additives. B, shows with the addition of hydroxyl amine, reducing any non-amide bonded thioester components 
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Appendix B - 
1H/
15N-HSQC spectrumof 15N ezrin 1-297 
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Appendix C - 
2H/




15N-HSQC spectra of 100 µM : 
2H/
15N ezrin with: A, 0 µM ICAM2 peptide, B, 20 µM ICAM2 peptide, C, 80 
µM ICAM2 peptide, D 100 µM ICAM2 peptide. The ICAM2 peptide causes line broadening in the 
1H/
15N HSQC 
spectrum of ezrin FERM 
 
 